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Introduction and Overview of the Thesis 
 
In-stent restenosis has long been considered the main 
limitation hampering the long-term efficacy of coronary 
stenting. Although stent implantation itself has been 
associated with reduced rates of restenosis compared to 
balloon angioplasty, in-stent restenosis still persists in up 
to 40% of patients with complex presentations. Even 
though a number of “predictors” of restenosis are known 
and are helpful in characterizing “high-risk” populations, 
the incidence of restenosis remains largely unpredictable 
in an individual basis.1-3 In addition to its relatively high 
rate in some subsets, the treatment of restenosis has 
been proven to be frequently challenging. In-stent 
restenosis in its more complex forms may re-occur in up 
to 80% of patients following percutaneous re-treatment 
with conventional techniques.4 Moreover, although 
intracoronary brachytherapy has been shown effective in 
reducing the recurrence rate of in-stent restenosis, 
treatment failure still occurs in approximately 30% of 
cases after endovascular irradiation. 
Recently, sirolimus-eluting stents implantation has 
been shown in feasibility studies 5-9 and in randomized 
trials 10-13 to markedly decrease restenosis in selected 
patients. In the early First-In-Man (FIM) study with 45 
patients, no cases of restenosis were detected up to two 
years.5-9 These results were further confirmed in the 
RAVEL trial (RAndomized study with the sirolimus-eluting 
Bx VElocity balloon-expandable stent in the treatment of 
patients with de novo native coronary artery Lesions),10 
where restenosis was also not detected after sirolimus-
eluting stent implantation. Based on these findings, 
sirolimus-eluting stents received CE Mark approval in 
Europe in April 2002 and are since then commercially 
available for routine clinical use. 
Although sirolimus-eluting stents have virtually 
abolished restenosis in the FIM 5-9 and RAVEL,10 these 
studies have mainly included elective patients with 
relatively non-complex lesions. In the subsequent SIRIUS 
(SIRolImUS-eluting Bx velocity balloon expandable stent 
trial),11 and E-SIRIUS 12 trials, which included patients 
with increased risk profiles, restenosis occurred in 8.9% 
and 5.9% of cases in the sirolimus groups respectively 
(compared to 36.3% and 42.3% of patients treated with 
conventional stents, respectively; p<0.01 for both).11,12 
Indeed, the effects of SES implantation in complex, 
unselected patients, such as those commonly treated in 
daily practice, remains largely unknown.  
The purpose of this thesis was to comprehensively 
evaluate the impact of sirolimus-eluting stent implantation 
on the outcomes of patients treated in the “real world” of 
interventional cardiology. Sirolimus-eluting stents were 
utilized as the strategy of choice for all consecutive 
candidates to percutaneous revascularization, in a clinical 
scenario where virtually every patient, with any clinical or 
anatomical conditions, were considered potentially eligible. 
The relative benefits and limitations of this approach were 
evaluated in comparison with conventional approaches in 
use immediately prior to the introduction of sirolimus 
stents. The short- and long-term outcomes of several high 
risk subsets not included in the currently available 
randomized trials were evaluated in detail. 
The safety and efficacy of unrestrictive utilization of 
sirolimus-eluting stents in the “Real World” were analyzed 
in the Part 2 of the thesis. The global impact of sirolimus-
eluting stent implantation on the overall outcomes of a 
population of consecutive patients was described in 
Chapter 3. Subsequently, patients at high clinical risk of 
complications and patients with complex anatomical 
characteristics were examined in separate reports. 
Chapters 4, 5, and 6 evaluated the impact of sirolimus-
eluting stents on the short- and long-term clinical 
outcomes and restenosis rates of patients with acute 
coronary syndromes. Chapter 7 described the relationship 
between sirolimus or conventional stent implantation on 
the mortality of patients with or without decreased renal 
function. Percutaneous intervention utilizing sirolimus-
eluting stents for patient subsets most commonly 
considered for surgical revascularization was evaluated in 
Chapters 8 to 12: the effectiveness of sirolimus-eluting 
stent for chronic total occlusions was examined in Chapter 
8 and for left main coronary artery disease in Chapters 9 
and 10; for multivessel disease with left anterior 
descending artery involvement in Chapter 11; for chronic 
total occlusions in Chapter 12. Patients with very small 
vessels, patients with very long stented segments, and 
those with bifurcation stenting, cases at high risk for 
restenosis with conventional stenting, were studied in 
Chapters 13, 14, and 15 respectively. The merits of 
sirolimus-eluting stents for patients with previous failed 
percutaneous treatments were evaluated in Chapter 16 to 
18: the effectiveness of sirolimus-eluting stent 
implantation for in-stent restenosis was detailed in 
Chapter 16 and compared to vascular brachytherapy in 
Chapter 17; sirolimus-eluting stent implantation for 
recurrent in-stent restenosis after brachytherapy was 
studied in Chapter 18.  
Part 3 of this thesis examined the limitations and 
shortcomings of sirolimus-eluting stent implantation. 
Chapter 19 offered a morphological description and 
mechanistic analysis of a consecutive series of patients 
with post-sirolimus restenosis. Chapter 20 examined the 
incidence, as well as the predictors, of restenosis after 
sirolimus-eluting stents in complex patients, which 
statistical pattern of occurrence is further detailed in 
Chapter 21. The impact of over-dilatation of undersized 
sirolimus stents was studied in Chapter 22. Finally, 
Chapters 23 and 24 examined the costs and the balance 
between costs and effects of sirolimus-eluting stent 
implantation. 
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Introduction 
In-stent restenosis has long been considered the main 
complication limiting the long-term efficacy of coronary 
stenting. Although stent implantation itself has been 
shown to reduce restenosis compared to balloon 
angioplasty, in-stent restenosis still occurs in 10-40% of 
the patients. Although a number of “predictors” have been 
described and are helpful in characterizing “high-risk” 
populations, the occurrence of restenosis remains largely 
unpredictable for a particular patient.1-3 Moreover, in-stent 
restenosis in its more complex forms may re-occur in up 
to 80% of patients following percutaneous re-treatment 
with conventional techniques.4 Although intracoronary 
brachytherapy has been proven effective in reducing the 
recurrence rate of in-stent restenosis, treatment failure 
still frequenlty occurs. In a recent study, 60% of patients 
have been reported to experience at least one major 
cardiac event up to 4 years after endovascular irradiation. 
A large body of evidence has been accumulated in an 
attempt to understand the processes involved in 
restenosis. The initial injury caused by the mechanical 
dilatation and stent implantation triggers a “normal” 
healing vascular response that ultimately leads to 
neointimal formation, which, when excessive, may re-
narrow the vessel lumen (restenosis). An array of local 
reparative processes have been shown to occur after the 
initial vascular trauma, involving platelets, inflammatory 
cells, smooth muscle cells, endothelial cells, and the 
secretion of a number of growth factors and cytokines.5,6  
Based on the accumulated knowledge about the 
cellular and molecular mechanisms of restenosis, an 
endless list “concepts”, “strategies”, devices, and drugs 
have been tested, and failed, to decrease restenosis.7 
More recently, however, drug-eluting stents have emerged 
as an effective therapeutic option to reduce the incidence 
of in-stent restenosis. The present chapter will focus on 
describing the current clinical and pre-clinical information 
available for drug-eluting stents, as well as the limitations 
and future research directions for these devices. 
Rationale 
A proposed explanation for the repeated failure of 
clinical pharmacological studies with systemically 
administered drugs is that these agents cannot reach 
sufficient tissue levels at the site of dilatation without 
increasing the risk of systemic side effects. In this regard, 
local administration offers advantages by applying the 
drug to the precise site of injury, therefore yielding very 
high concentration of the active agent with low or 
negligible systemic concentrations. 
Utilizing the stent itself as the platform for local drug 
delivery is an appealing approach. Coronary stents have 
been extensively proven to be safe and effective in 
mechanically alleviating coronary obstructions, with 
predictable and stable short-term results in a wide range 
of clinical situations. By combining an agent with 
antiproliferative properties to a “conventional” metallic 
stent, one is able to preserve the mechanical scaffolding 
properties of stenting while the active agent is 
administered to the very spot of vascular injury, with no 
time delay, with high local doses, and with the potential to 
control the time (short- vs. long-course) and site (mural 
vs. luminal) of drug release, among other characteristics.
 
Table 1. Overview of possible anti-restenotic approaches for stent-based strategies 
Anti-proliferative Anti-thrombins Immunomodulators Migration inhibitors / ECM 
modulators 
Promote healing / 
endothelialization 
Paclitaxel Hirundin sirolimus and analogs Halofuginone VEGF 
QP-2 Iloprost tacrolimus Propyl hydroxylase inhibitors 17-E estradiol 
Vincristin Abciximab Biorest C-proteinase inhibtors Tkase inhibitors 
Methotrexate Mizoribine Metalloproteinase inhibitors BCP 671 
Angiopeptin Cyclosporin Batimastat Statins 
Mitomycin Biorest Probucol NO donors 
BCP 678 Interferon J1b EPC antibody 
Antisense c-myc Leflunomide 
ABT 578 Tranilast 
Actinomycin-D Cyclosporin 
RestenASE Corticosteroids 
1-chloro-
deoxyadenosine 
Micophenolic acid 
PCNA ribozyme Biphosphonates 
Celecoxib 
_______________________________________________________________________ DES state of the art 
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The delivery vehicles 
Coated stents have been subjected to extensive 
investigations long before being available for implantation 
in humans. The process of binding pharmacological agents 
to a metallic mesh has been early recognized to be 
challenging. The coating should be resistant to mechanical 
abrasion during the frequently laborious process of stent 
implantation, and should comply with a number of 
pharmacological practical requirements, such as drug 
release in a predictable (dose and time) way and 
suitability for sterilization. Furthermore, the coating itself 
should not induce an increased vascular reaction. It 
should be noted in addition that a potential universal 
coating is unlikely, and that different pharmacological 
agents may require different delivery vehicles. Currently, a 
variety of different formulations have been developed that 
provide appropriate stent coating for clinical use, including 
direct drug binding, and coatings with phosphorylcholine, 
nonerodable or bioabsorbable polymers, or ceramic layers. 
 
The agents 
The local agent should be one that inhibits the 
complex cascade of events that leads to neointimal 
formation after stent implantation. The inflammatory and 
proliferative mechanisms of the general tissue healing 
response and the specific role of blood and vessel wall 
components on the vascular reparative processes are all 
potential targets for therapeutic approaches aiming at 
reducing neointimal proliferation. A variety of potential 
candidates are available (Table 1) and an increasing 
number of clinical studies have been conducted to 
evaluate the efficacy of different eluting-stents. 
It is important to recognize that the clinical effect of 
these devices is highly dependent on each one of the 
components of the complex platform/vehicle/agent, as 
well as the interactions among these elements. It is 
therefore unlikely that a drug-eluting stent “class-effect” 
might exist, due to the myriad of possible therapeutic 
combinations. Indeed, different drug-eluting stents have 
been shown to significantly vary in their ability to reduce 
restenosis. Indeed, several drug-eluting stents have been 
already shown ineffective, as summarized in Table 2. 
Polymer-coated sirolimus- and paclitaxel-eluting stents 
have the largest clinical experience to date, with a total of 
8 already completed randomized trials comparing the 
effect of these devices against conventional stents. 
Sirolimus-eluting stents are available for clinical use in 
Europe, Asia, and South America since 2002 and in the US 
since 2003. Polymer-coated paclitaxel-eluting stents have 
been commercialized in Europe, Asia, and South America 
since 2003 and are expected to be launched in the US in 
the beginning of 2004. The main clinical information 
derived from randomized trials and from other clinical 
studies including post-marketing registries are detailed 
below. In addition to sirolimus and paclitaxel stents, an 
increasing number of other drug-eluting stents have been 
tested in preliminary clinical trials with promising results 
and are summarized in the sections below. 
Sirolimus 
Sirolimus (Rapamycin; Rapamune£) is a naturally 
occurring macrocyclic lactone with a potent 
immunosuppressive action, which was approved by the US 
Food and Drug Administration for use in renal transplant 
recipients in September 1999. Sirolimus inhibits cellular 
proliferation by blocking cell cycle progression at the G1 to 
S transition. Its action is mediated by binding to an 
intracellular receptor, the FK506 binding protein (FKBP12). 
The complex rapamycin-FKBP12 then inhibits the activity 
of a key regulatory kinase denominated mammalian 
Target Of Rapamycin (mTOR). The inhibition of mTOR 
suppresses cytokine-driven (IL-2, IL-4, IL-7 and IL-15) T-
cell proliferation. Its inhibition has several important 
effects, including the inhibition of translation of a family of 
mRNAs that code for proteins essential for cell cycle 
progression. The inhibition of mTOR prevents mitogen-
induced downregulation of p27Kip1.8,9 In addition, smooth 
muscle cell proliferation is shown to be inhibited by 
rapamycin-FKBP12 in p27Kip1(-/-) knockout mice, 
suggesting that neointimal inhibition may also operate via 
a pathway that is independent of p27Kip1.8 Human 
neointimal tissue extracted during atherectomy exhibited a 
peculiar upregulation of FKBP12 at mRNA and protein 
levels, indicating the potential for sirolimus in preventing 
coronary restenosis.10 
 
 
Table 2. Failed pharmacologic stent-based strategies to prevent restenosis 
Trial Agent vehicle Stent platform reason for clinical failure 
SCORE 47 Taxol derivative QP2 
(4000Pg)  
polymer sleeves QuaDS-QP2 
stent 
excessive incidence of stent thrombosis and 
myocardial infarction possibly due to the polymer 
sleeves 
DELIVER 38 Paclitaxel (3Pg/mm2)  direct binding Multi-link penta lack of efficacy 
ACTION 48 Actinomycin-D (10 and 
2.5Pg/mm2)  
Polymeric coating Multi-link tetra lack of efficacy 
BRILLIANT-EU 49 Batimastat  Phosphorylcholine 
coating 
BiodivYsio stent lack of efficacy 
PRESENT trials 50 Tacrolimus (60 and 
230Pg)  
Nanoporous ceramic 
coating 
FlexMaster 
ceramic stent 
lack of efficacy 
EVIDENT 50 Tacrolimus (352Pg)  PTFE PTFE-covered 
stent graft 
lack of efficacy 
IMPACT51 Micophenolic acid (14-
day or 45-day release 
3.3 Pg/mm2)  
"Unicoat" polymer Duraflex stent lack of efficacy 
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Systemic and local administration of sirolimus in 
porcine models of restenosis have been shown to 
significantly reduce neointimal hyperplasia.11,12 Sirolimus-
eluting stents have been first implanted in patients with 
coronary disease in the pioneer First-In-Man experience, 
which included 45 patients with relatively non-complex de 
novo lesions treated between December 1999 and 
February 2000.13-18 Patients were treated in São Paulo, 
Brazil (n=30), and Rotterdam, The Netherlands (n=15) 
and received sirolimus-eluting stents in 2 formulations. 
Both formulations contained 140 µg of sirolimus per cm2, 
but with different delivery kinetics (fast-release 
formulation [<15-day drug release], or slow release 
formulation [>28-day drug release]). Angiographic in-
stent restenosis was not detected in any case up to 2 
years and only one case had a 52% diameter stenosis 
proximal to the stent.13,18 Two-year intravascular 
ultrasound examination showed only minimal neointimal 
proliferation, with 6.3±5.5% percent intimal hyperplasia 
within the stent in the fast release group (São Paulo), 
7.5±7.3% in the slow-release group (São Paulo), and 
4.4±3.1% in the slow-release group Rotterdam.13,18 
Moreover, the 2-year event-free survival was 90.1%, with 
no major events occurring between 2 and 3 years.16 
Four randomized trials comparing the outcomes of 
patients treated with sirolimus-stents and conventional 
bare stents have been concluded to date, and are 
summarized in Tables 3 to 7.19-23 The Randomized Study 
with the Sirolimus-Eluting Bx Velocity Balloon-Expandable 
Stent in the Treatment of Patients with de Novo Native 
Coronary Artery Lesions (RAVEL) trial included 238 
patients with single non-complex de novo lesions. At six 
months follow-up, the angiographic restenosis rate of the 
treated group was zero, the loss in minimal lumen 
diameter was zero. The clinical outcomes were 
significantly better among patients treated with sirolimus 
stents, with 94% of patients being free of any major 
cardiac events at 1 year (compared to 71% in the bare 
stent group; p<0.01).20 Recently, data from the RAVEL 
trial with a more prolonged follow-up period have shown 
maintenance of the initial results, with a 2-year event-free 
survival of 90%.19  
The subsequent SIRolImUS-Eluting Bx Velocity™ 
Balloon-Expandable Stent (SIRIUS) trial, which 
randomized 1101 patients with de novo lesions to 
sirolimus or bare stents, confirmed the clinical efficacy of 
sirolimus-eluting stents.21 In-stent binary restenosis 
(within the margins of the stent) was reduced by 91% 
(3.2% vs. 35.4%; p<0.01) and in-segment restenosis 
(including the stented portion and the 5mm segments 
proximal and distal to the stent) was reduced by 75% 
(8.9% vs. 36.3%; p<0.01).21 At 9 months, the incidence 
of major adverse events was significantly lower in the 
sirolimus group (7.1% vs. 18.9%; p<0.01), mainly due to 
a decrease in the need of target lesion revascularization 
(4.1% vs. 16.6%; p<0.01). Prolonged follow-up data (up 
to 2 years) were recently presented and showed sustained 
benefit of sirolimus-eluting stent implantation in the 
SIRIUS trial.24 The recently published E-SIRIUS trial has 
enrolled 352 patients with longer lesions and smaller 
vessels than the RAVEL and SIRIUS trials.23 Nevertheless, 
the 8-month in-stent restenosis rate was 3.9% in the 
sirolimus and 41.7% in the bare stent group (p<0.01). 
Similarly, the incidence of in-segment restenosis (5-mm 
edges included) was significantly reduced (5.9% vs. 
42.3%; p<0.01). The 9-month incidence of major cardiac 
events was 8% vs. 22.6% in the sirolimus and bare 
groups (p<0.01). Similarly, in the C-SIRIUS trial, which 
randomized 100 patients to sirolimus or conventional 
stenting, in-segment restenosis was not detected in any 
patient after sirolimus-eluting stent implantation.22 
Differently from the previous trials, in the C-SIRIUS direct 
stenting was allowed (at the discretion of the operator), 
which did not affect the incidence of restenosis (i.e. zero 
restenosis rate in patients treated with pre-dilatation or 
direct stenting). Intravascular ultrasound examination at 
follow-up further confirmed the marked neointimal 
inhibition after sirolimus-eluting stent implantation. In the 
RAVEL trial, the percent neointimal obstruction at 8 
months was 1 ± 3% in the sirolimus group versus 29 ± 
20% in the bare group (p<0.001).25 Also, in the SIRIUS 
study, sirolimus-eluting stents were associated with a 
significant reduction of in-stent percent obstruction (3.1 % 
vs. 33.4%; p<0.001).21 
Subgroup analysis of patients included in the RAVEL 
and SIRIUS have shown that the overall benefit of 
sirolimus-eluting stents was also observed across many 
subsets of patients and lesion types.21,26 However, in the 
SIRIUS trial, post-sirolimus restenosis was significantly 
increased in diabetics, long lesions, and small vessels. 
Indeed, post-sirolimus restenosis has been shown to 
frequently occur in association with higher complexity 
characteristics.27 The impact of sirolimus-eluting stents for 
the treatment of more complex lesions has been 
addressed in recently released studies evaluating some 
patient subgroups not enrolled in the early randomized 
trials (Table 8). 
The Rapamycin Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital study (RESEARCH) was a single-center 
registry which included patients treated with SES 
according to a non-restrictive inclusion criterion. Virtually 
all consecutive patient subsets were considered eligible. 
Long-term (12-month) outcomes of the first 508 patients 
with de novo lesions treated exclusively with SES were 
compared with 450 patients treated with bare stents in 
the period just prior to the introduction of drug-eluting 
stents.28 Only 2 (0.4%) presented with thrombotic stent 
occlusion in the first month after the procedure, while the 
stent thrombosis rate in the bare stent group was 1.6% 
(p=0.1). There were no further thrombotic events up to 
one year. Sirolimus-eluting stents reduced by 38% the 1-
year risk of major cardiac events (9.7% vs. 14.8%; 
p<0.01), mainly due to a risk reduction of 65% in clinically 
driven repeat intervention (3.7% vs. 10.9%; p<0.01). 
Importantly, approximately 68% of patients included in 
the registry would have been excluded from the earlier 
clinical trials (e.g. patients with previous coronary surgery, 
patients admitted with acute myocardial infarction, and 
those with multivessel stenting, among other 
characteristics). 
Paclitaxel 
Paclitaxel was originally isolated from the bark of the 
Pacific Yew. It is an antineoplastic agent that is currently 
used to treat several types of cancer, most commonly 
breast and ovarian cancer. Paclitaxel exerts its 
pharmacological effects through formation of numerous 
decentralized and unorganized microtubules. This 
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enhances the assembly of extraordinarily stable 
microtubules, interrupting proliferation, migration and 
signal transduction.29,30 Unlike other anti-proliferative 
agents of the colchicine type, which inhibit microtubuli 
assembly, paclitaxel shifts the microtubule equilibrium 
towards microtubule assembly. It is highly lipophylic, 
which promotes a rapid cellular uptake, and has a long-
lasting effect in the cell due to the structural alteration of 
the cytoskeleton. 
Stent-based paclitaxel has been investigated by 
several groups, using different stent types and 
preparations (copolymer coatings for paclitaxel elution 31-35 
or direct dip-coating of paclitaxel on a stainless steel 
stent).36-39 Clinical studies utilizing direct dip-coating of 
paclitaxel stents are summarized in Tables 9 and 10. 
Contradictory clinical results have been obtained with 
these devices. While the European Evaluation of Paclitaxel 
Eluting Stent trial (ELUTES) 36 and the ASian Paclitaxel-
Eluting stent Clinical Trial (ASPECT) 37 have shown a 
significant, dose-dependent reduction in restenosis with 
paclitaxel stents, the larger RX Achieve™ Drug-Eluting 
Coronary Stent System In the Treatment of Patients With 
De NoVo NativE CoronaRy Lesions (DELIVER-I) study 
failed in demonstrating the beneficial effect of these 
devices. 
Clinical studies utilizing polymer-coated paclitaxel-
eluting stents are summarized in Tables 3 to 7.31-35 In 
total, more than 1,900 patients with de novo lesions have 
been enrolled in the TAXUS I,32 II,31 and IV trials 34,35 and 
randomized to paclitaxel or bare stents. A marked 
reduction in neointimal proliferation and binary restenosis 
was observed in the active groups, leading to 12-month 
target lesion revascularization rates that ranged from 0 to 
6.8% with paclitaxel stents, which was significantly lower 
than in controls (TLR rates from 10.0 to 16.7%).31,32,34,35 
Multivariate analysis from patients included in the TAXUS 
IV trial 34,35 have identified several multivariate predictors 
of 9-month target lesion revascularization. Apart from 
utilization of bare stents (OR 4.58 [95% CI: 2.64, 7.95]; 
p<0.0001), other independent predictors were: diabetes 
(1.78 [95% CI: 1.10, 2.88]; p=0.02), increase in stent 
length (1.04 [95% CI: 1.01, 1.07]; p=0.006), decrease in 
acute gain (2.08 [95% CI: 1.11, 3.88]; p=0.02), and 
lesion angulation (0.98 [95% CI: 0.97, 0.99]; p<0.03). 
Polymer-coated paclitaxel-eluting stents were shown to be 
safe, with rates of subacute stent thrombosis similar to 
those seen in the bare stents (Table 7). 
The WISDOM registry is a post-marketing registry 
conducted with the objective of evaluating unselected 
patients treated with paclitaxel stents in the “real world”. 
Preliminary results of this multinational registry on 
approximately 1,000 patients have been presented in the 
AHA annual meeting in November 2003 and confirmed the 
30-day safety of paclitaxel-eluting stents in more complex 
patients, with only 0.4% of patients presenting stent 
thrombosis.  
Other Drugs 
To date, sirolimus- and paclitaxel-eluting stents have 
the most extensive accumulated clinical experience and 
are the only drug-eluting stents commercially available for 
clinical use. However, a myriad of new devices have been 
recently tested and are currently in various stages of 
development for clinical use. New drug-eluting stents that 
have been already evaluated in preliminary clinical studies 
are summarized in Table 11. Several analogues of 
sirolimus have been investigated. 
Limitations 
A late “catch up” phenomenon has been described 
after implantation of a high dose (800 µg) paclitaxel 
derivative QP2-eluting stent, with the restenosis rate 
increasing from 13% at 6 months to 62% at 12 
months.40,41 However, long-term efficacy should be 
evaluated separately for each drug-eluting stent assembly, 
since a “class-effect” is unlikely for these devices and each 
platform/vehicle/agent complex should be evaluated 
separately. To date, the sirolimus-eluting stent has the 
largest body of long-term data available. The First In Man 
study has shown persistent positive results up to 2 and 3 
years, without any evidence of late catch-up 
restenosis16,18. In the RAVEL19 and SIRIUS24 trials, no 
further events due to restenosis were observed up to 2 
years. With paclitaxel, no rebound effect was seen from 6 
to 12 months in TAXUS-I,32 TAXUS II,31 TAXUS IV,34,35 
ELUTES,36 and ASPECT37 trials.  
In the RAVEL trial, stent malapposition (as observed 
by intravascular ultrasound) was more frequent at 6 
months in sirolimus-eluting stent patients than in the 
control arm 25. Moreover, in SIRIUS 42 late acquired stent 
malapposition was more commonly observed in the 
sirolimus group. However, in TAXUS-II 31 patients treated 
with bare stents or paclitaxel-eluting stents there were 
similar rates of late-acquired malapposition. Nevertheless, 
these observations of late malapposition by ultrasound 
have not been associated with any adverse events 
throughout the follow-up period in any of these 
studies.25,31,42-44. Also, late thrombotic stent occlusion was 
not seen to be more frequent in patients treated with 
sirolimus- or paclitaxel eluting stents, even after 
clopidogrel discontinuation. 
The costs of currently marketed drug-eluting stents 
(i.e. sirolimus- and paclitaxel-eluting stents) have been 
perceived as a major limitation for a more widespread use 
of these devices. In an analysis from the RAVEL trial, the 
utilization of the sirolimus-eluting stent resulted in a mean 
additional procedural cost of €1,286, as compared to the 
control group based on costs in the Netherlands.45 
However, due to the decrease in re-interventions 
attributable to the sirolimus-eluting stent at the end of the 
first year of follow-up the estimated cost difference had 
decreased to 54 €. In other words, in the RAVEL trial the 
reduction of major event risk from 28.8% to 5.8% after 
sirolimus-eluting was accomplished at an extra cost of €54 
per patient. Moreover, data from the the SIRIUS trial have 
shown that at 1 year the costs of sirolimus-eluting stent 
implantation were approximately US$ 300 higher per 
patient. In the SIRIUS, investigators have reported a ratio 
of  approximately US$1700 per repeat revascularization 
avoided, which has been considered to compare favorably 
with other medical treatments for patients with 
cardiovascular disease.46 Obviously, the cost and effect 
estimations derived from the RAVEL and SIRIUS trials 
cannot be directly extrapolated to other situations and 
formal analyses from other clinical scenarios are 
warranted. 
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Future Directions 
As restenosis rates are still not “zero” in the real world 
of interventional cardiology, the search for and testing of 
new drugs will continue. Next to newer drugs and 
optimalization of the drug carrier, other methods are 
currently being investigated to locally treat the injured 
vessel wall. For example, stent-based delivery of 
adenoviral gene vectors was recently achieved in vitro and 
in carotid arteries of rats. Though stent-based local gene 
delivery has not entered the clinical arena yet, it will be 
possible very soon and give a lot of new opportunities to 
attack coronary artery disease and the problems of 
restenosis. 
Another possibility to contain the detrimental effects of 
vessel wall injury after percutaneous interventions is to 
restore the integrity of the endothelial cell lining as soon 
as possible. This way, the attraction of inflammatory 
cytokines as well as activated platelets and macrophages 
can be limited.  
The most logical way to accomplish this is endothelial 
cell seeding of the stent. The problems of sterilization, 
mechanical stretch during implantation and endothelial cell 
viability have been the major limitations in this approach. 
Recently, a method has been developed to coat a stent 
with antibodies to CD-34 receptors on progenitor 
endothelial cells. In this way circulating endothelial cells 
can be captured from the circulation and provide an early 
re-endotheliazation on the stent surface. After promising 
animal data showing a confluent layer of endothelial cells 
very  early after stenting, clinical pilot trials are on-going. 
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Table 7. Randomized trials comparing bare metal stents with polymer-coated sirolimus- or paclitaxel-eluting stents – 
Clinical Outcomes 
Study Follow-up 
(months) 
Death 
(%) 
Myocardial 
infarction 
(%) 
Target vessel 
revascularization  
(%) 
Any event  
(%) 
Stent 
thrombosis  
(%) 
SIROLIMUS       
RAVEL 19,20,26 12      
Sirolimus  1.7 3.3 0* 5.8* 0 
Bare stent  1.7 4.2 22.9 28.8 0 
SIRIUS 21 9      
Sirolimus  0.9 2.8 3.8* 7.1* 0.4 
Bare stent  0.6 3.2 15.8 18.9 0.8 
E-SIRIUS 23 9      
Sirolimus  1.1 4.6 4.0* 8.0* 1.1 
Bare stent  0.6 2.3 20.9 22.6 0 
C-SIRIUS 22 9      
Sirolimus  0 2 4 4 0 
Bare stent  0 4 18 18 2 
PACLITAXEL 
(polymer-coated) 
      
TAXUS I 32 24      
Paclitaxel  0 0 3 3 0 
Bare stent  0 0 10 10 0 
TAXUS II 31  12      
Paclitaxel-SR  0 2.3 10.1* 10.9* 0.7 † 
Bare stent-SR  1.5 5.1 15.9 22.0 0 
Paclitaxel-MR  0 3.7 6.9* 9.9* 0 † 
Bare stent-MR  0 5.2 19.1 21.4 0 
TAXUS III 33 12 0 3.6 21.4 29.0 0 
TAXUS IV 34,35 12      
Paclitaxel  1.4 3.5 6.8* 10.6* 0.6 
Bare stent  1.2 4.6 16.7 19.8 0.8 
* p<0.05 vs. control 
† rates of angiographically documented stent thrombosis 
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Table 8. Sirolimus-eluting stents for complex subsets  
 Design Restenosis (%) late loss (mm) TVR (%) 
SES + SES (MV):  6.0 0.27±0.47 
SES+SES (SB):  24.0 0.52±0.60 
SES+SES:  11.1 
SES+balloon (MV):  6.2 0.14±0.24 
SIRIUS 
bifurcation 52 *§ 
Randomized: 
MV stenting + SB stenting 
(n=43 pts) vs. 
MV stenting + SB balloon 
(n=43 pts) 
SES+balloon (SB):  18.7 0.27±0.38 
SES+balloon:  4.5 
Degertekin 53 † || Series of cases with ISR 
(n=16 pts) 13.3  0.26±0.67 6.3  
Sousa 54 ‡ ¶ Series of cases with ISR 
(n=25 pts) 4.0  0.16±0.42 0  
Saia 55 * || Series of cases with post-
brachytherapy ISR (n=12 
pts) 
40  0.68±1.20 33.3  
RESEARCH AMI 
56 *§ 
Series of cases with ST 
elevation AMI (n=96 pts) 0  -0.04±0.25 0  
Bare stent: 10.9 
RESEARCH de 
novo 28 ¶ 
Consecutive cases treated in 
2 phases: 
bare stents (n=450 pts) vs. 
SES (n=508 pts) 
-  - 
SES: 3.7 
ISR=in-stent restenosis; MI=myocardial infarction; MV=main vessel; SB=side branch; SES=sirolimus-eluting stent; 
TVR=target vessel revascularization 
* angiographic follow-up at 6 months 
† angiographic follow-up at 4 months 
‡ angiographic follow-up at 12 months 
§ clinical follow-up at 6 months 
|| clinical follow-up at 9 months 
¶ clinical follow-up at 12 months 
 
 
 
 
 
Table 9. Clinical Studies with Dip-Coated Paclitaxel-eluting Stents – Study Design 
 Study groups design inclusion criteria 
ELUTES 36 2.7 µg/mm2 paclitaxel 
(n=37 pts) 
1.4 µg/mm2 paclitaxel 
(n=39 pts) 
0.7 µg/mm2 paclitaxel 
(n=39 pts) 
0.2 µg/mm2 paclitaxel 
(n=37 pts) 
Bare stent (n=38 pts) 
randomized de novo lesion 
native vessel 
single lesion 
ASPECT 37 3.1 µg/mm2 paclitaxel 
(n=60 pts) 
1.3 µg/mm2 paclitaxel 
(n=58 pts) 
Bare stent (n=59 pts) 
randomized Single lesion 
lesion length <15 mm 
vessel diameter 2.5 - 3.5mm 
DELIVER I 38 3.0 µg/mm2 paclitaxel 
(n=522 pts) 
Bare stent (n=519 pts) 
randomized Up to 2 native vessels treated (1 target and 1 non-target, 
with only 1 de novo lesion per vessel) 
lesion length <25 mm 
vessel diameter 2.5 – 4.0 mm 
DELIVER II 39 3.0 µg/mm2 paclitaxel 
(n=1531 pts) 
series of cases One of the following: 
- 1 target lesion: length < 25 mm, chronic total or subtotal 
occlusion, restenotic, or in a bifurcation site 
- 1 target lesion: length > 25 mm, de novo, chronic total 
or subtotal occlusion, restenotic, or involving a bifurcation  
- 2 target lesions: length < 25 mm, de novo, chronic total 
or subtotal occlusion, restenotic, or in a bifurcation  
CTO=chronic total occlusion; NA=not available; pts=patients 
 
  
27 
Ta
bl
e 
10
. 
Cl
in
ic
al
 S
tu
di
es
 w
ith
 D
ip
-C
oa
te
d 
Pa
cl
ita
xe
l-e
lu
tin
g 
St
en
ts
 –
 A
ng
io
gr
ap
hi
c 
an
d 
Cl
in
ic
al
 O
ut
co
m
es
 
 
R
es
te
no
si
s 
(%
) 
La
te
 lo
ss
 
(m
m
 ±
 S
D
) 
Cl
in
ic
al
 f
ol
lo
w
-u
p 
(m
on
th
s)
 
D
ea
th
 (
%
) 
M
yo
ca
rd
ia
l 
in
fa
rc
tio
n 
(%
) 
Ta
rg
et
 v
es
se
l 
re
va
sc
ul
ar
iz
at
io
n 
 (
%
) 
An
y 
ev
en
t 
 (
%
) 
St
en
t 
th
ro
m
bo
si
s 
(%
) 
AS
PE
CT
 3
7  
* 
† 
 
 
6 
 
 
 
 
 
3.
1 
µg
/m
m
2  
pa
cl
ita
xe
l 
4‡
 
0.
29
±
0.
72
‡ 
 
0 
3.
4 
1.
7 
10
 
5.
1 
1.
3 
µg
/m
m
2  
pa
cl
ita
xe
l 
12
‡ 
0.
57
±
0.
71
‡ 
 
1.
7 
1.
7 
1.
7 
7 
1.
7 
Ba
re
 s
te
nt
 
27
 
1.
04
±
0.
83
 
 
0 
1.
7 
1.
7 
5 
0 
EL
U
TE
S 
36
 §
 
 
 
12
 
 
 
 
 
 
2.
7 
µg
/m
m
2  
pa
cl
ita
xe
l 
3.
1 
0.
10
±
0.
12
 ‡
 
 
2.
7 
2.
7 
5.
4 
14
 
2.
7 
1.
4 
µg
/m
m
2  
pa
cl
ita
xe
l 
13
.5
 
0.
47
±
0.
11
 
 
0 
0 
10
.3
 
10
 
0 
0.
7 
µg
/m
m
2  
pa
cl
ita
xe
l 
11
.8
 
0.
47
±
0.
12
 
 
0 
0 
7.
7 
10
 
0 
0.
2 
µg
/m
m
2  
pa
cl
ita
xe
l 
20
.0
 
0.
72
±
0.
12
 
 
0 
0 
5.
4 
5 
0 
Ba
re
 s
te
nt
 
20
.6
 
0.
73
±
0.
12
 
 
0 
0 
15
.8
 
18
 
2.
6 
D
EL
IV
ER
 I
 3
8  
* 
||
 
 
 
12
 
 
 
 
 
 
3.
0 
µg
/m
m
2 
pa
cl
ita
xe
l 
16
.7
 
0.
43
‡ 
 
0.
2 
1.
4 
6.
2 
7.
5 
0.
4 
Ba
re
 s
te
nt
 
22
.4
 
0.
56
 
 
0.
8 
1.
0 
6.
8 
9.
4 
0.
4 
D
EL
IV
ER
 I
I 
39
 
- 
- 
6 
2.
3 
4.
9 
9.
6 
15
.7
 
- 
* 
In
-s
eg
m
en
t 
qu
an
tit
at
iv
e 
co
ro
na
ry
 a
ng
io
gr
ap
hy
 (
in
cl
ud
es
 t
he
 5
-m
m
 p
ro
xi
m
al
 a
nd
 d
is
ta
l e
dg
es
) 
† 
al
l s
te
nt
 t
hr
om
bo
si
s 
ev
en
ts
 o
cc
ur
re
d 
in
 p
at
ie
nt
s 
on
 a
sp
iri
n 
an
d 
ci
lo
st
az
ol
 (
in
st
ea
d 
of
 a
sp
iri
n 
an
d 
tic
lo
pi
di
n/
cl
op
id
og
re
l)
 
‡ 
p<
0.
05
 v
s.
 c
on
tr
ol
 
§ 
In
-s
te
nt
 q
ua
nt
ita
tiv
e 
co
ro
na
ry
 a
ng
io
gr
ap
hy
 
||
 a
va
ila
bl
e 
fo
r 
22
8 
pt
s 
in
 t
he
 p
ac
lit
ax
el
 g
ro
up
 a
nd
 f
ro
 2
14
 c
on
tr
ol
s 
  Ta
bl
e 
11
. 
Cl
in
ic
al
 s
tu
di
es
 w
ith
 n
ew
 d
ru
g-
el
ut
in
g 
st
en
ts
 
 
de
si
gn
 
in
cl
us
io
n 
cr
ite
ria
 
St
ud
y 
gr
ou
ps
 
R
es
te
no
si
s 
(%
) 
La
te
 lo
ss
 
(m
m
) 
EV
EL
O
LI
M
U
S 
 
 
 
 
 
Bi
oa
bs
or
ba
bl
e 
po
ly
m
er
-c
oa
te
d 
ev
er
ol
im
us
-e
lu
tin
g 
st
en
t 
(n
=
27
 p
ts
) 
0 
0.
11
* 
FU
TU
R
E 
I 
tr
ia
l 5
7  
ra
nd
om
iz
ed
 (
2:
1)
 
si
ng
le
-b
lin
d 
Si
ng
le
 d
e 
no
vo
  
Le
ng
th
 <
18
 m
m
, 
di
am
et
er
 2
.7
5 
–4
.0
m
m
 
Ba
re
 s
te
nt
 c
on
tr
ol
 f
or
 M
R
-p
ac
lit
ax
el
 (
n=
15
 p
ts
) 
9.
1 
0.
85
 
Bi
oa
bs
or
ba
bl
e 
po
ly
m
er
-c
oa
te
d 
ev
er
ol
im
us
-e
lu
tin
g 
st
en
t 
(n
=
21
 p
ts
) 
0 
0.
12
* 
FU
TU
R
E 
II
 t
ria
l 5
7  
ra
nd
om
iz
ed
 (
1:
2)
 
si
ng
le
-b
lin
d 
Si
ng
le
 d
e 
no
vo
  
Le
ng
th
 <
18
 m
m
, 
di
am
et
er
 2
.7
5 
–4
.0
m
m
 
Ba
re
 s
te
nt
 c
on
tr
ol
 f
or
 M
R
-p
ac
lit
ax
el
 (
n=
43
 p
ts
) 
19
.4
 
0.
85
 
17
E -
ES
TR
AD
IO
L 
 
 
 
 
EA
ST
ER
 t
ria
l 
se
rie
s 
of
 c
as
es
 
Si
ng
le
 d
e 
no
vo
, 
di
am
et
er
 3
.0
 -
 4
.0
 m
m
 
Ph
os
ph
or
yl
ch
ol
in
e-
co
at
ed
 e
st
ro
ge
n-
el
ut
in
g 
st
en
t 
(2
.5
4 
µg
/ 
m
m
2)
 (
n=
30
 p
ts
) 
6.
6 
0.
31
 
D
EX
AM
ET
H
AS
O
N
E 
 
 
 
 
ST
R
ID
E 
tr
ia
l 
se
rie
s 
of
 c
as
es
 
Si
ng
le
 d
e 
no
vo
, d
ia
m
et
er
 2
.7
5 
- 
4.
0 
m
m
 
Bi
od
iv
Ys
io
M
at
rix
 L
O
 s
te
nt
 im
m
er
se
d 
in
 d
ex
am
et
ha
so
ne
 s
ol
ut
io
n 
(1
5m
g/
m
l)
 (
n=
71
 p
ts
) 
13
.3
 
0.
45
 
AB
T-
57
8 
 
 
 
 
 
EN
D
EA
VO
R
 t
ria
l 
se
rie
s 
of
 c
as
es
 
Si
ng
le
 d
e 
no
vo
, 
di
am
et
er
 3
.0
 -
 3
.5
 m
m
 
Ph
os
ph
or
yl
ch
ol
in
e-
co
at
ed
 D
riv
er
 c
ob
al
t 
al
lo
y 
st
en
t 
(n
=
10
0 
pt
s)
 
N
A 
0.
20
 
N
iti
c 
O
xi
de
 d
ru
g-
el
ut
io
n 
 
 
 
 
N
O
BL
ES
SE
 t
ria
l 
se
rie
s 
of
 c
as
es
 
Si
ng
le
 d
e 
no
vo
, 
di
am
et
er
 2
.7
5 
- 
3.
5 
m
m
 
Bi
oa
bs
or
ba
bl
e 
po
ly
es
te
ra
m
id
e-
co
at
ed
 G
en
ic
 s
te
nt
 w
ith
 o
xi
ge
n 
fr
ee
 s
ca
ve
ng
er
 
co
va
le
nt
ly
 b
ou
nd
ed
 (
n=
45
 p
ts
) 
9.
5 
0.
69
 
*p
<
0.
05
 c
om
pa
re
d 
to
 c
on
tr
ol
s 
 
 
 
  
Chapter 3 Unrestricted Utilization of Sirolimus-Eluting 
Stents Compared to Conventional Bare Stent 
Implantation in the “Real World”. The 
Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital (RESEARCH) registry 
 
Pedro A. Lemos, MD 
Patrick W. Serruys, MD, PhD 
Ron T. van Domburg, PhD 
Francesco Saia, MD 
Chourmouzios A. Arampatzis, MD 
Angela Hoye, MB ChB, MRCP 
Muzaffer Degertekin, MD 
Kengo Tanabe, MD 
Joost Daemen 
Tommy K.K. Liu 
Eugene McFadden, MB ChB, FRCPI 
Georgios Sianos, MD, PhD 
Sjoerd H. Hofma, MD 
Pieter C. Smits, MD, PhD 
Willem J. van der Giessen, MD, PhD 
Pim de Feyter, MD, PhD 
 
Circulation 2004 Jan 20;109(2):190-5. Epub 2003 Dec 22 
 
Chapter 3 _______________________________________________________________________________ 
 
 30 
Unrestricted Utilization of Sirolimus-Eluting Stents Compared 
to Conventional Bare Stent Implantation in the “Real World”. 
The Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital (RESEARCH) registry 
 
Pedro A. Lemos, MD; Patrick W. Serruys, MD, PhD; Ron T. van Domburg, PhD; Francesco Saia, MD; 
Chourmouzios A. Arampatzis, MD; Angela Hoye, MB ChB, MRCP; Muzaffer Degertekin, MD; 
Kengo Tanabe, MD; Joost Daemen; Tommy K.K. Liu; Eugene McFadden, MB ChB, FRCPI; 
Georgios Sianos, MD, PhD; Sjoerd H. Hofma, MD; Pieter C. Smits, MD, PhD; 
Willem J. van der Giessen, MD, PhD; Pim de Feyter, MD, PhD 
 
Background: The effectiveness of sirolimus-eluting stents in unselected patients treated in the daily practice is 
currently unknown. 
Methods and Results: Sirolimus-eluting stent implantation has been utilized as the default strategy for all 
percutaneous procedures in our hospital, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology 
Hospital (RESEARCH) registry. Consecutive patients with de novo lesions (n=508) treated exclusively with sirolimus-
eluting stents (SES group) were compared to 450 patients who received bare stents in the period just before (pre-SES 
group). Patients in the SES had more frequently multivessel disease, more type C lesions, received more stents, and had 
more bifurcation stenting. At 1 year, the cumulative rate of major adverse cardiac events (death, myocardial infarction, 
or target vessel revascularization) was 9.7% in the SES group and 14.8% in the pre-SES group (HR 0.62 [95% CI 0.44–
0.89]; p=0.008). The 1-year risk of clinically driven target vessel revascularization in the SES group and in the pre-SES 
group was 3.7% vs. 10.9% respectively (HR 0.35 [95% CI 0.21–0.57]; p<0.001). 
Conclusions: Unrestricted utilization of sirolimus-eluting stents in the “real world” is safe and effective in reducing both 
repeat revascularization and major adverse cardiac events at one year compared to bare stent implantation. 
 
Circulation. 2003 Dec 22 [Epub ahead of print] 
 
 
Introduction 
In-stent restenosis has long been recognized as the 
main limitation of coronary stenting, with rates of as high 
as 50% in more complex subsets. Recently, sirolimus-
eluting stent (SES) implantation has been proven to 
markedly reduce the incidence of angiographic restenosis 
and repeat revascularization in selected patients.1-3 In the 
First-In-Man study, no cases of restenosis were detected 
in a series of 45 patients, with persistent neointimal 
inhibition demonstrated up to two years.4 These findings 
have been further confirmed in randomized trials 
comparing SES with conventional bare stents.2,3 In the 
RAndomized study with the sirolimus-eluting Bx VElocity 
balloon-expandable stent in the treatment of patients with 
de novo native coronary artery Lesions (RAVEL),2 there 
were no cases of binary angiographic restenosis in 
patients treated with SES implantation. Similarly, in the 
SIRolImUS-eluting Bx velocity balloon expandable stent 
trial (SIRIUS),3 restenosis occurred in 9% of cases in the 
SES group compared to 36% of patients treated with 
conventional stents (p<0.001).  
Based on these findings, since the first half of 2002, 
SES have progressively received clinical approval by 
official regulatory agencies and are currently available for 
routine use in Europe, Asia, South America, and more 
recently the U.S. However, all clinical trials completed so 
far have included elective patients with relatively non-
complex lesions. The effects of SES implantation in 
complex, unselected patients, such as those treated in 
daily practice, remains largely unknown. Notably, the 
occurrence of restenosis in a small, but relevant 
proportion of patients in the SIRIUS trial occurred mainly 
in patients with diabetes, small vessels, and long lesions,3 
characteristics frequently found in most series. Moreover, 
restenosis after SES implantation has been recently shown 
to occur in association with procedures with increased 
complexity.5 The present study was therefore conducted 
to investigate the impact of sirolimus-eluting stents on the 
outcomes of patients treated in the “real world” of 
interventional cardiology, as compared to a strategy 
utilizing conventional bare stent implantation.  
Methods 
Study Design and Patient Population 
The study protocol of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) 
has been described elsewhere.6 Briefly, the RESEARCH is 
a single-center registry conducted with the main purpose 
of evaluating the safety and efficacy of sirolimus-eluting 
stent implantation for patients treated in daily practice. To 
include a patient population representative of the “real 
world”, we have adopted since 16th April 2002 a policy of 
utilizing sirolimus-eluting stents (Cypher; Johnson & 
Johnson-Cordis unit, Cordis Europa NV, Roden, the 
Netherlands) as the default strategy for every 
percutaneous coronary intervention.  
In the first 6 months enrollment, a total of 508 
patients with de novo lesions were treated exclusively 
with SES and were included in the present report (SES 
_____________________________________________________________________ SES in the “real world” 
 31 
group) (72% of the 710 patients treated with stents in 
during the period). Patients treated with bare stents and 
SES in the same procedure (66 patients) and those 
treated only with bare stents (136 patients) were not 
included in the present report. At the initiation of the 
RESEARCH registry, SES were available in lengths of 8, 
18, and 33 mm and diameters from 2.25 to 3.00 mm, but 
post-dilatation with larger balloons was allowed (0.5-mm 
larger balloons were utilized in 55% of cases where a 3.0-
mm SES was used). However, unavailability of an 
appropriate SES size was still the reason for non-
utilization of SES in 77% of cases. Moreover, 5% of cases 
were included in other study and were not enrolled in the 
RESEARCH. In the remaining patients not included, SES 
were not utilized because of for a variety of reasons, 
predominantly operator’s personal choice.  
Patients treated solely with SES were compared to a 
group of consecutive patients treated with bare stents for 
de novo lesions in the preceding 6 months (pre-SES 
group). In order to better match the vessel sizes treated 
in the 2 study groups, patients receiving bare metal stents 
larger than 3.5-mm were excluded from this analysis 
(n=176). This cutoff value (instead of 3.0-mm diameter 
stents) was chosen due to the post-dilatation policy 
applied in the SES group, which extended the utilization of 
SES to patients with 3.5-mm vessels by visual estimation. 
In addition, patients treated with bare stents smaller than 
2.25 mm were not included (n=30). In total, 450 
consecutive patients thereby comprise the pre-SES group 
(69% of all patients with de novo lesions treated with 
stents during the period). The present study population 
was consequently composed of a total of 958 patients 
divided into two sequential cohorts, primarily 
distinguished by the interventional strategy applied (bare 
stent or SES implantation respectively). This protocol was 
approved by the hospital ethics committee and is in 
accordance with the Declaration of Helsinki. Written, 
informed consent was obtained from every patient. 
Procedures and Post-Intervention 
Medications 
All interventions were performed according to current 
standard guidelines7 and the final interventional strategy 
was entirely left to the discretion of the operator. 
Angiographic success was defined as residual stenosis < 
30% by visual analysis in the presence of TIMI 3 grade 
flow. Periprocedural glycoprotein IIbIIIa inhibitors and 
antithrombotic medications were used according to the 
operator’s decision. All patients were advised to maintain 
lifelong aspirin. One-month clopidogrel treatment 
(75mg/d) was recommended for patients treated in the 
pre-SES phase. For patients treated with SES, clopidogrel 
was prescribed for 3 months, unless one of the following 
was present (in which case clopidogrel was maintained for 
at least 6 months): multiple SES implantation (>3 stents), 
total stented length >36 mm, chronic total occlusion, and 
bifurcations. 
Endpoint Definitions and Clinical Follow-up 
The primary outcome was the occurrence of major 
adverse cardiac events, defined as 1) death, 2) non-fatal 
myocardial infarction, or 3) target vessel revascularization. 
Myocardial infarction was diagnosed by a rise in the 
creatine kinase level to more than twice the upper normal 
limit with an increased creatine kinase-MB. Target lesion 
revascularization was defined as a repeat intervention 
(surgical or percutaneous) to treat a luminal stenosis 
within the stent or in the 5-mm distal or proximal 
segments adjacent to the stent. Target vessel 
revascularization was defined as a re-intervention driven 
by any lesion located in the same epicardial vessel. 
Thrombotic stent occlusion was angiographically 
documented as a complete occlusion (TIMI flow 0 or 1) or 
a flow limiting thrombus (TIMI flow 1 or 2) of a previously 
successfully treated artery. 
Information about the in-hospital outcomes was 
obtained from an electronic clinical database for patients 
maintained in our institution and by review of the hospital 
records for those discharged to referring hospitals 
(patients were referred from a total of 14 local hospitals). 
Post-discharge survival status was obtained from the 
Municipal Civil Registries. All repeat interventions (surgical 
and percutaneous) and re-hospitalizations were 
prospectively collected during the follow-up. 
Questionnaires with information about anginal status and 
medication usage were sent to all living patients. The 
referring physicians and institutions were contacted 
whenever necessary for additional information. 
During follow-up, coronary angiography was obtained 
as clinically indicated by symptoms or documentation of 
myocardial ischemia. Additionally, late angiographic 
evaluation was eventually obtained from “complex” 
patients in the SES group, typically with SES implanted in 
bifurcations, left main coronary, chronic total occlusions, 
very small vessels, long stented length (>36mm), and 
acute myocardial infarction (in total, 38% patients in the 
SES group had angiographic follow-up between 6 and 9 
months). No angiographic re-study was performed in the 
pre-SES group. Due to the well-known effect of 
angiographic re-evaluation in increasing the incidence of 
repeat revascularization,8 all re-interventions were 
retrospectively adjudicated and classified as clinically 
driven or non-clinically driven by a group of clinicians not 
involved in the treatment of the particular patient 
analyzed. Clinically driven repeat revascularization was 
defined as any intervention motivated by a significant 
luminal stenosis (>50% diameter stenosis) in the 
presence of anginal symptoms and/or proven myocardial 
ischemia in the target vessel territory by non-invasive 
testing. 
Statistical Analysis 
Continuous variables were presented as mean ± 
standard deviation (SD) and were compared using 
Student’s unpaired t-test. Categorical variables were 
presented as counts and percentages and compared with 
the Fisher’s exact test. All statistical tests were 2-tailed. 
The cumulative incidence of adverse events was 
estimated according to the Kaplan-Meier method and Cox 
proportional hazards models were used to assess risk 
reduction of adverse events. Patients lost to follow-up 
were considered at risk until the date of last contact, at 
which point they were censored. Multivariate analyses 
were performed to identify independent predictors of 
adverse events using all clinical, angiographic and 
procedural variables included in Tables 1 and 2. 
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Table 1. Baseline characteristics of patients treated with 
conventional bare stents before the introduction of SES (Pre-SES 
group) and patients treated exclusively with SES implantation 
(SES Group). 
 Pre-SES 
Group 
(n=450) 
SES 
Group 
(n=508) 
P- value 
Male, % 72 68 0.4 
Age, years±SD 61±11 61±11 0.7 
Diabetes, % 15 18 0.3 
Non-insulin dependent 11 12 0.7 
Insulin-dependent 4 6 0.2 
Hypertension, % 48 41 0.2 
Hypercholesterolemia, % 55 56 1.0 
Current smoking, % 34 31 0.3 
Previous MI, % 40 30 <0.01 
Previous angioplaty, % 18 19 0.8 
Previous bypass surgery, % 8 9 0.5 
Single-vessel disease, % 52 46 0.05 
Multivessel disease, % 48 54 0.05 
Clinical presentation   0.7 
Stable angina, % 48 45  
Unstable angina, % 35 37  
Acute myocardial infarction, % 18 18  
Cardiogenic shock, %* 12 10 0.7 
*relative to patients with acute MI 
Results 
Baseline and Procedural Characteristics 
Baseline and procedural characteristics are shown in 
Table 1 and Table 2. Overall, approximately half of the 
patients in both groups were admitted with acute 
coronary syndromes and diabetes was present in 16% of 
cases. Patients treated with SES had significantly more 
multivessel disease, more type C lesions, more bifurcation 
stenting, more segments stented, and more stents used. 
Also, in the SES group, long stents and stents with smaller 
diameters were more frequenly used. Periprocedural 
administration of glycoprotein IIbIIIa inhibitors was more 
frequent in the pre-SES phase (33% vs. 19%; p<0.01). 
The angiographic success rate was similar in both groups. 
Clinical Outcomes 
Complete follow-up information was available for 
99.1% of patients (mean follow-up period 405 days). 
There were no significant differences between the SES 
group and the pre-SES group in the incidence of major 
adverse cardiac events during the first month (3.0% vs. 
4.2% respectively; p=0.3) (Table 3). Target vessel 
revascularization at 30 days was 1.0% (n=5) in the SES 
group and 2.2% (n=10) in the pre-SES group (p=0.2), 
which included emergency bypass surgery in 2 patients 
(0.4%) in the SES group and in 2 cases (0.4%) in the pre-
SES group (p=1.0) and early “redo” target vessel 
revascularization (e.g. residual dissection or compromised 
side branch in patients with continuing symptoms) in 1 
patient (0.2%) in the SES group and in 1 patient (0.2%) 
in the pre-SES group (p=1.0). In the remaining cases, 30-
day repeat intervention was due to angiographically 
documented stent thrombosis in 2 patients (0.4%) in the 
SES group and in 7 patients (1.6%) in the pre-SES group 
(p=0.1). No further thrombotic stent occlusion was 
observed in the late follow-up. 
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Figure 1 – One-year adverse events in patients treated with
bare stents before the introduction of SES (Pre-SES group)
and in patients treated exclusively with SES implantation
(SES Group). Cumulative risk of death (A); death or
myocardial infarction (B); death, myocardial infarction or
target lesion revascularization (C); and death, myocardial
infarction or target vessel revascularization (D). 
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Table 2. Angiographic and procedural characteristics of patients 
treated with conventional bare stents before the introduction of 
SES (Pre-SES group) and patients treated with SES implantation 
(SES Group). 
 Pre-SES 
Group 
(n=450) 
SES 
Group 
(n=508) 
P-value 
Treated Vessel    
Left anterior descending, % 59 59 0.8 
Left circumflex, % 33 32 0.7 
Right coronary artery, % 34 39 0.2 
Left main coronary, % 2 3 0.6 
Bypass graft, % 2 3 0.2 
Lesion type    
Type A, % 20 22 0.4 
Type B1, % 32 31 0.7 
Type B2, % 50 49 0.8 
Type C, % 30 43 <0.01 
Glycoprotein IIbIIIa inhibitor, % 33 19 <0.01 
Clopidogrel prescription, months±SD  2.9±2.0 4.0±2.0 <0.01 
Bifurcation stenting, % 8 16 <0.01 
Number of stented segments ±SD 1.8±0.9 2.0±1.0 <0.01 
Number of implanted stents ±SD 1.9±1.2 2.1±1.4 <0.01 
Individual stent length t33 mm, % 10 35 <0.01 
Total stented length per patient, 
mm±SD 
30±20 39±28.7 <0.01 
Nominal stent diameter d2.5 mm, % 23 36 <0.01 
Post-dilatation with a balloon t0.5 
mm larger, % 
19 55 <0.01 
Angiographic success of all lesions,% 97 97 1.0 
 
 
Table 3. 30-day outcomes of patients treated with conventional 
bare stents before the introduction of SES (Pre-SES group) and 
patients treated exclusively with SES implantation (SES Group). 
 Pre-SES 
Group 
(n=450) 
SES 
Group 
(n=508) 
P-
value* 
Death, % 2.0 1.6 0.6 
Non-fatal myocardial infarction, % 1.6 0.8 0.4 
Target lesion revascularization, % 1.8 1.0 0.4 
Target vessel revascularization, %† 2.2 1.0 0.2 
Any event, % 4.2 3.0 0.3 
Stent thrombosis, %‡ 1.6 0.4 0.1 
*by Fisher’s exact test 
†Includes target lesion revascularization 
‡Angiographically documented stent thrombosis requiring repeat 
intervention 
 
At 1 year, the cumulative incidence of death and death 
or myocardial infarction was similar between both groups 
(Figure 1A and B). Patients treated with SES had 
significantly less death, myocardial infarction or target 
lesion revasculari-zation at 1 year than patients treated in 
the pre-SES phase (8.8% vs. 12.6% respectively; HR 0.66 
[95% CI: 0.45–0.97]; p=0.03) (Figure 1C). Similarly, the 
1-year cumulative risk of major adverse cardiac events 
(death, myocardial infarction or target vessel 
revascularization) was significantly reduced in the SES 
group (9.7% vs. 14.8% in the pre-SES group; HR 0.62 
[95% CI 0.44–0.89]; p=0.008). The difference in out-
comes between both groups was mainly due to a 
decrease in the need for target vessel revascularization in 
the SES group (5.1% vs. 10.9% in the pre-SES group; HR 
0.49 (95% CI 0.29–0.82); p=0.007). Specifically, 
treatment with SES was associated with a marked 
reduction in clinically driven repeat interventions at 1 year 
(3.7% vs. 10.9% in the pre-SES group; HR 0.35 (95% CI 
0.21–0.57); p<0.001) (Figure 2). 
Figure 2 – One-year cumulative risk of clinically driven target 
vessel revascularization in patients treated with bare stents 
before the introduction of SES (Pre-SES group) and in patients 
treated exclusively with SES implantation (SES Group). 
Predictors of Adverse Events 
The impact of SES implantation on the risk of 
subsequent clinically driven target vessel revascularization 
in specific subsets is shown in Figure 3. Sirolimus-eluting 
stent implantation was associated with a risk reduction 
that ranged from 28% to 79% across the subgroups 
evaluated. However, the benefit of SES did not reach 
statistical significance in women (HR 0.59 [95% CI: 0.24–
1.45]; p=0.25) and diabetics (HR 0.72 [95% CI: 0.30–
1.77]; p=0.50). Patients treated with bifurcation stenting 
(HR 0.38 [95% CI: 0.13–1.13]; p=0.08) and patients 
receiving 33-mm or longer stents (HR 0.41 [95% CI: 
0.16–1.03]; p=0.06) presented a strong trend to have 
better outcomes with SES implantation. In the other 
subgroups, SES utilization significantly decreased the need 
of repeat intervention (Figure 3). Importantly, the post-
dilatation strategy applied in the present study did not 
influence the clinical benefit of SES implantation. The 
magnitude of the risk reduction was similar between 
patients treated with post-dilatation (HR 0.28 [95% CI: 
0.13–0.62]; p=0.002) or without post-dilatation (HR 0.35 
[95% CI: 0.18–0.70]; p=0.003). 
Multivariate Cox proportional hazards analysis 
identified sirolimus-eluting stent utilization to be 
independently associated with a reduced risk of adverse 
clinical events (Table 4). After adjustment for other 
independent variables, SES significantly decreased the risk 
of clinically driven target vessel revascularization 
(adjusted HR 0.33 [95% CI 0.20–0.56]; p<0.01) and the 
risk of major adverse cardiac events (adjusted HR 0.55 
[95% CI 0.38–0.80]; p<0.01). 
Discussion 
Sirolimus-eluting stent implantation has been shown to 
markedly decrease the incidence of in-stent restenosis in 
the context of randomized trials.2,3 However, these studies 
have enrolled relatively non-complex patient populations 
referred for elective intervention. As a consequence, the 
findings from these studies cannot be directly 
extrapolated to many patients treated in the everyday 
practice, where complex, non-elective cases are the rule, 
rather than the exception. In the present study, sirolimus-
eluting stents implantation was associated with a 
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reduction in the rates of repeat revascularization and 
major adverse cardiac events at one-year in a 
consecutive, unselected cohort of patients. Sirolimus-
eluting stent implantation resulted in a relative reduction 
of 51% in the overall rate of target vessel 
revascularization and of 65% in the rate of clinically 
driven target vessel revascularization. 
Our series compared a strategy of unrestricted usage 
of sirolimus-eluting stents with conventional approaches 
utilizing bare stents in the pre-sirolimus-eluting stent 
“era”. Although the two study groups were consecutively 
included over a total period of only one year, some 
important differences were noted in the interventional 
strategy applied. Patients in the sirolimus-eluting stent 
phase were treated with a less restrictive interventional 
approach, with a significant increase in the number and 
length of stents implanted, number of coronary segments 
dilated, bifurcation stenting, and decrease in the diameter 
of the stents. Possibly, this change in practice may reflect 
the early recognition by the operators that the acute 
results, even in this complex population, were maintained 
in medium-term. Also, it may reflect an attempt to 
accomplish more complete lesion coverage and ensure 
uniform drug-delivery over the entire diseased segment, 
since stent discontinuity and edge injury have been 
recently shown by our group to be associated with post-
SES restenosis.5 Moreover, the higher complex profile of 
patients treated with SES (e.g. high rates of multivessel 
disease, type C lesions, bifurcations) may translate a 
change in the decision-making process promoted by the 
availability of sirolimus-eluting stents in our institution. 
Although both study groups differed in some baseline and 
procedural characteristics, which may somewhat limit an 
unbiased comparison between them, it is worth noting 
that most, if not all, differences would be tradionally 
expected to increase the incidence of late complications in 
the SES-treated patients. Nevertheless, the treatment 
effect of sirolimus-eluting stents was significantly higher 
than bare stents, remaining virtually unaffected after 
adjustment for procedural characteristics. 
The reduction of adverse events after sirolimus-eluting 
stent implantation in our series is lower than that 
observed in the RAVEL trial, where no binary angiographic 
restenosis was diagnosed.2 The present findings more 
closely resembles those seen in the SIRIUS trial (75% 
reduction in clinically driven target lesion 
revascularization), in which patients with higher risk 
profiles were included.3 Compared to the RAVEL study, 
the relative decline in effectiveness in the SIRIUS trial and 
in the RESEARCH study may have been related to the 
complexity of the procedures included. Although SES 
implantation markedly reduced the risk of subsequent 
revascularization in most subsets, the benefit of the new 
treatment did not reach statistical significance in some 
subgroups in our series. Indeed, the presence of diabetes 
and treatment of long lesions were shown to 
independently increase the incidence of complications. 
These findings highlight the need of further analyses with 
enlarged number of patients in order to fully estimate the 
clinical impact of SES in these patients. Also, whether the 
outcomes of higher risk subgroups can be improved with 
refinements in the procedural techniques remain to be 
established. 
Importantly, the reduction of late complications was 
accomplished without any increase in unexpected sudden 
events. Our results extend the findings observed in an 
early report,6 and show that sirolimus-eluting stent 
implantation in complex patients is safe, with no increase 
in acute device-related adverse events. The incidence 
(0.4%) and timing (within the first month) of documented 
thrombotic stent occlusion in the SES group was 
compatible with the current results with conventional bare 
metal stents. The utilization of IIbIIIa inhibitors and 
clopidogrel differed between both study groups. However, 
these differences did not significantly influence the clinical 
outcome in our study. Nevertheless, it should be noted 
that these agents were not uniformly used across the 
various patient subsets, being mainly used in cases at a 
higher risk of complications, which may have blunted the 
overall positive effect of these drugs. 
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Although restenotic lesions have been shown to be 
amenable to treatment by sirolimus-eluting stents,9,10 the 
treatment of de novo lesions may be considered as the 
main field of application of the new device. In this regard, 
this study was conducted to evaluate the use of sirolimus-
eluting stent as a prophylactic strategy in preventing, 
rather than treating, in-stent restenosis in the “real 
world”.  
Some patients have not been treated with the 
sirolimus-eluting stents during the time period of the 
study. However, in most instances, this was due to 
unavailability of large-diameter sirolimus-eluting stents. As 
large vessels have been shown to present a lower risk of 
restenosis,3 it is quite possible that the non-inclusion of 
patients with larger vessels may have resulted in an 
underestimation of the overall treatment effect in the 
present report. The present study is a single-center 
experience from a tertiary referral center and lacks the 
obvious advantages of a multi-center, multi-national 
randomized study. Furthermore, it is unlikely that a 
randomized study will be conducted in the context in 
which this study was performed, with virtually no 
exclusion criteria. 
Conclusions 
This study demonstrates that unrestricted utilization of 
sirolimus-eluting stents in the “real world” is safe and 
effective in reducing the need of further revascularization 
and the incidence of major adverse cardiac events after 
one year, as compared to patients treated with bare stent 
implantation in the period immediately before. 
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Objectives: This study evaluated the early outcomes of patients with acute coronary syndromes (ACS) treated with 
sirolimus-eluting stents (SES). 
Background: The safety of SES for patients at high risk for early thrombotic complications is currently unknown.  
Methods: SES have been utilized as the device of choice for all percutaneous procedures in our institution, as part of 
the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. After 4 months of 
enrollment, 198 patients with ACS had been treated exclusively with SES (64% of those treated in the period) and were 
compared to a control group composed by 301 consecutive patients treated with bare stents in the same time period 
immediately prior. The incidence of major adverse cardiac events (MACE) during the first month was evaluated (death, 
non-fatal MI, or re-intervention). 
Results: As compared to controls, patients treated with SES had more primary angioplasty (95% vs. 77%; p<0.01), 
more bifurcation stenting (13% vs. 5%, p<0.01), less previous MI (28% vs. 45%; p<0.01), and less IIb/IIIa inhibitor 
utilization (27% vs. 42%; p<0.01). The 30-day MACE rate was similar between both groups (SES: 6.1% vs. controls: 
6.6%; p=0.8), with most complications occurring during the first week. Stent thrombosis occurred in 0.5% of SES 
patients and in 1.7% of controls (p=0.4). At multivariate analysis, SES utilization did not influence the incidence of 
MACE (OR 1.0 [95% CI: 0.4 –2.2]; p=0.97). 
Conclusions: Sirolimus-eluting stent implantation for patients with acute coronary syndromes is safe, with early 
outcomes comparable to bare metal stents.  
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INTRODUCTION 
Percutaneous intervention has been increasingly 
demonstrated to reduce the risk of adverse events in 
patients with acute coronary syndromes (ACS) (1,2). 
Several technical and medical advancements have all 
contributed to improve the results of angioplasty in this 
population. However, patients with acute coronary disease 
still present a higher risk for early events than chronic 
stable patients, possibly due to an increased propensity 
for thrombotic complications in the first days after the 
intervention (3-5). 
Sirolimus-eluting stent (SES) implantation has been 
demonstrated to virtually abolish in-stent restenosis in 
elective patients with relatively simple lesions (6,7). 
Notably, the reduction of in-stent restenosis with SES was 
achieved without compromising the high acute success 
rates currently accomplished with bare stents. However, 
the impact of SES for unselected complex cases is 
presently not known. Sirolimus has been described to 
decrease endothelial function in vitro (8) and to affect 
platelet physiology (9-11). Moreover, impaired local 
vascular healing with delayed endothelization and late 
fibrin persistence has not been ruled out after SES 
implantation (12,13). Therefore, evaluation of the safety 
of SES in patients with increased risk for early thrombotic 
events is warranted. 
The aims of this study were to investigate the impact 
of SES implantation on the occurrence of early adverse 
events (30 days) in a consecutive series of unselected 
patients with acute coronary syndromes enrolled in the 
RESEARCH (Rapamycin-Eluting Stent Evaluation At 
Rotterdam Cardiology Hospital) registry. 
METHODS 
The RESEARCH registry 
The sirolimus-eluting stent (Cypher™; Johnson & 
Johnson - Cordis unit) received Conformité Européenne 
(CE) mark approval in April 2002, since then being 
commercially available for routine use in Europe. From 
16th April 2002, it has been our policy to utilize the SES as 
the device of choice for every percutaneous coronary 
intervention performed in our institution, as part of the 
RESEARCH registry. The RESEARCH is a single-center 
registry conducted with the aims of evaluating the impact 
of SES implantation in the “real world” of interventional 
cardiology. All consecutive procedures were included, 
without any specific anatomical or clinical restriction. 
Additionally, a control group was formed by all patients 
treated with percutaneous interventions in the period 
immediately prior. Therefore, the control and the 
RESEARCH groups are constituted by 2 sequential 
cohorts, primarily defined by the interventional strategy 
applied (conventional bare stent or SES implantation 
respectively). 
All procedures were performed according to standard 
interventional techniques except by the utilization of SES 
as the device of choice during the RESEARCH period (at 
the initiation of the RESEARCH registry, SES were 
available in diameters from 2.25 to 3.00 mm and lengths 
of 8, 18, and 33 mm). Glycoprotein IIb/IIIa inhibitors 
were given at the discretion of the operator. 
Postprocedural antiplatelet regimen consisted in of aspirin 
lifelong and clopidogrel 75mg/d for 1 month (control 
group and patients treated with bare stent only) or 3 
months (patients treated with SES). Prolonged clopidogrel 
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prescription (6 months) was recommended for patients 
treated with SES and least one of the following 
characteristics: multiple SES (>3 stents), total stented 
length >36mm, chronic total occlusion, bifurcations, and 
in-stent restenosis. 
During the RESEARCH period, according to the actual 
SES utilization, 3 subgroups were a priori expected: 1) 
patients treated only with SES, 2) patients in whom both a 
SES and a non-SES device were utilized at the index 
procedure, and 3) patients treated without implantation of 
any SES. The specific reasons for non-utilization of SES 
were registered on a lesion-per-lesion basis. 
The RESEARCH registry was designed with the primary 
objective of evaluating the effectiveness of SES 
implantation, as compared to the control population. 
Effectiveness in both groups was measured by the 
survival time during which patients remain free of major 
adverse cardiac events (MACE) after 1 year of follow-up. 
Additionally, the following secondary objectives have also 
been predefined: 1) short-term (30-day) safety in patients 
with acute coronary syndromes, 2) survival free of MACE 
at 6-month follow-up, 3) cost-effectiveness analysis at 6 
months and 1 year, 4) anginal status and medication 
usage at 6 months and 1 year, and 5) quality of life and 
work status at 6 months and 1 year. 
In the present study we report on the 30-day 
outcomes patients with ACS treated with SES 
implantation, as compared to the control population. This 
study protocol was approved by the local ethics 
committee and is in accordance with the principles of 
Good Clinical Practice for Trials of Medicinal Products in 
the European Community and the Declaration of Helsinki. 
Written informed consent was given by every patient. 
Acute Coronary Syndrome Substudy  
In the present report, we evaluated the 30-day 
outcomes of all 198 consecutive patients with unstable 
angina or acute myocardial infarction (MI) treated 
exclusively with SES during the first 4 months of the 
RESEARCH registry (from 16th April 2002 to 15th August 
2002). This group represents 64% of all procedures 
performed in patients with ACS in the period (n=311 
patients). Patients receiving both bare stents and SES in 
the same procedure (32 patients; 10%) and those treated 
without SES implantation (81 patients; 26.0%) were not 
included in the present analysis. Among patients not 
included, non-utilization of SES was due to unavailability 
of an appropriate SES size (diameter or length) in 73% of 
cases, inclusion in other study in 5%, and impossibility to 
cross the lesion with the SES in 1%. In the remaining 
21%, SES were not utilized due to a variety conditions 
related to operator’s personal choice or other 
“medical/technical issues” (for instance, balloon dilatation 
instead of stent implantation in small coronary branch, 
mechanical thrombectomy without stent implantation for 
vessels with a high thrombotic burden, or heparin-coated 
stents due to contraindication for antiplatelet therapy). A 
Control Group for comparison was constituted by 301 
consecutive patients with ACS treated with bare stent 
implantation during the last 4 months (from 16th 
December 2001 to 15th April 2002) prior the initiation of 
the RESEARCH registry (94% of all patients treated in the 
period). Patients with unstable angina were categorized 
according to the Braunwald classification (14). Procedures 
performed in the first 24 hours of an acute MI were 
classified as rescue or primary angioplasty, if preceded or 
not by (failed) intravenous thrombolysis respectively. 
Patients treated after 24 hours but before discharge of an 
episode of myocardial infarction were classified as post-MI 
unstable angina (Braunwald Class C). 
Endpoint Definitions and Follow-up 
Major adverse cardiac events were defined as: 1) 
death, 2) non-fatal myocardial infarction, or 3) repeat 
target lesion or vessel revascularization. A definite 
diagnosis of myocardial infarction required an increase in 
the creatine kinase level to more than twice the upper 
normal limit with an increased level of creatine kinase MB 
(7). Target lesion revascularization (TLR) was defined as 
any surgical or percutaneous re-intervention motivated by 
a significant luminal narrowing within the stent or in the 
5-mm distal or proximal peristent segments. Target vessel 
revascularization (TVR) was defined as any re-intervention 
driven by lesions located in the treated vessel even 
beyond the target lesion limits. Additionally, we analyzed 
the incidence of stent thrombosis, defined as any 
angiographically documented thrombotic occlusion (TIMI 
flow 0 or 1) or flow limiting thrombus (TIMI flow 1 or 2) 
occurring after the procedure (after removal of the 
guiding catheter) in an artery previously treated with 
angiographic success (TIMI flow 3 immediately after stent 
placement and percent in-lesion diameter stenosisd30%). 
All procedures were performed in a tertiary cardiology 
center. As ruled by the local medical system organization, 
the majority of hospitalized patients treated in this tertiary 
facility were referred from other peripheral hospitals, to 
where they were discharged shortly after the procedure, 
unless a periprocedural complication occurs and/or 
specialized surveillance was required. In total, patients 
have been referred from a group of 14 local hospitals. 
Post-procedure medical care was performed at the 
discretion of the site of origin. Cardiac enzymes were 
measured serially after the procedure for all in-hospital 
patients maintained in our hospital. In most of the 
peripheral hospitals, cardiac markers were not collected 
routinely, unless a post-procedure myocardial infarction 
was suspected. For elective outpatient cases, it has been 
our practice to discharge the patients after a mean period 
of observation of 3 ± 1 hours (unpublished data), 
provided no post-procedural complications had occurred 
(access site hemostasis was routinely performed with a 
femoral closure device whenever possible). As a result of 
these policies for in- and outpatient cases, serial cardiac 
markers were only not available for patients in whom the 
likelihood of post-procedure myocardial infarction was 
judged to be low. Such policy has been supported by 
evidence from studies with large population cohorts 
showing that minor asymptomatic enzymatic elevation has 
no impact on either short- or long-term prognosis (15,16) 
and therefore is highly unlikely to influence the post-
procedural medical conduct. 
In-hospital outcome information was obtained by 
means of an electronic clinical database for patients 
maintained in our hospital after the procedure and by 
review of the hospital records for those discharged to 
secondary hospitals. During the follow-up, recordings of 
all repeat interventions (surgical and percutaneous) and 
re-hospitalizations were prospectively collected in a 
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dedicated database. Long-term survival status was 
assessed by written inquiries to the Municipal Civil 
Registries at 30 days, 6 months and 1-year after the 
procedures. Questionnaires were sent at 6 months and 1 
year to all living patients with information regarding post-
discharge anginal status, medication usage, and the 
occurrence of clinical events. Furthermore, a psychological 
questionnaire was sent and included forms with the SF-36 
quality of life (17), the HADS anxiety  and depression 
score (18) and the Type D personality score (19). The 
referring physician and institutions as well as the general 
practitioners were directly approached whenever 
necessary for additional information. For patients who 
went abroad, an effort was made to contact the local civil 
registries of their new residencies. Patients lost to follow-
up were considered at risk until the date of last contact, 
at which point they were censored. 
 
Table 1 – Baseline and procedural characteristics of patients 
treated with bare stents versus patients treated with SES. 
 Bare 
Stent 
(n=301) 
SES 
(n=198) 
p-
value 
Age, years ± SD 60±12 62±11 0.21 
Male sex, % 75 68 0.10 
Diabetes, % 12 18 0.07 
Hypercholesterolemia 48 49 0.93 
Current smoking, % 38 38 0.85 
Hypertension, % 63 63 0.93 
Previous MI, % 45 28 <0.01 
Previous angioplasty, % 18 21 0.56 
Previous coronary surgery, % 10 9 0.64 
Coronary artery disease, %   0.12 
Single-vessel disease 44 51  
Multivessel disease 56 49  
Unstable angina, % 68 68 1.0 
Braunwald classification, %*    
Class I to III-A 5 4 0.61 
Class I and II-B 45 42 0.65 
Class III-B 21 22 0.78 
Class I and II-C 14 9 0.23 
Class III-C 15 22 0.12 
Acute MI, % 32 32 1.0 
Cardiogenic shock † 13 13 1.0 
Rescue angioplasty † 23 5 <0.01 
Primary angioplasty † 77 95 <0.01 
Peak CKMB, UI/L±SD ‡ 317±256 217±236 0.04 
IIBIIIA inhibitor, % 42 27 <0.01 
Vessel treated, %    
LMC 3 4 0.60 
LAD 58 59 0.85 
LCx 31 29 0.69 
RCA 39 36 0.64 
Bypass 6 5 0.84 
Lesion type A/B1, % 42 44 0.71 
Lesion type B2/C, % 78 78 1.0 
Number of treated segments (±SD) 1.8±0.9 1.8±0.9 1.00 
Total stented length, mm±SD 28±13 29±15 0.30 
Bifurcation stenting 5 13 <0.01 
Angiographic success all lesions, % 97 96 0.48 
*relative to the number of patients with unstable angina; total 
sum may not result 100% due to rounding 
†relative to the number of patients with acute MI 
‡Upper limit of normal = 24 UI/L 
SES=sirolimus-eluting stent; MI=myocardial infarction; LMC=left 
main coronary; LAD=left anterior descending artery; LCx=left 
circumflex artery; RCA=right coronary  
 
Data Management and Statistical Analysis 
All consecutive procedures were included in the 
control group and in the RESEARCH, utilizing a dynamic 
registry design as previously described by Rothman and 
Greenland (20). For each patient, the time until the first 
MACE was computed (person-time). Any eventual repeat 
percutaneous intervention acts then as a new index 
procedure and the person-time contributes again to the 
cohort. A patient can therefore contribute to one, two, or 
more person-time. This design is of particular interest in a 
study like the RESEARCH, which intends to evaluate 2 
consecutive cohorts treated with coronary angioplasty. If 
re-entry is not allowed, the second group (in the present 
case, treatment with SES) is consequently emptied from 
cases with treatment for restenotic lesions. This design 
therefore permits the inclusion of patients with in-stent 
restenosis in both study periods, allowing the evaluation 
of the impact of each particular re-intervention on the 
subsequent outcomes. In view of the small applicability of 
this concept (person-time analysis) for short-term 
evaluations, no calculations with person-time units were 
performed in the current Acute Coronary Syndrome 
Substudy. 
Discrete variables were presented as percentages and 
compared by Fisher’s exact tests. Continuous variables 
were presented by their means and standard deviations 
and compared by Student’s T test or one-way ANOVA. 
Cumulative survival and MACE-free survival were 
calculated according to the Kaplan-Meier method. The 
log-rank test was used to compare survival and MACE-free 
survival among the different groups. Multivariate 
independent predictors of 30-day outcomes were 
evaluated by logistic regression. All baseline and 
procedural characteristics presented in Table 1 were 
tested, and a final multivariate model was constructed by 
backward deletion of the least significant variables. All 
tests were two-tailed and a p value < 0.05 was 
considered as significant. 
RESULTS 
Baseline and Procedural Characteristics 
Clinical and procedural characteristics of the 499 
patients included in the present report are depicted in 
Table 1. As compared to the controls, patients treated 
with SES had more frequently primary angioplasty (95% 
vs. 77%; p<0.01), more bifurcation stenting (13% vs. 
5%; p<0.01), less previous MI (28% vs. 45%; p<0.01), 
and less glycoprotein IIb/IIIa inhibitor utilization (27% vs. 
42%; p<0.01) (Table 1). Also, peak creatine kinase MB 
was lower for acute MI patients treated with SES 
(217r236 UI/L vs. 317r256 UI/L; p=0.04) (Table 1). 
Procedural angiographic success was achieved in all 
attempted lesions in a similar proportion of cases in the 
SES and the control groups (96% vs. 97% respectively, 
p=0.48)(Table 1). 
30-day Outcome 
The 30-day outcomes of the SES and control groups 
are shown in Table 2. Complete follow-up information was 
available for all patients in the SES group and for all 
except 1 patient in the control group (99.7%). There were 
no differences in the incidence of adverse events between 
patients treated with bare stents and those treated with 
SES (30-day MACE rate 6.1% vs. 6.6%, respectively; 
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p=0.8), with most complications occurring in the first 
week after the procedure (Figure 1). Stent thrombosis 
occurred in 1 patient (0.5%) in the SES group and in 5 
patients (1.7%) in the control group (p=0.4) (Table 2). 
We performed a multivariate analysis to determine 
independent predictors of MACE at 30 days. Figure 2 
shows the 4 significant predictors of 30-day MACE 
identified in the final model. The presence of multivessel 
disease (OR 4.4 [95% CI: 1.8-10.8]; p<0.01), cardiogenic 
shock (OR 3.9 [95% CI: 1.2-12.8]; p=0.02), and acute MI 
at presentation (OR 3.3 [95% CI: 1.4-7.6]; p<0.01) were 
associated with an increased risk of MACE, while right 
coronary angioplasty (OR 0.4 [95% CI: 0.2-0.9]; p=0.04) 
was related to a decrease in the odds of early adverse 
events. When forced into the model, SES utilization (OR 
1.0 [95% CI: 0.4–2.2]; p=0.97) did not predict the 
occurrence adverse events, with virtually no influence in 
the predictive strength of model (Figure 3). 
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Figure 1 – Cumulative MACE rate (death, non fatal MI, or re-
intervention) during the first month for controls (bare stent) and 
patients treated with sirolimus-eluting stents. Note that > 50% of 
events occurred during the first week in both groups. 
DISCUSSION 
In this study we analyze for the first time the impact 
of sirolimus-eluting stent implantation on the early 
outcomes of patients with acute coronary syndromes. As 
compared to conventional bare stents, utilization of SES in 
unselected patients with acute MI or unstable angina was 
observed to be safe at 30 days, with similar rates of 
procedural success and early adverse events. 
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Figure 2 – Multivariate independent predictors of 30-day MACE 
(death, non fatal MI, and re-intervention) derived from the final 
logistic regression model. The odds ratios are shown on 
logarithmic scale together with their 95% confidence interval. 
Patients treated with SES differed in some aspects 
from that included in the control group. Control patients 
presented more rescue angioplasty for failed thrombolysis 
(instead of primary angioplasty), which could have 
increased the risk of events in this group. Conversely, SES 
patients were more frequently treated for bifurcation 
lesions, a well-known risk factor for periprocedural 
complications (21,22). Moreover, glycoprotein IIb/IIIa 
inhibitors were less commonly used in patients treated 
with SES, which may have posed these patients to a 
higher procedural risk (23). It seems unlikely that the 
lower utilization of IIb/IIIa blockers in these group could 
be explained by a lower risk profile perceived during the 
procedure since both the control and SES populations 
were equally composed predominantly by patients with 
acute MI or high grade unstable angina, with no 
significant difference in their diabetic status. Nevertheless, 
after adjusting for baseline and procedural differences, 
the type of stent used, either bare or SES, was not 
significantly associated with the occurrence of early 
adverse events. 
Recently, sirolimus has been reported to reduce 
endothelium-dependent relaxation in vitro in a porcine 
model, although the authors did not ruled out an effect of 
the drug vehicle (8). Additionally, sirolimus has been 
described to increase platelet aggregation and secretion 
in transplant recipients (11). However, recent studies 
have demonstrated that this drug efficiently blocks the 
synthesis of Bcl-3, a regulatory protein expressed when 
platelets adhere to collagen via integrin ĮIIbǃIII (9,10,24). 
Regardless of these contradictory laboratory findings, SES 
were not associated with clinically relevant device-related 
complications in our series, with no modification of the 
risk profile for procedural failure or event occurrence. 
Patients treated with SES presented a similar timing of 
post-procedural complications as compared to controls, 
with most events occurring in the first days after the 
procedure, a typical pattern previously reported after bare 
stent implantation (4,5). In this context, a relatively 
delayed hazardous effect of the drug leading to an 
increase in “late” thrombotic complications after the first 
week was not observed in our patients. 
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Figure 3 – Predictive strength (Chi-square values) for 30-day 
MACE (death, non fatal MI, and re-intervention) of multivariate 
models. Model 1 is the final model selected in the logistic 
regression and included the variables displayed in Figure 2. The 
forced inclusion of SES utilization (model 2) did not enhance the 
predictive strength of the model, as reflected by the negligible 
change in the Chi-square values. 
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STUDY LIMITATIONS 
The present investigation suffers from the inherent 
limitations of a non-randomized trial, which explains some 
unbalance in the baseline characteristics among the 
treatment groups. However, the study population is 
representative of the “real world” of interventional 
cardiology, with findings more readily applicable to the 
daily clinical practice. Post-procedure cardiac markers 
were not collected routinely for all patients (available for 
42% of controls and 46% of patients in the SES subgroup 
[p=NS]). This was justified by the fact that high grade 
enzymatic elevations, those with proven prognostic impact 
(15,16), rarely occur “unnoticed” in asymptomatic 
patients. When comparing pts with and without post-
procedure enzymes collected, 30-day death rate was 7.1 
% vs. 0 % (p<0.001) and re-intervention rate was 4.7% 
vs. 0% (p<0.001), reflecting the low risk nature of 
patients for whom cardiac markers were not measured. 
Similarly, the relatively low frequency of utilization of 
IIbIIIa inhibitors in our study reflects the current practice 
of administration of these drugs in several countries 
worldwide (25). Risk stratification was based mainly on 
clinical characteristics. Although laboratorial tests are 
known to add important prognostic information, the 
validated Braunwald classification for unstable angina 
applied in the present study provides a powerful clinical 
tool for individual risk assessment (14). 
CONCLUSIONS 
Sirolimus-eluting stent implantation for acute coronary 
syndromes was safe, with early outcomes comparable to 
conventional bare metal stents. Maintenance of the 
excellent short-term results already achieved with the 
current techniques is crucial for the validation of SES as a 
useful strategy in treatment of complex cases. Further 
evaluation in the context of randomized trials is warranted 
to confirm the present findings. 
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Background—Sirolimus-eluting stents (SES) have recently been proven to reduce restenosis and reintervention 
compared 
with bare stents. Safety and effectiveness of SES in acute myocardial infarction remain unknown. 
Methods and Results—Since April 16, 2002, a policy of routine SES implantation has been instituted in our hospital, 
with 
no clinical or anatomic restrictions, as part of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital) registry. During 6 months of enrollment, 96 patients with ST-elevation acute myocardial infarction 
underwent percutaneous recanalization and SES implantation; these patients comprise the study population. The 
incidence of major adverse cardiac events (death, nonfatal myocardial infarction, reintervention) was evaluated. 
Six-month angiographic follow-up was scheduled per protocol. At baseline, diabetes mellitus was present in 12.5% and 
multivessel disease in 46.9%. Primary angioplasty was performed in 89 patients (92.7%). Infarct location was anterior 
in 41 (42.7%) of the cases, and 12 patients (12.5%) had cardiogenic shock. Postprocedural TIMI-3 flow was achieved 
in 93.3% of the cases. In-hospital mortality was 6.2%. One patient (1.1%) had reinfarction and target lesion 
reintervention the first day as a result of distal dissection and acute vessel occlusion. During follow-up (mean follow-up 
of 218±75 days), 1 patient died (1.1%), no patient had recurrent myocardial infarction, and there were no additional 
reinterventions. No early or late stent thromboses were documented. At angiographic follow-up (70%), late loss was 
-0.04±0.25mm, and no patient presented angiographic restenosis. 
Conclusions—In this study, sirolimus-eluting stent implantation for patients with ST-elevation acute myocardial 
infarction was safe without documented angiographic restenosis at 6 months. 
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Routine stent implantation has been shown to have a 
better procedural success rate and clinical outcome than 
bal-loon angioplasty in patients presenting with acute 
myocardial infarction (AMI).1 However, in-stent restenosis 
and vessel reocclusion remain significant clinical problems 
limiting the long-term success of percutaneous 
treatment.1,2 
Sirolimus-eluting stents (SES) have been proven to 
virtually abolish in-stent restenosis in elective patients 
with relatively simple lesions,3 with persistent neointimal 
growth inhibition up to 2 years.4 Recently, we have 
demonstrated that the 30-day outcomes of SES 
implantation for patients with acute coronary syndromes 
were similar to those of a control population treated with 
bare stents.5 Nevertheless, no specific information is 
presently available regarding the safety of these new 
devices in patients with AMI. Furthermore, the long-term 
clinical efficacy of SES for AMI is unknown. The rationale 
of the present study is therefore to evaluate the short- 
and midterm clinical and angiographic outcomes of SES 
implantation in a consecutive series of patients treated 
during the acute phase of AMI. 
Methods 
Patient Population 
Since April 16, 2002, SES implantation (Cypher; 
Johnson & Johnson, Cordis Europa NV, Roden, the 
Netherlands) has been instituted as the default strategy 
for all percutaneous coronary interventions performed at 
our institution as part of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) 
registry, which has been described elsewhere.5 All clinical 
situations and lesion morphologies were considered 
eligible. After 6 months of enrollment, 96 consecutive 
patients within 12 hours of an episode of AMI underwent 
mechanical reperfusion of the infarct-related artery with 
SES implantation; these patients comprise the present 
study population. 
Procedure 
Except for SES utilization, all procedures were 
performed according to standard techniques, and the final 
interventional strategy was left to the discretion of the 
operator. Weight-adjusted heparin was administered to 
achieve an activated clotting time of >300 seconds, or 
200 to 250 seconds when platelet glycoprotein IIb/IIIa 
inhibitor was used. Postprocedural antiplatelet regimen 
consisted of lifelong aspirin use and 75 mg clopidogrel per 
day for 3 months. Prolonged clopidogrel prescription (6 
months) was recommended for patients with at least one 
of the following characteristics: multiple SES (>3 stents), 
total stent length >36 mm, bifurcations, or in-stent 
resteno-sis. The local ethics committee approved the 
study protocol, and informed consent was obtained from 
all patients.  
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Definitions and Follow-Up 
Patients were evaluated for the occurrence of death, 
reinfarction (clinical symptoms or new 
electrocardiographic changes, associated with re-elevation 
of the creatine kinase and creatine kinase MB levels of 
>1.5 times the previous value if within 48 hours, >3 times 
the upper normal limit if after 48 hours),2 and target 
lesion revascu-larization (surgical or percutaneous 
reintervention motivated by a significant stenosis located 
within the stent or in the 5-mm segments proximal or 
distal to the stent). Information regarding repeat inter-
ventions was prospectively collected in the local database. 
Survival status was assessed by written inquiries to the 
Civil Registry. Questionnaires to assess clinical status were 
sent to all living patients. The patient, referring physician, 
and peripheral hospitals were directly approached 
whenever necessary for additional information. To 
evaluate the incidence of restenosis after SES 
implantation for AMI, angiographic follow-up was 
scheduled at 6 months for all living patients. Binary 
restenosis was defined as a stenosis diameter >50% 
within the stent or in the 5-mm segments proximal or 
distal to the stent. Late loss was defined as the difference 
between the minimal luminal diameter immediately after 
the procedure and at follow-up. 
Statistical Analysis 
Continuous variables are expressed as mean±SD. 
Discrete variables are presented as count and 
percentages. Event-free survival curves were estimated 
according to the Kaplan-Meier method. Patients lost to 
follow-up were considered at risk until the date of last 
contact, at which point they were censored. 
Results 
At baseline, mean age was 57±12 years. Twelve 
patients (12.5%) had diabetes mellitus, 10 (10.4%) had 
had a previous myocardial infarction, and 45 (46.9%) 
presented multivessel disease. Six patients (6.2%) had 
prior coronary angioplasty, and 1 (1%) had prior coronary 
bypass surgery. Mean creatine kinase level was 
2685±2869 IU/L. Average time from the onset of 
symptoms to the beginning of the procedure was 3.6±2.9 
hours. Primary angioplasty was performed in 89 patients 
(92.7%) and rescue angioplasty after failed thrombolysis 
in the remaining 7 (7.3%). Cardiogenic shock was 
diagnosed in 12 patients (12.5%). Periprocedural 
glycoprotein IIb/IIIa inhibitor (abciximab) was used in 45 
patients (46.9%). Infarct location was anterior in 41 cases 
(42.7%). Overall, 104 culprit lesions were identified (in 8 
patients, we found 2 different lesions anatomically and 
clinically related to the development of the AMI). The 
lesions were located in the left main in 2 cases (1.9%), 
the left anterior descending in 51 (49.0%), the left 
circumflex in 10 (9.6%), and the right coronary in 41 
(39.4%). Before the procedure, TIMI flow 0 to 1 was 
present in 60.6% of the cases. Postprocedural TIMI-3 flow 
was achieved in 93.3%. Clopidogrel was prescribed for 3 
months in 54% of patients and for 6 months in the 
remaining cases. Complete follow-up was available for 
99% of the patients at 218±75 days. A total of 6 deaths 
occurred during the index hospitalization (6.2%). In 1 
case, death occurred as a result of brain death in a 
patient with prolonged out-of-hospital resus-citation. The 
other 5 cases were all admitted in cardiogenic shock; 3 of 
them died the same day of the procedure as a result of 
progressive hemodynamic deterioration. The other 2 
patients died of overwhelming sepsis at days 23 and 86 
after a prolonged, stormy course. One additional death 
(1.1%) resulting from heart failure occurred during follow-
up, shortly after hospital discharge, in a 77-year-old 
patient with 3-vessel disease, who was admitted with a 
large inferoposterior myocardial infarction and cardiogenic 
shock. In none of these cases, death occurred as an 
unexpected, sudden episode that could be attributable to 
stent thrombosis. Target lesion reintervention was 
necessary in 1 patient (1.1%) the same day as the 
procedure as a result of distal dissection, acute vessel 
occlusion, and reinfarction. There were no further cases of 
reinfarction or repeat intervention after discharge 
(Figure). Also, no early or late stent thromboses were 
documented. Six-month angiographic follow-up was 
obtained in 62 patients (70%). The angiographic 
outcomes are shown in the Table. Late loss was -
0.04±0.25 mm, and there were no cases of binary 
restenosis.  
 
Table 1. Quantitative coronary analysis in patients with acute 
myocardial infarction treated with sirolimus-eluting stent. 
 Pre-
procedure 
Post-
procedure 
Follow-up* 
Reference diameter, mm 2.73 ± 0.59 2.80 ± 0.47 3.04 ± 0.49 
Minimum lumen 
diameter, mm 
0.34 ± 0.50 2.54 ± 1.31 2.59 ± 0.42 
Diameter stenosis, % 86 ± 21 14 ± 12 15 ± 11 
Lesion length, mm 16.9 ± 9.9 - - 
Late loss, mm - - -0.04 ± 0.25 
Binary restenosis, % - - 0 
* related to 62 patients with 6-month angiographic follow-up 
Discussion 
The present study is the first report on SES 
implantation for patients with ST-elevation AMI. The main 
finding is that, in these patients, SES implantation appears 
highly effective in preventing neointimal proliferation and 
restenosis, with re-sults similar to those observed in a 
randomized trial for relatively simple lesions.3 Primary 
percutaneous coronary intervention has been dem-
onstrated to be more effective than thrombolytic therapy 
for the treatment of AMI.6 However, although consistently 
reduced by stent utilization, recurrent ischemia, 
restenosis, and reocclusion of the infarct-related artery 
occur in sizable proportions, increasing clinical events and 
healthcare costs. 
In the Stent PAMI (Stent Primary Angioplasty for 
Myocar-dial Infarction) trial, 6-month restenosis and 
target vessel revascularization rates were 20.3% and 
7.7%, respectively.2 In the CADILLAC (Controlled 
Abciximab and Device Inves-tigation to Lower Late 
Angioplasty Complications) trial, the corresponding values 
were 22.2% and 8.9%, and reocclusion of the infarct-
related artery 5.7%.1 In this context, the absence of 
restenosis and reinterventions by SES as found in our 
study could further improve clinical outcomes, although 
this hypothesis should be tested in dedicated randomized 
trials. 
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Figure 1. Kaplan-Meier curves for survival, and survival free from 
myocardial infarction (MI) and target lesion revascularization 
(TLR). It is evident the almost complete overlap of the curves, 
motivated by the very low incidence of recurrent myocardial 
infarction and reinterventions. 
 
Previous preclinical laboratory data suggested that 
siroli-mus could decrease endothelial function in vitro,7 
enhance agonist-induced platelet aggregation,8 and delay 
vascular healing.9 Altogether, these features can 
potentially increase the risk of thrombotic complications 
and adversely affect the outcome after SES implantation, 
especially in very suscepti-ble patients such as those 
treated during the acute phase of myocardial infarction. 
However, the clinical significance of these preliminary 
findings remains elusive. Indeed, we re-cently 
demonstrated the safety of SES for patients with acute 
coronary syndromes, although AMI at presentation was 
still associated with an increased risk of adverse events at 
follow-up.5 The present study, with the very low event 
rate and the absence of episodes of acute and subacute 
thrombosis, confirms the safety of SES utilization, 
specifically in patients with AMI. 
In this prospective, single-center registry of SES 
implan-tation in AMI, all the limitations inherent to this 
particular study design apply, and the patient number was 
relatively small. Notably, however, given the unrestricted 
inclusion criteria, this cohort of patients accurately reflects 
the daily practice in the “real world” of interventional 
cardiology, and therefore the results are extended to 
virtually all patients with AMI as a result of occlusion of 
native coronary vessels.  
Conclusions 
Routine SES implantation during mechanical 
reperfusion of AMI is safe and associated with no 
evidence of late luminal loss and restenosis at 6 months. 
Larger studies are necessary to confirm these findings and 
to evaluate the impact of SES implantation on clinical 
events for patients with AMI.  
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Objectives: To investigate the clinical outcomes of patients with ST-elevation myocardial infarction treated with 
sirolimus-eluting stents or conventional bare stents. 
Background: The clinical impact of sirolimus-eluting stent implantation for patients with ST-elevation myocardial 
infarction is currently unknown. 
Methods: Primary angioplasty was performed with sirolimus-eluting stents in 186 consecutive patients with acute 
myocardial infarction, who were compared with 183 patients treated with bare stents. The incidence of death, re-
infarction, and repeat revascularization was assessed at 30 and 300 days. 
Results: Post-procedure vessel patency, enzymatic release, and the incidence of short-term adverse events was similar 
in the sirolimus and bare stents (30-day rate of death, re-infarction, or repeat revascularization: 7.5% vs. 10.4% 
respectively; p=0.4). Stent thrombosis was not diagnosed in any patient in the sirolimus group and occurred in 1.6% of 
patients treated with bare stents (p=0.1). At 300 days, treatment with sirolimus-eluting stents significantly reduced the 
incidence of combined adverse events (9.4% vs. 17%; HR 0.52 [95% CI 0.30–0.92]; p=0.02), mainly due to a marked 
reduction in the risk of repeat intervention (1.1% vs. 8.2%; HR 0.21 [95% CI 0.06–0.74]; p=0.01).  
Conclusions: Sirolimus-eluting stents were not associated with an increased risk stent thrombosis and were effective in 
reducing the incidence of adverse events at 300 days in unselected patients with ST-elevation acute myocardial 
infarction referred for primary angioplasty, compared to conventional bare stents. 
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Introduction 
Routine stent implantation has been advocated for 
patients with acute myocardial infarction referred for 
primary angioplasty, with superior results compared to 
balloon dilatation (1-3). However, the late clinical efficacy 
is still hampered by the occurrence of in-stent restenosis 
and the need for repeat intervention. 
Sirolimus-eluting stents have proven effective in 
reducing late restenosis compared to conventional 
stenting in elective patients (4-6). We have recently 
shown in a relatively small consecutive series of cases 
that sirolimus-eluting stent implantation in patients with 
acute myocardial infarction was safe and associated with 
an extremely low (zero) incidence of angiographic 
restenosis at 6 months (7). However, the clinical benefit 
of sirolimus-eluting stents in comparison to conventional 
stent implantation remains currently unknown. We 
therefore evaluated the long-term clinical outcomes of a 
large series of patients with acute myocardial infarction 
treated with primary angioplasty utilizing sirolimus-eluting 
stents or conventional metal stents. 
Methods 
Since April 2002, sirolimus-eluting stent (SES) 
implantation (Cypher; Johnson & Johnson-Cordis unit, 
Cordis Europa NV, Roden, the Netherlands) has been 
utilized as the strategy of choice for patients treated with 
percutaneous intervention in our institution (8). Up to 
January 2003, a total of 186 consecutive patients with ST-
elevation acute myocardial infarction have been treated 
with primary angioplasty utilizing exclusively sirolimus-
eluting stents and were included in the present report. 
The first 89 patients of the present series were included in 
an angiographic substudy, of which the results have been 
reported previously (7). A control group for comparison 
was composed of 183 consecutive patients with ST-
elevation acute myocardial infarction treated with 
conventional bare stents in the period immediately prior 
to the introduction of sirolimus-eluting stents. The 
following bare metal stents were used: BX Sonic or BX 
Velocity in 53% (Cordis, Johnson & Johnson Company, 
Warren, New Jersey), Multi-Link Penta in 22% (Guidant 
Corp., Santa Clara, California), Multi-Link Tetra in 6% 
(Guidant Corp., Santa Clara, California), R-Stent in 6% 
(Orbus Medical Technologies, Ft. Lauderdale, Florida), and 
other stents in 12%. In both study phases, all patients 
were enrolled regardless of the clinical or anatomical 
presentation, including patients admitted with cardiogenic 
shock (defined as persistent systolic blood pressure <90 
mm Hg, or the need of vasopressors or intra-aortic 
balloon pumping required to maintain blood pressure >90 
mm Hg with evidence of end-organ failure and elevated 
left ventricular filling pressures). Therefore, the total study 
population comprised all 369 consecutive patients with 
ST-elevation acute myocardial infarction undergoing 
primary angioplasty with either bare stents or sirolimus-
eluting stents in the 2 study phases respectively. Patients 
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with angioplasty after failed thrombolytic therapy were 
excluded from the present analysis. This study protocol 
was approved by the local ethics committee and written 
informed consent was given by every patient. 
The final interventional strategy, as well as the 
utilization of periprocedural glycoprotein IIbIIIa inhibitors 
and antithrombotic medications, was entirely left to the 
discretion of the operator. Baseline and post-procedure 
antegrade flow were evaluated off-line according to the 
TIMI criteria (9) by cardiologists blinded to the stent 
group and to the clinical outcomes. Clopidogrel was 
recommended for at least one month in the control group. 
In the SES group, clopidogrel was prescribed for 3 
months, unless one of the following was present (in which 
case clopidogrel was maintained for at least 6 months): 
multiple SES implantation (>3 stents), total stented length 
>36 mm, bifurcation stenting, and in-stent restenosis. 
 
Table 1. Baseline and procedural characteristics of patients 
treated with bare stents  or SES implantation. 
 Bare 
stents 
(n=183) 
SES 
(n=186) 
P-
value 
Male, % 79 75 0.4 
Age, years±SD 57±12 60±12 0.04 
Diabetes, % 12 11 0.9 
Current smoking, % 47 46 0.8 
Previous myocardial 
infarction, % 
24 14 0.03 
Previous angioplasty, % 9 7 0.4 
Previous bypass surgery,% 3 2 0.3 
Coronary disease   0.3 
Single-vessel, % 48 55  
Double-disease, % 29 27  
Triple-vessel, % 24 18  
Cardiogenic shock, % 10 13 0.3 
Time from symptom onset to 
angioplasty, hours±SD 
3.0±2.7 3.2±1.9 0.6 
Infarct-related vessel   0.3 
Right coronary artery,% 30 37  
Left anterior descending, % 57 53  
Left circumflex artery,% 10 8  
Left main coronary, % 1 2  
Bypass graft, % 2 -  
TIMI flow baseline   0.7 
Grade 0/I, % 73 73  
Grade II, % 15 17  
Grade III, % 13 10  
TIMI flow after angioplasty   0.5 
Grade 0/I, % 4 2  
Grade II, % 17 15  
Grade III, % 79 83  
Number of stents±SD 1.7±1.0 1.9±1.2 0.03 
IIbIIIa inhibitor, % 56 37 <0.01 
Clopidogrel prescription, 
months±SD  
2.1±1.5 3.7±2.1 <0.01 
Peak CK, IU/L±SD* 3957± 
5135 
3126± 
3126 
0.1 
Peak CK-MB, IU/L±SD† 319± 
230 
296± 
255 
0.5 
CK=creatine kinase; SD=standard deviation; SES=sirolimus-
eluting stents 
* Upper limit of normal 199 U/L 
† Upper limit of normal 23 U/L 
 
Patients were prospectively followed-up for the 
occurrence of major adverse cardiac events: 1) all-cause 
death, 2) non-fatal myocardial infarction, or 3) target 
vessel revascularization. Re-infarction was diagnosed by 
recurrent symptoms and/or new electrocardiographic 
changes in association with re-elevation of the creatine 
kinase and creatine kinase MB levels of >1.5 times the 
previous value, if within 48 hours, or >3 times the upper 
normal limit, if after 48 hours from the index infarction 
(1,7). Target vessel revascularization was defined a 
repeat intervention (surgical or percutaneous) driven by 
any lesion located in the same epicardial vessel treated at 
the index procedure. Thrombotic stent occlusion was 
angiographically documented as a complete occlusion 
(TIMI flow 0 or 1) or a flow limiting thrombus (TIMI flow 
1 or 2) of a previously successfully treated artery. Routine 
angiographic follow-up was obtained only for patients 
treated with sirolimus-eluting stents enrolled during the 
first 6 months; results of this subanalysis have been 
previously reported (7). 
 Continuous variables were presented as 
mean±standard deviation and were compared using 
Student’s unpaired t-test. Categorical variables were 
presented as counts and percentages and compared with 
the Fisher’s exact test. Survival free of adverse events 
was estimated using the Kaplan-Meier method and 
differences between curves were evaluated by the log-
rank test. Cox proportional hazards models were used to 
assess risk reduction. Multivariate analyses were 
performed to identify independent predictors of long-term 
major adverse cardiac events. Baseline and procedural 
characteristics associated with the incidence of adverse 
events at univariate analysis (p-value for selection d0.2) 
were tested for their multivariate predictive value (tested 
variables: SES utilization, diabetes, cardiogenic shock, 
multivessel disease, culprit vessel, pre-procedure TIMI 
flow, post-procedure TIMI flow, current smoking). The 
final model was built by backward stepwise variable 
selection with an entry and exit criteria set at the P=0.05 
and P=0.1 levels respectively.  
Results 
Baseline characteristics were similar between both 
study groups, except by an older age and a lower 
incidence of previous myocardial infarction in the sirolimus 
group (Table 1). Procedural characteristics differed 
between both groups in terms of the utilization of IIbIIIa 
inhibitors (sirolimus: 37% vs. bare stents: 56%; p<0.01) 
and the number of stents implanted (sirolimus: 1.9±1.2 
vs. bare stents: 1.7±1.0; p=0.03). As defined by the 
study protocol, the duration of clopidogrel prescription 
was longer for patients with sirolimus stents (Table 1). 
There were no significant differences in the 30-day 
outcomes between patients treated with sirolimus or bare 
stents (Table 2). Stent thrombosis was diagnosed in 3 
patients (1.6%) treated with bare stents and was not 
detected in the SES group (p=0.1) (Table 2). 
At 300 days, there were no differences between both 
study groups in the incidence of death and death or re-
infarction (Table 2). However, the incidence of 300-day 
major adverse events was significantly lower in the 
sirolimus stent group compared to the bare stent group 
(9.4% vs. 17% respectively; hazard ratio 0.52 [95% 
confidence interval 0.30–0.92]; p=0.02) (Table 2; Figure), 
mainly due to a marked reduction in the risk of repeat 
intervention (1.1% vs. 8.2% respectively; HR 0.21 [95% 
CI 0.06–0.74]; p=0.01). A multivariate analysis was 
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performed to adjust for baseline and procedural 
imbalances between the study groups (Table 3). 
Sirolimus-eluting stent utilization was identified as 
independent predictor of 300-day death, re-infarction, or 
repeat revascularization (HR 0.53 [95% CI 0.29–0.95]; 
p=0.03). 
 
Table 2. Kaplan-Meier estimates of 30-day and 300-day adverse 
events. 
 Bare 
stents 
(n=183) 
SES 
(n=186) 
P-
value 
30-day outcomes    
Death, % 5.5 5.9 1.0 
Death or non-fatal re-infarction, % 7.1 6.5 0.8 
Target vessel revascularization, % 4.4 1.1 0.1 
Any event, % 10.4 7.5 0.4 
Stent thrombosis, %* 1.6 0 0.1 
    
300-day outcomes    
Death, % 8.2 8.3 0.8 
Death or non-fatal re-infarction, % 10.4 8.8 0.5 
Target vessel revascularization, % 8.2 1.1 <0.01 
Any event, % 17.0 9.4 0.02 
SES=sirolimus-eluting stents 
*Angiographically documented stent thrombosis 
Discussion 
The main finding of the present study was that 
sirolimus-eluting stent implantation was effective in 
reducing the incidence of adverse events at 300 days in 
unselected patients with ST-elevation acute myocardial 
infarction, compared to conventional bare stenting. 
Furthermore, the risk of subacute thrombosis within the 
first 30 days did not appear higher compared with bare 
metal stents. Sirolimus-eluting stents were associated with 
a relative reduction of 48% in the risk of death, re-
infarction, or repeat intervention and a relative reduction 
of 79% in the risk of repeat intervention at 300 days. 
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Survival free of re-infarction or target vessel revascularization in 
the sirolimus-eluting stent and conventional stent groups. 
 
In our series, reperfusion treatment with sirolimus-
eluting stents was associated with similar rates of vessel 
patency, enzymatic release, and 30-day complications 
compared to bare stents. The death rate and the 
incidence of death or re-infarction were similar in both 
study groups, but somewhat higher than those reported in 
randomized trials with selected patients (1,2). These 
findings most probably reflect the unrestrictive inclusion 
criteria of our series (10), which frequently enrolled 
patients not included in randomized studies, like for 
instance, cardiogenic shock, multivessel disease, and 
unprotected left main lesions. Importantly, stent 
thrombosis has not been identified in any patient treated 
with sirolimus stents and occurred in 3 controls (1.6%), 
with no statistical difference between the groups. 
Although the incidence of stent thrombosis in the bare 
stent group was at a somewhat higher range, our results 
in this group was not discrepant from historical series with 
conventional stents (1,2,11-13). 
Coronary stenting for the treatment of acute 
myocardial infarction has been limited by the need of late 
repeat intervention, which has been reported to occur in 
approximately 9% of cases at 6 months, ranging from 
3.6% to 22.7% (1-3). The incidence of repeat 
intervention after conventional stenting in our series 
(8.2%) was in line with these previous figures. 
Conversely, patients treated with sirolimus-eluting stent 
implantation had clearly a reduced risk of re-intervention 
at 10 months. Of note, between 30 days and 10 months, 
no additional patient was referred for repeat 
revascularization, which is consistent with the lack of 
angiographic restenosis after sirolimus stent implantation, 
as previously shown in a subset of patients from the 
present population (7). 
 
Table 3. Multivariate predictors of 300-day major adverse cardiac events. 
 Hazard 
ratio 
95% confidence 
interval 
P-value 
SES utilization 0.53 0.29–0.95 0.03 
Cardiogenic shock 3.31 1.72–6.34 <0.01 
Culprit vessel left main 
coronary 
6.05 1.60–22.87 <0.01 
Culprit vessel left anterior 
descending 
2.02 1.10–3.71 0.02 
Post-procedure TIMI flow   <0.01 
Grade 0/I (reference) 1.00 -  
Grade II 0.29 0.11–0.76  
Grade III 0.17 0.07–0.40  
Current smoking 0.57 0.31–1.02 0.06 
SES=sirolimus-eluting stents 
*Angiographically documented stent thrombosis 
 
The peri- and post-procedural antiplatelet therapeutic 
scheme differed between patients treated with bare or 
sirolimus stents in our series. Patients in the sirolimus 
group received less glycoprotein IIbIIIa inhibitors but had 
a longer clopidogrel prescription time. However, none of 
these characteristics were identified as independent 
predictors influencing the outcomes of patients. The 
impact of clopidogrel and IIbIIIa inhibitors on the long-
term clinical outcomes of patients with ST elevation acute 
myocardial infarction still remain to be established 
(2,14,15). 
Conclusions 
Sirolimus-eluting stent implantation for unselected 
patients with ST elevation acute myocardial infarction was 
associated with similar procedural and 30-days outcomes 
compared to bare stents, but markedly reduce the risk of 
major adverse events and repeat intervention at 10 
months. By providing effective mechanical reperfusion 
with similar results to the current therapeutic standard, 
and decreasing the incidence of late complications, 
sirolimus-eluting stents appeared as an attractive 
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approach for this patient admitted with acute myocardial 
infarction. The promising results of the present study 
warrant further confirmation in the context of a 
randomized trial. 
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Impact of Baseline Renal Function on Mortality After Percutaneous 
Coronary Intervention With Sirolimus-Eluting Stents or Bare Stents 
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Pim de Feyter, MD, PhD; Sjoerd H. Hofma, MD; Ron T. van Domburg, PhD; Patrick W. Serruys, MD, PhD 
 
Background: Renal impairment is an important predictor of mortality after percutaneous coronary intervention and 
may increase the restenosis rate. However, the relationship between restenosis and the risk of death in patients with 
renal impairment remains unclear. We evaluated the incidence of repeat revascularization and mortality in patients with 
or without renal impairment treated with sirolimus-eluting stents or bare stents. 
Methods and Results: A total of 1080 consecutive patients treated during a period of 1 year had available data to 
calculate the baseline creatinine clearance. Patients were treated with bare stents (first 6 months; n=543) or sirolimus-
eluting stents (last 6 months; n=537) and grouped according to the presence or absence of renal impairment 
(creatinine clearance <60ml/min). Patients with renal impairment had a higher mortality at 1 year (7.6% vs. 2.5%; 
hazard ratio 3.14 [95% CI: 1.68 – 5.88]; p<0.01), with no differences in mortality between the bare and sirolimus 
groups (hazard ratio 0.91 [95% CI: 0.49 – 1.68]; p=0.8). The incidence of target vessel revascularization was 
significantly reduced by sirolimus stents in patients without renal impairment (hazard ratio 0.59; [95% CI 0.39 – 0.90]; 
p=0.01) and in patients with decreased renal function (hazard ratio 0.37; [95% CI 0.15 – 0.90]; p=0.03).  
Conclusions: SES implantation reduce clinical restenosis in patients with renal impairment compared to conventional 
stenting. However, this benefit was not paralleled by a reduction in the risk of death in this population. It seems unlikely 
that restenosis could contribute as a factor influencing the increased mortality of patients with impaired renal function. 
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Introduction 
Chronic kidney disease has been shown to strongly 
increase the risk of short- and long-term adverse events 
in patients with atherosclerotic disease.1-14 The impact of 
this association is further maximized by its rising 
prevalence, which is expected to more than double 
between 1998 and 2010.13 In face of its growing 
frequency and the increased recognition of renal 
dysfunction as a powerful risk factor for future 
cardiovascular complications, the American Heart 
Association has recently released a scientific statement 
highlighting the clinical importance of this condition for 
the management of patients with coronary disease.13 
Unfortunately, the treatment of atherosclerotic heart 
disease in patients with renal impairment is often 
problematic due to the presence of multiple co-morbidities 
and to frequent limitations in drug prescription. Moreover, 
neither surgical nor percutaneous revascularization have 
been shown to eliminate the increased risk of patients 
with renal impairment.4-6,9,10,12 
Patients with renal failure have previously shown to 
have higher mortality rates even after successful 
percutaneous coronary intervention.4,5,10 Whether the 
occurrence of late restenosis contributes to the increased 
risk of death in this population remains unkown.4,10 
Dialysis patients have been reported to present high rates 
of angiographic restenosis after percutaneous 
intervention.15 However, observational studies without 
angiographic re-evaluation have failed to shown an 
increase in clinical restenosis in patients with renal 
failure.5,9 Moreover, previous reports have shown 
conflicting results regarding the impact of coronary stents 
on the outcomes of patients with renal impairment.4,5,10  
Sirolimus-eluting stents (SES) have proven to 
markedly decrease neointimal growth and in-stent 
restenosis in comparison with conventional stents, with an 
impressive reduction in the risk of subsequent repeat 
revascularization.16-19 However, all clinical trials conducted 
to date excluded this subset of patients with impaired 
renal function and, as a consequence, the impact of SES 
implantation on the outcomes of this subset of patients is 
currently unknown. The present study aimed therefore to 
evaluate the impact of baseline renal function on the 1-
year mortality of patients treated with either conventional 
bare stents or sirolimus-eluting stents. 
Methods 
Patient Population and Procedures 
Since April 2002, sirolimus-eluting stent implantation 
(Cypher; Johnson & Johnson-Cordis unit, Cordis Europa 
NV, Roden, the Netherlands) has been adopted as the 
default interventional strategy for all patients treated in 
our institution, as described elsewhere.19,20 For 
comparison, a control group was composed of all 
consecutive patients treated with conventional bare stents 
in the period prior the introduction of sirolimus-eluting 
stents.19,20 From October 2001 until October 2002 (6-
month enrollment for both the pre-sirolimus and the 
sirolimus phases), a total of 1262 consecutive non-dialysis 
patients were treated with bare stents or sirolimus 
eluting-stents in the 2 study periods. From these, 1080 
patients (86%) had pre-procedure serum creatinine 
measured in our institution and compose the present 
study population (bare stent group=543 patients; 
sirolimus-eluting stent group=537 patients).  
All interventions were performed utilizing standard 
techniques and the final strategy was left at the operators’ 
choice. Angiographic success was defined as residual 
stenosis < 30% by visual analysis with TIMI 3 antegrade 
flow. Periprocedural glycoprotein IIbIIIa inhibitor 
utilization was left to the discretion of the operator. All 
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patients were advised to maintain lifelong aspirin. 
Clopidogrel was prescribed for at least for 1 month in the 
bare stent group. For patients treated with sirolimus-
eluting stents, clopidogrel was recommended for 3 
months, unless for those with at least one of the following 
characteristics (in which case clopidogrel was maintained 
for at least 6 months): multiple SES implantation (>3 
stents), total stented length >36 mm, chronic total 
occlusion, bifurcation, and in-stent restenosis. The study 
was approved by the local ethics committee and written, 
informed consent was obtained from every patient. 
Clinical Follow-up and Endpoints 
In-hospital clinical information was retrieved from an 
electronic database for patients maintained in our hospital 
and by review of the hospital records for those discharged 
to referring hospitals. Post-discharge survival status was 
obtained from the Municipal Civil Registries. Repeat 
revascularization procedures (surgical or percutaneous) 
and re-hospitalizations were prospectively collected during 
the follow-up. Patients were directly approached and/or 
the referring physicians and institutions were contacted 
whenever necessary for additional information. 
The primary endpoint of the present study was all-
cause mortality at 1 year. The incidence of target vessel 
revascularization was assessed to evaluate the anti-
restenotic effect of sirolimus-eluting stents in comparison 
with bare stents. Target vessel revascularization was 
defined as a re-intervention (surgical or percutaneous) to 
treat any lesion located in the same epicardial vessel 
treated at the index procedure. 
Renal Function Evaluation 
The closest creatinine values before the procedure 
were used to calculate baseline creatinine clearance 
according to the formula proposed by Cockcroft and 
Gault: creatinine clearance (ml/min)=(140 - age) x weight 
(kg) y 72 x serum creatinine (mg/dl) (x 0.85 for 
women).21 Renal impairment was defined as a calculated 
creatinine clearance below 60 ml/min, a cutoff value 
previously proposed by the National Kidney Foundation - 
Kidney Disease Outcome Quality Initiative Advisory Board 
to identify patients with moderate renal impairment 11 and 
the American Heart Association Councils on Kidney in 
Cardiovascular Disease, High Blood Pressure Research, 
Clinical Cardiology, and Epidemiology and Prevention.13
 
Table 1. Baseline and procedural characteristics of patients with or without renal impairment treated with bare stents or SES 
 Normal renal function  Renal impairment  
 Bare stent (n=451) SES (n=443)  Bare Stent (n=92) SES (n=94) p-value* 
Male, % 79 73  48 50 <0.01 
Age, years±SD 59±11 59±10  72±8 72±9 <0.01 
Height, cm±SD 174±8 173±9  167±10 167±9 <0.01 
Weight, kg±SD † 84±13 82±14  71±11 70±11 <0.01 
Hypercholesterolemia, % 56 58  51 62 0.9 
Hypertension, % 36 39  49 50 <0.01 
Current smoking, % † 37 31  20 17 <0.01 
Diabetes, % 14 18  20 20 0.2 
Insulin-dependent diabetes 4 5  9 6 0.1 
Non insulin-dependent diabetes 10 13  11 14 0.7 
Previous MI, %  39 33  39 31 0.8 
Previous bypass surgery, % 7 9  25 21 <0.01 
Previous percutaneous intervention, % † 21 27  25 31 0.2 
Clinical presentation      0.1 
Stable angina, % 47 50  55 38  
Unstable angina, % 34 35  35 47  
Acute myocardial infarction, % 19 16  10 15  
Coronary vessel disease      <0.01 
1-vessel disease, % 49 48  36 33  
2-vessel disease, % 36 34  29 31  
3-vessel disease, % 16 19  35 36  
Vessel treated       
Right coronary artery, % 39 39  32 28 0.02 
Left anterior descending, % 57 57  52 63 0.9 
Left circumflex artery, % 34 31  33 33 1.0 
Left main coronary, % 4 2  5 5 0.2 
Bypass graft, % 3 3  12 11 <0.01 
Treatment of ISR (at least 1 lesion), % † 4 10  6 13 0.2 
Number of stents implanted per pt,±SD ‡ 1.9±1.1 2.1±1.4  2.1±1.4 2.4±1.6 <0.01 
Angiographic success for all lesions, % 97 97  98 98 0.8 
Periprocedural IIbIIIa inhibitor, % † 39 17  29 21 0.5 
Statin at discharge, % 66 65  59 62 0.2 
ACE inhibitor at discharge, % 30 25  26 28 1.0 
Clopidogrel prescription, months±SD ‡ 3.0±2.1 4.2±2.0  3.0±1.8 4.1±2.0 0.9 
Serum creatinine, mg/dl±SD 0.9±0.8 0.9±0.2  1.3±0.4 1.3±0.4 <0.01 
Creatinine clearance, ml/min±SD 101±29 98±25  49±9 50±9 <0.01 
ISR=in-stent restenosis; pt=patient; SD=standard deviation; SES=sirolimus-eluting stents 
* for the comparison between patients with normal renal function and patients with renal impairment pooled over stent type group 
† p<0.05 for bare stents vs. sirolimus-eluting stents pooled over renal function group 
‡ p<0.01 for bare stents vs. sirolimus-eluting stents pooled over renal function group 
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Figure 1. Incidence of all-cause death for patients with or without 
renal impairment. Top panel: total study population pooled over 
stent type. Mid panel: patients treated with bare stents. Lower 
panel: patients treated with sirolimus-elutings stents. 
Statistical Analysis 
Continuous variables were presented as mean ± 
standard deviation (SD) and were compared using 
Student’s T-test. Categorical variables were presented as 
counts and percentages and compared with the Fisher’s 
exact test. The unadjusted cumulative incidence of death 
and target vessel revascularization was evaluated by the 
Kaplan-Meier method. Cox proportional hazards models 
were utilized to examine the effect of renal impairment, 
sirolimus-eluting stent implantation and the interaction 
between stent type vs. renal function on the clinical 
endpoints. In order to adjust for baseline differences 
between the study groups, all variables associated with 
the clinical endpoints at univariate analyses (p-value for 
selection d 0.2) were tested in multivariate analyses to 
identify independent predictors of 1-year mortality (tested 
variables: sex, acute myocardial infarction at admission, 
triple vessel disease, hyphercholesterolemia, current 
smoking, diabetes, angiographic success, statin 
prescription, left anterior descending stenting, left main 
coronary stenting, bypass graft stenting, renal function 
impairment) and target vessel revascularization (tested 
variables: previous bypass surgery, acute myocardial 
infarction at admission, triple vessel disease, 
hyphercholesterolemia, current smoking, diabetes, left 
main coronary stenting, bypass graft stenting, number of 
stents implanted, treatment of in-stent restenosis, SES 
utilization). The final models were built by backward 
stepwise variable selection with a p-value <0.05 used as a 
criterion for both entry and removal of variables. All 
reported p values were two-tailed and a p-value <0.05 
was regarded as significant. 
Results 
Baseline and procedural characteristics 
From the 543 patients treated with bare stents, a total 
of 92 patients had renal dysfunction at baseline (17%), 
and among the 537 patients treated with sirolimus-eluting 
stents, renal dysfunction was present in 94 patients 
(18%). Table 1 summarizes the baseline and procedural 
characteristics of patients with normal renal function or 
renal impairment, according to the type of stent utilized. 
Pooled over the stent type utilized, patients with renal 
impairment were older and more frequently female; had 
more hypertension, previous coronary surgery, triple-
vessel disease, bypass graft stenting, and a higher 
number of stents implanted per procedure. Also, patients 
with a lower clearance had lower weights and heights, 
and were less likely to smoke and to have received stent 
in the right coronary artery. Overall, in patients with or 
without renal impairment, the average serum creatinine 
was 0.9 ± 0.2 mg/dl vs 1.3 ± 0.4 mg/dl respectively 
(p<0.01), and the average creatinine clearance was 99 ± 
27 mg/min vs 49 ± 9 mg/dl respectively (p<0.01). 
Pre-procedure baseline characteristics between 
patients treated with sirolimus-eluting stents or bare 
stents were similar, except for a lower frequency of 
current smokers and a higher rate of previous 
percutaneous intervention and treatment of restenotic 
lesions in patients receiving sirolimus stents (Table 1). 
The average creatinine clearance was similar between 
patients treated with sirolimus or bare stents. In the 
sirolimus group, utilization of IIbIIIa inhibitors was lower 
and the number of stents implanted per procedure was 
higher (Table 1). Clopidogrel utilization was longer in the 
sirolimus group as per the pre-defined treatment protocol. 
There were no differences with regard to the post-
procedure prescription of statin between the sirolimus and 
bare groups. 
1-year mortality 
Clinical follow-up data was available for 99.4% of 
patients (median follow-up period 421 days; interquartile 
range: 391 – 459 days). When all patients were pooled 
together, regardless of SES or bare stent utilization, the 
unadjusted risk of death at 1 year was significantly higher 
in patients with renal impairment than in patients with 
normal renal function (7.6% vs. 2.5% respectively; 
hazard ratio 3.14 [95% CI: 1.68 – 5.88]; p<0.01) (Figure 
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1). Similarly, when analysed separately, baseline renal 
impairment significantly increased the risk of death in 
patients treated with either bare stents or sirolimus-
eluting stents (Figure 1). When evaluated irrespective of 
renal function, patients treated with bare stents or 
sirolimus-eluting stents had similar 1-year mortality rates 
(3.6% vs. 3.2% respectively; hazard ratio 0.91 [95% CI: 
0.49 – 1.68]; p=0.8) (Figure 2). The interaction factor for 
the relationship of the effect of renal impairment and 
stent type on the risk of death was not significant (p-value 
for the interaction = 0.7).  
Figure 2. Unadjusted 1-year incidence of all-cause death for 
patients treated with bare stents vs. sirolimus-elutings stents 
polled over renal function. 
 
At multivariate analysis, female sex (adjusted hazard 
ratio 2.00 [95% CI: 1.04 – 3.85]; p=0.04), renal 
impairment (adjusted hazard ratio 2.15 [95% CI: 1.10 – 
4.28]; p=0.03), acute myocardial infarction (adjusted 
hazard ratio 3.00 [95% CI: 1.54 – 5.86]; p<0.01), and 
triple-vessel disease (adjusted hazard ratio 2.75 [95% CI: 
1.44 – 5.22]; p<0.01) were identified as independent 
predictors of 1-year mortality (Table 2). The utilization of 
sirolimus-eluting stents had no influence in the risk of 
death at 1 year (adjusted hazard ratio 1.10 [95% CI: 0.59 
– 2.07]; p=0.8) (Table 2). 
Repeat revascularization 
Overall, sirolimus-eluting stent significantly reduced 
the incidence of target vessel revascularization at 1 year 
compared to bare stent implantation (unadjusted hazard 
ratio 0.54 [95% CI 0.37 – 0.79]; p<0.01). Sirolimus-
eluting stent implantation was effective in reducing the 
risk of target vessel revascularization both in patients 
without (unadjusted hazard ratio 0.59; [95% CI 0.39 – 
0.90]; p=0.01) and in patients with renal impairment 
(unadjusted hazard ratio 0.37; [95% CI 0.15 – 0.90]; 
p=0.03). At multivariate analysis, sirolimus-eluting stent 
utilization remained as an important factor reducing the 
risk of repeat revascularization (adjusted hazard ratio 
0.43; [95% CI 0.29 – 0.64]; p<0.01). Importantly, the 
presence of renal impairment did not significantly 
influence the risk of target vessel revascularization 
(adjusted hazard ratio 1.22; [95% CI 0.79 – 1.88]; 
p=0.4). Other independent predictors of 1-year target 
vessel revascularization are presented in (Table 2). 
 
Table 2. Independent multivariate predictors of 1-year all-cause 
mortality and repeat revascularization 
 Hazard 
ratio 
95% 
confidence 
interval 
p 
value 
1-year mortality    
Female sex 2.00 1.04 – 3.85 0.04 
Renal impairment 2.15 1.10 – 4.28 0.03 
Acute myocardial infarction  3.00 1.54 – 5.86 <0.01 
Triple-vessel disease  2.75 1.44 – 5.22 <0.01 
Sirolimus-eluting stent utilization 1.10 0.59 – 2.07 0.8 
1-year target vessel revascularization    
Renal impairment 1.22 0.79 – 1.88 0.4 
Sirolimus-eluting stent utilization 0.43 0.29 – 0.64 <0.01 
Current smoking 0.56 0.36 – 0.88 0.01 
Treatement of in-stent restenosis 3.29 2.05 – 5.28 <0.01 
Number of stents implanted 1.23 1.09 – 1.38 <0.01 
Discussion 
The main finding of the present study was that 
impaired renal function significantly increases 1-year 
mortality after percutaneous coronary revascularization, 
regardless of the use of sirolimus-eluting stents or 
conventional bare stents. Despite the clear anti-restenotic 
effect of sirolimus-eluting stents, which markedly reduced 
the incidence of target vessel revascularization compared 
to bare stents, mortality rates in patients with and without 
renal dysfunction were similar in both treatment 
strategies. 
Impaired renal function has been previously shown to 
negatively influence survival rates after percutaneous 
intervention.4-6,9,10,12 Although patients with renal 
impairment are well-known to have an increased 
prevalence of associated risk factors, it has been identified 
in our series and in previous reports to be an important 
independent predictor of mortality. A number of 
inflammatory, procoagulant, and atherogenic markers 
have been described in patients with renal impairment,22-
29 which may potentially accelerate disease progression 
and account for a higher tendency to acute events. Some 
of these factors have been previously associated with an 
increased risk of late restenosis.15,30,31 Accordingly, 
patients with end-stage renal failure have been shown to 
present increased levels of fibrinogen and higher rates of 
restenosis than non-dialysis patients.15 It has been 
hypothesized that the high incidence of restenosis could 
possibly contribute to the increased mortality seen in 
patients with renal impairment.4,10 Our results challenge 
this concept by demonstrating that the strikingly reduction 
of clinical restenosis after sirolimus-eluting stents is not 
paralleled by any reduction in mortality among patients 
with renal impairment.  
Even though drug-eluting stents did not decrease the 
mortality risk following coronary intervention, the 
reduction of restenosis represent an important therapeutic 
achievement for the clinical management of patients with 
renal impairment. In our series, sirolimus-eluting stents 
decreased the risk of repeat revascularization in patients 
with renal impairment by more than half of the risk seen 
with bare stents. The marked reduction in the risk of 
repeat revascularization may shift the focus of clinical 
attention after percutaneous intervention from restenosis 
prevention towards the institution of more aggressive 
disease-modifying strategies.  
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Although the present study suffers from the limitations 
related to its non-randomized nature, both study groups 
(bare and sirolimus groups) had comparable baseline 
characteristics. Creatinine clearance was calculated, as it 
has been shown to correlate well with actual values21 and 
provide a better estimate of renal function than serum 
creatinine alone.32 Complete data for pre-procedure 
creatinine clearance calculation were available for 86% of 
patients, which may introduce a selection bias in the 
analysis. Nevertheless, patients excluded from this study 
due to missing creatinine clearance data had an 1-year 
mortality rate of approximately 5.5%, which is 
intermediate between patients with and without renal 
impairment, indicating that the excluded cases may have 
a similar proportion of both groups of renal function. 
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Effectiveness of the Sirolimus-eluting Stent in the Treatment of 
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Objective: Percutaneous coronary intervention in patients with a history of previous coronary artery bypass grafting 
(CABG) is associated with an increased rate of subsequent adverse events compared to those without prior CABG. We 
evaluated the impact of utilizing the sirolimus-eluting stent (SES) in this high risk population. 
Methods: Since April 2002, SES implantation was utilized as the default strategy for all percutaneous procedures in our 
hospital. Consecutive patients with a history of previous CABG and de novo lesions (n=47) treated exclusively with SES, 
were compared to 67 patients who received bare stents in the 6 month period just before SES introduction.  
Results: There were no significant differences between SES and bare stent with respect to baseline clinical or lesion 
characteristics. The only difference between the groups related to the nominal diameter of stent utilized, which was 
smaller in the SES group than the bare stent group (maximum diameter of SES available was 3.0mm). At 1 year, the 
cumulative incidence of death, myocardial infarction, or target vessel revascularization was significantly lower in the SES 
group than the bare stent group (8.5% versus 30.3%, HR 0.37 [95% CI 0.15-0.91]; p=0.03) 
Conclusions: The utilization of sirolimus-eluting stents for percutaneous intervention in patients with previous coronary 
surgery is associated with a significant reduction in the 1-year incidence of major adverse cardiac events.  
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Introduction 
More than 300,000 people undergo coronary artery 
bypass graft (CABG) surgery every year in the U.S. alone, 
yet CABG is not a definitive therapy and patients continue 
to have considerable cardiovascular morbidity and 
mortality. Recurrence of ischemia and angina relates to 
either progression of native vessel atherosclerosis, or 
failure of the bypass grafts themselves. Indeed, 
angiographic studies have shown that by 10-12years, 75-
79% vein grafts are occluded or severely diseased.[1,2] 
Furthermore, studies have also suggested that following 
bypass implantation, atherosclerosis within the native 
vessels may actually progress more rapidly compared to 
vessels in the same patient which were not grafted.[3,4] 
In the large Coronary Artery Surgery Study (CASS) of 
more than 9,500 patients, angina recurred in 24% within 
the first year and in 40% by the sixth year.[5] Therefore, 
an increasing number of people with a history of previous 
CABG are being considered for further revascularization. 
Repeat CABG surgery is associated with a higher 
mortality than the first operation.[6,7] Percutaneous 
revascularization is therefore an attractive alternative 
strategy. However, following PCI, patients with prior CABG 
have been shown to have an increased combined risk of 
death and myocardial infarction.[8-13] They have a higher 
risk profile than those without previous CABG, tend to be 
older, and have more extensive vessel disease. 
Furthermore, intervention with stent implantation within 
venous bypass grafts themselves, is associated with a 
high subsequent rate of restenosis of 37-53%.[14,15] 
Drug-eluting stents have been shown to be highly 
successful in reducing restenosis in native coronary 
disease in a select patient population.[16,17] This study 
evaluates the sirolimus-eluting stent (SES) for 
percutaneous intervention in patients with previous CABG, 
compared to both those without prior CABG, and those 
treated in the preceding 6 months with bare stents. 
Methods 
From April 2002, all percutaneous coronary intervention 
at our centre was done with a policy of SES usage, 
irrespective of clinical presentation or lesion morphology, 
further details of the methodology are described elsewhere. 
[18,19] All procedures were performed with standard 
interventional techniques except with the use of SES as the 
device of choice. SES were available in lengths between 8mm 
and 33mm, and diameters of between 2.25-3.0mm. All 
patients were treated with long-term aspirin therapy and 
received a loading dose of 300mg clopidogrel followed by a 
daily dose of 75mg for at least 3 months. The procedural 
utilization of glycoprotein IIb/IIIa inhibitor therapy and distal 
protection devices was at the discretion of the operator.  
The current study cohort comprises of 47 patients with a 
previous history of CABG who were treated for de novo 
lesions solely with SES. A control group (n=66) comprised of 
patients who had been treated similarly in the preceding 6-
months though with bare stents. The protocol was approved 
by the local ethics committee an all patients signed a written 
informed consent.  
Patients were followed up and evaluated for major 
adverse cardiac events (MACE), defined as: 1) death, 2) 
myocardial infarction (AMI), or 3) repeat target vessel 
revascularization. The diagnosis of myocardial infarction 
required an elevation of creatine kinase levels to 2X upper 
limit of normal, together with a rise in creatine kinase-MB.  
Target vessel revascularization (TVR) was defined as a 
reintervention in the treated vessel.  
MACE-free estimates were calculated with the Kaplan-
Meier method. Hazard ratios of adverse events were 
calculated by Cox proportional hazard models. A p<0.05 was 
considered as significant. 
Results 
Baseline patient demographics and procedural data 
are presented in table 1. There were no significant 
differences between the 2 groups treated with either bare 
stents or SES, except in the mean nominal diameter of 
stent utilized, which was smaller in the SES group. 
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Intervention within native coronary arteries only, occurred 
in 59.9% of the bare stent group, and 63.8% of the SES 
group. The angiographic success rate in both groups was 
high at >97%. Table 3 presents the Kaplan-Meier 
estimates of the rate of major adverse cardiac events of 
the two groups at 1 year. There is a significantly lower 
rate of events in the SES group, predominantly related to 
a reduced need for repeat target vessel revascularization 
(Table 2; Figure).  
 
Table 1: Baseline patient demographics 
 Bare stent 
n=66 
SES group 
n=47 
p value 
Male sex (%) 66.7 70.3 0.5 
Mean age (years) 69 ± 11 68 ± 9 1.0 
Current smoker (%) 16.7 10.6 0.4 
Diabetes mellitus (%) 19.7 21.3 1.0 
Previous MI (%) 47.7 31.9 0.2 
Previous PCI (%) 39.4 42.6 0.9 
Multivessel disease (%) 95.5 91.5 0.5 
Clinical presentation 0.2 
Stable angina (%) 48.5 63.8  
Unstable angina (%) 43.9 34.0  
Acute MI (%) 7.6 2.1  
GP IIb/IIIa inhibitor 36.4 21.3 0.1 
Treated vessel 
Left anterior descending (%) 34.8 42.6 0.4 
Left circumflex (%) 33.3 29.8 0.8 
Right coronary artery (%) 27.3 17.0 0.3 
Left main coronary (%) 15.2 10.6 0.6 
 
Bypass graft (%) 40.9 36.2 0.7 
Mean number of stents  2.1 ± 1.4 1.9±0.9 0.7 
Mean stent diameter (mm) 3.3 ± 0.6 2.8±0.3 <0.01 
Stented length per patient (mm) 35.1±24.7 32.6±22.1 1.0 
Angiographic success (%) 98.5 97.9 1.0 
 
 
Table 2: Kaplan-Meier estimates of 1-year major adverse events  
 Bare 
stents 
SES HR 95% CI p-
value 
Death, % 6.1 2.1 0.34 0.04 – 3.09 0.3 
Death or myocardial 
infarction, % 
10.6 6.4 0.80 0.24 – 2.71 0.7 
Target vessel 
revascularization, % 
23.0 2.1 0.23 0.07 – 0.80 0.02 
Any event, % 30.3 8.5 0.37 0.15 – 0.91 0.03 
 
Discussion 
Previous data show that percutaneous intervention 
with bare stents in patients with a history of previous 
CABG, is associated with an increased rate of MACE 
compared to those without prior CABG. [8-13] This 
relates, at least in part, to the association of this group of 
patients with an adverse risk profile as patients tend to be 
older, and have a higher prevalence of diabetes, and 
multivessel disease. [8-13] Moreover, this increase in 
MACE is evident whether patients are being treated in the 
context of either stable angina, or an acute coronary 
syndrome. [8-13] However, we have demonstrated that in 
a consecutive series of patients with previous CABG 
treated with PCI and stent implantation, the utilization of 
the sirolimus-eluting stent significantly reduces the rate of 
MACE compared to those treated with bare metal stents.   
It is 20 years since Douglas et al demonstrated the 
feasibility of PCI in patients with a history of CABG. [20] 
More recently, the AWESOME randomized trial and 
registry demonstrated that at three years, the overall 
survival of patients with previous CABG and medically 
refractory angina, was similar whether treated with either 
PCI or re-do CABG. [21] Moreover, when given the choice 
of PCI or re-do CABG, the majority of patients preferred 
the former option. The Investigators concluded that PCI 
may be the preferred revascularization strategy.In the 
present study, 40.9% in the bare stent group, and 36.2% 
of the SES group underwent intervention within at least 
one bypass graft. Compared to native vessels, 
percutaneous revascularization of diseased saphenous 
vein grafts is hampered by an increased rate of adverse 
events thereby contributing to the worse outcome of post-
CABG patients. Procedural complications may relate to 
distal embolisation of friable material within the graft, and 
at follow-up, grafts are subject to an increased rate of 
restenosis. Historically, results of balloon-only therapy 
were disappointing. [22-24] In one study of 454 patients, 
procedural success was 90%, with a 5-year MACE-free 
survival of only 26%. [24] Subsequently, a randomized 
trial demonstrated the benefit of stenting over balloon 
angioplasty. At 6-months, the rate of survival free from 
either death, myocardial infarction, repeat CABG, or TLR 
was 73% in the stented group versus just 58% in the 
balloon-only group (p=0.03). [15] However, the 
angiographic restenosis rate remained high (37% versus 
46% respectively, p=0.24).  
Cumulative incidence of major adverse events 
 
The major limitation of PCI has always been the 
development of instent restenosis and subsequent need 
for repeat revascularization. In particular, restenosis rates 
utilizing bare stents within saphenous venous bypass 
grafts range between 37-53%. [14,15] Intervention solely 
within native vessels was undertaken in 59.9% of the 
bare stent group, and 63.8% of the SES group. The type 
of native vessel disease manifested in a population with a 
history of previous CABG can be difficult to effectively 
treat percutaneously; lesions may be ostial, or chronically 
occluded, or the disease may be diffuse and the arteries 
small and calcified. These features, together with the 
increased prevalance of diabetes in these patients, tend to 
increase the risk of developing restenosis.[25,26] 
Studies evaluating the SES have demonstrated low 
rates of restenosis compared with bare stents when used 
in relatively simple lesions. [16,17] The current study 
evaluated the results of PCI in a high risk population with 
a history of previous CABG. Both cohorts were comparable 
with respect to baseline clinical and lesion characteristics, 
and all procedures were carried out as a consecutive 
series, in a single center by the same operators. The only 
difference between the groups was a significantly smaller 
mean nominal diameter of stent utilized in the SES group. 
This is likely to reflect the fact that the maximum nominal 
diameter of SES available was 3.0mm [27] (though post-
dilatation was freely allowed) which is often small 
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particularly within venous bypass grafts. A smaller stent 
(associated with a smaller minimal lumen diameter) is 
more likely to be associated with subsequent restenosis 
[28] which might have tended towards an increased need 
for target vessel revascularization in the SES group. 
However, at 1 year, those treated with SES had a 
significantly lower rate of MACE compared to those 
patients treated with bare stent implantation, 
predominantly related to a reduction in the need for 
repeat target vessel revascularization.  
Our study accurately reflects the “real world” practice 
of interventional cardiology, and clearly demonstrates the 
applicability of the sirolimus-eluting stent in reducing the 
subsequent rate of adverse events at one year, in a high 
risk population with a history of previous coronary artery 
bypass graft surgery. 
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The present study reports on the clinical outcome of 31 consecutive patients with left main coronary artery disease 
treated with a sirolimus-eluting stent. The implantation of this stent was associated with aboli-tion of post-discharge 
fatal events and percutaneous reintervention.  
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Several trials have reported on the safety and fea-sibility 
of stent implantation to treat left main (LM) coronary 
disease, with favorable procedural and long-term 
results.1–4 However, restenosis remains the major 
complication limiting late outcome after percu-taneous 
intervention. In patients treated with LM stenting, the 
occurrence of restenosis has been partic-ularly associated 
with hazardous clinical manifesta-tions.5 In this viewpoint, 
although percutaneous inter-vention has increasingly been 
reported as a possible therapeutic alternative, surgical 
revascularization re-mains the most appropriate therapy.6 
The sirolimus-eluting stent (SES) (Cypher, Johnson & 
Johnson– Cordis, Miami, Florida) has recently proved its 
effi-cacy to reduce restenosis 7 in selected populations. 
Importantly, by maintaining all mechanical properties, the 
late benefit observed with the SES was accom-plished 
without compromising the excellent proce-dural and acute 
results already obtained with conven-tional metallic 
stents. Currently, the impact of SES implantation on 
patients with LM disease is unknown. We evaluated the 
efficacy of the SES on the short- and long-term clinical 
outcomes in 31 patients treated for LM disease.  
••• 
Since April 16, 2002, SES implantation has been 
adopted as the default strategy for all patients treated in 
our institution as part of the Rapamycin Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) 
registry. Briefly, the RESEARCH is a single-center registry 
whose aim is to evaluate the efficacy of SES implantation 
in the “real world” of interventional cardiology. All 
consecutive patients were enrolled irrespective of clinical 
presentation and lesion characteristics, and the incidence 
of major ad-verse cardiac events was evaluated during 
follow-up. At 6 months after enrollment, a total of 563 
consec-utive patients were treated solely with SES. Of 
these, 31 patients (5.5%) were treated for LM artery 
disease and formed the present study population. In our 
institution, patients with LM disease are routinely treated 
with surgical revascularization. Therefore, patients 
enrolled in this study were divided into 3 groups: (1) 5 
patients treated within the acute phase of myocardial 
infarction, (2) 17 elective patients who were refused 
surgical treatment due to high preoperative risk (n = 9) or 
to patient’s preference for percutaneous treat-ment (n = 
8), and (3) 9 patients with bailout stenting for LM 
dissection that occurred during angioplasty (4 had 
dissection induced by the guiding catheter, 1 due to wire 
exit, and 3 due to proximal left anterior de-scending 
stenting) or during conventional diagnostic procedures (1 
patient). The protected LM segment was defined by the 
presence of a patent coronary artery bypass graft (n = 
11). LM dilatation was performed with implantation of a 
3.0-mm SES in all patients (largest diameter available at 
the time of this study). Use of glycoprotein IIb/IIIa agents 
was left to the operator’s discretion. All patients were 
receiving long-term doses of aspirin (>75 mg/day) and 
received a loading dose of 300 mg of clopidogrel, followed 
by a 75-mg daily single dose for 6 months. Patients’ 
informed written consent was obtained in accordance with 
the rules of the institutional ethics committee that 
approved the study.  
In-hospital outcome information was retrieved by 
means of an electronic clinical database for patients 
maintained in our hospital after the procedure and by 
review of the hospital records for those discharged to 
secondary hospitals. After discharge, recordings of all 
repeat interventions (surgical and percutaneous) and 
repeat hospitalizations were prospectively collected in a 
dedicated database. Follow-up information was ob-tained 
by regular outpatient evaluation, by phone contact, or by 
mail.  
Clinical outcomes were evaluated by the incidence of 
major adverse cardiac events, defined as death, 
myocardial infarction, or any target vessel revascular-
ization, either surgical or percutaneous. Deaths were 
classified as either cardiac or noncardiac. Deaths that 
could not be classified were considered to be cardiac 
related. Procedural success was characterized by 
Thrombolysis In Myocardial Infarction grade flow 3 and 
residual in-lesion stenosis d30%. Clinical success was 
defined by the summation of procedural success in the 
absence of major in-hospital events. 
Discrete variables are presented as counts and per-
centages. Continuous variables are expressed as mean ± 
SD.  
Baseline clinical and procedural characteristics of the 
study group are listed in Table 1. Overall, unpro-tected LM 
disease was present in 20 patients (65%). Four patients 
with acute myocardial infarction were admitted with 
cardiogenic shock (80%). Intra-aortic balloon pump or left 
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ventricular assistance devices were used in patients with 
either hemodynamic com-promise (n = 5) or in elective 
patients deemed to have a very high procedural risk (n = 
3).8 Postdilatation after SES deployment (with 3.5- to 4.5-
mm balloons) was performed in 24 patients (77%). The 
distal LM  bifurcation was treated in 15 patients (48%); in 
these patients, both the parent and side branch vessels 
re-ceived a SES. Segments other than the LM segment 
were treated in 19 patients (61%).  
 
Table 1. Baseline clinical and procedural characteristics (n=31) 
 Acute 
myocardial 
infarction 
(n=5) 
Bail out 
stenting 
(n=9) 
Elective 
(n=17) 
Age (years) 64±9 65±16 65±9 
Men 3 (60%) 4 (45%) 10 (59%) 
Hypercholesterolemia  3 (60%) 5 ( 56%) 12 (70%) 
Treated diabetes mellitus 1 (20%) 3 (33%) 7 (41%) 
Treated systemic 
hypertension 
0 (0%) 3 (33%) 13 (76%) 
Prior myocardial infarction 0 (0%) 3 (33%) 7 (41%) 
Prior angioplasty 0 (0%) 2 (22%) 6 (35%) 
Prior coronary bypass 0 (0%) 1 (11%) 10 (59%) 
Clinical presentation    
Stable angina pectoris - 6 (67%) 17 (100%) 
Unstable angina  - 3 (33%) 0 (0%) 
Lesion location    
Ostial 2 (40%) 6 (67%) 5 (29%) 
Body 2 (40%) 0 (0%) 1 (6%) 
Bifurcation 1 (20%) 3 (33%) 11 (65%) 
Stents per patient 3±2.3 4.5±1.9 2.8±1.6 
Direct stenting 3 (60%) 9 (100%) 5 (29%) 
IIb/IIIa inhibitors 4 (80%) 5 (56%) 5 (29%) 
Cardiogenic shock 4 (80%) 0 (0%) 0 (0%) 
Hemodynamic assist    
Intra aortic balloon  4 (80%) 1 (11%) 0 (0%) 
Left ventricle assist 
device 
0 (0%) 0 (0%) 3 (18%) 
Minimal luminal diameter 
(mm±SD), pre 
1.31± 0.32 1.66±0.65 1.12±0.45 
Minimal luminal diameter 
(mm±SD), post 
2.95±0.03 2.67±0.48 2.71±0.60 
Reference vessel diameter 
(mm±SD), post 
2.94±0.34 3.18±0.51 3.22±0.60 
 
Table 2 lists the clinical outcomes for patients with 
acute myocardial infarction, bailout stenting, and elective 
angioplasty. The incidence of in-hospital major cardiac 
events was 60%, 22%, and 12% in the 3 groups, 
respectively. The in-hospital mortality rate in patients with 
acute myocardial infarction was 60%, in the bailout group 
11%, and in elective patients, the rate was 0%. All 3 
deaths in the acute myocardial infarction group occurred 
in patients admitted in cardiogenic shock (2 presented 
with a totally occluded LM seg-ment). In-hospital repeat 
revascularization occurred in only 1 patient. This patient 
had been successfully treated for LM dissection, but 
developed cardiac tamponade after the procedure and 
underwent surgical pericardial drainage, during which 
time he received a venous graft to the first obtuse 
marginal branch.   
Postdischarge complete clinical follow-up is reported in 
Table 3 and was available for all living patients, except for 
1 patient (who could not be contacted). Mean follow-up 
was 5.1 months (range 3.3 to 6.9). There were no 
postdischarge deaths, myocardial infarctions, or 
percutaneous revascularizations. One patient underwent 
elective minimally invasive coronary bypass (total target 
vessel revascularization rate of 4%). Initially, this patient 
had an SES implan-tation for iatrogenic dissection of the 
LM segment. This patient’s nontreated vessel (chronic, 
totally occluded left anterior descending artery) 
underwent elective revascularization 1 month later. 
 
Table 2. In-hospital events (n=31) 
 Acute 
MI 
(n=5) 
Bailout stenting 
(n=9) 
Elective  
(n=17) 
Deaths  3 (60%) 1 (11%) 1 (6%) 
Myocardial Infarction 0 (0%) 0 (0%) 2 (12%)* 
Percutaneous 
revascularization 
0 (0%) 0 (0%) 0 (0%) 
Coronary bypass 0 (0%) 1 (11%) 0 (0%) 
Major cardiac events 3 (60%) 2 (22%) 2 (12%) 
*Both cases with non-Q wave infarction (patient-1 with peaked Creatine 
kinase MB 185U/I, patient-2 with 36U/I) 
 
••• 
Recently, several studies have demonstrated that 
stenting of the LM artery may be a safe and effective 
alternative to the surgical approach in carefully selected 
patients.1,3,4 Although the in-hospital success rates are 
extremely acceptable, the death rate increases gradually 
for nearly 6 months after the index procedure, and 
thereafter reoccurrence of major cardiac events is mainly 
attributed to progression of atherosclerosis.5 Solving 
restenosis apparently is the key to improving the long-
term outcome in these patients. The SES has thus far 
displayed reduced restenosis rates and a reduced need for 
reintervention.9,10  
The extremely high in-house mortality rate in the 
myocardial infarction group mirrors the fatal risk of 
patients having LM disease in this clinical scenario. Our 
findings agree with previous studies reporting in-hospital 
mortality rates of acute myocardial infarction due to LM 
lesions of 55% to 80%.11,12 The major finding of this 
report is the absence of fatal events in all patients 
discharged from the hospital; this study highlights the 
outstanding performance of the SES. The 0% rate of 
percutaneous reintervention reinforces the efficacy of the 
SES. 
 
Table 3. Post-discharge events (mean follow-up 5.1 ± 1.8 
months, n=27) 
 Acute MI 
(n=2) 
Bailout 
stenting 
(n=8) 
Elective 
(n=17) 
Deaths 0 (0%) 0 (0%) 0 (0%) 
Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 
Percutaneous 
revascularization 
0 (0%) 0 (0%) 0 (0%) 
Coronary bypass 0 (0%) 1 (12%) 0 (0%) 
Major cardiac events 0 (0%) 1 (12%) 0 (0%) 
 
In the present study, post– high-pressure dilatations 
with larger balloons were used to optimize stent-to-wall 
apposition, and overcame the 3-mm width availability of 
the SES. It is not known whether this (sometimes 
extreme) postdilatation will affect the elution properties 
and compromise the polymer’s performance. Furthermore, 
by spreading the struts widely apart, the amount of drug 
per square millimeter of artery may be reduced and thus 
impair the efficacy of the SES. However, in this study, the 
rate of out-of-hospital clinical events was extremely low. 
Thus, the discrepancy between stent and postdilatation 
balloon size does not appear to be of clinical significance. 
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Further investigation to confirm this is warranted. This 
was a single-center observational study, and our results 
may have been confounded by unmeasured factors. 
However, the 0% follow-up mortality rate warrants clinical 
recognition. The importance of our findings is supported 
by the fact that our study popu-lation was representative 
of the real world of patients who undergo percutaneous 
coronary intervention, thus denoting the everyday practice 
of an interventional cardiologist.   
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The effectiveness of sirolimus-eluting stent (SES) implantation in patients treated electively for left main (LM) stenoses 
has not been yet ascertained. The present study reports on the clinical and angiographic outcome of 16 consecutive 
patients treated electively for de novo stenoses in the LM. The impact of SES implantation on major adverse cardiac 
events (MACE) was evaluated. Mean age was 65±11 years. Unprotected LM was present in 9(56%), and 8 patients 
(50%) received stents extending into both the left anterior descending and circumflex arteries for stenoses of the distal 
left main bifurcation. In-house mortality and reintervention rate was zero. One patient developed a non-Q wave 
myocardial infarction related to the index procedure. At one-year clinical follow-up there were no deaths or further 
myocardial infarctions, one (6%) patient required target lesion revascularization (TLR). A total of 12 patients (75%) 
underwent 6-month angiographic follow up with a late lumen loss of 0.04±0.65mm, and one focal restenosis (8% of 
patients). Elective SES implantation for LM disease was associated with zero mortality and a very low incidence of 
additional major adverse events at 1 year. 
 
Catheter Cardiovasc Interv. In press 
 
 
Introduction  
A number of studies have reported on the safety and 
feasibility of left main (LM) coronary artery stenting, with 
various degrees of success depending on the particular 
clinical scenarios under which the patient was treated(1-
4). More widespread use of this approach is hampered by 
the potentially fatal consequences of in-stent restenosis in 
this situation. Thus, the treatment of choice in most 
centers remains surgical revascularization based on trials 
conducted in the early 1980s(5). 
Accumulating data have repeatedly confirmed that 
sirolimus-eluting stent implantation has been associated 
with unparalleled results in reducing restenosis rates(6) 
and neointimal hyperplasia formation(7). In this study we 
report the angiographic and clinical outcomes of 16 
consecutive patients, scheduled for percutaneous 
treatment of de novo LM stenoses.   
Materials and methods  
The present study population comprised 16 consecutive 
patients undergoing elective angioplasty for LM de novo 
stenoses. The LM was considered protected if there was a 
patent coronary artery bypass graft to the left anterior 
descending or circumflex coronary arteries. All patients were 
treated with the largest available diameter SES (3mm), at the 
time of the study. Additional dilatation with largest balloons 
was used if necessary. Use of glycoprotein IIb/IIIa agents 
was left to the operator’s discretion. All patients were on 
chronic aspirin (!75mg daily) and received a loading dose of 
300mg clopidogrel followed by a 75mg daily single dose for 6 
months. The patients’ informed written consent was obtained 
in accordance with the rules of the Institutional Ethics 
Committee, which approved the study.  The analysis, 
interpretation, and submission for publication of this study 
were conducted independently of the trial sponsor. 
A detailed description of the RESEARCH registry has been 
provided elsewhere(8). Briefly, the RESEARCH is a single-
centre registry, which aims to evaluate the efficacy of SES 
(Cypher™; Cordis Europa NV, J&J, Roden, NL). All 
consecutive patients were enrolled irrespective of clinical 
presentation and lesion characteristics, and the incidence of 
major adverse cardiac events (MACE) was evaluated during 
the follow-up.  
In-hospital outcome information was retrieved by means 
of an electronic clinical database for patients maintained in 
our hospital after the procedure and by review of the hospital 
records for those discharged to their referring physicians. 
After discharge, recordings of all repeat interventions 
(surgical and percutaneous) and re-hospitalizations were 
prospectively collected in a dedicated database. Living 
patients were evaluated at our outpatient clinic department, 
by telephone interviews, or by mail. Clinical follow-up was 
obtained in all 16 patients. 
We evaluated the incidence of death, myocardial 
infarction, or any repeat vessel revascularization, either 
surgical or percutaneous. Target lesion revascularization 
(TLR) was defined as either surgical or percutaneous 
reintervention driven by significant (>50%) luminal narrowing 
either within the stent or the 5mm borders proximal and 
distal to the stent, and was undertaken in the presence of 
either anginal symptoms or objective evidence of ischemia. 
All patients had a successful procedure as characterized by 
Thrombolysis in Myocardial Infarction (TIMI) flow 3 and 
residual in-lesion stenosisd30%. In addition, the patients 
were invited to have a follow-up angiographic evaluation at 
6-months. The binary restenosis rate, was defined as >50% 
diameter stenosis occurring in the segment inside the SES or 
within the 5-mm proximal or distal edges. 
Discrete variables are presented as counts and 
percentages. Continuous variables are shown as mean ± SD. 
Results 
Patients’ baseline and procedural characteristics are 
presented in table 1. Mean age was 65±11 years, 11 
(69%) were male and 7 (44%) had diabetes.  Overall, 9 
(56%) of the patients were treated for unprotected LM 
disease and 10 (63%) had a LM lesion involving the distal 
bifurcation. Of these, 8 (50%) received SES in both the 
left anterior descending and the circumflex artery. In 
three patients deemed to be at very high procedural risk, 
a left ventricular assist device (tandem heart®) was used 
successfully. The mean number of stents used per patient 
was 2.9±1.6. Three patients (19%) received SES in 
segments other than the LM, including a vein graft. In 13 
patients (81%) dilatation with larger diameter balloons 
was used to overcome the undersized 3.0mm stent. 
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Table 1. Baseline and procedural characteristics of patients with LM disease treated electively with SES implantation. 
Pt# Age Clinical 
presentation 
Risk factors Previous 
MI 
Previous 
PCI 
Unprotected 
LM 
Lesion location Bifurcation 
stenting 
Largest 
diameter 
balloon used 
Direct 
stenting 
1 78 SA-III HC No No Yes Distal “crush”* Yes No 
2 64 SA-II HT Yes No No Distal No Yes Yes 
3 83 SA-III No No No Yes Distal T-stent No No 
4 69 SA-III DM No No Yes Body T-stent Yes Yes 
5 75 SA-II HC Yes No Yes Distal T-stent No No 
6 50 SA-III CS No No Yes Distal No Yes Yes 
7 65 SA-II HC No No No Ostial No Yes Yes 
8 50 SA-III CS-DM No Yes Yes Ostial No Yes Yes 
9 61 SI DM No Yes Yes Distal T-stent Yes No 
10 56 SA-IV HT No No Yes Distal T-stent Yes Yes 
11 68 SA-III DM No No No Ostial No Yes No 
12 59 SA-III DM Yes No No Ostial No No No 
13 48 SA-IV DM No Yes Yes Distal “crush” Yes No 
14 56 SA-III DM Yes Yes No Distal Kissing stent Yes No 
15 68 SA-III CS Yes Yes No Distal No Yes No 
16 75 SA-III HC No No No Ostial No Yes No 
* “crush” is defined when the stent of the side branch is firstly deployed being almost in parallel position with the stent in the main 
vessel. The second stent is situated in the parent vessel ensuring coverage of the side branch ostium. The stent in the main vessell is 
then deployed, crushing the proximal part of stent at the side branch. If necessary, further kissing balloon inflations were performed. 
UA=unstable angina ; SA=stable angina ; SI=silent ischemia ; CS=current smoker ; DM=diabetes mellitus 
 
One patient developed a non-Q wave infarction, in 
hospital, with a peak creatine kinase of 875 U/l (MB 
fraction of 125 U/l). This patient was a diabetic female 
(patient #15), with a distal LM stenosis protected by a left 
internal mammary artery (LIMA). After optimizing the 
bifurcation with kissing balloons there was a small 
dissection distal to the stent in the left anterior 
descending artery. The operator accepted the result and 
the patient went to the ward painfree.  
Complete clinical follow-up information was available 
for all patients. Mean duration of follow-up was 11.8±1.5 
(range 10-15) months and is summarized in table 2. 
There were no cases of acute, subacute or late 
thrombosis, or death. One patient required TLR, for 
proximal edge restenosis. This patient was a diabetic 
male, with LM ostial stenosis protected by a patent LIMA 
(patient#12). The stenosis was very heavily calcified as 
indicated by the fact that the cutting balloon ruptured, 
and was stented with a 3X18mm and 3X8mm SES. Post 
dilatation was done with a 4.0mm balloon and the post-
procedure diameter stenosis was 43%. Follow-up 
intracoronary ultrasound revealed an underexpansion of 
the stent, due to severe calcification at the ostium.  
 Six-month angiographic follow-up was obtained in 12 
(75%) patients. Quantitative coronary angiographic 
analysis is presented at table 3. The late lumen loss was 
0.04 ± 0.65mm. There was one patient with recurrent 
restenosis, which represents an 8% angiographic 
restenosis rate at 1 year. 
 
Table 2. In-hospital and 1-year clinical outcome in patients 
treated electively for LM disease with SES implantation 
 In-hospital 
events 
Late 
outcome 
Deaths, % 0 0 
Myocardial infarction, % 1(6%) 0 
Reintervention  
  Percutaneous revascularization 
  Coronary bypass 
 
0 
0 
 
1(6%) 
0 
Cumulative incidence of MACE* 1(6%) 1(6%) 
*MACE=major adverse cardiac events 
Discussion  
To our knowledge this is the first consecutive series of 
patients treated electively for LM stenoses with SES. In 
this study we have shown that elective SES implantation 
in patients with LM stenoses was associated with total 
absence of death, and low incidences of reintervention 
and restenosis. Park et al, have reported that treatment of 
LM bifurcation is technically demanding and associated 
with a 28% angiographic restenosis rate(9). However, in 
more than half of the patients in the present study, both 
the parent and the side branch vessel received SES in the 
distal bifurcation. Among these 73% underwent follow-up 
angiography with no evidence of restenosis. We had only 
one case of restenosis. This diabetic patient had a very 
complex procedure in the ostium of the LM and the stent 
was clearly underexpanded. The largest reported series of 
LM stenting so far, had rates of death, target lesion 
revascularization and restenosis of 7.4%, 16.7% and 
21.1% respectively(3). In addition, the mortality rate in 
published data ranges from <10% in protected to 30% 
with unprotected LM stenting(10). This explains why 
patients with LM stenoses continue to be considered 
primarily as candidates for surgery. 
 
Table 3. Quantitative coronary angiography   
 Index procedure Follow-up 
 Pre Post  
Reference diameter, 
mm±SD 
2.92±0.66 3.45±0.66 3.24±0.57 
Minimum luminal diameter, 
mm±SD 
1.19±0.49 2.83±0.73 2.97±0.66 
Acute gain, mm±SD  1.65±0.43  
Late loss, mm±SD   0.04±0.65 
Restenosis rate, %   1 (8%)* 
* Related to 12 patients with 6-month angiographic follow-up 
 
Thus far, the outstanding results of SES implantation 
have been reported in the context of randomized trials. 
Moreover, in these studies LM stenoses were excluded. 
We have recently reported zero percent post discharge 
mortality rate in a very complex patient population that 
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received SES in the LM segment(11).The zero percent 
mortality rates underline the efficacy of SES implantation 
and further corroborate the remarkable results reported 
thus far with this device. The results are particularly 
impressive given that there was a 44% incidence of 
diabetes in the study population. The very low late loss of 
on 0.09mm is also of note in this setting. These data 
suggest that the use of SES may be expanded to the 
treatment of LM stenoses with extremely favorable 
results. However, a word of caution is in order. It is 
critically important to insure that the SES size chosen can 
be expanded to the appropriate diameter for the LM, 
which is generally greater than 3 mm and often 4-5 mm 
in diameter, since stent under deployment and the 
resulting risk of thrombosis can be rapidly fatal in this 
setting. 
  Randomized trials to specifically compare LM stent 
implantation with coronary artery bypass surgery have 
until now been avoided to due to logistic considerations, 
prohibitive sample size and cost requirements. However, 
taking into account the impact of SES on restenosis, 
percutaneous intervention with the SES may now be a 
safe and effective alternative to bypass surgery for this 
group of patients. The time for a multicenter, randomized 
trial of SES versus bypass surgery for LM stenoses may 
have arrived. 
 This is a single center observational study with a 
limited number of patients and it is possible that our 
results are confounded by unmeasured factors. Moreover 
the 75% angiographic follow-up rate somewhat limits 
confidence in the angiographic evaluation. Although small, 
this is the first series of patients that have been electively 
treated with SES in the LM segment. The 12% overall 
MACE rate is very encouraging, and the total absence of 
fatal events warrants recognition.  
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The aim of this study was to evaluate the effectiveness of sirolimus-eluting stent (SES) implantation for patients with 
multivessel disease, that included left anterior descending artery (LAD) treatment. Since April 2002, SES has been 
utilized as the device of choice for all interventions in our institution, as part of the Rapamycin Eluting Stent Evaluated 
At Rotterdam Hospital (RESEARCH) registry. In the first 6 months of enrolment, 99 consecutive patients (17.6% of the 
total population) were treated for multivessel disease involving the LAD. The impact of SES implantation on major 
adverse cardiac events (MACE) was evaluated. 
All the patients received SES in the LAD. Additional stent implantation in the right coronary artery (RCA), the left 
circumflex (LCx), or in all three major vessels was attempted successfully in 32 (32%), 51 (52%) and 16 (16%) of the 
treated patients respectively. During a mean follow-up of 360 ± 59 days (range 297 to 472 days) we had one death, 
one non-Q myocardial infarction and 8 patients required subsequent intervention. The event-free survival of MACE at 
one year was 85.6%. 
Sirolimus-eluting stent implantation for multivessel disease in a consecutive series of patients is associated with low 
incidence of adverse events. The reported results are related predominantly to the reduction in repeat revascularization.  
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Introduction  
The widespread use of percutaneous treatment for 
multivessel disease has been limited by the need for 
repeat revascularization(1-3). Indeed, the restenosis rate 
may be quite high, on a per-patient basis, since 
multilesion stenting is performed. Additionally, the ERACI 
II investigators have shown higher revascularization rates 
(27%) when the LAD was involved(4). Thus, in patients 
with multivessel disease the dominant form of 
revascularization remains bypass surgery. 
The SES has recently proven its efficacy in reducing 
restenosis(5) in single de novo lesions. Importantly, the 
late benefit observed with SES was accomplished without 
compromising the excellent procedural and acute results 
already obtained with conventional metallic stents. The 
aim of the present study was to determine whether 
utilization of SES for a consecutive series of patients with 
multivessel stenoses and LAD involvement would be 
correlated with a reduced incidence of major events. 
Methods  
Study design and patient population 
The RESEARCH study is a single center registry, which 
aims to evaluate the efficacy of SES (Cypher™; Cordis Europa 
NV, J&J, Roden) implantation. A detailed description of this 
study has been provided elsewhere(6,7). The SES was 
utilized as the device of choice in all patients treated, 
irrespective of clinical presentation or lesion characteristics. 
From 16th April 2002 until 15th October 2002 a total of 563 
patients were treated solely with SES. In the present study, 
we report on 99 consecutive patients (17.6%) without 
previous bypass surgery treated electively with SES 
implantation in the left anterior descending (LAD) territory, 
together with stenting in the left circumflex (LCx) and/or right 
coronary artery (RCA) territories (i.e. revascularization of 
multivessel stenoses involving the LAD). Routinely, in our 
hospital, an experienced interventional cardiologist and a 
cardiothoracic surgeon discuss all patients referred for 
revascularization. When both agree on equivalence of 
revascularization then the patient is treated percutaneously in 
the first instance. The patients’ informed written consent was 
obtained in accordance with the rules of the Institutional 
Ethics Committee, which approved the study.  The analysis, 
interpretation, and submission for publication of this study 
were conducted independently of the trial sponsor. 
Procedures, definitions and follow-up 
The final interventional strategy was left entirely to the 
operator’s judgment. Angiographic success rate defined as 
residual stenosis <30% by visual estimation in the presence 
of TIMI 3 flow. Peri- and post-procedural antithrombotic 
medications were used at the operator’s discretion. The 
coronary arteries were subdivided into 15 segments 
according to the American Heart Association/American 
College of Cardiology (AHA/ACC) criteria(8). All patients were 
on chronic aspirin (!75mg daily) and received a loading dose 
of 300mg clopidogrel followed by a 75mg daily single dose 
for at least 3 months. Patients considered to be at higher 
thrombotic risk due to lesion complexity had a total of 6 
months clopidogrel (multiple SES implantation [>3 stents], 
total stent length >36mm, chronic total occlusion, and 
bifurcations)(6). 
We evaluated the incidence of MACE: death, myocardial 
infarction (MI), or repeat revascularization. Myocardial 
infarction was documented by a rise in the creatine kinase 
level of more than twice the upper limit with an increased 
creatine kinase-MB. Cardiac markers were measured serially 
for all patients maintained in our institution. Among those 
discharged to their community hospitals, cardiac markers 
were collected only if a post-procedural MI was suspected. 
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Consequently, enzymatic assessment was not available for all 
patients, but for those whom the likelihood of post-procedure 
MI was high. Target lesion revascularization (TLR) was 
defined as either surgical or percutaneous reintervention 
driven by significant (>50%) luminal narrowing either within 
the stent or the 5mm borders proximal and distal to the 
stent. Target vessel revascularization was defined as any 
reintervention in the treated vessel.  
 
Table 1. Baseline and procedural characteristics in 99 patients 
treated with SES for multivessel disease involving the LAD 
Age, years ± SD 64 ± 11 
Male, % 66 
Treated diabetes, % 25 
Treated hypertension, % 51 
Treated hypercholesterolemia, % 68 
Current smoking, % 24 
Previous MI, % 31 
Previous PCI, % 19 
Stable angina, % 
Unstable angina, % 
58 
42 
LCx treated (including LAD), % 52 
RCA treated (including LAD), % 32 
Triple vessel treatment, % 16 
Glycoprotein IIbIIIa inhibitor, % 25 
ACC/AHA lesion type*, n=293 lesions 
Type A, B1, % 
Type B2, C, % 
 
38 
62 
Number of implanted stents per patient ± SD 3.5 ± 1.5 
Total stented length per patient, ± SD 62.6 ± 32.1 
Nominal  stent diameter utilized, mm ± SD 2.6 ± 0.3 
LAD=left anterior descending, MI=myocardial infarction, LCx=left 
circumflex, RCA=right coronary artery 
 
In-hospital outcome information was retrieved by means 
of an electronic clinical database for patients maintained in 
our hospital after the procedure and by review of the hospital 
records for those discharged to secondary hospitals. After 
discharge, recording of all repeat interventions (surgical and 
percutaneous) and re-hospitalizations was performed 
prospectively in a dedicated database. Living patients were 
evaluated at our outpatient clinic department, by telephone 
interviews, or by mail contact.  
Statistical analysis 
 Continuous variables were expressed as mean ± SD and 
discrete variables as counts and percentages. Event-free 
survival distribution was estimated according to the Kaplan-
Meier method. Patients lost to follow-up (n=2) were 
considered at risk until the date of last contact, at which point 
they were censored. 
 
Results  
Baseline and procedural characteristics are depicted in 
table 1. The mean age of our cohort was 64 ± 11 years, 
42 patients (42%) were treated for unstable angina, 
diabetes was present in 25 patients (25%), and 31 (31%) 
had previous myocardial infarction. Overall, we had 15 
patients (15%) treated for at least one chronic total 
occlusion (> 3-month duration) and 5 patients (5%) with 
in-stent restenosis. As was indicated by the study 
protocol, all patients received SES in the LAD. Among the 
99 patients treated, 46 (46%) received SES in the 
proximal LAD, 56 (56%) in the middle LAD, 7 (7%) in the 
distal and 24 (24%) were treated in any of the diagonal 
branches. Additional SES stenting was undertaken in the 
RCA, LCx, and in both vessels 32 (32%), 51 (52%), 16 
(16%) respectively. Overall, 295 lesions were treated 
(2.9±1.1 lesions per patient) with a mean stent utilization 
of 3.5±1.5 per patient; a total of 20 patients (20%), 
received more than 5 stents. 
  One patient died in-hospital following a complicated 
procedure with emergent bypass surgery due to left main 
stem dissection. Additionally, there was one post-
procedure non-Q wave myocardial infarction [peaked 
creatine kinase 567U/I (MB fraction: 62U/I)].   
Clinical follow-up was available for all but 2 patients 
(98%). Clinical outcomes at 30 days and 9-months are 
presented in table 2. Follow-up at 9 months was available 
for 100% of the patients and the cumulative incidence of 
MACE was 10%. 
 
Table 2. 30-day and 9-month cumulative incidence of adverse 
events of patients treated with SES for multivessel disease 
involving the LAD.                                                                  
 30-day 9-month 
Death, % 1 1 
Non-fatal myocardial infarction*, % 1 1 
TLR, % 1 4 
TVR, % (including TLR) 1 8 
SES thrombosis†, % 0 0 
Overall incidence of adverse events, % 3 10 
* non-Q wave myocardial infarction [peaked creatine kinase 
567U/I (MB fraction: 62U/I)].   
†Angiographically documented SES thrombosis requiring 
reintervention The average follow-up was 360 ± 59 days (range 
297 to 472 days).  
 
There were no cases of acute or subacute thrombosis 
(angiographically documented stent thrombosis requiring 
repeat intervention). No further patients died or had MI. 
Overall 8 patients (8%) required subsequent 
revascularization. Among these, 4 patients (4%) had TLR. 
Two patients, originally treated for chronic total occlusion, 
had focal in-stent restenosis in the overlapping segment 
of two SES. The third had an underexpanded stent at the 
ostium of the RCA (which was heavily calcified) and had 
additional cutting balloon dilatation. The fourth patient 
had a TLR due to restenosis at the proximal edge of the 
SES. A further 4 patients (4%) had percutaneous 
reintervention in an untreated segment due to 
progression of atherosclerosis. The survival rate free of 
events at one year was 85.6% (Figure 1). 
Discussion  
In the present study, we report a low incidence of 
adverse events in patients treated with SES in a scenario 
of multivessel stenting, involving the LAD. This reduction 
is related to the reduced rates of repeat revascularizations 
presented in this study, predominantly to the reduction of 
target lesion reintervention. To our knowledge this is the 
first study reporting a freedom from revascularization of 
92% at one year in patients with multivessel stenting. 
Although the utilization of stents in the ARTS, ERACI II 
and SOS trials was very high, freedom from 
revascularization was 79%, 83.2% and 79% 
respectively(1,9,10). The event-free survival rate reported 
in the ARTS trial within the stent group was 73.8%. The 
85.6% survival rate reported in this study warrants further 
evaluation. The absence of death or myocardial infarction 
during the follow-up period is noteworthy. The majority of 
the patients (87%) were treated with dual anti-thrombotic 
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therapy (aspirin combined with clopidogrel) for six 
months. Moreover, statins as adjunctive medication were 
widely used (89%). We hypothesize that this aggressive 
treatment in combination with the use of drug-eluting 
stent might be related with this observation.  
 
Figure 1. Event-free survival curves of 99 patients treated with 
SES for multivessel disease and LAD involvement. 
 
The fact that 2 out of 4 TLR events were located in 
overlapping SES segments merits further investigation. It 
is unknown if the elution properties are compromised in 
overlapping sites, although preliminary results of 
overlapping SES from the RESEARCH population suggest a 
higher late luminal loss in this specific site but with no 
restenosis. We have recently reported that SES 
discontinuity and edge injury are related with post SES-
restenosis(6). Therefore, when treating multivessel 
stenoses, complete lesion coverage is mandatory to 
ensure a homogeneous drug release over the entire 
diseased segment. This explains the high number and 
length of SES, compared to the aforementioned trials, 
used in the present study. The impact of SES in restenosis 
is of great clinical importance, and enhances the 
encouraging results presented thus far. The ARTS II trial 
is consequently undergoing to investigate the outcomes 
and costs of SES implantation for multivessel disease. The 
evolution in interventional cardiology has been 
tremendous. The domination of bypass surgery for 
multivessel disease was based on the historical results 
comparing angioplasty versus bypass surgery reported in 
the 1980s and 1990s. The future management of patients 
with multivessel disease needs to take into account the 
current evidence.  
Limitations  
This is an observational subanalysis of a single centre 
study with a limited number of patients and it is possible 
that our results are confounded by unmeasured factors. 
No comparison with other invasive modalities (e.g. 
conventional stenting and surgery) was reported. Knowing 
the outcomes of multivessel patients treated with these 
strategies(1,4,10), the relatively limited number of cases 
in our series (99 patients) precluded any attempt to 
comparatively evaluate, with enough statistical power, 
surgery or bare stent implantation with sirolimus-eluting 
stents. In the ARTS II trial, a sample size of 600 patients 
was calculated to guarantee a power of at least 90% to 
test the hypothesis that sirolimus-eluting stents were at 
least as effective as surgery(11). Only 16% of the patients 
were treated for triple-vessel disease. Therefore, the very 
low incidence of adverse events reported in this study, 
may not be applicable for larger groups of patients with 
triple-vessel disease. However, this is the first series of 
consecutive patients treated with SES in a multivessel 
setting and the 85.6% one-year event-free survival rate 
warrants recognition.  
Conclusions  
Sirolimus-eluting stent implantation for patients with 
multivessel disease involving the LAD is associated with 
low incidence of adverse events at one year, particularly 
of subsequent revascularization. 
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Objectives: To assess sirolimus-eluting stent (SES) implantation for the treatment of chronic total occlusions (CTO). 
Background: Long-term results following percutaneous coronary intervention (PCI) in the treatment of CTO`s is 
hindered by a significant rate of restenosis and re-occlusion. In the treatment of relatively simple non-occlusive lesions, 
SESs have shown dramatically reduced restenosis rates compared with bare stents (BMS), but whether these results are 
more widely applicable is unknown.    
Methods: From April 2002, all patients at our institution were treated with SES as the device of choice during PCI. 
During the first 6-months, 563 patients were treated solely with SES, with treatment of a de novo CTO in 56 (9.9%). 
This CTO cohort was compared with a similar group of patients (n=28) treated in the preceding 6-month period with  
BMS.  
Results: At 1 year, the cumulative survival-free of major adverse cardiac events was 96.4% in the SES group versus 
82.8% in the BMS group, p<0.05. At 6-months follow-up, 33 (59%) patients in the SES group underwent angiography 
with a binary restenosis rate (>50% diameter stenosis) of 9.1% and in-stent late loss of 0.13 ± 0.46mm. One patient 
(3.0%) at follow-up was found to have re-occluded the target vessel.  
Conclusions: The use of SESs in the treatment of chronic total coronary occlusions is associated with a reduction in the 
rate of major adverse cardiac events and restenosis compared to bare stents. 
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Introduction 
Chronic total occlusions (CTO) are common, and found 
in approximately one third of patients with significant 
coronary disease who undergo angiography. 1,2 
Percutaneous intervention (PCI) of CTOs accounts for 10-
15% of all angioplasties; however, following successful 
recanalization, there is an increased rate of subsequent 
restenosis and re-occlusion compared to non-occlusive 
stenoses. 3,4 Although several randomized trials 
demonstrated the efficacy of stent implantation over 
balloon-only angioplasty; even with stents, there remains 
a significant rate of both restenosis (32-55%) and re-
occlusion (8-12%). 5-9  
In the treatment of relatively simple lesions, sirolimus-
eluting stents (SES) markedly reduce the restenosis rate, 
with continued benefit documented up to 2 years follow-
up. 10,11 Whether these results can be extrapolated to 
more complex lesions such as CTO`s, has yet to be 
determined. We sought to evaluate the effectiveness of 
the SES in a consecutive series of patients with at least 
one de novo CTO compared to a similar series treated 
with bare stents (BMS). 
Methods 
Patient population 
Commencing in April 2002, all PCI at our institution was 
done solely with SESs, irrespective of clinical presentation or 
lesion morphology, these patients comprise the RESEARCH 
registry (further details of the methodology are described 
elsewhere). 12,13 Those deemed at an increased risk of 
restenosis (including the CTO population), were considered 
for 6-month angiographic follow-up. SES were available in 
lengths between 8mm and 33mm, and diameters 2.25mm to 
3.0mm. In the first 6-months, 563 patients were treated, 
including 56 (9.9%) with successful revascularization of at 
least one CTO. These patients make up the present study 
cohort; all received 6-months dual anti-platelet therapy with 
clopidogrel in addition to aspirin. As pre-determined by the 
RESEARCH protocol, this study cohort of patients were 
compared to all those treated for a CTO in the preceding 6-
months with bare metal stents (BMS), identified from the 
departments` dedicated database. Both groups were treated 
by the same operators utilizing standard techniques; the only 
difference being the type of stent. The protocol was approved 
by the local ethics committee and is in accordance with the 
principles of Good Clinical Practice for Trials of Medicinal 
Products in the European Community and the Declaration of 
Helsinki. All patients signed a written informed consent. 
Chronic total occlusion definition 
Complete occlusion on angiography with no antegrade 
filling of the distal vessel other than via collaterals. All 
patients included had a native vessel occlusion estimated to 
be at least 1-months` duration, 9 based on either a history of 
sudden chest pain, a previous acute myocardial infarction in 
the same target vessel territory, or the time between the 
diagnosis made on coronary angiography and PCI.  
Length of occlusion 
This was measured by quantitative coronary angiography 
either utilizing antegrade filling via collaterals, or assessment 
of the retrograde collateral filling. This was achieved by 
catheterizing both the left and right coronary arteries, and 
making a simultaneous injection to delineate the distance 
between the site of occlusion and the most proximal part of 
the vessel filled retrogradely. 
Follow-up 
Patients were followed up prospectively and evaluated for 
survival-free of major adverse cardiac events (MACE) using 
questionnaires and telephone enquiries. MACE was pre-
defined as: 1) death, 2) non-fatal myocardial infarction (AMI), 
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or 3) repeat target vessel revascularization (TVR). The 
diagnosis of AMI required an elevation of creatine kinase to 
twice the upper limit of normal, together with a rise in 
creatine kinase-MB fraction. TVR was defined as either 
surgical or percutaneous reintervention driven by significant 
(>50%) luminal narrowing within the treated vessel, and was 
undertaken in the presence of either anginal symptoms or 
objective evidence of ischemia.  
 
Table 1: Baseline patient demographics  
 Bare stents 
(n=28) 
SESs 
(n=56) 
p-value 
Mean age (years) 59.8±11.1 60.2±10.0 0.9 
Male sex (%) 85.7 71.4 0.2 
Current smoker (%) 35.7 26.8 0.5 
Diabetes mellitus (%) 7.1 14.3 0.5 
Hypertension (%) 39.3 39.3 1.0 
Hypercholesterolemia (%) 57.1 55.4 1.0 
Previous MI (%) 46.4 55.4 0.6 
Previous PCI (%) 21.4 12.5 0.3 
Previous CABG (%) 0 0 - 
IIb/IIIa inhibitor (%) 25.0 21.4 1.0 
Multivessel disease (%) 60.7 46.3 0.3 
PCI in at least one additional 
(non-occluded) major vessel (%) 
28.6 42.6 0.2 
SES: sirolimus-eluting stents, CABG: coronary artery bypass 
grafting, PCI: percutaneous coronary intervention 
 
Table 2: Baseline procedural characteristics 
 Bare stents 
(n=29) 
SESs 
(n=56) 
p value 
Target vessel   0.06 
LAD (%) 27.6 51.8  
LCX (%) 27.6 25.0  
RCA (%) 44.8 23.2  
Mean length of occlusion (mm), 
(range) 
12.7 
(2.4-31.8) 
11.3 
(4.0-32.1) 
0.5 
Bifurcation stenting (%) 17.9 14.3 1.0 
Mean number of stents implanted 1.8 2.0 1.0 
Mean stent diameter (mm) 3.03±0.56 2.75±0.26 <0.001 
Mean stent length (mm) 23.3±9.3 23.9±9.2 0.7 
Total stented length (mm), 
(range) 
41.8 
(18 - 112) 
45.2 
(8 – 117) 
0.7 
Post-procedure QCA data    
Reference diameter (mm) 2.37±0.50 2.35±0.46 0.9 
Minimal lumen diameter (mm) 2.18±0.49 2.06±0.48 0.3 
Diameter stenosis (%) 10.4 11.6 0.6 
LAD=left anterior descending artery; LCX=circumflex artery, 
RCA=right coronary artery; QCA=quantitative coronary 
angiography 
Angiographic analysis 
Quantitative analysis in those SES patients with follow-up 
angiography was undertaken in three coronary segments: in-
stent (encompassing the entire length of stented segment), 
and the 5-mm proximal and distal edge segments either side 
of the in-stent segment. The target lesion comprised the in-
stent plus the proximal and distal edge segments. Binary 
restenosis was defined as >50% diameter stenosis within the 
target lesion. Late lumen loss was calculated from the 
difference in minimal lumen diameter between post-
procedure and follow-up.  
Statistical analysis 
Discrete variables are presented as percentages and 
compared with Fisher exact test. Continuous variables are 
expressed as mean ± standard deviation and compared with 
Student’s t test. Cumulative survival and MACE-free survival 
were calculated according to the Kaplan-Meier method. The 
log-rank test was used to compare MACE-free survival 
between the two groups. All tests were two-tailed, and a p 
value of <0.05 was considered as significant.  
Results 
The baseline patient and lesion characteristics of the 
two groups are presented in tables 1 and 2. One patient 
in the BMS group underwent successful recanalization and 
stent implantation in two CTO`s, thereby making a total 
of 29 lesions in this group. Mean length of occlusion could 
be determined in 45 (80.0%) of the SES group and 17 
(62.1%) of the BMS group. There was no significant 
difference between the groups with respect to the post-
procedural quantitative angiography, however, the mean 
diameter of stent utilized was greater in the BMS cohort.  
There were no in-hospital major adverse events. 
Clinical follow-up data was obtained in 100% of both 
groups. There were no deaths or AMI in either group, 
with all events related to TVR. At one year, the cumulative 
survival-free of MACE was 96.4% in the SES group 
compared to 82.8% in the BMS group, p<0.05 (Figure 1). 
One patient in each group had a re-occlusion (1.8% SES 
group versus 3.6% BMS group, p=NS).  
 
Table 3. Post-procedural and 6-month follow-up quantitive 
angiographic data for the sirolimus-eluting stent (n=33) 
 Proximal 
5mm 
In-stent Distal 5mm 
Post-procedure    
Mean diameter (mm) 2.82 ± 0.66 2.58 ± 0.55 2.10 ± 0.64 
MLD (mm) 2.43 ± 0.51 2.04 ± 0.45 1.75 ± 0.53 
% diameter stenosis 14.1 12.9 21.8 
6 month follow-up    
MLD (mm) 2.33 ± 0.90 1.91 ± 0.68 1.81 ± 0.75 
% diameter stenosis 20.1 21.9 18.2 
Lumen loss (mm) 0.10 ± 0.80 0.13 ± 0.46 -0.06 ± 0.54 
MLD=minimal luminal diameter 
 
At 6-months, 33 (58.9%) patients in the SES group 
underwent follow-up angiography, (none in the BMS 
group). The binary restenosis rate was 9.1%: one 
occlusion, one stenosis at the ostium of a side branch 
following T-stenting, and the third at the distal outflow of 
the SES. The patient with occlusion underwent bifurcation 
T-stenting following successful recanalization of a heavily 
calcified left anterior descending artery. At follow-up, the 
artery had re-occluded, and there was new akinesis of the 
left ventricular anterior wall. This patient with occlusion 
was managed with medical therapy; the other 2 patients 
with restenosis underwent percutaneous revascularization. 
Discussion 
Previous studies have demonstrated the importance of 
revascularization of CTO`s, with improvement in anginal 
symptoms, exercise capacity, and left ventricular function. 
14-16 In addition, successful recanalization reduces the 
subsequent need for bypass surgery, the rate of AMI, and 
importantly, long-term evaluation has shown a 10-year 
survival advantage of 73.5% following successful PCI 
compared to 65.1% in those with unsuccessful PCI. 4,17  
To our knowledge this is the first report regarding the 
efficacy of SES in CTO`s, a subset of patients previously 
excluded from other protocols and, importantly, at 
increased risk of developing restenosis after conventional 
stent implantation. 3 Of the patients who underwent 
follow-up angiography, both the in-stent and proximal 
5mm segments analysed showed an encouraging late loss 
of 0.13 ± 0.46mm and 0.10 ± 0.80mm respectively. The 
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distal 5mm actually showed an overall benefit, with 
enlargement of the vessel (late loss -0.06 ± 0.54mm).  
 
 
 
Figure 1: Kaplan-meier curves for survival-free of MACE (defined 
as death, acute myocardial infarction, or target vessel 
revascularization) 
 
In addition to the angiographic data, the clinical 
follow-up is very encouraging with no death or myocardial 
infarction. Importantly, there were no significant 
differences in baseline demographics between the SES 
and BMS groups, and all procedures were carried out in 
the same centre by the same operators. The restenosis 
rate for BMS is inversely related to the post-procedural 
MLD and the number of stents utilized. 18 In the current 
study, although the mean diameter of stent used was 
significantly greater in the BMS cohort (related to a 
maximum available SES diameter of 3.0mm), with free 
utilization of post-dilatation, the post-procedural MLD was 
not significantly different between the 2 groups. All events 
in both groups related to TVR, and at one year, there was 
a significantly higher rate of survival-free of MACE of 
96.4% in the SES group versus 82.8% in the BMS group.  
Four major randomized trials have demonstrated the 
efficacy of stent implantation over balloon-only 
angioplasty in the treatment of CTO`s, reducing the 6-
month restenosis rate from 68-74% to 32-55%. 5-8 
Compared to this historical data, our study suggests that 
the SES confers a marked further advantage with a 
significantly lower binary restenosis rate of 9.1% 
(p<0.05). Figure 2. In addition, we had only one patient 
(3.0%) with vessel re-occlusion, compared to rates of 
between 8-12% in the same published trials utilising BMS. 
A recent study of the clinical results of 376 patients 
discharged from hospital without an adverse event 
following successful intervention of a CTO showed, at one 
year follow-up, a MACE-rate of 12.2%; 19 our results are 
therefore quite remarkable, with a MACE-free survival rate 
of 96.4%.   
 Limitations 
This study evaluated only a small cohort of patients 
and angiographic follow-up was not obtained in all, so 
additional patients with silent re-occlusion cannot be 
excluded. However, those who did not undergo repeat 
angiography were all symptomatically well at follow-up. In 
addition, despite the discrepancy in follow-up angiography 
rates between the two groups which might have biased 
the results towards more revascularization in the SES 
group, the MACE rate remained statistically significant 
with a beneficial effect in favor of the SES. The study was 
not randomized, and used a retrospective comparitive 
population, however the same operators and 
interventional techniques were utilized. 
 
Figure 2: The percentage binary restenosis rate (>50% diameter 
stenosis), and re-occlusion rate of RESEARCH compared with 
published data from the patients treated with stent implantation 
in the randomized trials SICCO,5 GISSOC,6 STOP,7 and TOSCA.8 
Conclusions 
The use of SESs in the treatment of complex patients 
with CTO`s is associated with a reduction in the rate of 
major adverse cardiac events and restenosis compared to 
bare stents. 
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A total of 91 patients were treated with 2.25-mm sirolimus-eluting stents (SES) for 112 lesions, which were compared to 
lesions treated with SES t2.5-mm diameter in the same procedure (n=109). The reference diameter was 1.88±0.34 mm 
and 2.52±0.57 mm respectively (p<0.01). At follow-up, the late late loss was 0.07±0.48 mm for 2.25-mm SES vs. 
0.03±0.38 mm for larger SES (p=0.5) and the binary restenosis rate was 10.7% vs. 3.9% respectively (p=0.1). The 12-
month target lesion revascularization rate was 5.5%. In conclusion, 2.25-mm SES were associated with low rates of 
clinical and angiographic late complications. 
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Implantation of 2.25-mm sirolimus-eluting 
stents in very small vessels of an unselected 
patient population treated in the “real world” was 
associated with low rates of restenosis and a 
reduced incidence of target lesion 
revascularization. 
The role of coronary stenting for small coronary 
vessels is not defined, with several randomized trials 
comparing stents with balloon angioplasty presenting 
contradictory results.1-6 Recently, sirolimus-eluting stents 
have strikingly reduced restenosis compared to 
conventional stents in the Randomized Study with the 
Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent in 
the Treatment of Patients with de Novo Native Coronary 
Artery Lesions (RAVEL) 7 and in the SIRolImUS-Eluting Bx 
Velocity Balloon-Expandable Stent (SIRIUS) trial.8  In both 
studies, sirolimus-eluting stent implantation has been 
associated with a marked treatment effect on target lesion 
revascularization across the entire spectrum of vessel 
sizes in the included population. However, the RAVEL and 
SIRIUS trials were restricted to relatively large vessels 
(minimum stent diameter available was 2.5 mm). In a 
post-hoc analysis of patients enrolled in RAVEL,9 
sirolimus-eluting stents effectively inhibited neointimal 
proliferation independently of vessel size. Conversely, in 
the SIRIUS trial, patients in the lower strata of vessel 
diameter presented higher rates of in-stent restenosis.8 
The rationale of the present study was, therefore, to 
evaluate the clinical and angiographic outcomes after 
implantation of sirolimus-eluting stents dedicated to the 
treatment of very small vessels. 
••• 
Since 16th April 2002, sirolimus-eluting stent (SES) 
implantation (Cypher; Johnson & Johnson-Cordis unit, 
Cordis Europa NV, Roden, the Netherlands) has been 
utilized as the default strategy in our institution, as part of 
the RESEARCH (Rapamycin-Eluting Stent Evaluated At 
Rotterdam Cardiology Hospital) study.10 At 6 months 
enrollment, a total of 91 consecutive patients (16% from 
the total population in the period) had been treated with 
2.25-mm diameter SES for 112 de novo lesions. Among 
these 91 patients, 60 patients had also lesions treated 
with SES t2.5 mm diameter (n=109 lesions) (average 
stent diameter in these lesions 2.9±0.2 mm). The 
angiographic outcomes of lesions treated with larger SES 
were utilized as a reference for comparison with lesions 
treated with 2.25-mm SES. 
 
Table 1. Baseline and follow-up clinical characteristics of patients treated 
2.25-mm diameter sirolimus-eluting stents (n=91 patients). 
Men 56 (62 %) 
Age (years ± SD) 64±12 
Diabetes mellitus 24 (26 %) 
On insulin 9 (10 %) 
Systemic hypertension 51 (56 %) 
Current smoking 21 (23 %) 
Previous myocardial infarction 29 (32 %) 
Previous percutaneous intervention 23 (25 %) 
Previous coronary bypass surgery 10 (11 %) 
Acute coronary syndrome 34 (37 %) 
Multivessel coronary disease  66 (72 %) 
12-month follow-up  
Death 2 (2.2 %) 
Death + myocardial infarction 3 (3.3 %) 
Target lesion revascularization 5 (5.5 %) 
Any major adverse cardiac event 7 (7.7 %) 
 
Sirolimus-eluting stents were available in diameters of 
2.25, 2.50, 2.75, and 3.00 mm. The interventional 
strategy applied was entirely left to the discretion of the 
operator, including the choice of the most appropriate 
stent size. On-line quantitative coronary analysis guidance 
was available for all cases and is routinely used in our 
institution. This protocol was approved by the hospital 
ethics committee and written informed consent was 
obtained from every patient. 
Major adverse cardiac events were defined as death, 
non-fatal myocardial infarction, or target lesion 
revascularization. Myocardial infarction was diagnosed by 
a rise in the creatine kinase level of more than twice the 
normal limit with increased MB fraction. Target lesion 
revascularization was defined as any re-intervention to 
treat a stenosis within the stent or in the 5-mm distal or 
proximal segments adjacent to the stent. All living 
patients were considered eligible for 6-month 
angiographic follow-up. Binary angiographic restenosis 
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was defined by diameter stenosis 50% at follow-up 
angiography. Late loss was calculated by the difference 
between the minimal luminal diameter after stenting and 
at follow-up.  
Continuous variables were presented as 
mean±standard deviation and compared using Student’s 
t-test. Categorical variables were presented as counts and 
percentages and compared with the Fisher’s exact test. All 
statistical tests were 2-tailed. A p-value <0.05 was 
considered significant. 
••• 
Baseline clinical characteristics are shown in Table 1. 
Angiographic findings of lesions treated with 2.25-mm SES 
and lesions treated with larger diameter stents in other 
vessel segments are presented in Table 2. Lesions treated 
with 2.25-mm SES’s were more frequently located at 
secondary branches, non-proximal segments, and ostial 
lesions, and had significantly smaller reference diameters 
(1.88±0.34 mm vs. 2.52±0.57 mm; p<0.01). 
Angiographic follow-up (7.1±1.3 months) was available 
for 62 patients (70% of eligible patients) and 151 lesions. 
Late loss was similar between both lesion groups 
(0.07±0.48 mm for 2.25-mm SES vs. 0.03±0.38 mm for 
larger SES; p=0.5), as illustrated in Figure 1.  
 
Table 2. Angiographic characteristics of lesions treated with 
sirolimus-eluting stents of larger diameters and lesions treated 
with 2.25-mm diameter sirolimus-eluting stent. 
 Larger SES 
(n=109) 
2.25-mm 
SES 
(n=112) 
P 
Treated coronary arteries   <0.01 
Left anterior descending  35 (32 %) 18 (16 %)  
Diagonal 2 (2 %) 33 (30 %)  
Left circumflex artery 22 (20 %) 15 (13 %)  
Obtuse marginal or intermedius 12 (11 %) 21 (19 %)  
Right coronary artery 30 (28 %) 8 (7 %)  
other branches 8 (7 %) 17 (15 %)  
Proximal location 34 (31 %) 11 (10 %) <0.01 
Ostial location 21 (19 %) 47 (42 %) <0.01 
Pre-procedure    
Reference diameter (mm±SD) 2.52±0.57 1.88±0.34 <0.01 
Minimal luminal diameter 
(mm±SD) 
0.82±0.53 0.57±0.37 <0.01 
Diameter stenosis (%±SD) 67.8±18.5 69.4±19.1 0.5 
Lesion length (mm±SD) 15.8±9.8 12.3±9.3 0.02 
Post-stenting    
Minimal luminal diameter 
(mm±SD) 
2.23±0.62 1.74±0.35 <0.01 
Diameter stenosis (%±SD) 16.5±12.8 15.9±10.9 0.7 
Follow-up*    
Minimal luminal diameter 
(mm±SD) 
2.18±0.64 1.61±0.57 <0.01 
Diameter stenosis (%±SD) 20.4±16.7 25.1±24.0 0.2 
Late loss (mm±SD) 0.03±0.38 0.07±0.48 0.5 
Binary restenosis (%) 3.9 10.7 0.1 
SD=standard deviation; SES=sirolimus-eluting stent 
*Refers to 62 patients (70% of eligible patients) with 
angiographic follow-up at 6 months (76 lesions in the larger SES 
group and 75 lesions in the 2.25-mm SES group) 
 
Binary restenosis was identified in 8 lesions (10.7%) 
treated with 2.25-mm SES’s and in 3 lesions (3.9%) 
treated with larger SES’s (p=0.1). From the 8 restenotic 
lesions in 2.25-mm SES’s, 3 (38%) occurred in stents 
implanted at the vessel ostium. Similarly, from the 3 
restenotic lesions treated with larger SES’s, 1 lesion 
(33%) was ostial. Restenosis rates for non-ostial lesions 
were 6.7% in the 2.25-mm SES group (n=45 lesions with 
angiographic follow-up) and 3.0% in the larger SES group 
(n=66 lesions) (p=0.4). All restenoses occurred within the 
stent.Follow-up clinical information was complete for 90 
patients (99%) at an average of 258±92 days (Table 1). 
There were 2 in-hospital deaths (both in patients admitted 
with myocardial infarction and cardiogenic shock). Non-
fatal ST-elevation myocardial infarction was diagnosed in 
one patient (creatine phosphokinase elevation 2.8 times 
the upper normal limit), and occurred in the same day of 
the index procedure due to thrombotic occlusion of a 
2.25-mm SES implanted in the distal left anterior 
descending artery. A distal edge dissection was seen by 
intravascular ultrasound examination and treated with 
implantation of another 2.25-mm SES overlapping the 
previous stent. This patient was asymptomatic after 7 
months, with widely patent SES’s at angiographic 
evaluation. There were no other cases of stent thrombosis 
or myocardial infarction. Target lesion revascularization 
was performed in other 4 patients to treat restenosis 
occurring after 2.25-mm SES implantation (overall target 
lesion revascularization rate 5.5%) and the major adverse 
cardiac event rate was 7.7%. 
••• 
The main findings of this study were that implantation 
of very small (2.25-mm) sirolimus-eluting stents for de 
novo lesions was associated with markedly low lumen loss 
and restenosis rates. The reduced incidence of restenosis 
was translated in a very low need for repeat target lesion 
revascularization at 12 months (5.5%). 
Small vessel size has been shown to be an important 
independent predictor of restenosis after percutaneous 
intervention.11 Currently, the best interventional approach 
for patients small coronary vessels is unclear, even though 
a number of strategies have been tested in several 
randomized trials.1-6 In the present report, implantation of 
2.25-mm sirolimus-eluting stents strikingly inhibited 
neointimal proliferation in vessels with an average 
reference diameter of 1.88 mm, which is consistently 
smaller than the vessel size of all randomized studies 
published to date, ranging from 2.23 mm to 2.55 mm 
(Figure 2).1-6 Although SES were implanted in very small 
vessels in our study, the late lumen loss (0.07 mm) was 
clearly smaller than after conventional stenting in previous 
series (1.12 mm to 0.54 mm).1-6 Moreover, the late loss 
observed after 2.25-mm SES was similar to the late loss in 
previous trials with larger sirolimus-eluting stents, even 
Figure 1. Cumulative frequency of late loss in lesions treated 
with 2.25-mm SES and lesions treated with larger stents 
(t2.5 mm). 
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when considering only vessels in the lowest tercile of 
vessel size included in these studies (Figure 2).8,9 
It is worth noting that restenosis was relatively 
common after treatment of ostial lesions. Placement of 
drug-eluting stents at ostial lesions may constitute a 
challenging technical problem in accomplishing complete 
lesion scaffolding. Indeed, we have recently shown that 
post-sirolimus-eluting stent restenosis is commonly 
associated with a discontinuity in stent coverage, which 
may be of particular concern for ostial (and bifurcation) 
lesions.12 Drug-eluting stents especially designed for these 
lesions may be needed to improve the outcomes in this 
setting. 
  
Figure 2. Reference diameter and late loss in the stent arm of 
randomized trials comparing stenting vs. balloon angioplasty for 
small vessels, in the SIRIUS and RAVEL trials (lowest vessel size 
range), and in the RESEARCH registry (2.25-mm SES). 
 
This study presents several limitations related to its 
limited sample size and its non-randomized nature. 
Lesions treated with 2.25-mm SES showed a trend 
towards a greater incidence of binary restenosis and a 
larger late lumen loss compared to SES of larger 
diameters. Although not reaching statistical significance, 
our findings were in line with the recent SIRIUS trial, 
which identified small vessel size as a independent risk 
factor for restenosis after sirolimus-eluting stent 
implantation.8 The present results warrant further 
investigation of the angiographic outcomes of 2.25-mm 
SES in studies including a larger number of patients. 
Although the present study lacks a true control group, this 
limitation is partially overcome by the comparison of 
vessels treated with the 2.25-mm SES with those treated 
with larger stents in multi-lesion procedures. A higher rate 
of angiographic follow-up (70% in this study) would be 
desirable to fully evaluate the angiographic outcomes. 
However, it should be noted that the present study 
enrolled an unselected cohort of consecutive patients 
treated in the daily practice, and that not consenting with 
angiographic follow-up was not an exclusion criterion. 
Obviously, this scenario differs substantially from that of 
randomized trials and limits the compliance to 
angiographic re-study. Importantly, all eligible patients for 
whom angiographic re-evaluation was not obtained 
remained event-free throughout the follow-up period. 
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Long length stenting has a poor outcome when bare metal stents are utilized. The safety and efficacy of the sirolimus-
eluting stent (SES) in long lesions has not yet been evaluated. Therefore, the aim of the present study was to evaluate 
the clinical and angiographic outcomes of SES implantation over a very long length coronary artery segment. Since April 
2002, all patients treated percutaneously at our institution received SES as the device of choice as part of the 
RESEARCH (Rapamycin Eluting Stent Evaluated At Rotterdam Cardiology Hospital) registry. During the RESEARCH 
registry, stents were available in lengths of 8, 18, and 33 mm. The present report included a pre-defined study 
population composed by patients treated with >36mm long stented segments.  Patients had a combination of at least 2 
overlapping stents in a minimum length of 41mm (i.e. one 33-mm SES overlapping an 8-mm SES) to treat native de 
novo coronary lesions. The incidence of major cardiac adverse events (death, non-fatal myocardial infarction, and target 
lesion revascularization) was evaluated. The study population is composed of 96 consecutive patients (102 lesions). 
Clinical follow-up was available for all patients at a mean of 320 days (range 265-442 days) In total, 20% of long-
stented lesions were chronic total occlusions, mean stented length per lesion was 61.2±21.4mm (range 41mm-134mm). 
Angiographic follow-up at 6 months was obtained in 67 patients (71%). Binary restenosis rate was 11.9% and in-stent 
late loss was 0.13± 0.47mm. At long-term follow-up (mean 320 days), there were 2 (2.1%) deaths and the overall 
incidence of major cardiac events was 8.3%. As a conclusion, SES implantation appears safe and effective for de novo 
coronary lesions requiring multiple stent placement over a very long vessel segment. 
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Treatment of complex coronary artery stenosis with a 
long segment of bare metal stent (BMS) is associated with 
high restenosis rates and poorer clinical outcome1-7. 
Therefore, in contrast to shorter lesions, stent placement 
for diffusely diseased coronary segments is commonly 
avoided.  The efficacy of the sirolimus-eluting stent (SES) 
implantation has been recently evaluated in the context of 
two large randomized trials. The RAVEL trial 8 
(Randomized Study with the Sirolimus- Coated Bx Velocity 
Balloon-Expandable Stent in the Treatment of Patients 
with de Novo Native Coronary Artery Lesions) included 
only single lesions covered by an 18mm long stent and 
had a zero restenosis rate. In the SIRIUS trial9 (US 
Multicenter, Randomized, Double-Blind Study of the 
Sirolimus-Eluting Stent in De Novo Native Coronary 
Lesions) relatively long stent placement was allowed 
(maximum of 2 overlapping 18-mm long SES) and the 
restenosis rate was 9.2%. The efficacy of SES implanted 
over a total coronary length > 36 mm has not been tested 
to date. In the present study, we sought to evaluate the 
outcomes of patients receiving overlapping stents 
implanted over a length >36 mm to treat native de novo 
coronary lesions.  
METHODS 
Since April 16, 2002, it has been our policy to utilize the 
SES (Cypher™; Cordis Europa NV, Roden, The Netherlands) 
as the device of choice for every percutaneous coronary 
intervention (PCI) performed in our institution, as part of the 
RESEARCH registry. Further details of the methodology has 
been previously described10. 
Study group and Stent Implantation: During the 
RESEARCH registry, SES were available at lengths of 8, 18, 
and 33 mm. The present report included a pre-defined study 
population composed of patients treated with stented 
segments >36 mm long. Therefore, due to the availability of 
stent lengths, all included patients had a combination of at 
least 2 overlapping stents in a minimum length of 41 mm (i.e. 
one 33-mm SES overlapping a 8-mm SES Patients receiving 
SES to treat in-stent restenotic lesions were excluded from 
the present analysis. Also, lesions with angiographically 
visible gaps between stents were not included in this study. 
During 6 months of enrollment, 96 consecutive patients (102 
lesions) fulfilled the above criteria and composed the present 
study population. The stented length was based on the 
cumulative length of the individual adjacent stents. All 
procedures were performed according to standard 
interventional techniques except with the utilization of SES as 
the device of choice. However, the final interventional 
strategy was entirely left at the discretion of the operator 
(angiographic success defined as <30% residual diameter 
stenosis by visual assessment in the presence of TIMI-3 
antegrade flow). All patient received aspirin lifelong and 
clopidogrel 75 mg/day for six months. Glycoprotein IIb/IIIa 
inhibitors were given at the discretion of the operator. The 
hospital ethics committee approved the study protocol and 
written informed consent was obtained from all patients.  
Definitions and Follow-up 
All patients were evaluated for the occurrence of major 
cardiac adverse events, defined as death, myocardial 
infarction, target lesion revascularization (TLR) and target 
vessel revascularization (TVR). In-hospital outcome 
information was retrieved by means of an electronic clinical 
database for patients maintained in our hospital after the 
procedure and by review of the hospital records for those 
discharged to secondary hospitals. After discharge, recordings 
of all repeat interventions (surgical and percutaneous) and 
re-hospitalizations were prospectively collected in a dedicated 
database. Follow-up information was obtained by regular 
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outpatient evaluation, by phone contact, or by mail. 
Myocardial infarction was documented by a rise in the 
creatine kinase level of more than twice the upper limit with 
an increased creatine kinase-MB. Cardiac markers were 
measured serially for all patients maintained in our institution. 
Among those discharged to their community hospitals, 
cardiac markers were collected only if a post-procedural MI 
was suspected. Consequently, enzymatic assessment was not 
available for all patients, but for those whom the likelihood of 
post-procedure MI was high10. TVR was defined as either 
surgical or percutaneous reintervention driven by significant 
(>50%) luminal narrowing either within the stent or the 5mm 
borders proximal and distal to the stent, and was undertaken 
in the presence of either anginal symptoms or objective 
evidence of ischemia. All living patients at 6 months were 
considered eligible for angiographic follow-up. Binary 
restenosis was defined as diameter stenosis > 50% within 
the stent or in the 5-mm segments proximal or distal to the 
stent. Late loss was defined as the difference between the 
post- procedure minimal luminal diameter and at follow-up. 
Statistical Analysis 
Discrete variables are presented as counts and 
percentages. Continuous variables are presented as mean ± 
standard deviation and compared by Student’s T test. 
 
Table 1. Demographics and procedural data (96 pts; 102 lesions) 
Age (years) 64±12 
Male  (%) 62 
Diabetes (%) 18 
Current smoking (%) 26 
Hypercholesterolemia (%) 57 
Hypertension (%) 45 
Previous myocardial infarction (%) 32 
Previous Balloon Angioplasty (%) 19 
Target vessel  
Left anterior descending artery (%) 47 
Left circumflex artery (%) 9 
Right coronary artery (%) 44 
Chronic Total Occlusion (%) 20 
Direct stenting (%) 53 
Primary angioplasty,(%) 8 
Glycoprotein IIb/IIIa inhibitor use (%) 31 
Number of stents (per lesion) 2.66±0.9 (2-6) 
Stented length (per lesion), (mm [range]) 61.2±21.4 (41-134) 
Mean nominal stent diameter (mm, [range]) 2.82 ± 0.24 
 RESULTS 
Baseline and procedural characteristics of the 96 
patients (102 lesions) are presented in Table 1. 
Approximately half of lesions were located in the left 
anterior descending coronary artery (47%) or in the right 
coronary artery (44%). The mean number of stents per 
lesion was 2.66 ± 0.9 (range 2 to 6 stents) and the 
average stented length was 61.2 ± 21.4 mm. 
Angiographic success rate was 97%.  Follow-up coronary 
angiography was performed in 67 patients (71% of 
eligible cases) (Table 2). Binary restenosis (diameter 
stenosis >50%) was identified in 8 lesions (11.9%).  
Among the 8 lesions (8 patients) with binary restenosis, 5 
occurred within the stent, 1 in the proximal and 2 in the 
distal 5-mm adjacent vessel segment. All post-SES 
restenosis were focal and less than 10mm in length. 
Among these 8 patients, 4 were asymptomatic and did 
not undergo repeat revascularization. Complete clinical 
follow-up was available for all patients at an average of 
320 ± 67.4 days (range: 265-442 days) and is 
summarized in Table 3.  
Two patients died. One patient died during the in-
hospital period after emergent bypass surgery for 
procedure related to left main stem dissection, caused by 
the guiding catheter. The second was admitted in 
cardiogenic shock due to post infarction unstable angina. 
He had 3-vessel disease but the treatment was restricted 
to the culprit lesion. In total, six 2.25-mm diameter SES 
were implanted in the LAD/diagonal bifurcation. The 
patient died suddenly 43 days after the procedure. 
Although there is no clear evidence, subacute stent 
thrombosis cannot be rule out in this case. Non-fatal 
myocardial infarction occurred in one patient. He 
developed, no-reflow phenomenon after stent placement 
which was resolved after intracoronary adenosine and 
nitropruside infusion. At 6 months follow-up angiography, 
the patient was asymptomatic with patent long stented 
segment.  
 
Table 2: Quantitative coronary angiography post-procedure and 
at 6-months for patients with follow-up data (n=67). 
 
Proximal 
5mm 
 
In-stent 
 
 
Distal 5mm 
 
Post-procedure    
RD (mm) 3.17±0.55 2.68±0.51 2.45±0.51 
MLD (mm) 2.76±0.54 2.17±0.47 1.94±0.53 
Diameter stenosis, (%) 12 18 20 
6-month follow-up    
RD (mm) 3.30±0.61 2.82±0.59 2.63±0.62 
MLD (mm) 2.74±0.58 2.04±0.64 2.12±0.60 
Diameter stenosis (%) 17 27 19 
Late lumen loss (mm) 0.02±0.52 0.13±0.47 -0.16±0.47 
MLD=Minimal lumen diameter ; RD=Reference diameter 
 
Two patients underwent emergent bypass surgery for 
left main dissection. One patient died in-hospital as 
mentioned above, and the other had been successfully 
treated for left main dissection, but developed cardiac 
tamponade after the procedure and underwent surgical 
pericardial drainage, during which he received a venous 
graft to the first obtuse marginal branch. 
A total of 4 patients were successfully treated with 
repeat PCI electively for focal restenotic lesions. Overall 
MACE-free survival was 91.7% at 320 days follow-up. 
DISCUSSION 
We report that the use of long length of SES 
implantation for de novo coronary lesions is associated 
with a low rate of major adverse cardiac events, mainly 
due to a reduced incidence of target lesion 
revascularization. In particular, SES demonstrated 
effective suppression of neointimal hyperplasia with a late 
lumen loss of 0.13 mm which is substantially lower than 
that of major published studies with bare metal stents for 
long segments, ranging from 0.79 to 1.41 mm1,3-5. 
Accordingly, the restenosis rate observed after SES was 
strikingly lower. It is noteworthy that the average stented 
length in our study was at least 10 mm longer than in 
previous series with bare metal stents. 
Longer stented segment length using bare metal 
stents is an independent predictor of restenosis and 
adverse events 1.  Long stenting is frequently associated 
with prolonged intra-coronary manipulation due to 
multiple and overlapping stent placement, which may lead 
to injury to the vessel wall integrity. Moreover, the greater 
metal density may be potentially associated with a higher 
degree of local vascular injury, which altogether may 
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increase the risk of cardiac events and restenosis. Indeed, 
the incidence of late complications has been reported to 
be directly proportional to the total length of stents 
implanted. Previously, Schalij et. al reported a 25% 
incidence of major adverse events for patients treated 
with bare metal stents in a mean stented length of 45mm 
6. In the Additional Value of NIR Stents for Treatment of 
Long Coronary Lesions (ADVANCE)3 Study, the reported 
MACE was 23%. The present results are reassuring, since 
the relatively low incidence of adverse events (8.3%) 
presented in our series occurred in association with a 
markedly long length of SES implanted (average 61 mm).   
 
Table 3. 320—day major adverse cardiac events (n=96) 
Death, n (%) 2 (2.1) 
Non-fatal myocardial infarction, n (%) 1 (1.0)* 
Target vessel revascularization, n (%) 
percutaneous intervention  
coronary artery bypass graft surgery  
6 (6.2) 
4 (4.2) 
2 (2.1)† 
Any major adverse cardiac event , n (%) 8 (8.3) 
* non-Q wave myocardial infarction [CPK 567U/I (MB: 62U/I)].   
†One of 2 patients who underwent emergency CABG for left main 
stem dissection died in hospital. 
 
Among 5 patients (7.4%) with in-stent restenosis, only 
1 focal in-stent restenosis was seen in the overlapped 
stented segment. Furthermore, consistent with previous 
reports regarding angiographic pattern of restenosis of 
SES11, all our restenosis were focal and therefore easy to 
treat with repeat PCI. Since all patients with 
angiographically visible gaps between stents were 
excluded from the present analysis, incomplete lesion 
coverage was not identified as a possible mechanism of 
restenosis in any case. 
There have been concerns that the risk for thrombosis 
might increase after implantation of long length of stent. 
In the current study, no documented thrombotic stent 
occlusion was observed, although we cannot rule out 
stent thrombosis in the patient that died suddenly 43 days 
after the index procedure. There is no consensus for the 
period of clopidogrel prescription following SES 
implantation especially after treatment of complex lesions. 
Although, no late thrombotic events were diagnosed after 
clopidogrel discontinuation in our series (i.e. after 6 
months), additional studies are warranted for further 
evaluate the best antiplatelet scheme for these patients.  
 Several limitations are note-worthy due to evaluation 
of a small cohort of patients without direct comparative 
control group. Angiographic follow-up could not be 
obtained in all patients. However those who did not have 
control follow-up angiography were all uneventful. Post-
procedure cardiac markers were not collective routinely 
for all patients (available for 46 patients [46%] in the 
study group). This was justified by the fact that high-
grade enzymatic elevations, those with proven prognostic 
impact, rarely occur undetected in asymptomatic patients.  
Conclusions 
Sirolimus eluting stent implantation appear safe and 
effective treatment for de novo coronary lesions requiring 
multiple stent placement over a very long vessel segment. 
Funding sources 
This study was supported with health care funds allotted 
by the Erasmus Medical Center, Rotterdam, The Netherlands, 
and with an institutional grant from Cordis, Johnson & 
Johnson, Miami Lakes, Florida, USA. 
References 
1. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, 
Reimers B, Finci L, Di Mario C, Colombo A. Stented segment 
length as an independent predictor of restenosis. J Am Coll 
Cardiol 1999;34:651-9. 
2. Kornowski R, Mehran R, Hong MK, Satler LF, Pichard AD, 
Kent KM, Mintz GS, Waksman R, Laird JR, Lansky AJ, Bucher 
TA, Popma JJ, Leon MB. Procedural results and late clinical 
outcomes after placement of three or more stents in single 
coronary lesions. Circulation 1998;97:1355-61. 
3. Serruys PW, Foley DP, Suttorp MJ, Rensing BJ, Suryapranata 
H, Materne P, van den Bos A, Benit E, Anzuini A, Rutsch W, 
Legrand V, Dawkins K, Cobaugh M, Bressers M, Backx B, 
Wijns W, Colombo A. A randomized comparison of the value 
of additional stenting after optimal balloon angioplasty for 
long coronary lesions: final results of the additional value of 
NIR stents for treatment of long coronary lesions (ADVANCE) 
study. J Am Coll Cardiol 2002;39:393-9. 
4. Hoffmann R, Herrmann G, Silber S, Braun P, Werner GS, 
Hennen B, Rupprecht H, vom Dahl J, Hanrath P. Randomized 
comparison of success and adverse event rates and cost 
effectiveness of one long versus two short stents for 
treatment of long coronary narrowings. Am J Cardiol 
2002;90:460-4. 
5. Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH, 
Jukema JW, van der Wall EE. Intravascular ultrasound 
guidance improves angiographic and clinical outcome of stent 
implantation for long coronary artery stenoses: final results of 
a randomized comparison with angiographic guidance (TULIP 
Study). Circulation 2003;107:62-7. 
6. Schalij MJ, Udayachalerm W, Oemrawsingh P, Jukema JW, 
Reiber JH, Bruschke AV. Stenting of long coronary artery 
lesions: initial angiographic results and 6-month clinical 
outcome of the micro stent II-XL. Catheter Cardiovasc Interv 
1999;48:105-12. 
7. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, 
Pichard AD, Hong MK, Kent KM, Mehran R, Stone GW, Leon 
MB. Procedural results and late clinical outcomes after 
percutaneous interventions using long (> or = 25 mm) 
versus short (< 20 mm) stents. J Am Coll Cardiol 
2000;35:612-8. 
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, 
Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, 
Molnar F, Falotico R. A randomized comparison of a 
sirolimus-eluting stent with a standard stent for coronary 
revascularization. N Engl J Med 2002;346:1773-80. 
9. Moses JW LM, Popma JJ, Kuntz RE, Fitzgerald P. A US 
multicenter,Randomized, Double Blind study of the 
SIRoLImUS-eluting stent in de novo native coronary lesions. 
TCT-2002. 2002. 
10. Lemos PA, Lee C, Degertekin M, Saia F, Tanabe K, 
Arampatzis CA, Hoye A, van Duuren M, Sianos G, Smits PC, 
de Feyter P, van der Giessen WJ, van Domburg RT, Serruys 
PW. Early outcome after sirolimus-eluting stent implantation 
in patients with acute coronary syndromes. Insights from the 
Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology 
Hospital (RESEARCH) registry. J Am Coll Cardiol 
2003;41:2093-9. 
11. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, 
Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, 
Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van 
Domburg RT, Serruys PW. Coronary restenosis after 
sirolimus-eluting stent implantation: morphological 
description and mechanistic analysis from a consecutive 
series of cases. Circulation 2003;108:257-60. 
  
Chapter 15 Multi-lesion “Culotte” and “Crush” bifurcation 
stenting with sirolimus-eluting stents: long-term 
angiographic outcome 
Joost Daemen 
Pedro A. Lemos, MD 
Patrick W. Serruys, MD, PhD 
 
J Invasiv Cardiol. 2003 Nov;15(11):653-6 
 
Chapter 15 ______________________________________________________________________________ 
 
 88 
A B C
ED
Multi-lesion “Culotte” and “Crush” bifurcation stenting with 
sirolimus-eluting stents: long-term angiographic outcome  
 
Joost Daemen; Pedro A. Lemos, MD; Patrick W. Serruys, MD, PhD 
 
J Invasiv Cardiol. 2003 Nov;15(11):653-6 
 
 
 
Figure 1. (A) left coronary angiogram (caudal right anterior oblique 
projection) showing diffuse disease with distal occlusion of the left 
circumflex artery and severe ostial stenosis in first obtuse marginal 
branch. (B) stent deployed covering the origin of the first marginal 
branch. A guidewire was placed in the marginal branch through the 
struts of the circumflex stent. (C) residual stenosis in the ostium of 
the first marginal branch after implantation of the stent in the 
circumflex. (D) implantation of a 3.0 X 18mm sirolimus-eluting stent 
in the LCx - OM using the “culotte” technique. (E) final angiographic 
result 
 
 
 
 
Case report 
A 63 year-old man, ex-smoker, with a history of 
hypertension and previous myocardial infarction was 
admitted with stable angina (Canadian Cardiovascular 
Society Class 1) for elective percutaneous coronary 
intervention. Pre-procedure coronary angiogram revealed 
diffuse disease in the proximal and mid segments of the 
left circumflex artery (LCx) that was totally occluded in its 
distal portion (Figure 1a). The first obtuse marginal 
branch (OM) presented a severe ostial stenosis (figure 
1a). Also, the left anterior descending artery (LAD) 
presented a long stenosis in its mid portion, involving the 
origin of the first and second diagonal branches (figure 
2a). The right coronary artery showed mild irregularities 
without any localized significant stenosis. 
The left coronary was cannulated with a 7 french Vista 
Brite Amplatz Left guiding catheter (Johnson & Johnson-
Cordis unit). The ostial lesion in first OM was crossed with 
a PT Graphix Intermediate 0.014” guidewire. Another PT 
Graphix Intermediate 0.014” guidewire was inserted in the 
LCx but the total occlusion in its distal segment could only 
be partially recannalized. A 2.5 X 18mm sirolimus-eluting 
stent (Cypher; Johnson & Johnson-Cordis unit) was 
deployed (14 atm) in a stenotic lesion in the LCx just 
proximal to the site of the vessel occlusion in an attempt 
to facilitate further measures to recannalize the vessel; 
the stent was deployed covering the origin of the first 
marginal branch (figure 1b). A 3.0 X 18mm sirolimus-
eluting stent (Cypher; Johnson & Johnson-Cordis unit)) 
was then implanted in the LCx-OM using the “culotte” 
technique (20 atm) 1 (figure 1c and d). A residual stenosis 
in the proximal LCx was treated with an additional 3.0 x 
18mm sirolimus-eluting stent (Cypher; Johnson & 
Johnson-Cordis unit)) overlapping the distal stent (20 
atm). Further attempts to recannalize the distal LCx were 
unsuccessful. The final result is depicted in Figure 1e. 
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Figure 2. (A) left anterior descending artery (cranial right 
anterior oblique projection) presenting a long stenosis in its mid 
portion, involving the origin of the first and second diagonal 
branches. (B) “Crush” stenting: a 2.25 X 8mm sirolimus-eluting 
stent and a 3 X 33mm sirolimus-eluting-stent (Cypher; Johnson & 
Johnson-Cordis unit) concomitantly positioned in the second 
diagonal and mid LAD respectively. Note that the proximal portion 
of the stent placed in the diagonal is protruding into the LAD.   
(C) Residual stenosis noted in the proximal LAD together with 
ostial compromise of the first diagonal branch after implantation 
of the distal stent in the LAD. (D) “Crush” stenting in the LAD-
first diagonal bifurcation: a 2.25 X 8mm sirolimus-eluting stent 
(Cypher; Johnson & Johnson-Cordis unit) in first diagonal branch 
is positioned with its proximal portion partially located though the 
LAD. An undeployed 3 X 8mm sirolimus eluting-stent was 
concomitantly positioned in the LAD along the diagonal ostium. 
(E) A 3 X 8mm SES deployed at a small gap between the two 
LAD SES. The radiopaque stents implanted in the 2 previously 
treated bifurcations are noted. F, Final angiographic result of the 
treatment of the LAD with a TIMI 3 grade flow and minimal 
residual stenosis in all treated lesions. 
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Figure 3. (A) Angiographic follow-up of the LCx – OM ostial 
lesions. No restenosis has occurred. (B) Excellent result after 6 
months angiographic follow-up of the LAD.  
Two PT Graphix Intermediate 0.014” guidewires were 
inserted in the LAD and second diagonal branch. A “crush” 
stent implantation was performed: a 2.25 X 8mm 
sirolimus-eluting stent and a 3 X 33mm sirolimus-eluting-
stent (Cypher; Johnson & Johnson-Cordis unit) were 
concomitantly positioned in the second diagonal and mid 
LAD respectively (figure 2b). The 2.25 X 8mm sirolimus-
eluting stent was deployed (12 atm) with its proximal 
portion partially placed through the LAD (figure 2b). 
Importantly, the LAD-diagonal stent was implanted while 
the undeployed 3 X 33mm sirolimus-eluting-stent was 
already positioned in the LAD in the site of its future 
implantation (covering the origin of the diagonal branch) 
(figure 2b). Subsequently, the balloon-catheter was 
retrieved from the diagonal branch and the LAD stent was 
deployed (22 atm) (figure 2b). After implantation of the 
LAD stent, a residual stenosis was noted in the proximal 
stent edge together with ostial compromise of the first 
diagonal branch, possibly due to plaque shiftening 
towards its origin (figure 2c). Additional “crush” stenting 
was performed to treat the LAD- first diagonal bifurcation 
(figure 2d). Following the same strategy as describe 
above, a 2.25 X 8mm sirolimus-eluting stent (Cypher; 
Johnson & Johnson-Cordis unit) was implanted in the first 
diagonal (12 atm) with its proximal portion partially 
deployed in the LAD (Figure 2d) while an undeployed 3 X 
8mm sirolimus eluting-stent was already placed in the 
LAD (along the diagonal ostium) (figure 2d). The LAD 
stent was then deployed (20 atm) covering the ostium of 
the first diagonal branch (figure 2d). A small gap between 
the two LAD stents was noted and a 3 X 8mm sirolimus-
eluting stent (Cypher; Johnson & Johnson-Cordis unit) 
was implanted (20 atm) to accomplish complete lesion 
coverage (figure 2e). Final high-pressure post-dilatation 
(22 atm) was performed in the mid LAD (Maverick balloon 
3.0 X 9mm; Boston Scientific). Care was taken to inflate 
the balloon inside the stented area in order to avoid 
vessel injury in the non-stented edges. Excellent final 
angiographic result was achieved with TIMI 3 grade flow 
and minimal residual stenosis in all treated lesions (figure 
2f). 
The patient was included in the RESEARCH 
(Rapamycin Eluting-Stent Evaluated At Rotterdam 
Cardiology Hospitals) registry and agreed to undergo late 
angiographic follow-up 2. After 208 days the patient 
remained asymptomatic and a stress test was negative. 
No adverse events had occurred. At coronary 
angiography, the right coronary artery was unchanged. All 
stents were widely patent with no angiographic evidence 
of stenosis (figure 3a and 3b).  
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The percutaneous treatment of coronary 
bifurcation stenoses is hampered by an increased 
rate of subsequent restenosis. The present study 
reports on the outcomes of a consecutive series of 
unselected patients with de novo bifurcation 
stenoses, treated with sirolimus-eluting stent 
implantation in both the main vessel and side 
branch. At 6 months, the incidence of major 
adverse cardiac events was 10.3% (one death and 
5 target lesion revascularizations), with no 
episodes of acute myocardial infarction or stent 
thrombosis. 
Percutaneous coronary intervention of bifurcation 
lesions is associated with lower procedural success rates, 1 
and an increased subsequent rate of major adverse 
cardiac events (MACE) and restenosis. Various techniques 
and strategies have been applied in attempt to improve 
outcomes including kissing balloon dilatation, and the use 
of stent implantation in both branches.2 The use of 
adjunctive atherectomy was found to be not 
advantageous in the CAVEAT I trial.3 Although there was 
an improved initial angiographic result with less residual 
stenosis, this was at the expense of a higher rate of side 
branch occlusion and acute myocardial infarction. In the 
long-term, results of angioplasty in bifurcations have been 
hampered by problems of restenosis particularly following 
stent implantation within the side branch.4, 5 Recently 
sirolimus-eluting stents (SESs) have demonstrated 
dramatically reduced restenosis rates in patients with 
relatively simple lesions.6, 7 We sought to investigate the 
safety and efficacy of SES in a consecutive series of 
unselected patients with de novo bifurcation lesions 
enrolled in the RESEARCH (Rapamycin-Eluting Stent 
Evaluation At Rotterdam Cardiology Hospital) registry. 8 
••• 
Since April 2002, SES implantation (Cypher™, Johnson 
& Johnson- Cordis unit) was adopted as the default 
strategy for all patients treated in our institution, as part 
of the RESEARCH registry.8 Briefly, this single-centre 
registry, aims to evaluate the efficacy of SES implantation 
in the “real world” of interventional cardiology. All 
consecutive patients were enrolled irrespective of clinical 
presentation and lesion characteristics, and the incidence 
of MACE was prospectively evaluated during the follow-
up. At 6-months, a total of 563 consecutive patients were 
treated solely with SES. Among these, 58 (10.3%) 
patients with de novo bifurcation lesions were treated 
with SES implantation in both the main and side branches, 
and compose the present study population. The patients’ 
informed written consent was obtained in accordance with 
the rules of the Institutional Ethics Committee, which 
approved the study. 
All procedures were performed with standard 
interventional techniques except with the use of SES as 
the device of choice. The strategy of bifurcation stenting 
employed, and the use of kissing balloon dilatation post-
procedure was at the operators’ discretion. One of 4 
methods of stenting was used: T-stenting, culotte 
stenting, kissing stents, or the `crush` technique. T- and 
culotte stenting have been previously described.5, 9 Kissing 
stents involved simultaneous implantation of the stents 
within both branches, with the proximal edges alongside 
each other thereby bringing forward the point of 
divergence. The `crush` technique involves positioning 
both stents, with the proximal part of the side branch 
stent lying well within the main vessel, whilst ensuring 
that the edge of the stent in the main vessel is more 
proximal than the side branch stent. The side branch 
stent is deployed first, and the balloon and wire carefully 
withdrawn. The main vessel stent is then deployed 
thereby crushing the proximal part of the side branch 
stent.10 SESs were available in diameters from 2.25mm to 
3.00mm and lengths from 8mm to 33mm. During the 
procedure, intravenous heparin was given to maintain an 
activated clotting time t250 seconds. All patients received 
lifelong aspirin, with clopidogrel for 6-months. The use of 
glycoprotein IIb/IIIa inhibitors was at the discretion of the 
operator. 
Clinical and angiographic follow-up was performed at 
6-months. Major adverse cardiac events (MACE) were pre-
defined as death, myocardial infarction, or target lesion 
revascularization. The diagnosis of myocardial infarction 
required an elevation of creatine kinase levels to twice the 
upper limit of normal, together with a rise in creatine 
kinase-MB fraction. Target lesion revascularization was 
defined as either surgical or percutaneous reintervention 
driven by significant (>50%) luminal diameter narrowing 
either within the stent or the 5mm borders proximal and 
distal to the stent, and was undertaken in the presence of 
either anginal symptoms or objective evidence of 
ischemia.  
Coronary angiograms were obtained in multiple views 
after intracoronary injection of nitrates. For the main 
branches, three coronary segments were subjected to 
quantitative angiography: in-stent, proximal edge, and 
distal edge segment. The in-stent analysis encompassed 
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the length of all stents used during the procedure. The 
proximal and distal edge segment included up to 5mm 
from the proximal and distal edge of the total segment 
treated with the study stents, respectively. For the side 
branches, 2 segments were analysed: in-stent and distal 
edge 5mm segment. Quantitative coronary angiographic 
(QCA) analysis was performed using the Cardiovascular 
Angiography Analysis System II (CAAS II) (Pie Medical, 
Maastricht, The Netherlands). The reference vessel 
diameter, minimal lumen diameter and percent diameter 
stenosis were measured at pre-, post-procedure and 
follow-up. The late loss was calculated as the difference 
between the minimal lumen diameter post procedure and 
that at follow-up. Binary restenosis was defined as the 
presence of >50% diameter stenosis within the target 
lesion.   
 
Table 1 Baseline Clinical Characteristics (n=58) 
Age (years) 63 r 10 
Men  42 (72%) 
Hypertension  26 (45%) 
Hypercholesterolemia  35 (60%) 
Diabetes mellitus 16 (28%) 
Current smoker  16 (28%) 
Previous myocardial infarction  22 (38%) 
Previous coronary angioplasty 5 (9%) 
Previous coronary artery bypass surgery 3 (5%) 
Number of coronary arteries significantly narrowed  
1  15 (26%) 
2  28 (48%) 
3  15 (26%) 
Acute coronary syndrome 18 (31%) 
Values are presented as the numbers (relative percentages) or 
mean value r SD. 
 
Fifty-eight patients with 65 bifurcation lesions were 
included in this study. Baseline patient characteristics are 
summarized in table 1. The lesion characteristics and 
stenting technique utilized are documented in table 2. At 
6-months, the survival-free of MACE was 89.7%. One 
patient died following bifurcation stent implantation of the 
left main stem for an acute myocardial infarction. He was 
admitted in cardiogenic shock, and despite the use of 
abciximab and intra-aortic balloon pump support, died 
shortly after the procedure due to left ventricular failure. 
There were no episodes of acute or subacute stent 
thrombosis, and no patient had a myocardial infarction. 
Target lesion revascularization was undertaken in 5 
patients (8.6%) as outlined below.  
 
Table 2. Procedural and Lesion Characteristics (n = 65 lesions) 
Coronary artery treated with bifurcation stenting  
Left anterior descending / diagonal  39 (60%) 
Left circumflex / obtuse marginal  16 (25%) 
Right coronary / posterior descending  4 (6%) 
Left main stem – left anterior descending / 
circumflex  
6 (9%) 
Stenting technique  
T-stenting  41 (63%) 
Culotte stenting  5 (8%) 
Kissing stenting  2 (3%) 
Crush stenting  17 (26%) 
Kissing balloon dilatation after stenting  20 (31%) 
Glycoprotein IIb/IIIa inhibitor use  20 (31%) 
Values are presented as the numbers (relative percentages). 
 
 
Table 3 Quantitative Coronary Angiography 
 Proximal In-stent Distal  
Main branch (n = 44)    
Reference diameter (mm) N/A 2.64 N/A 
Minimal lumen diameter (mm)    
Pre-procedure N/A 0.64 N/A 
Post-procedure 2.39 2.19 1.86 
6-month follow-up 2.26 2.07 1.85 
Diameter stenosis at 6-month (%) 28.3 22.9 25.4 
Late lumen loss (mm) 0.12 0.12 0.01 
Restenosis rate (%) 2.3 6.8 0 
    
Side branch (n =44)    
Reference diameter (mm) … 1.99 N/A 
Minimal lumen diameter (mm) …   
Pre-procedure … 0.61 N/A 
Post-procedure … 1.80 1.57 
6-month follow-up … 1.49 1.47 
Diameter stenosis at 6-month (%) … 31.0 21.9 
Late lumen loss (mm) … 0.31 0.09 
Restenosis rate (%) … 13.6 0 
Values are presented as mean values or relative percentages 
 
Of 65 lesions, 6-month angiographic follow-up was 
performed in 44 lesions. The binary restenosis rate was 
22.7% (10 of 44 lesions). QCA data are presented in 
Table 3. Angiographic restenosis occurred in 4 lesions 
within the main branch (1 in the proximal segment; 3 in 
the in-stent segment), yielding a restenosis rate of 9.1%. 
Angiographic restenosis occurred in 6 of the side 
branches, all within the in-stent segment. Of these 6 
restenoses, 5 occurred at the ostium of side branch 
following the use of T-stenting (figure 1).  All 4 patients 
with a restenosis within the main vessel, and 1 patient 
with a restenosis at the ostium of a side branch, 
underwent percutaneous target lesion revascularization 
with new drug-eluting stent implantation. Directional 
coronary atherectomy was additionally used in 1 patient. 
The remaining 5 patients, all with ostial side branch 
restenoses were asymptomatic and treated with medical 
therapy alone. 
••• 
 
The major findings of this study of bifurcation stenting 
are the following: 1) SES implantation in both the main 
and side branches is feasible and associated with a low 
procedural complication rate, and no episodes of stent 
thrombosis. 2) The target lesion revascularization rate of 
8.6% is seemingly diminished as compared to historical 
controls. 3) Angiographic restenosis rates of the main and 
side branches are 9.1% and 13.6%, with an overall 
restenosis rate of 22.7%. 4) Five of the 6 restenoses 
occurring in the side branch were located at the ostium 
following T-stenting technique. 
Drug-eluting stent deployment in both vessels to treat 
bifurcation lesions may raise theoretical concerns that it 
could result in a propensity to stent thrombosis. When we 
treat bifurcation lesions with sirolimus-eluting stents using 
the culotte, kissing, or crush stenting techniques, there 
are some overlapping stent struts, where the higher 
concentration of sirolimus may induce endothelial function 
impairment and thus be associated with an increased rate 
of stent thrombosis. Although these stenting techniques 
were applied in 37% of the lesions treated, no stent 
thrombosis was reported during the follow-up period, 
implying that sirolimus has a wide safety margin. 
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A 3.0 x 33mm sirolimus-eluting stent (SES) was implanted in the 
circumflex artery, and a 2.25 x 8mm SES was implanted in the 
side branch (obtuse marginal) with T-stenting technique (A). At 
6-months angiographic follow-up, restenosis occurred at the 
ostium of the side branch (arrowhead) (B). 
 
Several strategies have been advocated to treat 
bifurcation lesions with PCI, such as deployment of stents 
in both vessels, stenting in one branch with balloon 
angioplasty in the other, and mechanical debulking. The 
published reports regarding the subsequent need for 
target lesion revascularization utilizing bare stents range 
from 17% to 53%, 5,11,12 thus the rate of 8.6% in our 
study is therefore very favorable. In addition, the rate 
observed in the current study may underestimate the true 
beneficial treatment effect of SES as explained below. 
Five of the 6 restenoses in the side branch occurred at 
the ostium following T-stenting. When we apply T-
stenting, stent positioning must be extremely accurate to 
ensure complete coverage of the side branch ostium. This 
is particularly difficult / impossible to achieve when the 
angle between the 2 branches is much 90q. Restenosis 
at this site may therefore be mainly a reflection of 
incomplete coverage. The restenosis rate in the side 
branch following T-stenting was 16.7% (5 of 30 lesions), 
whilst that following the other stent techniques was 7.1% 
(1 of 14 lesions). The present study is limited because the 
choice of strategy was non-randomized, and there is no 
comparison with alternative strategies such as the use of 
stent implantation in the main vessel alone, with balloon-
only angioplasty of the side branch. In addition, the 
sample size was relatively small, and any difference 
between the different techniques was not statistically 
significant. However, our results suggest that it seems 
wise to ensure the complete coverage of the ostium with 
SES using stenting techniques other than T-stenting. The 
“crush” technique is technically easier and quicker to do 
than a culotte, but further data with longer follow-up from 
a larger population is needed to fully determine the 
efficacy of these techniques.  
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The long-term efficacy of percutaneous coronary 
intervention for mildly obstructive coronary narrowings is 
limited by the occurrence of restenosis, limiting the 
applicability of this therapy for these lesions. The present 
study reports on a consecutive series of 20 patients 
treated with sirolimus-eluting stent implantation for 23 
angiographically mild de novo lesions, (defined as a 
diameter stenosis <50% by quantitative coronary 
angiography). At a mean follow-up of 399 ± 120 days, the 
survival-free of major adverse events was 95%, with no 
patient requiring target lesion revascularization.  
Mildly obstructive coronary lesions do not cause 
anginal symptoms and ischemia per se. However, non-
flow limiting lesions such as these can be associated with 
plaque rupture and erosion, potentially leading to acute 
myocardial infarction or sudden death.1-6 Recent focus has 
been given to the development of novel technologies 
designed to detect regions of plaque thought to be at 
most risk, though the currently available information is 
limited by the lack of understanding of the natural 
progression of plaques. Previous data have shown that 
stent implantation for narrowings <50% stenosed, are 
subject to a not insignificant rate of adverse events at 1 
year of 17%, particularly related to the need for repeat 
revascularization for restenosis.7 The present report is an 
observation of the clinical outcomes of a first series of 
consecutive patients with angiographically mildly 
narrowed coronary arteries treated by sirolimus-eluting 
stent implantation. 
••• 
From April 2002, the sirolimus-eluting stent (SES) 
(CypherTM; Johnson & Johnson – Cordis) was utilized as 
the device of choice for every percutaneous coronary 
intervention performed in our institution, irrespective of 
clinical presentation or lesion morphology. Further details 
of the methodology are described elsewhere.8,9 In brief, 
this single-centre registry was conducted with the aim of 
evaluating the impact of SES implantation in the “real 
world” of interventional cardiology.  
During the first 6-months, 20 patients were treated 
solely with SES, for 23 angiographically mild, 
intermediate, or ambiguous lesions (4% of the total 
population treated). In order to exclude characteristics 
known to limit the angiographic determination of lesion 
severity, all of the following criteria had to be met: 1) the 
lesion was de novo 2) diameter stenosis by on-line 
quantitative coronary angiography (QCA) was <50%, 2) 
non-ostial location, 3) no visible angiographic thrombus, 
4) not located in a diffusely diseased segment (as 
assessed by visual analysis).  
The diagnostic approach to evaluate the clinical 
significance of the lesions utilizing invasive and / or non-
invasive investigations, and the decision to proceed to 
stent implantation, was left at the operator’s discretion. 
Patients were maintained on long-term aspirin medication, 
together with clopidogrel which was given for a minimum 
of 3 months. The protocol of the Registry was approved 
by the local ethics committee and is in accordance with 
the principles of Good Clinical Practice for Trials of 
Medicinal Products in the European Community and the 
Declaration of Helsinki. Written informed consent was 
obtained from every patient. 
Coronary angiograms were obtained in multiple 
projections after intracoronary nitrate administration. 
Quantitative analyses were performed with the 
Cardiovascular Angiography Analysis System II (CAAS II; 
Pie Medical, Maastricht, The Netherlands) using validated 
edge-detection techniques. The empty tip of the 
angiographic catheter was utilized for image calibration. 
Lesion measurements were performed in the “worst” view 
with the end diastolic frame selected for analysis. 
Patients were followed up prospectively and evaluated 
for survival free of major adverse cardiac events (MACE) 
using questionnaires and telephone enquiries when 
necessary. MACE was pre-defined as: 1) death, 2) non-
fatal myocardial infarction, or 3) repeat target lesion 
revascularization. A definite diagnosis of myocardial 
infarction required an increase in the creatine kinase level 
to more than twice the upper normal limit, together with 
an increased level of the creatine kinase MB fraction. 
Target lesion revascularization was defined as any surgical 
or percutaneous re-intervention motivated by a significant 
luminal narrowing within the stent or in the 5-mm 
proximal or distal peri-stent segments. In the present 
cohort treated for angiographic mild lesions, follow-up 
data were obtained in all patients. 
Discrete variables were presented as percentages and 
compared by Fisher’s exact tests. Continuous variables 
were presented as means and standard deviations and 
compared by Student’s T test. All tests were two-tailed 
and a p value < 0.05 was considered as significant.  
The mean age of the patients was 54 ± 9 years, and 
17 (85%) were men. Risk factors were diabetes mellitus 
in 1 patient (5%), hypercholesterolemia in 12 (60%), 
current smoking in 8 (40%), hypertension in 7 (35%). 
There was a history of previous acute myocardial 
infarction in 5 (25%), and prior coronary angioplasty in 6 
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(30%), no patient had undergone coronary artery bypass 
surgery. Of the 20 patients, 7 (35%) were treated for at 
least one additional severely stenotic lesion (>50% 
diameter stenosis) during the same procedure. Clinical 
presentation was stable angina pectoris in 12 (60%) and 
unstable angina pectoris in the remaining 8 (40%). The 
23 lesions were treated with implantation of 26 SESs, with 
direct stent implantation in 21 lesions (91%). Glycoprotein 
IIb/IIIa inhibitor therapy was used in 4 patients (20%). 
The decision to treat was based on a good history of 
stable angina pectoris in 5 patients (25%), a positive 
thallium scan in 3 patients (15%), presentation with an 
acute coronary syndrome (with ECG changes and / or 
troponin elevation) thought to relate to the target lesion 
in 4 patients (20%), IVUS examination documenting a 
minimum lumen area <4.0mm2 in 4 patients (20%), a 
fractional flow reserve 0.75 in 3 patients (15%), and a 
positive methergine test in 1 patient (5%).  
The mean lesion length was 10.8 ± 4.7mm, and mean 
reference diameter 2.70 ± 0.60mm. Minimal luminal 
diameter increased from 1.66 ± 0.43mm at baseline, to 
2.42 ± 0.59mm post-procedure (p<0.01). Pre-procedure 
diameter stenosis decreased from 39 ± 8% (range 14 – 
49%) to 14 ± 10% (range 0 – 35%) (p<0.001). Mean 
diameter of stent was 2.9 ± 0.2mm with a mean length of 
14.5 ± 7.5mm.  
One patient had a peri-procedural non-Q wave 
myocardial infarction, with an elevation of creatine kinase 
1-3x the upper limit of normal together with a rise in 
creatine kinase-MB fraction (maximum creatine kinase 
532U/l, upper limit of normal 169U/l). Review of the final 
procedural angiogram showed dissection of the distal left 
anterior descending artery with TIMI II flow; this probably 
related to preceding difficult wire passage in a very 
tortuous part of the vessel. Follow-up angiography at 6-
months showed that the dissection had healed with TIMI 
III distal flow. In-hospital, the survival-free of MACE was 
1/20 (95%). 
After a mean follow-up period of 399 ± 120 days 
(median 428 days) all patients were alive and free of 
myocardial infarction, and there were no further 
interventions in any mild lesion treated with SES. In total, 
7 patients underwent control angiography at 6-months 
with no evidence of restenosis in any of the mild lesions. 
One patient, treated for a mild lesion of the left anterior 
descending artery, underwent angioplasty to a diagonal 
branch at follow-up. Review of the index procedure 
showed that the diagonal lesion had previously been 
present but not treated. The survival-free MACE was 95%. 
••• 
 
Our findings indicate that SES implantation for 
coronary narrowings with a diameter stenosis of <50% by 
quantitative angiography, is safe and associated with a 
very low incidence of adverse events at 1 year. Our 
results resemble those observed in the RAVEL trial, in 
which no patient had repeat revascularization after 
treatment of relatively “simple” lesions with SES.10 
Accordingly, mildly obstructive lesions do not generally 
present a “complex” morphology, and percutaneous 
therapy is usually not technically challenging. Indeed in 
our series, direct stent implantation was successful in 
91% lesions.  
The present study is observational, and limited by the 
small number of patients evaluated, and its non-
randomized, non-controlled nature. Although the majority 
of our patients were treated on the basis of an evidence-
based indication such as the IVUS assessment or 
fractional flow reserve, some were treated in the absence 
of objective ischemia (n=5). The use of SESs has been 
associated with evidence of delayed re-endothelialization 
raising concerns regarding a propensity to stent 
thrombosis which is associated with significant morbidity. 
Thus far, the published data from several SES trials show 
a rate of acute / subacute thrombosis that is comparable 
to that of bare metal stents. The decision as to whether to 
proceed to percutaneous coronary intervention for 
angiographically mild lesions, in the absence of 
documented ischemia, is a dilemma that is frequently 
encountered in current clinical practice. None of our 
patients had an episode of stent thrombosis, however the, 
albeit small, risk must be taken into account before 
proceeding to SES implantation in the absence of an 
evidence-based indication.   
Evaluation of lesion severity by intracoronary 
measurements has been advocated to discriminate 
between patients who should receive invasive treatment 
from those in whom further treatment should be 
deferred.11-17 Accordingly, the rate of subsequent events 
and need for target lesion revascularization has been 
shown to be low (4.4% at one year) if IVUS examination 
demonstrates a minimum lumen area of 4.0mm2. 11 In 
addition, patients with an abnormal fractional flow reserve 
(<0.75) have been reported to present a higher risk for 
future complications than those with normal 
measurements.15,16 In our series, stent implantation was 
undertaken in 7 patients (35%) following either IVUS 
examination showing a minimum lumen area <4.0 mm2, 
and/or a fractional flow reserve of 0.75. However, such 
historical algorithms were produced when angioplasty was 
carried out with bare metal stents, and rely heavily on the 
prohibitively high incidence of adverse events following an 
eventual percutaneous treatment, which has been found 
to be around 17% at 1 year.7,15 Even after following these 
algorithms, patients with “normal” findings at lesion 
assessment, who have been considered to be at “low risk” 
if left untreated, at one year, the rate of adverse events 
may still be as high as 11%.12 Our results suggest that by 
altering the risk / benefit ratio of stent implantation versus 
deferred invasive therapy, the introduction of drug-eluting 
stents into clinical practice may potentially change the 
current treatment algorithms for patients with mild to 
moderate lesions. In addition, if the propensity to 
accelerated plaque progression or vulnerability to plaque 
rupture or erosion could be better evaluated, this might 
enable localization of areas of coronary artery plaque 
which could benefit most from stabilization with stent 
implantation. Although the present study did not 
specifically address this issue, this may broaden the 
applicability of percutaneous coronary intervention with 
drug-eluting stent implantation. 
References 
1. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: 
biology. Lancet 1999;353 Suppl 2:SII5-9. 
Chapter 17 ______________________________________________________________________________ 
 
 98 
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. 
Circulation 1995;92:657-671. 
3. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-
Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. 
Angiographic progression of coronary artery disease and the 
development of myocardial infarction. J Am Coll Cardiol 
1988;12:56-62. 
4. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, 
Smialek J, Virmani R. Healed plaque ruptures and sudden 
coronary death: evidence that subclinical rupture has a role 
in plaque progression. Circulation 2001;103:934-940. 
5. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. 
Lessons from sudden coronary death: a comprehensive 
morphological classification scheme for atherosclerotic 
lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275. 
6. Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, 
Specchia G, Virmani R. Plaque erosion is a major substrate 
for coronary thrombosis in acute myocardial infarction. Heart 
1999;82:269-272. 
7. Mercado N, Maier W, Boersma E, Bucher C, de Valk V, O'Neill 
WW, Gersh BJ, Meier B, Serruys PW, Wijns W. Clinical and 
angiographic outcome of patients with mild coronary lesions 
treated with balloon angioplasty or coronary stenting. 
Implications for mechanical plaque sealing. Eur Heart J 
2003;24:541-551. 
8. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, 
Arampatzis CA, Hoye A, van Duuren M, Sianos G, Smits PC, 
de Feyter P, van der Giessen WJ, van Domburg RT, Serruys 
PW. Early outcome after sirolimus-eluting stent implantation 
in patients with acute coronary syndromes: insights from the 
Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology 
Hospital (RESEARCH) registry. J Am Coll Cardiol 
2003;41:2093-2099. 
9. Lemos PA, Serruys PW, Van Domburg RT, Saia F, Arampatzis 
CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, 
McFadden E, Sianos G, Hofma SH, Smits PC, Van Der Giessen 
WJ, De Feyter PJ. Unrestricted Utilization of Sirolimus-Eluting 
Stents Compared With Conventional Bare Stent Implantation 
in the "Real World." The Rapamycin-Eluting Stent Evaluated 
At Rotterdam Cardiology Hospital (RESEARCH) Registry. 
Circulation 2003. 
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, 
Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, 
Molnar F, Falotico R. A randomized comparison of a sirolimus-
eluting stent with a standard stent for coronary 
revascularization. N Engl J Med 2002;346:1773-1780. 
11. Abizaid AS, Mintz GS, Mehran R, Abizaid A, Lansky AJ, 
Pichard AD, Satler LF, Wu H, Pappas C, Kent KM, Leon MB. 
Long-term follow-up after percutaneous transluminal 
coronary angioplasty was not performed based on 
intravascular ultrasound findings: importance of lumen 
dimensions. Circulation 1999;100:256-261. 
12. Rieber J, Schiele TM, Koenig A, Erhard I, Segmiller T, 
Stempfle HU, Theisen K, Jung P, Siebert U, Klauss V. Long-
term safety of therapy stratification in patients with 
intermediate coronary lesions based on intracoronary 
pressure measurements. Am J Cardiol 2002;90:1160-1164. 
13. Ferrari M, Schnell B, Werner GS, Figulla HR. Safety of 
deferring angioplasty in patients with normal coronary flow 
velocity reserve. J Am Coll Cardiol 1999;33:82-87. 
14. Bech GJ, De Bruyne B, Bonnier HJ, Bartunek J, Wijns W, 
Peels K, Heyndrickx GR, Koolen JJ, Pijls NH. Long-term 
follow-up after deferral of percutaneous transluminal 
coronary angioplasty of intermediate stenosis on the basis of 
coronary pressure measurement. J Am Coll Cardiol 
1998;31:841-847. 
15. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, 
Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns 
W. Fractional flow reserve to determine the appropriateness 
of angioplasty in moderate coronary stenosis: a randomized 
trial. Circulation 2001;103:2928-2934. 
16. Chamuleau SA, Meuwissen M, Koch KT, van Eck-Smit BL, Tio 
RA, Tijssen JG, Piek JJ. Usefulness of fractional flow reserve 
for risk stratification of patients with multivessel coronary 
artery disease and an intermediate stenosis. Am J Cardiol 
2002;89:377-380. 
17. Chamuleau SA, Tio RA, de Cock CC, de Muinck ED, Pijls NH, 
van Eck-Smit BL, Koch KT, Meuwissen M, Dijkgraaf MG, de 
Jong A, Verberne HJ, van Liebergen RA, Laarman GJ, Tijssen 
JG, Piek JJ. Prognostic value of coronary blood flow velocity 
and myocardial perfusion in intermediate coronary 
narrowings and multivessel disease. J Am Coll Cardiol 
2002;39:852-858. 
  
Chapter 18 Clinical and Angiographic Outcomes After Over-
Dilatation of Undersized Sirolimus-Eluting Stents 
With Largely Oversized Balloons. An 
Observational Study 
 
Francesco Saia, MD 
Pedro A. Lemos, MD 
Chourmouzios A. Arampatzis, MD 
Angela Hoye, MB ChB, MRCP 
Eugene McFadden, MB ChB, MRCPI, FACC 
Georgios Sianos, MD 
Pieter C. Smits, MD, PhD 
Willem J. van der Giessen, MD, PhD, FACC 
Pim J. de Feyter, MD, PhD, FACC 
Ron T. van Domburg, PhD 
Patrick W. Serruys, MD, PhD, FACC 
 
Catheter Cardiovasc Interv. In press 
 
Chapter 18 ______________________________________________________________________________ 
 
 100 
Clinical and Angiographic Outcomes After Over-Dilatation of 
Undersized Sirolimus-Eluting Stents With Largely Oversized 
Balloons. An Observational Study 
 
Francesco Saia, MD; Pedro A. Lemos, MD; Chourmouzios A. Arampatzis, MD; Angela Hoye, MB ChB, MRCP 
Eugene McFadden, MB ChB, MRCPI, FACC; Georgios Sianos, MD; Pieter C. Smits, MD, PhD 
Willem J. van der Giessen, MD, PhD, FACC; Pim J. de Feyter, MD, PhD, FACC; Ron T. van Domburg, PhD 
Patrick W. Serruys, MD, PhD, FACC 
 
Purpose: To assess the safety and effectiveness of sirolimus-eluting stent (SES) post-dilatation with largely oversized 
balloons. 
Methods: We evaluated the clinical outcome of 68 consecutive patients enrolled in the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry that underwent percutaneous coronary intervention 
with SES implantation and further post-dilatation with balloons >1mm larger than the stent nominal size. Angiographic 
follow-up was either scheduled for selected subgroups or clinically-driven. 
Results: Overall, 75 lesions were treated. The procedure was successful in 98.5% of the cases. One patient (1.5%) 
underwent emergency coronary bypass surgery for acute vessel occlusion. During 10.1±1.7 months follow-up, 3 
patients (4.5%) died, 1 (1.5%) had acute myocardial infarction, and 4 patients (6%) had target vessel revascularization. 
At angiographic follow-up, loss index was 0.13±0.34  and restenosis rate 7.7%. 
Conclusions: Although not routinely recommended in every patient, sirolimus-eluting stent post-dilatation with largely 
oversized balloons appears a safe and effective strategy for selected patients. 
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INTRODUCTION 
Stent-based local drug delivery is a relatively new 
concept developed to prevent  neointima hyperplasia 
growth and restenosis following coronary angioplasty and 
stenting (1). While the stent, with its mechanical 
properties, prevents elastic recoil and negative vessel 
remodeling, the drug bound on its surface exerts an 
inhibitory action toward smooth muscle cells proliferation 
and migration, the most important determinants of in-
stent restenosis (ISR). 
Sirolimus-eluting stents (SES) have been shown in 
randomized trials to virtually abolish in-stent restenosis in 
selected patients with de novo lesions (2). The 
revolutionary results obtained in the first studies have 
encouraged, in a few pioneer centers, the routine 
utilization of these new devices, with the double aim to 
give the best treatment available to all patients and, at 
the same time, to assess the efficacy of SES in more 
complex clinical subsets of patients and lesions, such as 
those found in the daily practice (3).  
Several intravascular ultrasound (IVUS) studies have 
shown that optimal stent deployment was rarely achieved 
with angiographically-guided angioplasty alone (4-6). The 
major effect of these studies was the introduction of 
routine high pressure stenting (5,7). Moreover, stent post-
dilatation with larger balloons has become common 
practice after the documentation of the frequent 
mismatch between the angiographic and the real vessel 
diameter (8-10), and the very low incidence of in-stent 
restenosis observed in the MUSIC study with IVUS-guided 
stent deployment (11). The choice to post-dilate a stent 
depends on many factors: operator’s habit, attempt to 
improve suboptimal angiographic results, IVUS-guided 
stenting. In the AVID study, which evaluated the effects 
of IVUS-guided stent, additional balloon dilatation based 
on IVUS findings was performed in 43% of the patients 
(12). Similarly, in the CRUISE study, after IVUS 
examination the operators decided to use oversized 
balloons in 34% of the patients (13). This strategy has 
been proven to be safe with bare stents, and was not 
reported to hamper the efficacy of drug-eluting stents in 
the RAVEL trial (2), where it was allowed in order to 
achieve a less than 20% residual diameter stenosis. 
In daily practice, based on angiographic or 
intravascular ultrasound findings, extreme over-dilatation 
with balloon >1mm larger than the stent nominal size 
might be required in selected cases to achieve a good 
procedural result. Moreover, temporary limited availability 
of properly sized stents could be related to local 
laboratory or manufacturers’ problems. In the SES, 
sirolimus is blended in a 5-µm-thick layer of nonerodable 
polymer. Appropriate drug delivery depends on the 
polymer integrity and on the proper spacial distribution of 
the stent struts. Extreme post-dilatation of the stent could 
impair the effectiveness of SES in different ways: by 
enhancing tissue proliferation in response to greater 
vessel injury (14), by altering the mechanical properties of 
the stent, by disrupting the polymer coating, and by 
increasing the distance between the stent struts, 
therefore reducing local drug distribution. 
In the present study, we evaluated the clinical and 
angiographic outcomes of 68 patients treated with SES 
implantation in which a post-dilatation with largely 
oversized balloons was performed. 
METHODS 
SES implantation was adopted as the default strategy for 
all patients undergoing PCI at our institution, as part of the 
RESEARCH (Rapamycin-Eluting Stents Evaluated At 
Rotterdam Cardiology Hospital) Registry (3). The SES was 
available in limited lengths (8, 18, and 33mm) and diameters 
(2.25, 2.5, 2.75 and 3.0mm). In a four months period from 
June to October 2002, 68 consecutive patients underwent 
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SES implantation and further post-dilatation with balloons 
>1mm larger than the stent nominal size and comprise the 
present study population. 
All procedures were performed according to standard 
techniques and the final interventional strategy, as well as 
periprocedural adjunctive medications and intravascular 
ultrasound utilization, was left to the operator’s discretion. All 
patients were pre-treated with aspirin and clopidogrel. Aspirin 
was maintained lifelong and at least 3 months of clopidogrel 
treatment was recommended thereafter.  Prolonged 
clopidogrel prescription (6 months) was recommended for 
patients treated with SES and at least one of the following 
characteristics: multiple SES (>3 stents), total stented length 
>36 mm, chronic total occlusion, bifurcations, and in-stent 
restenosis. The study protocol was approved by the 
institutional ethics committee and written informed consent 
was obtained from all patients. 
A procedure was considered successful when residual 
stenosis was < 30% by quantitative coronary analysis 
together with TIMI flow 3. During follow-up, coronary 
angiograms were obtained as clinically indicated by 
symptoms or positive ischemic tests. In addition, follow-up 
angiograms were scheduled for patients with SES 
implantation to treat in-stent restenosis, bifurcations, left 
main, chronic total occlusions, very small vessels (SES 
diameter 2.25mm), long stent length (>36mm), and acute 
myocardial infarction. Post-SES binary restenosis at follow-up 
was defined as >50% diameter stenosis occurring in the 
segment inside the SES or within 5-mm segment proximal or 
distal to the stent. Acute gain was defined as the difference 
between minimal luminal diameter (MLD) post- and MLD pre-
procedure. Late loss was calculated as the difference 
between the MLD immediately after the procedure and the 
MLD at six months. Loss index was defined as the ratio 
between late loss and acute gain. The incidence of major 
adverse cardiovascular events (MACE), defined as death, 
myocardial infarction or target vessel revascularization (TVR), 
was evaluated. A definite diagnosis of MI required an 
increase in the creatine kinase (CK) level to more than twice 
the upper normal limit with an increased level of CK-MB. 
Target lesion revascularization (TLR) was defined as any 
surgical or percutaneous re-intervention motivated by a 
significant luminal narrowing within the stent or in the 5-mm 
distal or proximal peristent segments. Target vessel 
revascularization (TVR) was defined as any re-intervention 
driven by lesions located in the treated vessel beyond the 
target lesion limits. 
Discrete variables are reported as counts and relative 
percentages. Continuous variables are expressed as mean ± 
standard deviation. 
RESULTS 
Baseline clinical characteristics of the 68 patients are 
shown in table 1. Around 15% of the patients had 
diabetes mellitus, and 56% multivessel coronary disease. 
Notably, 23.5% of the patients presented acute 
myocardial infarction. Overall, 75 lesions were treated 
with 101 sirolimus-eluting stents, with an average stent 
length per lesion of 26.9±18.0 mm. Among the lesions, 7 
(9.3%) were in the left main, and 9 (12%) in a saphenous 
vein graft. Chronic total occlusions (> 3 months) 
accounted for 24% of the procedures. Nominal stent 
diameter was 3.0 mm in 98 cases, 2.75 mm in 2, and 2.5 
in 1. Further stent post-dilatation was performed with a 
4.0 mm balloon in 70 lesions, and with 4.5 mm balloon in 
the remaining 5. Average inflation pressure was 15.9 ± 
3.6 atm. Nominal balloon to artery ratio was 1.31±0.29. 
IVUS was used in 21 patients (30.8%). In 85.3% of the 
cases, the SES was implanted to treat a de novo lesion, in 
9.3% to treat in-stent restenosis, and in 4% to treat a 
guiding catheter-induced vessel dissection (table 2). 
Glycoprotein IIb/IIIa inhibitors were used in 38.2% of the 
patients. The procedure was successful in 67 patients 
(98.5%). One patient developed diffuse distal vessel 
dissection after post-dilatation of the 3x18 mm SES with a 
4x15 mm balloon, inflated up to 12 atmospheres, and 
underwent successful emergency CABG. 
 
Table 1. Baseline patient characteristics (n=68) 
Age, years 60±10 
Men 45 (66.2%) 
Risk Factors  
Current smoker 24 (35.3%) 
Diabetes mellitus 10 (14.7%) 
Family history of coronary heart disease 32 (47.1%) 
Clinical Presentation  
Silent ischemia 3 (4.4%) 
Stable angina pectoris 30 (44.1%) 
Unstable angina pectoris 19 (27.9%) 
Acute myocardial infarction 16 (23.5%) 
Multivessel coronary disease 38 (55.9%) 
Previous myocardial infarction 21 (30.1%) 
Previous coronary bypass 9 (13.2%) 
Previous percutaneous coronary intervention 17 (25%) 
 
 
Table 2. Angiographic and procedural characteristics 
Lesions, n 75 
Target coronary artery  
Left anterior descending 21 (28.0%) 
Left circumflex artery 6 (8.0%) 
Right coronary artery 32 (42.7%) 
Left main 7 (9.3%) 
Saphenous vein graft 9 (12.0%) 
Lesion type  
De novo 64 (85.3%) 
In-stent restenosis 7 (9.3%) 
Early re-intervention 1 (1.3%) 
Guiding catheter injury/dissection 3 (4.0%) 
Lesion type (AHA/ACC classification)  
Type A/B1 22 (29.3%) 
Type B2/C 53 (70.7%) 
Thrombus-containing lesions 16 (21.3%) 
Moderate/severe calcifications 9 (12.0%) 
Ostial lesions 23 (30.7%) 
Bifurcation stenting 4 (5.2%) 
Chronic total occlusions 18 (24%) 
Glycoprotein IIb/IIIa inhibitors* 26 (38.2%) 
Stent per lesion, n 1.35 ± 0.65 
Stents length per lesion, mm 26.9 ± 18.0 
*percentage relative to the number of patients (68) 
 
Clinical follow-up was available for 67 patients 
(98.5%). During an average follow-up of 10.1±1.7 
months, 3 (4.5%) patients died, 1 (1.5%) had acute 
myocardial infarction, and  4 patients (6%) had a TVR, of 
which 3 were TLR (4.5%). Overall MACE rate was 12.0%. 
One patient was admitted with acute large infero-
posterior myocardial infarction and cardiogenic shock, 
which was irreversible despite positioning of intra-aortic 
balloon pump. A second patient died 5 months after the 
procedure because of end-stage renal failure. The cause 
of death of the third patient, who died 141 days after the 
revascularization procedure, is unknown: he was 75 years 
old, diabetic, with 3 vessel disease and moderate aortic 
valve stenosis, and had received a SES in the proximal 
right coronary artery. One patient had a small 
periprocedural myocardial infarction (CK max=346 UI/L, 
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MB=73 UI/L). The angioplasty was performed in a 
saphenous vein graft, which was totally occluded due to 
in-stent restenosis. Among the 4 target vessel re-
interventions, only 1 was motivated by restenosis. The 
remaining were 1 case of  emergency bypass surgery, 
already described, 1 early (5 days) percutaneous re-
intervention caused by incomplete ostial coverage of the 
rigth coronary artery during the index procedure, and one 
case of in-stent re-dilatation driven by IVUS diagnosis of 
stent undersizing despite the absence of angiographic 
restenosis (the patient was symptomatic and presented 
angiographic restenosis in another lesion located distally 
in the same vessel, a saphenous vein graft). There were 
no episodes of early or late stent thromboses. 
 
Table 3. Paired quantitative angiographic analysis. 
 Baseline Post Follow-up 
RD, mm 3.18±0.63 3.36±0.40 3.43±0.46 
MLD, mm 0.68±0.62 2.88±0.42 2.66±0.77 
Diameter stenosis, % 77±22 14±9 20±21 
Lesion length, mm 20.1±14.1 - - 
Acute gain, mm - 2.22±0.73 - 
Late loss*, mm - - 0.24±0.61 
Loss index - - 0.13±0.34 
Binary restenosis*, % - - 7.7% 
MLD=minimal luminal diameter; RD=reference diameter 
*including one total re-occlusion 
 
Angiographic follow-up was obtained in 34 patients for 
39 lesions after 210±29 days (range 156-309 days). As 
previously specified, the reasons for repeat catheterization 
were: elective follow-up because the patient was included 
in selected subgroups in 32 cases (72.7% of the 44 
patients scheduled for 6-months angiography), and 
clinically-driven re-catheterization in 2 patients. At 
baseline, mean reference diameter was 3.21 ± 0.58mm, 
MLD 0.86 ± 0.61mm, percent diameter stenosis 72 ± 
21%, and lesion length 17.9 ± 11.5 mm. Paired 
quantitative coronary analysis for patients with 
angiographic follow-up is shown in table 3. Late loss was 
0.24 ± 0.61 mm, with 76% of the cases in the range 
between –0.5 and +0.5 mm. Loss index was 0.13 ± 0.34. 
Overall, post-SES binary restenosis was observed in 3 
lesions (7.7%): 2 were proximal edge restenosis, and in 
one patient the vessel was occluded approximately 30 mm 
proximally to the target lesion. 
DISCUSSION 
The present study shows that post-dilatation of SES 
with largely oversized balloons is relatively safe and 
associated with good angiographic results. 
IVUS studies have demonstrated that incomplete stent 
deployment may occur in a considerable number of 
patients even with high-pressure techniques (6,15). 
Optimal stent expansion plays a key role in the prevention 
of stent thrombosis (4). Moreover, previous studies have 
shown that residual percent diameter stenosis after stent 
implantation is directly related to the development of 
restenosis (16,17). Similarly, in-stent minimal lumen cross 
sectional area measured by IVUS is inversely related to 
restenosis (18). All together, these findings provide the 
rationale to pursue optimal stent expansion. This outcome 
is often achieved by performing stent post-dilatation with 
balloons oversized with respect to the nominal stent size. 
Over-dilatation with balloons >0.25 mm larger has been 
shown to improve lumen gain and possibly reduce the 
need for target vessel revascularization, without 
increasing complications (9,10,19). However, in one study 
IVUS examination revealed that even with this strategy no 
stent reached its nominal size (19). Thus, it is commonly 
believed that post-dilatation with balloons up to 0.5 mm 
larger than the stent nominal size can be safely 
accomplished in most of the cases. Conversely, dilatation 
with balloons >0.5 mm larger than the stent nominal size 
is a rare procedure. In clinical practice, this extreme post-
dilatation is performed in selected patients, commonly 
when the operator has the perception, based on 
angiographic or IVUS findings, that the stent implanted is 
markedly undersized relatively to the vessel diameter. In 
other situations this choice could be driven, in a bail-out 
procedure, by unavailability of the proper size of stents. 
In both cases, this strategy should be regarded as an 
extreme solution, not free from potential complications. 
Possible stent structure distortion and disruption must be 
taken into account, as well as the chance of extensive 
intimal dissection and vessel wall rupture. When the same 
strategy is applied with drug-eluting stents, further 
possible shortcomings should be considered. In fact, the 
success of drug-eluting stents depends critically on the 
achievement of the appropriate local drug concentration, 
which warrants potent antiproliferative effects and 
preserved vascular healing. The elution profile/release 
kinetics of the drug depend on the biological properties of 
the drug and of the coating matrix (1). Apart from the 
potential mechanical damages to the stent, excessive SES 
post-dilatation could impair their antiproliferative 
properties by damaging the polymer coating. Moreover, 
by increasing the distance between the drug-carrying 
stent struts, over-dilatation could decrease local sirolimus 
concentration to a sub-optimal or ineffective level. The 
results of the present study suggest that these potential 
risks do not have an evident impact on the the favorable 
clinical and angiographic outcome of SES, although some 
negative influence cannot be ruled out in single cases 
(20). In our series, extreme SES post-dilatation was not 
associated with an high rate of acute complication, 
although one patient had to be referred for emergency 
coronary surgery. The clinical outcome at mid-term 
follow-up was favorable, and the 12% incidence of MACE 
appears very satisfactory if we consider the unselected 
nature of the population analyzed, which included 24% of 
the patients with acute myocardial infarction. Notably, 9% 
of the lesions treated were in the left main and 12% in a 
saphenous vein graft. Moreover, at angiographic follow-
up, restenosis was observed in a very limited number of 
patients. Although only 50% of the patients underwent 
repeat catheterization, the selection criteria of these 
patients (“complex” lesions and symptomatic patients) 
would have been expected to increase the chance of 
finding restenotic lesions, thus indirectly confirming the 
very positive results obtained. Remarkably, almost one 
fourth of the lesions were chronic total occlusions, 
condition traditionally associated with higher restenosis 
rates (21,22). Indeed, the loss index of the present series 
(0.13 ± 0.34), compares favorably with the historical 
series of the BENESTENT trial (0.46 ± 1.39), the 
BENESTENT II Pilot study (0.41 ± 1.18), and the MUSIC 
study (0.45 ± 0.33) using bare stents  (table 4) (11). 
In conclusion, angiographically or intravascular-guided 
post-dilatation of SES with largely oversized balloons 
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could be considered an extreme solution for stent 
undersizing. Although careful case by case evaluation in 
these situations is necessary, this strategy appears 
relatively safe and does not seem to impair the 
effectiveness of sirolimus-eluting stents. 
 
Table 4. Angiographic findings compared to the MUSIC trial (11). 
 MUSIC SES 
overdilatat. 
Reference diameter pre, mm 3.09±0.49 3.18±0.63 
Reference diameter post, mm 3.40±0.54 3.36±0.40 
Reference diameter at 6 months, mm 3.04±0.51 3.43±0.46 
Minimum lumen diameter pre, mm 1.13±0.34 0.68±0.62 
Minimum lumen diameter post, mm 2.90±0.36 2.88±0.42 
Minimum lumen diameter at 6 m., mm 2.12±0.67 2.66±0.77 
Diameter stenosis pre, % 63±10 77±22 
Diameter stenosis post, % 15±6 14±9 
Diameter stenosis at 6 m., % 30±17 20±21 
Nominal balloon/artery ratio 1.20±0.15 1.31±0.29 
Maximal inflation pressure 15.8±3.33 15.9±3.6 
Acute gain, mm 1.79±0.39 2.22±0.73 
Late loss, mm 0.78±0.56 0.24±0.61 
Loss index 0.45±0.33 0.13±0.34 
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Objective: To assess the effectiveness of routine sirolimus-eluting stent (SES) implantation for unselected patients with 
in-stent restenosis (ISR), and to provide preliminary information about the angiographic outcome for different lesion 
subgroups and for different ISR patterns. 
Patients: We evaluated 44 consecutive patients (53 lesions) without previous brachytherapy that were treated with 
SES for in-stent restenosis at our institution. Routine angiographic follow-up was obtained at 6 months and the 
incidence of major adverse cardiac events was evaluated. 
Results: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% total occlusions. Small 
vessel size (reference diameter <2.5mm) was present in 49%, long lesions (>20mm) in 30%, treatment of bypass 
grafts in 13%, and bifurcation stenting in 18%. At follow-up, post-SES restenosis was observed in 14.6%. No restenosis 
was observed in focal lesions. For more complex lesions, restenosis rates ranged 20-25%. At 1-year follow-up, the 
incidence of death was 0%, myocardial infarction 4.7%, and target lesion revascularisation 16.3%. Target lesion 
revascularisation due to restenosis was performed in 11.6%. 
Conclusions: Routine sirolimus-eluting stent implantation is highly effective for focal in-stent restenosis and appears to 
be a promising strategy for more complex patterns of restenosis. 
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INTRODUCTION 
Despite major advances in the field of percutaneous 
coronary interventions (PCI), long-term outcome is still 
limited by the occurrence of in-stent restenosis (ISR), 
which has been reported to occur in 10 to 50% of the 
patients in several series.[1] Furthermore, treatment of 
ISR is frequently a challenging clinical problem, with 
recurrent restenosis being reported in up to 80% in the 
most complex cases.[2] Currently, vascular brachytherapy 
is the only strategy proven to be more effective for the 
treatment of ISR than other conventional 
approaches.[3][4][5][6][7] However, post-brachytherapy 
recurrent restenosis has been reported to occur in 17% to 
32% of patients at 1 year.[3][4][5][6][7] Moreover, 
despite the relative improvement in outcomes, 
brachytherapy has not been extensively adopted as 
routine therapy in many centers, mostly due to logistic 
and technical limitations. 
Sirolimus-eluting stents (SES) have been shown in 
randomized trials to virtually abolish in-stent restenosis in 
selected patients with de novo lesions.[8][9] Moreover, 
prolonged (up to 2 years) inhibition of the proliferative 
response has been documented in two series of patients 
with non-complex lesions.[10][11] Due to the potent 
antiproliferative and antimigratory effects of the drug on 
vascular smooth muscle cells and the clinical efficacy 
demonstrated for de novo lesions, SES implantation has 
been recently tested in two preliminary studies to treat in-
stent restenosis.[12][13] In one study with 25 relatively 
non-complex cases, zero recurrent binary restenosis was 
observed after SES.[13] In the other study, among 16 
patients with more complex lesions, repeat in-stent 
restenosis was observed in 20% of cases.[12] However, 
due to the limited number of patients in both reports, the 
outcome in patients with complex lesion morphology, a 
condition commonly seen in daily practice, is currently 
unclear.  
In the present study, we evaluated the clinical and 
angiographic outcomes of 44 consecutive patients treated 
with routine SES implantation for in-stent restenosis with 
a broad range of morphological lesion patterns.  
METHODS 
Patient population and Procedures 
Since the 16th of April 2002, SES implantation has 
been adopted as the default strategy for all patients 
undergoing PCI at our institution, as part of the 
RESEARCH (Rapamycin-Eluting Stents Evaluated At 
Rotterdam Cardiology Hospital) Registry.[14] Fourty-four 
consecutive patients without previous brachytherapy were 
treated for in-stent restenosis during a 6-month 
enrolment period and comprise the present study 
population. No patient with in-stent restenosis was 
treated in the same period exclusively with other 
percutaneous devices (e.g. bare metal stents, cutting 
balloon) or with brachytherapy and therefore excluded 
from this report. The study protocol was approved by the 
hospital ethics committee and written informed consent 
was given by every patient. 
The CYPHERTM sirolimus-eluting stent (Cordis Europa 
NV, Roden, NL) was utilized in all patients. The stents 
were available in lengths of 8, 18 or 33mm and in 
diameters of 2.25, 2.5, 2.75 and 3.0mm. All procedures 
were performed according to standard techniques and the 
final interventional strategy was left to the operator’s 
discretion. Complete lesion coverage was recommended, 
as well as a small region of overlap of adjacent stents 
when treating lesions that required more than one stent. 
Periprocedural adjunctive medications were left to the 
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discretion of the operator. All patients were pre-treated 
with aspirin and clopidogrel. Aspirin was maintained 
lifelong and at least 3 months of clopidogrel treatment 
was recommended thereafter.  
 
Table 1. Baseline patient characteristics  
Patients 44 
Age, years±SD 63±13 
Men 73% 
Risk Factors  
Current smoker 27% 
Hypercholesterolemia* 68% 
Systemic hypertension 48% 
Diabetes mellitus 25% 
Family history of coronary heart disease 43% 
Clinical Presentation  
Silent ischemia 9% 
Stable angina pectoris 64% 
Unstable angina pectoris 25% 
Acute myocardial infarction 2% 
Multivessel coronary disease 50% 
Previous myocardial infarction 52% 
Previous coronary bypass 23% 
Recurrent episodes of in-stent restenosis (>1) 25% 
*Total cholesterol > 200mg/dl and/or on lipid lowering treatment 
Definitions and Follow-up 
Restenotic lesions were angiographically classified by 
two independent operators according to Mehran 
classification as: 1) focal (<10 mm), 2) diffuse, 3) 
proliferative, or 4) total occlusion.[2] A procedure was 
considered successful when residual stenosis was < 30% 
by quantitative coronary analysis (QCA) with TIMI flow 3. 
All patients were requested to undergo an elective repeat 
angiogram after 6 months following a successful 
procedure. Post-SES binary restenosis at follow-up was 
defined as >50% diameter stenosis occurring in the 
segment inside the SES or within 5-mm segment proximal 
or distal to the stent. Late luminal loss was calculated as 
the difference between the minimal luminal diameter 
(MLD) after the procedure and at six months. 
Patients were prospectively followed-up to evaluate 
the incidence of major adverse cardiovascular events 
(MACE), defined as death, myocardial infarction or target 
lesion revascularisation (TLR). Target lesion 
revascularisation (TLR) was defined as any surgical or 
percutaneous re-intervention motivated by a significant 
luminal narrowing within the stent or in the 5-mm distal 
or proximal peristent segments. 
Statistical analysis 
Discrete variables are reported as counts and relative 
percentages and compared with Fisher’s exact test. 
Continuous variables are expressed as mean ± standard 
deviation and compared with the Student T test. A p value 
< 0.05 was considered to be significant. All tests were 
two-tailed. Analyses were performed with SPSS version 
8.0 statistical package (SPSS Inc. Chicago, IL, USA). 
RESULTS 
Baseline and procedural data 
Baseline clinical characteristics of the 44 patients with 
ISR are shown in table 1. Diabetes was present in 25% of 
the patients. Clinical presentation was an acute coronary 
syndrome in 27% of cases. A quarter of the patients had 
previous recurrent episodes of ISR. According to the 
Mehran classification, 42% of the lesions were class I, 
21% class II, 26% class III, and 11% class IV (table 2). 
Small vessel size (reference diameter < 2.5 mm) was 
present in 49%, long lesions (>20mm) in 30%, treatment 
of bypass grafts in 13%, and bifurcation stenting in 18%. 
The patients received on average 2.0±1.4 stents, with a 
mean stent length per lesion of 28±20mm (range 8-84 
mm). Direct stenting was performed in 13 lesions 
(24.5%). Seven lesions (13.2%) were pre-dilated with a 
cutting balloon. Endovascular ultrasound was used in 25% 
of the procedures for stent sizing or to optimize the result. 
The procedure was successful in 43 patients (97.7%). 
One patient underwent emergency bypass surgery due to 
intimal dissection and acute vessel occlusion during the 
procedure. 
 
Table 2. Angiographic and procedural characteristics 
Lesions 53 
Target coronary artery  
Left anterior descending 49% 
Left circumflex artery 11% 
Right coronary artery 26% 
Left main 2% 
Saphenous vein graft 9% 
Left internal mammary artery 2% 
Mehran class  
I (Focal) 42% 
II (Diffuse) 21% 
III (Proliferative) 26% 
IV (Total occlusion) 11% 
Small vessel size* 49% 
Bifurcation stenting† 18% 
Multivessel stenting† 25% 
Glycoprotein IIb/IIIa inhibitors† 9% 
Stent length per lesion, mm 28 ± 20 
Stents per patient, n 2.0 ± 1.4 
*pre-procedure reference diameter d 2.5 mm 
†percentages relative to the number of patients 
 
Table 3. Quantitative angiographic analysis at baseline, post-
procedure and follow-up*. 
 Pre-
procedure 
Post-
procedure 
Follow-up 
Reference diameter, mm 2.64±0.56 2.73±0.54 2.83±0.50 
Minimum lumen diameter, 
mm 
0.90±0.55 2.33±0.59 2.20±0.81 
Diameter stenosis, % 66±19 16±15 23±25 
Lesion length, mm 17.5±12.1 - - 
Acute gain, mm - 1.42±0.70 - 
Late loss, mm - - 0.17±0.76 
Late loss excluding 
occlusions, mm 
- - 0.11±0.67 
Post-SES restenosis†, %   14.6 
SES=sirolimus-eluting stent 
*related to 41 lesions with angiographic follow-up 
†including one total re-occlusion 
Angiographic results 
The pre-procedure, post-procedure and follow-up 
quantitative angiographic data are shown in table 3. 
Representative sequences of angiograms from two 
patients are shown in figure 1. Mean reference diameter 
was 2.64±0.56 mm and mean lesion length was 
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17.5±12.1 mm. Angiographic follow-up was obtained in 
33 patients (77% of patients with successful index 
procedure) with 41 lesions (79%). Late loss was 
0.17±0.76 mm. Cumulative distribution curves of 
angiographic late loss (figure 2) show that the vast 
majority of the lesions (79%) had a late loss between – 
0.5 and +0.5 mm. Overall, post-SES binary restenosis was 
observed in 14.6% of the lesions. Table 4 shows the 
frequency of post-SES restenosis for some subgroups. No 
restenosis was observed in Mehran class I lesions; class 
II, III and IV lesions had post-SES restenosis in 22%, 
25% and 20%, respectively (p=NS). In 5 out of 6 cases 
with post-SES restenosis the restenosis was focal or 
multifocal. For patients with post-SES restenosis, the 
average lesion length decreased from 31.7±15.3mm at 
baseline to 10.0±4.8mm at follow-up (p=0.01). One 
patient presented post-SES with silent total occlusion. 
Post-SES restenotic lesions were located within the SES in 
5 lesions and at the proximal edge in the remaining 1. In 
two patients, post-SES restenosis occurred in an 
uncovered region injured during the procedure (gap 
between two SES implanted to treat two separate lesions 
in one patient and stent discontinuity by ultrasound 
examination due to possible stent fracture in another 
case).[15] Marked SES undersizing (stent diameter 
2.7mm; vessel diameter 5.7mm) was found in another 
patient with post-SES restenosis. 
The patients that developed post-SES restenosis had 
baseline clinical characteristics similar to the others. 
However, the lesions who developed binary restenosis 
were considerably longer (29.1±15.0 mm vs 16.1±11.0, 
p=0.01), were treated with more stents (2.2±0.7 vs 
1.5±0.7, p=0.04), and the stented segment was longer 
(average stent length per lesion: 49.0±30.0 mm vs 
25.5±16.3 mm, p<0.01) compared to lesions who 
presented less than 50% diameter stenosis at follow-up. 
 
Table 4. Binary post-SES restenosis in subgroups* 
 Post-SES restenosis 
Total population (n=41) 14.6 % 
Diabetics (n=8) 25.0 % 
Small vessel size (n=20) † 10.0 % 
Vein grafts (n=5) 20.0 % 
Lesion length > 20mm (n=14) 28.6 % 
Bifurcating stents‡ (n=7) 14.3 % 
Mehran class2  
Type I (n=15) 0 
Type II (n=9) 22.2 % 
Type III (n=12) 25.0 % 
Type IV (n=5) 20.0 % 
Numbers in parenthesis are related to lesions with follow-up 
* related to 41 lesions with angiographic follow-up 
† pre-procedure reference diameter d 2.5 mm 
‡ related only to the in-stent restenosis lesions; in these series, 
there was no case of restenosis in the side-branches treated for 
de novo lesions. 
Clinical Follow-up 
Complete clinical follow-up was available for 43 
patients (98%). After 1 year, the cumulative incidence of 
MACE was 20.9%. There were no deaths, 2 patients had 
non-Q-wave myocardial infarction (4.7%), of which 1 peri-
procedural and 1 after 7 months, and 7 patients (16.3%) 
underwent TLR (including the patient who underwent 
emergency CABG). Target lesion revascularisation due to 
restenosis was performed in 5 patients (11.6%). One 
additional target lesion revascularisation was performed 5 
days after the index procedure in a patient with recurrent 
angina and intravascular ultrasound evidence of 
incomplete right coronary artery ostium coverage. All 
repeat revascularisations were within 7 months follow-up. 
There were no documented episodes of early or late stent 
thromboses. It is worth noting that patients who refused 
to undergo angiographic re-evaluation had no adverse 
events during follow-up. 
 
A B C
A’ B’ C’
1
2
3
4
5
6
 
Figure 1. Sirolimus-eluting stent implantation for total occlusion 
due to in-stent restenosis: representative sequences of 
angiograms from two patients. Patient 1. A. Diagnostic 
angiogram showing total occlusion of the proximal right coronary 
artery due to ISR (arrows). B. Final result after implantation of 
two overlapping SES, 3x18 mm proximal (1), and 3x33 mm distal 
(2). Some minimal residual stenosis is visible at the distal stent 
edge. C. Six-month angiographic follow-up showing persistence 
of the good result obtained previously. Patient 2. A’. Diagnostic 
angiogram showing in-stent restenosis giving total occlusion of 
the mid part of the left anterior descending artery (LAD) 
(arrows), immediately after the origin of the second diagonal 
branch. B’. Final result after implantation of three overlapping 
SES in the LAD, 2.75x8 mm proximal (3), 2.5x33 mm in the 
middle (4), and 2.25x8 mm distal (5). Bifurcation stenting was 
necessary to preserve the second diagonal (6, SES 2.25x8 mm). 
C’. Six-month angiographic follow-up showing persistence of the 
good result in both vessels. 
DISCUSSION 
The major finding of the present study is that routine 
sirolimus-eluting stent implantation for in-stent restenosis 
is safe and associated with low recurrence rates in a 
broad range of clinical and anatomical settings. 
The present series comprises patients and lesions 
commonly not included in previous reports,[12][13] [16] 
such as very long lesions, chronic total occlusions, small 
vessels, bypass grafts, and bifurcations. In fact, the 
majority of patients in our consecutive series, 
representative of the everyday practice, presented at least 
one of the aforementioned characteristics. Despite the 
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unselected nature of this population, clinical and 
angiographic outcomes appear superior to previous results 
for conventional approaches.[2] [18][19][20][21] Indeed, 
our findings compare favorably with those reported for 
vascular brachytherapy, which has been advocated as the 
treatment of choice for complex in-stent 
restenosis.[3][4][5][6][7] Moreover, SES implantation 
does not deviate from practice with conventional bare 
stents, and avoids most of the technical and logistical 
limitations that have hampered a more widespread use of 
brachytherapy.  
 
The outcomes of patients with in-stent restenosis after 
repeat treatment have been reported to be closely related 
to the baseline lesion morphology.[2] A progressive 
increase in risk profile occurs from lesions with a focal 
pattern to lesions with a more diffuse appearance and 
total occlusions.[2] Accordingly, in our series, SES was 
associated with a remarkably low incidence of recurrent 
restenosis in focal lesions. Indeed, all cases of repeat 
restenosis occurred in patients with more complex 
baseline characteristics. However, no clear differences in 
the rates of repeat restenosis were noted among higher 
risk categories (i.e Mehran classes II, III, and IV), in 
whom the rates of repeat restenosis have been reported 
to be 35, 50 and 85%, respectively, with conventional 
therapy. Thus, it is possible that SES implantation may 
reduce the prognostic value of the lesion pattern of in-
stent restenoses for non-focal ISR, although the limited 
number of our observations does not allow a definitive 
conclusion. Conversely, our data suggest that lesion 
length may still have an impact on recurrent restenosis. 
Recently, sirolimus-eluting stents have been consistently 
shown to reduce neointimal proliferation in ISR as 
effectively as in de novo lesions.[21] Instead of reflecting 
an intrinsic drug resistance, repeat restenosis in complex 
lesions may actually be more closely related to local 
mechanical conditions that impair the therapeutic effect of 
the device (p.e. incomplete coverage of balloon-injured 
areas of neointimal hyperplasia, under-expanded stents). 
In fact, a possible technical reason for failure was 
documented in 3 of 6 cases (50%) of recurrent restenosis 
in our series, although the significance of these findings 
remains elusive. Two recent reports have confirmed these 
observations in a larger number of patients treated with 
sirolimus-eluting stents. [22][23]  
This study evaluates a relatively limited number of 
patients and lesions. However, this is the largest series of 
patients described to date (table 5). Moreover, to the best 
of our knowlegde, this is the first study to assess the 
impact of sirolimus-eluting stent implantation in a broad 
range of different anatomical subsets of in-stent 
restenosis. 
The rate of angiographic follow-up (79% of all 
lesions), although similar to other studies that enrolled 
patients with recurrent ISR, [3] [6][7] is not very high and 
could not represent the true binary restenosis for the 
entire cohort. This could be explained by the considerable 
number of recurrent restenosis and previous procedures 
suffered by some patients, therefore not willing to 
undergo 6-month angiography in the absence of 
symptoms. This was indirectly confirmed by the clinical 
follow-up of the patients who refused the angiographic 
control, who were all asymptomatic. Patients with failed 
brachytherapy were not included in the current report. We 
have recently shown that recurrent in-stent restenosis 
following vascular brachytherapy may exhibit a peculiar 
and different biological and clinical response to sirolimus-
eluting stent implantation,[24] therefore representing a 
potentially confounding factor if analyzed conjointly with 
patients without prior local irradiation. 
 
Table 5. Eluting-stents implantation for in-stent restenosis: angiographic results of the principal studies. 
 TAXUS-III16 FIM – Rotterdam12 FIM - São Paulo13 ISR post-
brachytherapy24 
RESEARCH Registry 
Drug Paclitaxel Sirolimus Sirolimus Sirolimus Sirolimus 
Patients 28 16 25 12 44 
Inclusion criteria - Single lesion 
- native coronary artery 
- Vessel size 3.0-3.5 mm 
- Single lesion 
- native coronary artery 
- Vessel size 2.5-3.5 mm 
- Single lesion 
- native coronary artery 
- Vessel size 2.5-3.5 mm 
- Previous 
brachytherapy 
- All clinical and 
anatomical 
conditions 
Exclusion criteria - Acute MI 
- Length > 30 mm 
- Total occlusion 
- LVEF<30% 
- renal dysfunction 
- Saphenous vein graft 
 
-  Previous 
brachytherapy 
- Length > 36 mm in  
- Total occlusion 
 - Previous 
brachytherapy 
Reference diameter 2.75±1.20 2.68±0.33 2.78±0.30 2.83±0.48 2.64±0.56 
Lesion length 13.6 ± 6.4 18.4 ± 13.1 13.6 ± 7.65 - 17.5 ± 12.1 
Stent length 22 ± 8 28 ± 18 22 ± 7 34 ± 30 28 ± 20 
Time of follow-up 6 months 6 months 4 months 12 months 6 months 6 months 
Late loss* 0.54 ± 0.51† 0.26 ± 0.67 - 0.05±0.30 0.16±0.42 0.68 ± 1.2 0.17 ± 0.76 
Binary restenosis* 16.0% 20.0 % 0 % 4.0 % 40.0 % 14.6% 
* in-stent plus 5-mm segment proximal and distal to the stent 
 †in-stent only 
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Figure 2. Cumulative distribution of late loss at angiographic follow-up. 
Lesions with binary restenosis are indicated by empty squares. Clinical 
outcome of each restenotic lesion is reported corresponding to the 
respective late loss value. This curve resembles a bimodal distribution 
and suggests that the failures cases might share unique features.
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CONCLUSIONS 
Routine utilization of sirolimus-eluting stent 
implantation to treat in-stent restenosis appeared safe 
and effective in an unselected series of cases, especially in 
patients with focal lesions. Sirolimus-eluting stent 
implantation also seems to be a promising strategy for 
complex in-stent restenosis. Further analysis with larger 
series and more prolonged follow-up, as well as a direct 
comparison with brachytherapy in a randomized fashion 
are needed to clarify the role of sirolimus-eluting stents in 
this context. 
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Purpose: To compare the mid-term clinical outcome of sirolimus-eluting stent (SES) implantation and vascular 
brachytherapy (VBT) for in-stent restenosis (ISR). 
Methods: We assessed the 9-month occurrence of major adverse cardiac events (MACE) in 44 consecutive patients 
with ISR treated with SES implantation, and 43 consecutive patients treated with VBT in the period immediately prior. 
Results: Baseline clinical and angiographic characteristics of the two groups were similar. During follow-up, 3 patients 
(7%) died in the VBT group and 0 in the SES group. The incidence of myocardial infarction was 2.3% in both groups. 
Target lesion revascularization was performed in 11.6% of the VBT patients and 16.3% of the SES patients (p=NS). The 
9-month MACE-free survival was similar in both groups (79.1% VBT vs 81.5% SES; p=0.8 by log rank). 
Conclusions: The result of this non-randomized study suggests that sirolimus-eluting stent implantation is at least as 
effective as vascular brachytherapy in the treatment of in-stent restenosis. 
 
Catheter Cardiovasc Interv. In press 
 
 
INTRODUCTION 
In-stent restenosis (ISR) represents the major 
limitation of coronary stenting (1). Treatment of ISR with 
conventional strategies is limited by the high rate of 
recurrence, which gradually increase from focal lesions to 
proliferative patterns and total occlusions (2). 
The “mechanical” approach to treat ISR, with 
utilization of additional stents or debulking devices, has 
failed to show substantial benefits (3-6). Vascular 
brachytherapy (VBT), by targeting the “biological” 
component of neointimal proliferation, is the only strategy 
proven to be effective in randomized trials (7-11). 
However, its utilization is limited by complex logistic 
requirements and the necessity of highly trained 
operators. Moreover, recurrent restenosis still occurs in 
approximately one third of the patients treated with 
vascular brachytherapy (7-11). 
Sirolimus- (12-13) and paclitaxel-eluting stents (14) 
have been shown in randomized trials to strongly 
suppress the development of neointimal hyperplasia in 
selected de novo lesions compared to bare stents. Also, 
promising results have been recently reported with drug-
eluting stents for the treatment of in-stent restenosis, 
especially for patients with less complex forms of 
restenosis (15-17). A relatively low incidence of repeat 
restenosis has been shown after drug-eluting stent 
implantation in these preliminary series of cases. 
However, to date, the clinical efficacy of this new 
therapeutic approach has not been compared to 
conventional percutaneous techniches or to the “gold 
standard” vascular brachytherapy. 
In this study we therefore aimed to comparatively 
evaluate the outcomes of patients with in-stent restenosis 
treated with sirolimus-eluting stent implantation or with 
catheter-based brachytherapy. 
METHODS 
Patient population 
Since the 16th of April 2002, we have adopted a policy 
of sirolimus-eluting stent implantation for all patients 
undergoing percutaneous coronary interventions at our 
institution, as previously described elsewhere (18). In the 
first six months enrollment, 44 consecutive patients with 
in-stent restenosis and no previous brachytherapy at the 
same site were treated with SES implantation (SES 
group). A comparison group was composed by 43 patients 
treated with vascular brachytherapy (group VBT) in the 
months immediately prior, between 1st January 2001 and 
15th of april 2002. This time period was selected to 
approximately match the number of patients with 
brachytherapy with the number of patients treated with 
sirolimus-eluting stent. All patients treated with both 
modalities were included in the present report. Informed, 
written consent was obtained from all patients. 
Procedures 
All patients were pre-treated with aspirin (at least 75 
mg/d) and clopidogrel (75 mg/d or 300 mg bolus). During 
the procedure weight-adjusted heparin was administrated 
to achieve an activated clotting time of >300 sec. 
Vascular brachytherapy was performed in all patients with 
catheter-delivered beta-radiation. Two systems were used 
during the study period: BetacathTM (Novoste, Norcross, 
GA), and GalileoTM (Guidant corporation, Santa Clara, CA, 
USA), which have been described in detail elsewhere (11, 
19). Operators were strongly advised to avoid 
implantation of new stents (20), and to avoid insufficient 
radiation dose delivery to injured areas (geographic miss) 
(21). Clopidogrel prescription was decided on an individual 
patient basis by the attending interventional cardiologist 
according to current practice guidelines. In the SES group, 
restenotic lesions were treated with implantation of the 
CypherTM sirolimus-eluting stent (Cordis Europa NV, 
Roden, NL). Complete lesion coverage by this stent was 
recommended. In case additional stents were needed, 
care was taken to avoid gaps between adjacent stents. 
The final treatment strategy and device utilization other 
than SES were left to the operator’s discretion. At least 3 
months of clopidogrel treatment was prescribed 
thereafter. In both study periods, periprocedural 
adjunctive medications were left to the discretion of the 
operator. 
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Table 1. Baseline clinical characteristics and demographics of the 
two study cohorts. 
 
 
VBT 
(n. 43) 
SES 
(n. 44) 
 
p value 
Age, y 61±10 63±13 ns 
Males, n (%) 31 (73) 32 (73) ns 
Diabetes Mellitus, n (%) 11 (26) 11 (25) ns 
Hypertension, n (%) 13 (30) 21 (48) ns 
Hypercholesterolemia, n (%) 26 (60) 30 (68) ns 
Previous MI, n (%) 20 (47) 23 (52) ns 
Previous CABG, n (%) 9 (21) 10 (23) ns 
Multivessel disease, n (%) 20 (47) 22 (50) ns 
Clinical presentation, n (%) 
Stable Angina 
ACS 
 
34 (79) 
9 (21) 
 
32 (73) 
12 (27) 
ns 
Number of ISR lesions treated 44 53 - 
ISR lesions treated per patient 1.0 ± 0.2 1.2 ± 0.5 0.02 
Target Vessel, n (%) 
LAD 
LCX 
RCA 
LM 
Bypass grafts 
 
16 (36) 
9 (20) 
15 (34) 
1 (2) 
3 (7) 
 
26 (49) 
6 (11) 
14 (26) 
1 (2) 
6 (11) 
ns 
 
 
 
 
 
Mehran classification, n (%) 
Type I 
Type II 
Type III 
Type IV 
 
10 (23) 
19 (43) 
10 (23) 
5 (11) 
 
22 (42) 
11 (21) 
14 (26) 
6 (11) 
 
0.05 
0.02 
ns 
ns 
Multivessel procedure, n (%) 9 (21) 11 (25) ns 
Procedural success*, n (%) 42 (98) 43 (98) ns 
IIb/IIIa inhibitors, n (%) 14 (33) 4 (9) 0.007 
Clopidogrel prescription, mo 7.5 ± 5.5 5.9 ± 2.6 0.005 
ACS=Acute Coronary syndromes; CABG=Coronary Artery Bypass 
Graft; LAD=left anterior descending artery; LCX=left circumflex 
artery; MI=Myocardial Infarction; RCA=right coronary artery; 
LM=left main stem; TL=Target Lesion 
*as judged by the operator, in the absence of in-hospital 
complications. 
Definitions and follow-up 
ISR was defined as a significant stenosis within a 
previous stented segment on visual assessment, together 
with objective evidence of ischemia. The lesions were 
angiographically classified according to Mehran et al. (2) 
by two independent operators. The primary composite 
endpoint was the incidence of major adverse 
cardiovascular events (MACE) during 9 months of follow-
up, defined as death, myocardial infarction or target lesion 
revascularization (either percutaneous or surgical). The 
diagnosis of myocardial infarction was based on an 
increased level of creatine kinase to more than twice the 
upper limit of normal with an increased level of creatine 
kinase-MB isoform. Target lesion revascularization (TLR) 
was defined, for the patients in the brachytherapy group, 
as any surgical or percutaneous re-intervention due to 
restenosis within the irradiated segment or the 5mm 
proximal or distal segments, and for the patients in the 
SES group as any revascularization in the stent and in the 
5 mm proximal and distal segments. Target vessel 
revascularization (TVR) was defined as any re-intervention 
driven by lesions located in the treated vessel beyond the 
target lesion limits. Survival status at follow-up was 
assessed by written inquires to the Municipal Civil 
Registries. Repeat revascularization procedures and 
episodes of acute myocardial infarction were prospectively 
collected in the hospital data base. For patients admitted 
to peripheral hospitals in the acute phase, the diagnosis of 
myocardial infarction was confirmed by the referring 
physician based on the same criteria. All re-interventions 
were prospectively collected in a dedicated electronic 
database. 
Statistical methods 
Discrete variables were presented as count and 
relative percentages and compared with Fisher exact tests 
or Chi-square. Continuous variables were presented as 
mean and standard deviations and compared with Student 
t test. Event-free survivals were calculated according to 
the Kaplan-Meier method and compared by the log-rank 
test. All tests were two-tailed, and a p value <0.05 was 
considered as significant. 
RESULTS 
Baseline characteristics 
The baseline characteristics of the two groups were 
similar (table 1). Specifically, no difference was observed 
in the incidence of diabetes ( 26% VBT vs 25% SES; 
p=0.1), previous myocardial infarction (47% VBT vs 52% 
SES; p=0.6), previous coronary artery bypass graft 
(CABG) surgery (21% VBT vs 23% SES; p=0.8), or 
multivessel disease (47% VBT vs 50% SES; p=0.7). The 
majority of the patients in both groups had stable angina 
at hospital admission (79% VBT vs 73% SES; p=0.5). 
Almost all patients in the VBT group had single-lesion 
brachytherapy, except by one patient with 2 lesions 
treated. In the SES group, 53 ISR lesions were treated 
(1.2 ± 0.5 lesion per patient). In the SES group there 
were more lesions classified as Mehran type I (23% VBT 
vs 42% SES; p=0.05), whilst type II was more common in 
the VBT group (43% VBT vs 21% SES; p=0.02). 
However, both treatment groups had similar numbers of 
lesions with non-complex (Mehran Type I/II: 66% VBT vs 
63% SES) or complex (Mehran Type III/IV: 34% VBT vs 
37% SES; p=0.7 for all) morphologies. Quantitative 
coronary analysis did not show significant differences in 
baseline lesions’ characteristics between the two groups 
(table 2). Average lesion length was 15.7±10.4 mm in the 
VBT group and 17.5±12.1 mm in the SES group (p=0.4). 
As expected, post-procedure minimal lumen diameter was 
bigger (1.84±0.41 mm VBT vs 2.33±0.59 mm SES; 
p=0.0008) and diameter stenosis smaller (28±12 % VBT 
vs 16±15 % SES; p=0.004) in the SES group. 
In the VBT group average irradiated length was 48 ± 
12mm, and average radiation dose administered was 23 ± 
2 Gy. A new stent was implanted in 27% of the VBT 
patients. In the SES group each patient received on 
average 2.0 ± 1.4 stents, with a mean stent length of 28 
± 20 mm per lesion. In the VBT group periprocedural 
glycoprotein IIb/IIIa inhibitors utilization was more 
common (33% vs 9%; p=0.007), and clopidogrel 
prescription longer (7.5±5.5 months vs 5.9±2.6 months; 
p=0.005). 
Clinical outcome 
Complete information at follow-up was available in 
100% of VBT patients and 97.7% of SES patients (1 
patient moved abroad and was lost to follow-up). During 
nine months of follow-up, 3 patients (7%) died in the VBT 
group and 0 in the SES group (p=0.08 by log rank)(table 
3). They were all thought to be cardiac deaths: one 
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patient with previous CABG operation developed severe 
hypotension after balloon angioplasty and irradiation of 
the right coronary artery and died 2 days after the 
procedure; two patients had a sudden death 3 months 
after treatment of a lesion in the proximal left anterior 
descending while still on combined antiplatelet treatment 
(one of them had a new stent implanted during the 
brachytherapy procedure). Subacute stent thrombosis 
could not be ruled out in these last 2 cases. A definite 
diagnosis of acute MI was made in 1 patient in each 
group. Target lesion revascularization was performed in 5 
patients (11.6%) in the VBT group, and  7 patients 
(16.3%) in the SES group (p=NS). In the VBT group 
these recurrent restenosis were treated with 2 CABG 
operations, 1 balloon angioplasty, 1 stent implantation, 
and 1 sirolimus-eluting stent implantation. In the SES 
group 1 patient underwent emergency CABG surgery for 
vessel dissection and acute occlusion during treatment of 
a lesion in the proximal left circumflex artery, and the 
remaining 6 TLRs were accomplished percutaneously (3 
with additional SES implantation, 3 with taxol-eluting stent 
implantation). Overall, the MACE-free survival at 9 months 
was similar in both groups (79.1% VBT vs 81.5% SES; 
p=0.8 by log rank) (figure 1). 
 
 
Table 2. Quantitative coronary analysis at baseline 
 
 
VBT 
(n. 44) 
SES 
(n. 53) 
 
p value 
Pre-procedure    
Reference diameter, mm 2.44 ± 0.45 2.64 ± 0.56 ns 
MLD, mm 0.74 ± 0.52 0.90 ± 0.55 ns 
Diameter stenosis, % 69 ± 20 66 ± 19 ns 
Lesion length, mm 15.7 ± 10.4 17.5 ± 12.1 ns 
Post-procedure    
Reference diameter, mm 2.61 ± 0.51 2.73 ± 0.54 ns 
MLD, mm 1.84 ± 0.41 2.33 ± 0.59 0.0008 
Diameter stenosis, % 28 ± 12 16 ± 15 0.004 
MLD = Minimal Lumen Diameter  
 
 
Table 3. Nine-month clinical outcome. 
 
 
VBT 
(n. 43) 
SES 
(n. 44) 
All MACE, % 20.9 18.6 
Death, % 7.0 0 
Myocardial infarction, % 2.3 2.3 
Target Lesion Revascularization, % 11.6 16.3 
Target Vessel Revascularization, % 4.7 4.7 
Coronary bypass graft, % 7.0 2.3 
Percutaneous coronary 
intervention, % 
9.3 18.6 
MACE=Major Adverse Cardiovascular Events 
DISCUSSION 
Vascular brachytherapy has been rigthly considered 
the gold-standard treatment for in-stent restenosis, at the 
least for more complex cases, after several randomized 
trials have shown its superiority over other conventional 
approaches (7-11). Despite these favorable results, 
brachytherapy has not been widely utilized, being still 
currently restricted, at least in Europe, to a limited 
number of centers. Complex logistic and technical 
requirements, as well as lack of reimbursement in some 
countries, have limited a more generalized utilization of 
brachytherapy. Furthermore, the identification of possible 
shortcomings such as geographical miss (21) and delayed 
re-endothelialization, which is associated with an 
increased risk of subacute thrombosis especially when a 
new stent is implanted (22), have made mandatory a 
specific training for the operators involved in 
brachytherapy procedures. 
In the present study, treatment of in-stent restenosis 
with sirolimus-eluting stents was associated with similar 
clinical results at 9 months compared to vascular 
brachytherapy. These findings are of potential major 
interest. Routine utilization of sirolimus-eluting stent 
implantation does not deviate from the standard practice 
with conventional bare stents. Indeed, no additional 
requirements are needed to readily apply this new therapy 
at any catheterization laboratory. 
Widespread utilization of drug-eluting stents is 
expected to change the current scenario, by reducing ISR 
to a minority of patients. (12,23) Moreover, recurrent 
restenosis after drug-eluting stent implantation presents 
peculiar characteristics, such as predominantly focal 
pattern, (24,25) which could improve its response to the 
various percutaneous treatments. However, despite the 
enthusiasm raised by the publication of the first clinical 
studies, drug-eluting stent penetration in common 
practice is still limited by cost restrains (26), and ISR 
remains the major limitation of PCI. In this early drug-
eluting stents era, “provisional” SES utilization in case of 
bare stent failure is appealing and, based on the results of 
the present study and two prior reports (15,16), seems to 
be a feasible and effective strategy. 
Kaplan-Meier curves of survival-free from major adverse cardiac 
events (MACE) in the brachytherapy (VBT) and in the sirolimus-
eluting stent (SES) groups. 
 
In the evaluation of our results, two additional pieces 
of information should be taken into account. Although not 
statistically significant, a slightly higher rate of TLR was 
observed in the SES group. However, in this group routine 
angiographic follow-up was scheduled by protocol, and 
performed in 77% of the patients, while only a minority of 
patients in the VBT group underwent elective angiography 
(30%). We have previously shown that angiographic 
follow-up have a negative impact on clinical outcome due 
to more repeat revascularization procedures (“oculo-
stenotic reflex”) (27). Furthermore, a late “catch-up” 
phenomenon (continuous increasing of angiographic late-
loss after 6 months) has been reported for VBT (28,29), 
while data regarding SES for both de novo (30) and ISR 
(16) lesions suggest that the early results are predictive of 
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the long-term findings. On the other hand, although not 
statistically significant, we observed an increased mortality 
in the brachytherapy group (VBT: 7%; SES: 0%; p=0.08), 
suggesting once again the possibility of serious adverse 
events related to the prolonged endothelial damage after 
vessel irradiation.  
 Study limitations 
Our study presents a number of limitations that 
suggest some caution when interpreting the results. First 
of all, the two groups were not randomized, and were 
treated in different time periods. Moreover, while the SES 
group was composed of a consecutive series of patients, 
the patients undergoing VBT group were selected by the 
operators based on clinical and morphological 
consideration. Accordingly, more patients in the SES 
group presented Mehran type I lesions (23% VBT vs 42% 
SES), because in the VBT phase most of these patients 
underwent percutaneous re-intervention with conventional 
techniques. However, we cannot ignore the fact that 
baseline clinical characteristics of the 2 cohorts of patients 
were remarkably similar. Additionally, if we consider 
together lesions of Mehran class I and II, the difference 
among the two groups disappears (66% VBT vs 63% SES; 
p=0.7). This was indirectly confirmed by the lack of 
difference in lesion length between the two groups. Other 
imbalances were observed in procedural characteristics 
and peri-procedural medications. The higher rate of 
glycoprotein IIb/IIIa inhibitors in the VBT-treated 
patients, and the longer clopidogrel prescription in the 
same group, could have generated a clinical advantage, 
especially in those with acute coronary syndromes 
(31,32). More lesions were treated per patient in the SES 
group; while on one side this strategy could favour 
recurrent restenosis and repeat revascularizations, 
especially in patients with angiographic follow-up, on the 
other side a possible positive impact of a more complete 
revascularization on clinical outcome cannot be ruled out.  
Another limitation is represented by the low number of 
patients in both groups. It should be noticed, however, 
that the present study is, to the best of our knowledge, 
the first comparison between VBT and SES in the 
treatment of ISR, and in this setting the study which 
included the higher number of patients treated with SES 
reported so far (15,16). Moreover, the first randomized 
trial comparing vascular brachytherapy with conventional 
balloon dilatation included only 55 patients (8). 
CONCLUSIONS 
In this study, routine sirolimus-eluting stent 
implantation to treat in-stent restenosis appeared at least 
as effective as vascular brachytherapy in the treatment of 
in-stent restenosis, with the advantage of simpler logistic 
and technical requirements.  Further prospective, 
randomized investigation with larger study population and 
longer follow-up are mandatory to confirm these findings. 
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Coronary vascular brachytherapy is, to date, the only 
effective treatment available for complex instent 
restenosis (ISR).1 However, its efficacy is hampered by 
late restenosis,2 late thrombosis,3,4 edge effect,5 
geographic miss,6 and delayed healing.3 Moreover, the 
fate of the patients after “failed” brachytherapy is 
uncertain, as well as the result of the various 
percutaneous treatments employed thereafter. Sirolimus 
is a macrolide antibiotic produced by Streptomyces 
hygroscopicus with immunosuppressive effects; it is 
approved for the prevention of renal transplant rejection.7 
The main effect of sirolimus is the interruption of G1 to S 
cell cycle progression mediated by its binding to a 
cytosolic receptor (FK506 protein binding protein 12) and 
a cascade of subsequent actions. Importantly, sirolimus 
inhibits proliferation and migration of vascular smooth 
muscle cells, a key element in the development of 
restenosis after percutaneous coronary interventions 
(PCIs). Recently, stent-based local sirolimus delivery has 
been shown to strongly suppress neointimal hyperplasia 
and prevent restenosis in de novo lesions followed up for 
2 years.8,9 The revolutionary results obtained with 
drugeluting stents have encouraged the assessment of 
their efficacy in more complex clinical and morphologic 
subsets. The first human experience evaluating the 
sirolimus- eluting stent (SES) for the treatment of ISR has 
been recently reported; it showed this strategy to be 
highly effective.10 We describe here the first series of SES 
implantation for recurrent ISR after brachytherapy. 
• • • 
The patients described in this report consist of 2 
cohorts treated during separate time periods. The first 
cohort was treated between March 2001 and June 2001, 
as part of a pilot study on SESs for treatment of ISR. 
Since April 2002, shortly after European Community 
market approval, SES implantation has been adopted as 
the default strategy in all patients treated with PCI at our 
institution, irrespective of clinical presentation and 
coronary morphology. These latter patients have been 
included in the RESEARCH Registry (Rapamycin-Eluting 
Stent Evaluated At Rotterdam Cardiology Hospitals) and 
will be followed up for 1 year.11 The only exclusion criteria 
were unavailability of an adequately sized SES at the time 
of the procedure and enrollment in another 
revascularization protocol (SESs were available in 
diameters from 2.25 to 3.0 mm and lengths of 8, 18, and 
33 mm). All patients treated with SES after “failed” 
brachytherapy were scheduled for 6-month angiography. 
ISR was defined as >50% diameter stenosis by 
quantitative coronary angiography within a previously 
stented vessel segment and classified as proposed by 
Mehran et al.12 Treatment strategy and device utilization 
other than stenting was left to the physician’s discretion. 
The procedure was considered successful when residual 
stenosis _30% by quantitative coronary angiography was 
achieved together with Thrombolysis In Myocardial 
Infarction (TIMI) flow grade 2 to 3. The study stent 
utilized was the sirolimus-eluting Cypher (Cordis Europa 
NV, Johnson & Johnson, Roden, The Netherlands), which 
contains a 140 µg sirolimus/ cm2 metal surface area in a 
slow release formulation (>28 days). Pretreatment with 
clopidogrel for 48 hours or a 300-mg loading dose was 
required. During the procedure, intravenous heparin was 
given to maintain an activated clotting time >300 
seconds. After the procedure, all patients received aspirin 
indefinitely (>75 mg/day) and clopidogrel (75 mg/day) for 
at least 2 months. Clinical status information was collected 
at follow-up visits or by telephone contact with the patient 
or referring physician. Data are presented as number and 
relative percentage or mean ± SD. Median and range 
have been reported when nedded for a better description. 
From the beginning of the study until August 15, 
2002, 12 consecutive patients (both cohorts) underwent 
PCI with SES implantation for recurrent ISR after local 
radiation therapy. All of them presented with angina 
pectoris and/or myocardial ischemia as documented by 
stress test or thallium scan. Coronary brachytherapy had 
been previously performed in 11 patients with catheter-
based local irradiation (10 beta, 1 gamma) and in 1 
patient with phosphorus-32 radioactive stent implantation. 
Baseline clinical and angiographic characteristics are 
listed in Tables 1 and 2, respectively. Nine patients (75%) 
had had more than 1 previous episode of restenosis. 
Average time from the preceding percutaneous 
reintervention was 24 months (range 111 to 1,678 days, 
median 719). Remarkably, 9 patients (75%) presented 
with a proliferative pattern of restenosis, 5 of whom 
(42%) had a totally occluded target vessel. The occlusion 
dated more than 3 months in 4 patients. 
Overall, we implanted 18 SESs (average 1.5/patient). 
Mean stent length was 33.9 ± 30.1 mm (range 8 to 92; 
median 18), and mean stent diameter was 2.88 ± 0.33 
mm. Multivessel PCI was performed in 3 patients (25%). 
Angiographic success was obtained in 11 of 12 patients 
(92%). The remaining patient showed a 34% residual 
stenosis during quantitative coronary angiography and 
stent underexpansion despite very highpressure inflation 
(24 atm). Individual clinical outcomes are listed in Table 
3. With the obvious exception of the single patient 
presenting with acute myocardial infarction, no 
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postprocedural cardiac enzyme elevation was observed, 
and all the patients were discharged free from events. 
  
Table 1. Patients’ baseline characteristics and demographics 
Patients 12 
Age, years 62±11 
Men 9 (75%) 
Current smoker 4 (33%) 
Hypercholesterolemia* 11 (92%) 
Systemic hypertension 6 (50%) 
Diabetes mellitus 3 (25%) 
Family history of coronary heart disease 4 (33%) 
Stable angina pectoris 7 (58%) 
Unstable angina pectoris 4 (33%) 
Acute myocardial infarction 1 (8%) 
Multivessel coronary disease 10 (83%) 
Previous myocardial infarction 9 (75%) 
Previous coronary bypass 4 (33%) 
Time from last target lesion 
revascularization, (d) 
111-1678 (719) 
Time from brachytherapy, (d) 111-1968 (792) 
Episodes of in-stent restenosis  
 > 1  9 (75%) 
 > 2  5 (42%) 
*Total cholesterol > 200mg/dl and/or on lipid lowering treatment 
Values are mean±SD, range (median), or number of patients (%) 
 
Table 2. Angiographic and procedural characteristics 
Variable  
Target coronary artery  
Left anterior descending 2 (17%) 
Left circumflex artery 5 (42%) 
Right 4 (33%) 
Left main 1 (8%) 
Pre-procedure  
Reference diameter (mm) 2.83±0.48 
Minimum lumen diameter (mm) 0.67±0.76 
Diameter stenosis (%) 77±25 
Post-procedure  
Reference diameter (mm) 2.76±0.38 
Minimum lumen diameter (mm) 2.38±0.45 
Diameter stenosis (%) 13±11 
Acute gain (mm) 1.71±0.58 
Late loss (mm) 0.68±1.20 
Multivessel coronary procedure 3 (25%) 
Other devices utilization  
Cutting Balloon 3 (33%) 
Cross Safe *  1 (8%) 
* Intraluminal Therapeutics Inc. Carlsbad, California 
 
Average follow-up was 8.5 ± 4.5 months. Ten patients 
(83%) underwent angiography between 4 and 7 months 
after the procedure. Two patients who refused 
angiographic follow-up were asymptomatic after 4 and 6 
months. One patient died after 9.5 months because of 
congestive heart failure, shortly after hospital admission 
for acute pulmonary edema. He was 79 years old, with a 
history of 2 coronary artery bypass graft operations and 2 
PCIs. Left ventricular dysfunction and end-stage 
congestive heart failure were diagnosed before the last 
coronary angioplasty. During the 4-month follow-up, no 
intravascular ultrasound evidence of neointimal 
hyperplasia was found. 
Recurrent ISR after SES implantation was found in 4 
out of 10 patients who underwent angiography during 
follow-up (40%). One of them, in whom complete stent 
expansion could not be achieved at index procedure, was 
found to have silent reocclusion after 4 months. No 
further treatment was performed, and at 19 months the 
patient remained asymptomatic. Two other patients, both 
diabetics, presented with stable angina (Canadian 
Cardiovascular Society class 3) and ISR that required 
target lesion revascularization. In 1 of them, intravascular 
ultrasound showed a clearly underexpanded stent with a 
very small minimal instent diameter (1.3 mm). In the 
fourth case, a very focal restenosis (>5 mm) was 
diagnosed by elective angiography 5 months after the 
procedure. Originally, the patient had been treated with 4 
SESs (overall length 92 mm) for chronic total occlusion of 
the left anterior descending artery (ISR). Intravascular 
ultrasound examination confirmed the absence of 
neointimal hyperplasia in the remaining portion of the 
stents. The patient was asymptomatic, but percutaneous 
revascularization was performed based on intravascular 
ultrasound findings. 
Another patient had recurrent angina 4 months after 
the procedure. Angiography showed minimal in-stent 
hyperplasia in the region of interest, whereas a severe 
lesion due to ISR requiring percutaneous treatment was 
found in a different vessel. 
 
 
Table 3. Individual clinical and angiographic outcome 
Patient Vessel BT Mehran 
Class 
No. of 
ISR 
Clopidogrel 
(months) 
Follow-up 
(months) 
Clinical follow-up 
(months) 
Clinical Status 
follow-up 
Angiographic Control 
(time-%DS) 
1 Right Beta II 3 6 9.5 Death (9.5) Death 4 months - 7% 
2 Right Beta IB 2 8 12 0 symptomatic 4 months - 15% 
3 Right Beta II 2 2 14 0 symptomatic 6 months - 13 % 
4 Right Gamma IV 4 L 7 0 symptomatic 7 months - 25 % 
5 Circumflex Beta IV 1 6 19 0 symptomatic 4 months -  100% 
6 Circumflex Beta IV 2 L 5 TLR (5) Stable angina 5 months - 71% 
7 Circumflex Beta III 3 2 6 0 symptomatic - 
8 Circumflex Beta IB 3 3 7 TVR * (7) symptomatic 7 months - 17 % 
9 Circumflex Beta III 1 6 8 TLR (6) Stable angina 6 months - 98 % 
10 Left main 
/circumflex 
Beta IC 2 L 
5 Non-TVR (5) 
Stable angina 5 months - 13 % 
11 Left anterior 
descending 
32P Rx 
Stent 
IV 1 6 
4 
0 symptomatic - 
12 Left anterior 
descending 
Beta IV 3 L 
5 TLR (5) 
Stable angina 5 months - 62 % 
*Distal to the index lesion due to disease progression 
BT=Brachytherapy; ISR=in-stent restenosis; L=lifelong; Non-TVR=non-Target Vessel Revascularization; TLR=Target Lesion 
Revascularization; TVR=Target Vessel Revascularization; %DS=percentage diameter stenosis by quantitative coronary analysis. 
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One of the lesions treated with an SES during the 
index procedure was composed of echolucent tissue 
(“black hole”).13 Interestingly enough, the intravascular 
ultrasound examination at follow-up showed a 
reappearance of this tissue, although it did not 
significantly affect the lumen area. 
• • • 
SESs have been recently shown to strongly prevent 
the development of neointimal hyperplasia after stenting. 
The first randomized clinical trial reported an exceptional 
0% binary restenosis rate.8 Whether a similar result is 
obtainable in different clinical situations and for more 
complex coronary lesion subsets is the subject of 
extensive investigation. Preliminary results for their use in 
the treatment of ISR are positive, although less 
impressive than in de novo lesions.10  
In the present investigation, we sought to assess the 
safety and outcome of SES implantation in patients with 
recurrent ISR after brachytherapy. The strategy evaluated 
is safe and is believed to be clinically effective, 
considering the complex population under investigation. 
The 0% incidence of in-hospital events as well as the 
absence of subacute stent thrombosis is noteworthy 
because the average stent length was remarkably high, 
and these patients are likely to have endothelial 
dysfunction. The only death that occurred is highly 
unlikely to be related to either the procedure or to the 
stent, but rather to the severely compromised left 
ventricular function. Nevertheless, our report raises a 
series of unresolved issues. The antiproliferative effect of 
sirolimus after brachytherapy seems to be strongly 
reduced compared with other situations. The 40% 
incidence of restenosis in our population is noteworthy. 
Diabetes mellitus, a well-known risk factor for restenosis, 
may also represent a predisposing factor for failure in this 
setting. However, in 2 cases, technical causes of failure 
(stent underexpansion) could be implicated, and in a third 
patient, a very focal neointimal growth was observed 
compared with the very long baseline lesion and total 
stent length. The optimal duration of combined 
antiplatelet therapy is unclear. In this series there was a 
striking variety in the duration of clopidogrel prescribed 
after the procedure due to decisions made on an 
individual patient basis. Currently, we prescribe combined 
antiplatelet therapy for at least 12 months after long stent 
implantation, but this deserves further evaluation.  
Our investigation presents a few limitations. First, we 
do not have a control population. Whether a conventional 
approach would have provided comparable results cannot 
be inferred from our data. Second, the present series of 
patients is quite heterogenous; this is not surprising given 
the “real world” setting. The time elapsed from the last 
target vessel revascularization was considerably different 
among patients. The underlying physiopathologic process 
of late (around 2 years) recurrent restenosis after 
brachytherapy and subsequent response to treatment is 
not known (whether it is neointimal tissue or late 
atherosclerotic progression is unclear). Moreover, the 
incidence of black hole may be higher than suspected, 
and the biologic properties of this tissue may be 
responsible for a blunted response to antiproliferative 
drugs. Last, but not least, the number of patients in our 
investigation was low, and larger studies with extended 
follow-up are warranted to draw definitive conclusions. 
In this investigation, 12 patients were treated 
with sirolimus-stent implantation for recurrent ISR 
after failed brachytherapy. The strategy evaluated 
was safe and is believed to be clinically effective, 
although our data suggest a different attenuated 
efficacy of sirolimus in preventing neointimal 
growth in this setting compared with the 
treatment of de novo lesions.  
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Sirolimus-eluting stents (SES) have been used in our institution for all percutaneous interventions, without clinical or 
anatomical exclusion criteria as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital 
(RESEARCH) registry. We analyzed the incidence of (sub)acute stent thrombosis (SAT) after sirolimus-eluting stent 
implantation in an unselected population of 510 consecutive patients. At 3-month follow-up, SAT was diagnosed in 2 
patients (0.4%), 6 hours and 11 days after the procedure, respectively. Both cases occurred in diabetic females with 
complex coronary lesions. Intravascular ultrasound examination revealed inadequate stent expansion and uncovered 
distal dissection as possible mechanical explanations in both. 
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We analyzed the incidence of (sub)acute stent 
thrombosis after sirolimus-eluting stent 
implantation in an unselected population. 510 
consecutive patients received sirolimus eluting 
stents, without clinical or anatomical exclusion 
criteria. During 3 months follow-up sirolimus-
eluting stents showed a low incidence of 
(sub)acute thrombosis of 0.4% that is comparable 
to data previously reported for bare metal stents. 
Sirolimus-eluting stents (SES) have proven to 
significantly reduce restenosis in selected patients with 
relatively simple lesions1. Importantly, this late benefit 
was accomplished without compromising the well-
established low incidence of short-term complications with 
currently available bare stents. Specifically, in these earlier 
studies SES have been associated with a low incidence of 
stent thrombosis, a condition largely reported to a carry 
high morbidity and mortality risk2. However, these results 
cannot be directly extrapolated to patients with more 
complex profiles, such as those commonly treated in the 
daily practice. After bare metal stent implantation, the 
incidence of sudden stent thrombosis has been previously 
shown to be increased in patients with acute coronary 
syndromes, long stents, small vessels, chronic total 
occlusion and multivessel intervention3. We therefore 
investigated the incidence of (sub)acute stent thrombosis 
(SAT) occurring in the first 3 months after the procedure 
in an unselected cohort of consecutive patients treated 
with sirolimus-eluting stent implantation at our institution. 
• • • 
Since 16th April 2002, the sirolimus-eluting stent 
(Cypher™; Cordis Corp., Johnson & Johnson, Warren, NJ, 
USA) has been utilized as the device of choice for all 
percutaneous coronary interventions (PCI) performed at 
our institution, as part of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospitals (RESEARCH) 
registry. The study design has been described elsewhere4. 
In brief, the RESEARCH is a single-center registry 
conducted with the main purpose of evaluating the 
effectiveness of SES implantation in the patients treated in 
the “real world”. Therefore, SES has been utilized for 
virtually all clinical situations and lesion morphologies, 
with no specific contraindication.  
 
Table 1: Baseline and Procedural Characteristics (n=510) 
 Men (n=359) Women 
(n=151) 
Age, years 61±12 63±11 
Diabetes mellitus, % 16.0 23.7 
Current smoker, % 39.3 32.6 
Systemic hypertension , % 40.9 59.0 
Previous myocardial infarction, % 34.8 22.8 
Previous angioplasty, % 26.5 20.3 
Previous coronary bypass, % 10.1 10.7 
Double-vessel disease, % 31.7 25.7 
Triple-vessel disease, % 22.5 28.4 
Stable angina pectoris , % 52.1 51.7 
Unstable angina pectoris, % 31.5 33.1 
Acute myocardial infarction, % 16.7 13.9 
GP IIB/IIIA inhibitors, % 27.9 21.3 
Treated coronary artery*   
Left main stem, % 3.7 3.3 
Left anterior descending, % 57.4 57.0 
Left circumflex, % 36.5 29.8 
Right , % 34.3 41.1 
Multivessel SES implantation, % 25.3 23.2 
Number of SES per procedure 2.1±1.3 2.1±1.2 
Total stented length, mm/patient 38±27 38±27  
Adjacent stented length > 36mm, % 17.5 17.2 
Small stent diameter (d2.5mm) , % 36.5 33.9 
Postdilatation performed, % 56.6 51.0 
Intravascular ultrasound use, % 20.6 20.5 
Maximum pressure, atm 17.2±2.6 17.2±2.8 
Reference diameter, mm 2.70±0.49 2.70±0.54 
Minimal lumen diameter pre, mm 0.75±0.45 0.71±0.45 
Diameter stenosis pre, mm 71±17 71±18 
Minimal lumen diameter post, mm 2.31±0.49 2.35±0.46 
Diameter stenosis post, mm 15±12 14±9 
* not mutually exclusive -  in patients with multivessel disease, 
several arteries have been treated. 
_________________________________________________________________ SAT after SES implantation 
 
 123 
All procedures were performed according to standard 
techniques and the final interventional strategy was left to 
the discretion of the operators. At the time of the initiation 
of this study, SES were available in diameters from 2.25 
mm to 3.00 mm and lengths of 8, 18, and 33 mm. 
GPIIb/IIIa inhibitors were given at the discretion of the 
operator including all situation associated with high risk 
for subacute stent thrombosis such as acute coronary 
syndromes, long stents, small vessels, chronic total 
occlusion and multivessel intervention. All patients were 
on life-long aspirin administration and received a loading 
dose of clopidogrel (300mg), which was maintained for at 
least 3 month (75mg/d). 
Clinical follow-up at 3 month was performed by 
scheduled visits at the outpatient clinic or by direct 
contact (phone call or regular mail). Recordings of all 
repeat interventions (surgical and percutaneous) and re-
hospitalizations were prospectively collected in a 
dedicated database. Survival status at 30 days was 
assessed by written inquiries to the Municipal Civil 
Registries. The local ethical committee approved the study 
and written informed consent was obtained in all patients.   
Thrombotic stent occlusion was angiographically 
documented as a complete occlusion (TIMI flow 0 or 1) or 
a flow limiting thrombus (TIMI flow 1 or 2) of a previously 
successfully treated artery (TIMI flow 3 immediately after 
stent placement and percent in-lesion diameter stenosis  
<30%).  Acute was defined as occurring <24 hours, 
subacute as occurring > 24 hours to <30 days following 
the study procedure. Late was defined as occurring > 30 
days after the index procedure. Discrete variables were 
presented as count and percentages and continuous 
variables were expressed as mean ± 1 standard deviation. 
Between 16th April and 17th September 2002, a total 
of 510 consecutive patients (842 lesions) were treated 
with 1093 SES (2.1 ± 1.3 SES per patient). The baseline 
characteristics are shown in Table 1. Overall, 15.7% of 
patients had acute myocardial infarction and 32.4% 
unstable angina at admission. Multivessel stent 
implantation was performed in 25%, stents with small 
nominal diameter (2.5 or 2.25mm) were implanted in 
25.7%, and a long stented segment (> 36mm) was 
recorded in 17.5%. Glycoprotein IIbIIIa inhibitors were 
used in 24% of cases. 
Clinical 3 month follow-up information was obtained in 
all patients. During the first 3 month after the procedure, 
2 patients (0.4%) developed SAT. Both patients were on 
therapy with aspirin and clopidogrel at the time point  of 
event. 
• • • 
In the present study, SAT occurred in 2 among 510 
consecutive unselected patients treated sirolimus-eluting 
stent. The 0.4% incidence of SAT at 3 month observed in 
our series is low and comparable to that previously 
reported for conventional bare metal stents2,5. Both 
patients with stent thrombosis were diabetic females with 
complex coronary lesions. In these two cases IVUS 
examination revealed mechanical factors that had possibly 
predisposed to the complication (inadequate stent 
expansion and uncovered distal dissection). This is in 
accordance with recent findings in a large series of bare 
metal stents6. SAT was found to be mainly related to 
inadequate postprocedure lumen dimensions or 
procedurally related abnormal lesion morphologies 
(dissection, thrombus, or tissue prolapse). Stents in the 
left anterior descending artery have been reported to be 
more often involved in stent thrombosis than other 
vessels, but in that series diameters of the left anterior 
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Figure 1. 
1A) Pre-intervention angiogram. Multiple lesions in the distal (I) 
and mid (II) RCA. Lesions in the distal LAD (lesion length 
6.91mm; RD pre 2.63mm, MLD pre 1.58mm; DS pre 40%) and 
apical  LAD (lesion length 9.82mm; RD pre 1.71mm, MLD pre 
0.89mm; DS pre 48%) (III).  
1B) Final result after SES implantation in the distal LAD (SES 
3.0/8mm, 2.25/18mm; both at 12 atm; RD post 2.51mm, MLD 
post 2.58mm; DS post 0%) and apical  LAD (SES 2.25/8mm; 10 
atm;  RD post 1.95mm; MLD post 1.75mm; DS post 10%).  
1C) Coronary angiography 6h after the index procedure showed 
total occlusion of the SES in the apical  LAD (apart from the 
stents in the distal LAD) (I).  IVUS showed an under-expansion 
of the apical stent (III; minimal stent area 2.00mm2) in 
comparison to the proximal (II; lumen area 3.81mm2) and distal 
(IV; lumen area 3.10mm2) reference and a distal edge 
dissection (V, arrows) that was not visible on the angiogram at 
the time of the index procedure.  
Chapter 22 ______________________________________________________________________________ 
 
 124 
descending were smaller than in the right coronary 
artery7. 
 
Figure 2:  
2A) Pre-intervention angiogram showing spontaneous 
recanalization of the RCA (I) and a chronic total occlusion of the 
LAD (II). The LAD is visualized by simultaneous contrast injection 
in the left and right coronary arteries (LAD is filled by collateral 
flow from the RCA). 
2B) Final result after recanalization of the LAD and implantation 
of two SES stents (3.0/33mm, 16 atm and 2.5/33mm, 14 atm; 
RD post 2.59mm; MLD post 1.79mm; DS post 33%).  
2C) Coronary angiogram 11 days after the index procedure 
showing occlusion of the distal LAD (I, II). IVUS showed speckled 
echolucent material within the lumen (IV) and revealed an under-
expansion of the stent (V; minimal stent area 2.27mm2) in 
comparison to the proximal reference (III, gap between two 
stents; lumen area 8.55mm2) and distal reference (VI, lumen 
area 2.54mm2). 
 
While diabetes is a well established predictor of 
adverse outcome8, the impact of gender is controversial. 
In recent studies comparing the outcome for women and 
men after with bare metal stent implantation, a higher 
event rate9, a lower event rate10 or similar event rates11 
have been reported in women as compared to men. 
Combined oral antiplatelet therapy12 and systematic 
high-pressure stent implantation13 have contributed to 
reduce the incidence of thrombotic occlusion after 
conventional coronary stenting14. Due to the fact that SES 
have virtually the same physical properties of bare metal 
stents, a similar approach was utilized to accomplish 
optimum SES deployment. In our series, the average 
implantation pressure was 17 atmospheres and balloon 
post-dilatation was performed in approximately half of the 
cases. All patients were maintained under dual antiplatelet 
treatment. 
Previous studies suggested that sirolimus could 
significantly enhance agonist-induced platelet 
aggregation15 and induce endothelial function 
impairment16.  Animal models showed focal remnants of 
residual fibrin deposition adjacent to the struts that may 
reflect a delay in arterial repair or simply impaired fibrin 
degradation secondary to the local effects of the drug17. 
However, although these features could potentially 
increase the risk of thrombotic complications, our findings 
suggest a minimal risk of SAT after SES implantation, 
even in patients with well-known risk factors for short-
term thrombotic complications. Importantly, though 
similar SAT rates have been reported in clinical trials with 
SES1, the present report allowed a comprehensive 
evaluation of the risk of SAT in a large range of clinical 
settings, including patients commonly not enrolled in 
randomized studies. 
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Coronary Restenosis After Sirolimus-Eluting Stent 
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Background: We described the clinical and morphological patterns of restenosis after sirolimus-eluting stent (SES). 
Methods and Results: From 121 patients with coronary angiography obtained> 30 days after SES implantation, 
restenosis (diameter stenosis>50%) has been identified in 19 patients and 20 lesions (located at the proximal 5-mm 
segment in 30% or within the stent in 70%). Residual dissection after the procedure or balloon trauma outside the stent 
was identified in 83% of the proximal edge lesions. Lesions within the stent were focal and stent discontinuity was 
identified in some lesions evaluated by intravascular ultrasound.  
Conclusions: Sirolimus-eluting stent edge restenosis is frequently associated with local trauma outside the stent. In-
stent restenosis occurs as a localized lesion, commonly associated with a discontinuity in stent coverage. Local 
conditions, instead of intrinsic drug-resistance to sirolimus, are likely to play a major role in post-SES restenosis. 
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Introduction 
Sirolimus-eluting stents (SES) have been reported to 
reduce restenosis by inhibiting neointimal growth,1 though 
post-SES restenosis may still occur in some cases.2 
Currently, the clinical and morphological features of 
restenosis after SES implantation are unknown. In this 
study we described a consecutive series of patients with 
angiographic restenosis after SES implantation. 
Methods and Results 
Since April 2002, SES (Cypher™; Cordis Europa NV, 
Roden, The Netherlands) have been utilized as the device 
of choice for percutaneous coronary intervention (PCI) in 
our institution, as part of the Rapamycin-Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) 
registry,3 a single-center registry designed to evaluate the 
impact of SES implantation in the “real world”. During 
follow-up, coronary angiograms were obtained as clinically 
indicated by symptoms or positive ischemic tests. In 
addition, follow-up angiograms were obtained at 6±1 
months for “complex” patients, typically with SES 
implantation to treat in-stent restenosis, bifurcations, left 
main, chronic total occlusions, very small vessels (SES 
diameter 2.25mm), long stented length (>36mm), and 
acute myocardial infarction. Intravascular ultrasound 
(IVUS) was performed at the discretion of the operator. 
The study protocol was approved by the institutional 
ethics committee and written informed consent was 
obtained from all patients. 
Binary restenosis was defined by diameter stenosis 
>50% and classified as 1) in-stent, if inside the stent or 
2) edge restenosis, if located within the 5-mm segments 
distal or proximal to the stent margins. Restenosis at an 
ostial location was classified as in-stent, unless clearly 
located outside the limits of the SES, in which case it was 
classified as edge restenosis. Discrete variables were 
presented as counts and percentages. Continuous 
variables were presented as mean±standard deviation 
and compared by Student’s T test. 
To date, 192 patients with at least one of the 
aforementioned “complex” characteristics have completed 
t 7 months from the index procedure. A coronary 
angiogram performed >30 days after the angioplasty has 
been obtained in 121 patients (221 lesions). Among these, 
post-SES restenosis was identified in 19 patients and 20 
lesions (Table). IVUS was available at follow-up for 11 
patients with restenosis (58%). In total, 6 lesions (30%) 
were located at the proximal edge and 14 were in-stent 
(70%). Local injury outside the stent was observed in 5 
edge restenosis (83%), as evidenced by the presence of 
angiographic or IVUS residual dissection after the 
procedure (patients #1, 3, and 4), by balloon dilatation at 
a non-stented area in a patient with extensive 
manipulation before and after implantation of 4 stents due 
to acute occlusion (patient #2), or by balloon post-
dilatation outside the stent (patient #5).  
Among the 14 in-stent lesions, 12 (86%) were focal 
(restenosis length < 10mm)4 and presented a peculiar 
angiographic pattern manifested by a very localized 
stenotic site bordered by segments without evidence of 
lumen compromise (Figure 1). Stenosis length decreased 
from 19.1±19.1mm at baseline to 7.6±5.6mm at follow-
up (p=0.046). The ratio restenosis length/stent length 
was 0.3±0.2. A gap between stents or stent fracture at 
the site of the restenosis was detected by IVUS in 4 
patients at follow-up. A gap was diagnosed by the 
absence of stent struts in at least one IVUS cross-section 
in the examination of the region between two stents 
(patients #13, 18, and 19); a stent fracture was 
diagnosed by the non-visualization of struts within the 
stent (patients #15, and 18). One patient presented both 
stent gap and fracture in separate sites (patient #18). In 
this patient, no IVUS was performed at the index 
procedure (IVUS was done only at follow-up). In the other 
patient with stent fracture (patient #15), the stent   
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Patients with restenosis after sirolimus-eluting stent implantation: clinical, procedural, and morphological characteristics 
 
Patient number 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 16 17 18 19 Total 
Age (years) 63 77 52 66 70 78  77 58 69 43 58 50 52 50 46 72 45 48 61 56r 
11 
Gender M M M M M F  M M F M M M M M M M M M M 89% 
(men) 
Diabetes 0 + 0 0 0 0  0 + + + 0 + + 0 0 0 + 0 0 37% 
Symptoms/ischemia at 
follow-up 
0 + + 0 + +  0 0 + + 0 0 + + 0 + + + 0 58% 
Lesions treated 1 1 3 1 3 3  2 3 2 3 2 3 2 1 2 6 1 1 2 42 
Lesions with restenosis 1 1 1 1 1 2  1 1 1 1 1 1 1 1 1 1 1 1 1 48% 
Vessel LAD LAD LAD DG SVG LAD LCx RCA RPL LCx DG DG LAD RCA LAD RCA SVG LCx RCA DG - 
Procedural, angiographic 
and IVUS findings 
                     
Treatment previous in-
stent restenosis  
0 0 0 0 0 0 0 0 0 +* 0 0 0 0 + 0 + +* + 0 25% 
Mod/sev calcification 0 + 0 + 0 + + 0 0 0 0 + 0 0 0 0 0 0 0 0 25% 
CTO 0 0 0 0 + + 0 0 0 0 0 0 + + + 0 0 + + 0 35% 
Trauma outside the 
stent/residual dissection 
+ + + + + 0 ... ... ... ... ... ... ... ... ... ... ... ... ... ... 83%† 
Residual edge lesion‡ 0 0 + + 0 0 ... ... ... ... ... ... ... ... ... ... ... ... ... ... 33%† 
Post-dilatation with 
balloont 0.5mm larger 
+ 0 + 0 + 0 0 0 0 + 0 0 0 0 + + + 0 + + 45% 
Bifurcation stenting 0 0 + § 0 0 + § 0 0 + || 0 + || + || 0 + § 0 0 0 0 0 + || 35% 
Ostial 0 0 0 + 0 0 + 0 + 0 + + 0 0 0 0 0 0 0 + 30% 
Stented length>33mm 0 0 + 0 + 0 0 + 0 0 0 0 0 + + + 0 + + 0 40% 
2.25-mm diameter SES 0 0 0 + 0 0 0 0 0 0 + 0 0 0 0 0 0 + 0 0 15% 
Stent fracture or gap 
between stents¶ 
0 0 0 NA NA NA NA NA NA NA NA NA 0 + 0 + 0 0 + + 50%# 
Stent underexpansion at 
restenosis site¶ 
0 0 0 NA NA NA NA NA NA NA NA NA + 0 0 0 + 0 0 0 25%# 
Number of any above 
(+diabetes) 
2 3 5 5 4 3 2 1 3 3 4 2 3 5 4 3 3 5 5 4 range 
1 - 5 
Post-SES restenosis 
characteristics 
                     
Location prox prox prox prox prox prox in-st in-st in-st in-st in-st in-st in-st in-st in-st in-st in-st in-st in-st in-st  
Total occlusion 0 0 0 0 + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10% 
 Focal lesion (length< 
10mm) 
+ + + 0 0 0 + + + + 0 0 + +** + + + + +** + 86%†† 
CTO=chronic total occlusion; DG=diagonal; IVUS=intravascular ultrasound; in-st=in-stent restenosis; LAD=left anterior descending;  LCx=left 
circumflex artery; M=male; NA=IVUS not available; prox=proximal edge restenosis; RCA=right coronary artery; RPL=right postero-lateral 
branch; SES=sirolimus-eluting stent; SVG=saphenous vein graft 
*ISR post-brachytherapy 
†relative to proximal edge restenosis 
‡angiographic diameter stenosis>30% or IVUS plaque burden>50% 
§main vessel restenosis 
||side branch restenosis 
¶diagnosed by IVUS 
#relative to the number of in-stent restenosis with available IVUS. 
**more than 1 “focal” site 
††relative to the number of in-stent restenosis 
 
discontinuity was not evident after the procedure, being 
only detected at the follow-up. In all cases, the stent gap 
or fracture could not be noticed angiographically and 
measured <1 mm in length by IVUS (Figure 1). 
Among the 6 ostial lesions (30%), the ostium was not 
covered by the stent at angiographic inspection in 1 case 
(classified as proximal edge restenosis). The remaining 5 
lesions seemed to be fully covered by stent on 
angiography. IVUS was available for only one of these 
cases. In this patient, although angiographically 
unnoticed, a short area at the ostium was observed to be 
uncovered by SES (Figure 2). Among the 6 ostial lesions, 
4 were located in the side branch of bifurcation stenting 
treatment, all treated with “T” stent technique (stent in 
the side branch implanted with its proximal border located 
at the ostium of the branch; stent in the main vessel 
implanted encompassing the side branch ostium, thereby 
creating a “T” configuration).5 
Discussion 
In approximately 90% of patients with in-stent 
restenosis post-SES, the lesion was very localized and 
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bordered by segments with no evidence of neointima. The 
effect of the drug in the non-restenotic portions indicates 
that an intrinsic resistance to sirolimus was unlikely in 
most of our patients. Among lesions evaluated by IVUS, 
stent discontinuity was identified in 36% of cases (and in 
50% of restenosis located inside the stent), suggesting 
that a decrease in local drug availability may have 
contributed to the development of restenosis in these 
cases. Accordingly, our findings suggest that incomplete 
lesion coverage by the SES may also influence the 
occurrence of restenosis at the stent borders and at ostial 
sites. We may speculate that, although no clinical data is 
currently available, techniques that ensure complete 
vessel scaffold could constitute an alternative for SES 
implantation at bifurcations.6 Edge restenosis occurred 
more frequently in the proximal than the distal stent 
border. Whether this finding is associated with a more 
effective drug effect in the outflow stent border remains 
to be clarified. In addition, 37% of our cases were 
diabetics. It may be hypothesized that the presence of 
diabetes mellitus may lead to a higher predisposition to 
post-SES restenosis. 
The current study presents several limitations. 
Angiographic follow-up was available for complex patients 
or for those with recurrent symptoms, therefore 
precluding an evaluation of the total restenosis rate for 
the global treated population. Moreover, the lack of IVUS 
limits a more detailed description of the mechanisms 
involved in the occurrence of post-SES restenosis in some 
patients.   
Conclusions 
Restenosis after sirolimus-eluting stents occurs within 
or adjacent to the stent. Edge restenosis is frequently 
associated with local trauma outside the stented segment. 
In-stent restenosis occurs as a very localized lesion, 
associated with complex anatomy (especially ostial 
lesions), stent discontinuity, or diabetes. A systemic drug-
resistance to sirolimus seemed to be unlikely in most 
patients. 
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Focal restenosis at a gap between stents. In A, a
short restenosis (angiogram, arrow head) was
noted at a site were no stent struts were
visualized on IVUS examination (IVUS cross-
section, mid). Stent coverage was complete at
the proximal and distal segments, with no
neointimal tissue present (IVUS cross-sections
left and right respectively). Longitudinal IVUS
reconstruction showed the localized pattern of
the restenosis. In B, an ostial restenosis
(angiogram, arrow head) was associated with
incomplete coverage by the sirolimus-eluting
stent (IVUS cross-section left and longitudinal
reconstruction). The distal segment presented no
neointimal proliferation inside the stent (IVUS
cross-section right and longitudinal
reconstruction). 
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Background: The factors associated with the occurrence of restenosis after sirolimus-eluting stent (SES) implantation 
in complex cases are currently unknown. 
Methods and Results: A cohort of consecutive complex patients treated with SES implantation was selected according 
to the following criteria: 1) treatment of acute myocardial infarction, 2) treatment of in-stent restenosis, 3) 2.25-mm 
diameter SES, 4) left main coronary stenting, 5) chronic total occlusion, 6) stented segment > 36 mm, and 7) 
bifurcation stenting. The present study population was composed of 238 patients (441 lesions) from whom 6-month 
angiographic follow-up was obtained (70% of eligible patients). Significant clinical, angiographic, and procedural 
predictors of post-SES restenosis were evaluated. Binary in-segment restenosis was diagnosed in 7.9% of lesions (6.3% 
in-stent, 0.9% at the proximal edge, 0.7% at the distal edge). The following characteristics were identified as 
independent multivariate predictors: treatment of in-stent restenosis (OR 4.16; 95% CI: 1.63 – 11.01; p<0.01), ostial 
location (OR 4.84; 95% CI: 1.81 – 12.07; p<0.01), diabetes (OR 2.63; 95% CI: 1.14 – 6.31; p=0.02), total stented 
length (per 10 mm increase) (OR 1.42; 95% CI: 1.21 – 1.68; p<0.01), reference diameter (per 1.0 mm increase) (OR 
0.46; 95% CI: 0.24 – 0.87; p=0.03), and left anterior descending artery (OR 0.30; 95% CI: 0.10 – 0.69; p<0.01). 
Conclusions: Angiographic restenosis after sirolimus-eluting stent implantation in complex patients is an infrequent 
event, occurring mainly in association with lesion-based characteristics and diabetes mellitus. 
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Introduction 
In-stent restenosis is the major limitation hampering 
the medium-term efficacy of coronary stenting. Several 
reports have previously evaluated the impact of baseline 
and procedural characteristics on the risk of subsequent 
restenosis after bare metal stent implantation, with a 
number of high-risk parameters, such as diabetes, lesion 
length, and vessel size, been consistently identified in 
most studies.1-7 Unfortunately, these characteristics are 
commonly found in the daily practice, where treatment of 
complex patients frequently appears as a challenging 
therapeutic dilemma. 
Sirolimus-eluting stents (SES) have been proven to 
strikingly decrease neointimal growth, leading to a marked 
reduction in restenosis rates.8-10 In the RAndomized study 
with the sirolimus-eluting Bx VElocity balloon-expandable 
stent in the treatment of patients with de novo native 
coronary artery Lesions (RAVEL),8 no cases of binary 
angiographic restenosis were seen after sirolimus-eluting 
stent implantation. Moreover, restenosis was significantly 
reduced from 36.3% with conventional stents to 8.9% 
with sirolimus-eluting stents in the randomized 
SIRolImUS-eluting Bx velocity balloon expandable stent 
trial (SIRIUS)9 and from 42.3% to 5.9% in the E-SIRIUS 
trial,10 with diabetes, small vessel size, and long lesions 
being identified as predictors of post-sirolimus-eluting 
stent restenosis in the SIRIUS trial.9 Nevertheless, these 
randomized studies have been largely restricted to 
selected patients treated with single-lesion elective 
stenting. It is currently unknown what are the factors 
related to angiographic restenosis after sirolimus-eluting 
stent implantation in highly complex subsets. 
Sirolimus-eluting stent implantation was recently 
shown to effectively improve the 1-year clinical outcomes 
in the “real world” practice in patients enrolled in the 
Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital (RESEARCH) study.11 In the 
RESEARCH, a parallel angiographic substudy was 
conducted to evaluate the late angiographic findings of 
complex patients treated with sirolimus-eluting stents. 
The present report aimed to evaluate the value of clinical, 
angiographic, and procedural factors in predicting the risk 
of binary restenosis in highly complex patients treated 
with sirolimus-eluting stent implantation in the RESEARCH 
study.  
Methods 
Study Design and Patient Population 
The study design of the RESEARCH has been 
previously reported elsewhere.11 In brief, sirolimus-eluting 
stent implantation (Cypher; Johnson & Johnson-Cordis 
unit, Cordis Europa NV, Roden, the Netherlands) has been 
introduced as the default strategy for all patients 
undergoing percutaneous coronary interventions in our 
institution since April 2002. All procedures were 
performed according to standard techniques and the final 
interventional strategy was left to the discretion of the 
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operator with the aim of achieving a final residual stenosis 
< 50% by on-line quantitative coronary angiography in 
the presence of TIMI 3 grade flow. Also, the utilization of 
periprocedural glycoprotein IIbIIIa inhibitors and 
antithrombotic medications was entirely left at the 
discretion of the attending team.  
Patients receiving sirolimus-eluting stents were 
considered as candidates for angiographic re-evaluation if 
presenting at least one following: 1) treatment of acute 
myocardial infarction, 2) treatment of in-stent restenosis, 
3) utilization of very small sirolimus-eluting stent (2.25-
mm nominal diameter), 4) treatment of left main 
coronary, 5) treatment of chronic total occlusion (more 
than 3 months), 6) total adjacent stented segment longer 
than 36 mm, and 7) bifurcation stenting (sirolimus-eluting 
stent implanted in the both the main vessel and the side 
branch). Patients with the aforementioned characteristics 
who had not undergone repeat intervention in the first 
month and not presented any formal medical 
contraindication for angiographic re-study were 
considered eligible for angiographic follow-up at 6 to 8 
months. Coronary angiograms performed prematurely due 
to clinical indications were used as the follow-up 
angiography if performed after 4 months or if restenosis 
was detected. In other cases, a second angiogram was 
obtained between 6 and 8 months. Importantly, although 
all patients were approached for angiographic follow-up, 
patient refusal was not considered as an exclusion 
criterion to be enrolled in the RESEARCH. Angiographic re-
study was not requested for non-residents in The 
Netherlands.  
During the first 6 months of enrollment, a total of 362 
consecutive patients had at least one high-risk criterion 
above (57% of all patients treated with sirolimus-eluting 
stents in the period). From these, 2 patients moved to 
another country, 10 patients have died at 6-month follow-
up, 6 patients had repeat intervention before 30 days 
(surgical or percutaneous), and 3 patients were 
considered to have a medical contra-indication to the 
angiographic follow-up (one patient with previous stroke 
and disabling dementia, one patient with severe allergic 
contrast reaction at the index procedure, and one patient 
with end-stage hepatic failure due to auto-immune 
hepatitis). From the remaining 341 patients, angiographic 
re-evaluation at 204 ± 34 days was obtained from 238 
patients (70% of eligible patients), who compose the 
present study population. 
Quantitative Coronary Angiography 
Quantitative coronary angiographic analysis was 
performed as previously described, utilizing a validated 
computer-based edge-detection system (CASS II, Pie 
Medical, Maastricht, The Netherlands)12. Interpolated 
reference diameter, minimal luminal diameter, and 
diameter stenosis were obtained at baseline, post-
stenting, and at follow-up. In-stent restenosis was defined 
by diameter stenosis >50% and was classified as in-stent 
if inside the stent, or in-segment if located within the 
stented segment plus the 5-mm segments distal or 
proximal to the stent margins.9 Restenosis at an ostial 
location (within 3 mm of the vessel origin) was classified 
as in-stent, unless clearly located outside the limits of the 
SES.13 
Statistical Analysis 
Continuous variables were presented as mean ± 
standard deviation (SD) and were compared using 
Student’s unpaired t-test. Categorical variables were 
presented as counts and percentages and compared with 
the Fisher’s exact test. Demographic, clinical, procedural, 
and angiographic variables were tested in univariate and 
multivariate logistic analyses for their value in predicting 
binary restenosis. All variables shown in Table 1 and Table 
2 were considered in multivariate logistic regression 
analyses regardless of their univariate findings. The final 
model was built iteratively and evaluated for lack of fit 
with the Hosmer-Lemeshow test. The global predictive 
accuracy was assessed by means of the C-index (the area 
under the receiver operating characteristic curve). Finally, 
an internal validation was performed utilizing a bootstrap 
technique.14 The model was repeatedly applied to 1000 
replicated bootstrapped samples and the C-index for each 
individual sample was calculated. The C-index obtained 
from each bootstrapped sample was then subtracted from 
the initial C-index value of the original population. The 
average of the differences were considered as a measure 
of the optimism in the model fit. Finally, a corrected C-
index was calculated by subtracting the average of the 
optimism estimates from the original C-index. The 
bootstrap correction has been described as a nearly 
unbiased internal validation, penalizing for any model 
overfitting.14 Presented 95% confidence intervals of all 
multivariate estimates were derived from the 
bootstrapping analysis. 
 
Table 1. Clinical characteristics of 238 patients treated with SES 
implantation 
Male sex, % 73 
Age, years ± SD 60 ± 12 
Height, cm ± SD 172 ± 9 
Weight, kg ± SD 82 ± 14 
Hypercholesterolemia, %* 58 
Hypertension, % 56 
Diabetes mellitus, % 22 
Insulin-dependent diabetes 6 
Non insulin-dependent diabetes 16 
Previous myocardial infarction, % 32 
Previous bypass surgery, % 11 
Previous percutaneous intervention, % 28 
Vessel disease  
1-vessel disease, % 40 
2-vessel disease, % 35 
3-vessel disease, % 25 
Clinical presentation  
Stable angina, % 54 
Unstable angina, % 21 
Acute myocardial infarction, % 26 
Periprocedural IIbIIIa inhibitor, % 27 
*Total cholesterol>200mg/dl and/or receiving lipid-lowering 
treatment 
Results 
From the 238 patients (441 lesions) included in this 
analysis, 13 (6%) had left main coronary stenting, 35 
(15%) had at least one chronic total occlusion, 45 (19%) 
received sirolimus stents to treat at least one restenotic 
lesion, 50 (21%) had bifurcation stenting, 62 (26%) were 
in the acute phase of a myocardial infarction, 68 (28%) 
had at least one 2.25-mm SES implanted, and 83 (35%) 
had very long stenting (>36 mm) in at least one vessel 
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(Tables 1 and 2). On average, 1.41 ± 0.81 stents were 
implanted per lesion and 39% of lesions had at least 2 
stents overlapped. Most lesions were classified as type B2 
or C (71%), 22% received bifurcation stenting (stent 
implanted in both the main vessel and the side branch), 
8% were chronic total occlusions (duration >3 months), 
and 3% were located in the left main coronary. The mean 
vessel size was 2.50 ± 0.61 mm (range 1.00 – 4.59 mm), 
and the average stented length was 26.0 ± 20.3 mm 
(range 8 – 117 mm) 
 
Table 2. Procedural and angiographic characteristics of 441 
lesions treated with SES implantation 
Treated Vessel  
Left main coronary, % 3 
Left anterior descending, % 43 
Left circumflex artery, % 22 
Right coronary artery, % 30 
Bypass graft, % 3 
Lesion type  
Type A, % 6 
Type B1, % 23 
Type B2, % 43 
Type C, % 28 
Chronic total occlusion > 3 months, % 8 
Moderate / severe angiographic calcification, % 7 
Ostial location, % 22 
Bifurcation treatment* 22 
Treatment of in-stent restenosis, % 13 
Number of stents implanted ± SD 1.41 ± 0.81 
Overlapping, % 39 
Total stented length, mm ± SD 26.0 ± 20.3 
Stented length > 36 mm, % 17 
Utilization of 2.25-mm SES, % 18 
Reference diameter, mm ± SD 2.50 ± 0.61 
Pre-procedure minimal luminal diameter, mm ± SD 0.69 ± 0.54 
Pre-procedure diameter stenosis, % ± SD 72.2 ± 20.0 
Lesion length, mm ± SD 16.1 ± 11.8 
Post-procedure minimal luminal diameter, mm ± SD 2.13 ± 0.58 
Post-procedure diameter stenosis, % ± SD 17.2 ± 11.1 
Follow-up minimal luminal diameter, mm ± SD 2.10 ± 0.69 
Follow-up diameter stenosis, % ± SD 22.8 ± 19.9 
Late loss, mm ± SD 0.04 ± 0.49 
Binary restenosis, % 7.9 
In-stent, % 6.3 
Proximal edge, % 0.9 
Distal edge, % 0.7 
SD=standard deviation; SES=sirolimus-eluting stent 
*SES implantation in both the main vessel and the side branch 
 
At the follow-up angiogram, 7.9% of lesions had 
binary in-segment restenosis. Among these, 6.3% were 
located inside the stent (in-stent), 0.9% were located in 
the proximal edge, and the remaining 0.7% occurred at 
the distal edge. Due to the limited number of lesions with 
edge restenosis (7 observations), further analyses were 
performed for all lesions grouped as in-segment 
restenosis. 
Figure shows the univariate relationship between 
demographic, angiographic and procedural characteristics 
and the incidence of post-SES restenosis, and significant 
univariate parameters are shown in Table 3. In the 
multivariate analysis, the following variables were 
identified as independent predictors: treatment of in-stent 
restenosis, ostial location, diabetes mellitus, total stented 
length, reference diameter, and left anterior descending 
artery (Table 4). The final multivariate model fitted well 
the data (Hosmer-Lemeshow test p-value = 0.94; chi 
square value = 2.93; d.f.= 8) and had a good predictive 
accuracy (C-index = 0.83), which was virtually unchanged 
after the bootstrapping correction (corrected C-index = 
0.82). The actual restenosis rates for patients with “high-
risk characteristics” (as derived from the multivariate 
model) are shown in Table 5. 
 
 
Univariate odds ratio of binary angiographic in-segment restenosis 
after sirolimus eluting stent restenosis according to demographic, 
clinical, procedural, and angiographic characteristics. 
Discussion 
The present study reported on the predictors of 
angiographic restenosis following sirolimus-eluting stent 
implantation in complex patients. Overall, our series 
included patients with smaller vessels and longer lesions, 
compared to all trials conducted to date.8-10 Moreover, a 
considerable proportion of patients had previous in-stent 
restenosis, bifurcation stenting, chronic total occlusions, 
thrombus-containing lesions, and calcified vessels, 
conditions that were formally excluded from previous 
trials. Nevertheless, the binary restenosis rate after 
Diabetes
NIDDM
IDDM
Previous CABG
Stable angina
0.00 1.00 2.00 3.00 4.00 5.00
Thrombus
Type B2 / C
Chronic total occlusion (>3 mo.)
Ostial location
Moderate / severe calcification
In-stent restenosis
Bifurcation (main vessel position)
Bifurcation (side branch position)
Stented length (10mm units)
Number of stents
Stent diameter 2.25-mm
Age (by decade)
Female
Left anterior descending
Left circumflex
Right coronary artery
Left main coronary
Graft
Acute myocardial infarction
Minimal luminal diameter post
Minimal luminal diameter pre
Diameter stenosis pre (10% units)
Diameter stenosis post (10% units)
Lesion length
Current smoking
Abciximab
Reference diameter
Overlapping stents
Stented length > 36mm
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sirolimus-eluting stents in such a complex patient 
population was detected in only a minority of cases (7.9% 
of lesions). It is worth noting that the expected restenosis 
rate for de novo lesions included the present report would 
range from 40.1% to 43.0% if treated with bare metal 
stents, as calculated from prediction equations derived 
from previous metanalysis with conventional stents.3,6  
 
 
Table 3. Clinical, procedural, and angiographic univariate 
predictors of in-segment restenosis after SES restenosis. 
 OR 95% CI p-value 
Bypass graft 4.61 1.39–15.33 0.01 
Treatment of in-stent restenosis 3.66 1.68–7.96 <0.01 
Previous bypass surgery 3.24 1.42–7.41 <0.01 
Bifurcation stenting (side branch 
position) 
2.77 1.15–6.33 0.02 
Ostial location 2.66 1.30–5.46 <0.01 
Diabetes mellitus 2.54 1.24–5.21 0.01 
Number of stents implanted 1.62 1.19–2.22 <0.01 
Post-procedure diameter stenosis 
(per 10% increase) 
1.55 1.14–2.10 <0.01 
Total stented length (per 10 mm 
increase) 
1.30 1.14–1.48 <0.01 
Pre-procedure minimal luminal 
diameter 
0.46 0.22–0.95 0.04 
Post-procedure minimal luminal 
diameter 
0.39 0.20–0.76 <0.01 
Left anterior descending artery 0.37 0.16–0.82 0.02 
Acute myocardial infarction 0 - <0.01 
 
 
Table 4. Clinical, procedural, and angiographic multivariate 
predictors of in-segment restenosis after SES restenosis. 
 OR 95% CI p-value 
Intercept coefficient = -2.34   
Treatment of in-stent 
restenosis 
4.16 1.63 – 11.01 <0.01 
Ostial location 4.84 1.81 – 12.07 <0.01 
Diabetes mellitus 2.63 1.14 – 6.31 0.02 
Total stented length (per 
10 mm increase) 
1.42 1.21 – 1.68 <0.01 
Reference diameter (per 
1.0 mm increase) 
0.46 0.24 – 0.87 0.03 
Left anterior descending 
artery 
0.30 0.10 – 0.69 <0.01 
CI=confidence interval; OR=odds ratio; SES=sirolimus-eluting stent 
 
 
In the SIRIUS trial, small vessel size, long lesion 
length, and diabetes have been shown to significantly 
increase the incidence of restenosis after sirolimus-eluting 
stent.9 These characteristics were confirmed as predictors 
of post-SES restenosis in our study, which additionally 
extended the list of independent parameters to also 
include ostial location and treatment of in-stent restenosis 
(as negative factors) and left anterior descending artery 
location (as a protective factor). Interestingly, most 
characteristics identified as predictors of post-sirolimus-
eluting stent restenosis have long been recognized as 
major predictors of restenosis following balloon 
angioplasty or conventional bare stent implantation.1-7,15-17 
It seems intuitive to assume that the increased incidence 
of restenosis after SES in patients with these risk factors 
may reflect an extreme background tendency to tissue 
reaction and neointimal growth, which was not sufficiently 
inhibited by the antiproliferative action of the drug. 
 
Table 5. Actual rates of post-SES in-segment restenosis according 
to the presence of high risk characteristics* 
 In-segment restenosis 
rate 
Treatment of in-stent restenosis 19.6% 
Ostial location 14.7% 
Diabetes mellitus 14.3% 
Stented length > 26 mm † 13.9% 
Reference diameter < 2.17 mm ‡ 10.3% 
Non-LAD location 10.8% 
LAD=left anterior descending artery; SES=sirolimus-eluting stent 
* presence of multivariate independent predictors 
† higher tercile for stented length 
‡ lower tercile for reference diameter 
 
Restenosis after SES has been previously shown to be 
associated with incomplete lesion coverage in some cases, 
as detected by intravascular ultrasound.13 In the present 
study, lesions involving ostial sites had a higher risk of 
restenosis, which may be, at least partially, related to 
technical difficulties in stent positioning and vessel 
scaffolding at the ostium. We may speculate that the 
presence of “traditional” risk factors for restenosis may 
potentially act as a predisposing factor, which will lead to 
restenosis in case a subtle device-related or procedure-
related local failure is eventually superimposed. 
Unfortunately, small gaps between stents and minor 
ruptures in the metallic stent mesh or in the polymer 
integrity are not detectable by conventional coronary 
angiography13 and could not be evaluated in this report. 
The treatment of in-stent restenosis with SES was 
associated with a greater than 4-fold increase in the risk 
of restenosis after adjustment for other independent 
variables. Although SES implantation has been associated 
with low rates of repeat restenosis after treatment of non-
complex in-stent restenosis,18,19 the efficacy of this device 
for more complicated cases remains to be established.20,21 
Re-dilatation of restenotic lesions (i.e. exposure to 
“double injury”) has been previously shown to trigger a 
peculiar local vascular response, distinct from that 
observed after the first dilatation.22 Modifications in the 
reparative mechanisms, especially after endovascular 
brachytherapy,20 may decrease the responsiveness of 
restenotic lesions to the antiproliferative drug. 
Curiously, lesions located in the left anterior 
descending artery had a decreased restenosis rate in our 
series. Whether this factor represents a true protective 
characteristic has to be further investigated in future 
studies. Although post-SES restenosis was not detected in 
any patient admitted with acute myocardial infarction, this 
characteristic was not included in our final multivariate 
model, suggesting that perhaps acute myocardial 
infarction at admission per se was not an important factor 
affecting restenosis in our population. Post-sirolimus-
eluting stent restenosis in our study was almost entirely 
restricted to the segment inside the stent (approximately 
80% of the restenoses). This finding represent a major 
difference from previous trials with SES, where restenosis 
more frequently occurred at the stent edges.9,10 In the 
RESEARCH, all operators were strongly advised to actively 
cover the entire injured vessel area and to avoid residual 
dissection at the stent borders and gaps between stents. 
In addition, the stent placement strategy aimed to cover 
the treated segment “from healthy tissue to healthy 
tissue”, in order to avoid the free borders of the stents to 
terminate in grossly diseased segments. However, it 
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remains speculative whether these procedural strategies 
might have had any impact in reducing the incidence of 
restenosis at the stent edges. 
Study Limitations 
The present report may suffer from its relatively limited 
study population, which was restricted to complex patients 
fulfilling pre-defined criteria to be included in this 
angiographic substudy. Therefore our results cannot be 
directly extrapolated to the entire cohort of consecutive 
patients treated in the RESEARCH and further analyses are 
needed to fully assess the angiographic outcomes of subsets 
not included in the current study. Ten patients with early 
death could not be re-studied at 6 months, and a higher rate 
of angiographic follow-up (approximately 70% in this study) 
would be desirable for a comprehensive evaluation. However, 
it should be emphasized that the present study was designed 
to enroll all unselected patients treated in our institution, and 
that patient refusal for angiographic follow-up did not 
preclude enrollment in the RESEARCH study. Obviously, this 
“real life” scenario differs substantially from that of 
randomized trials and limits the compliance to angiographic 
re-study. 
Conclusion 
Angiographic restenosis after sirolimus-eluting stent 
implantation in complex patients is an infrequent event 
(7.9% of lesions), occurring mainly in association with 
local, lesion-based characteristics and diabetes mellitus. 
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Comparison of Late Luminal Loss Response Pattern Following 
Sirolimus-Eluting Stent Implantation or Conventional Stenting 
 
Pedro A. Lemos, MD; Nestor Mercado, MD, PhD; Ron T. van Domburg, PhD; Richard E. Kuntz, MD; William 
W. O'Neill, MD; Patrick W. Serruys, MD, PhD 
 
Background: We investigated the pattern of late luminal loss following sirolimus-eluting or bare stent implantation. 
Methods and Results: The study population comprised 238 patients treated with sirolimus-eluting stents and 526 
patients treated with conventional stents. The distribution of late loss of sirolimus stents was largely skewed to the right 
and differed from the distribution for bare stents. When divided according to the presence of binary restenosis (diameter 
stenosis > 50%), restenotic lesions in the bare stent group (26.0%) had a late loss of 1.40±0.64 mm and in the 
sirolimus group (7.9%) of 1.16±0.76 mm. Non-restenotic lesions in the bare stent group had a late loss of 0.58±0.44 
mm, whilst the late loss of non-restenotic lesions in the sirolimus group remained close to zero (-0.05±0.33 mm). 
Differences between post-stenting and follow-up measurements in the sirolimus group (“late loss”) resembled variations 
observed in repeated angiographic measurements, as assessed from a random sample of 30 segments measured 
repeatedly. After multivariate adjustment, stent type did not influence the degree of late loss in restenotic lesions. 
However, non-restenotic bare stents had a significantly larger estimated luminal loss (0.58 mm; 95% CI: 0.52 – 0.65 
mm) than sirolimus-eluting stents, for which the predicted late loss was almost zero (-0.04 mm; 95% CI: -0.10 – 0.02). 
Conclusions: The pattern of late loss after sirolimus-eluting stent implantation follows a peculiar behavior, different 
from lesions treated with conventional stents. Whether this is explained by an unusual statistical distribution or a 
biological all-or-none response of restenosis following sirolimus-eluting stenting remains to be investigated. 
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Introduction 
The pathophysiological processes involved in lumen 
renarrowing after percutaneous coronary intervention 
have been largely studied over the last decades. However, 
it remains a matter of debate whether restenosis simply 
represents an extreme form of the “normal” vessel healing 
response after mechanical dilatation, or if it is related to 
specific mechanisms that ultimately lead to vessel 
renarrowing.1-7 Although several cutoff criteria have been 
proposed to dichotomize patients with restenosis from 
those without restenosis, it has been widely recognized 
that, to some extent, late luminal reduction is an 
ubiquitous phenomenon, occurring even for those 
categorized as not having binary restenosis.1,7  
Recently, drug-eluting stents with the antiproliferative 
agent sirolimus have proven to markedly reduce 
neointimal growth in clinical trials. In the First-In-Man 
study8 and in the RAndomized study with the sirolimus-
eluting Bx VElocity balloon-expandable stent in the 
treatment of patients with de novo native coronary artery 
Lesions (RAVEL),9,10 no cases of binary angiographic 
restenosis were seen after sirolimus-eluting stent (SES) 
implantation. Restenosis (diameter stenosis > 50% at 
follow-up) after SES implantation occurred in 9% of cases 
(compared to 36% with bare stents; p<0.001) in the 
recent randomized SIRolImUS-eluting Bx velocity balloon 
expandable stent trial (SIRIUS).11 However, SIRIUS 
included more complex patients than RAVEL and FIM, 
which could at least partially account for the occurrence of 
restenosis in some cases. Moreover, we have recently 
shown that post-SES restenosis frequently occurs in 
association with particular local conditions in complex 
cases.12 Nonetheless, the late luminal renarrowing 
response after sirolimus-eluting stent implantation is 
currently poorly understood. In the present study, we 
examine the pattern of late luminal loss following 
sirolimus-eluting stents in comparison with conventional 
bare metal stent implantation. 
Methods 
Study Design and Patient Population 
Since April 2002, sirolimus-eluting stents (Cypher; 
Johnson & Johnson-Cordis unit, Cordis Europa NV, Roden, 
the Netherlands) have been utilized as the device of 
choice for every percutaneous procedure in our 
institution, as detailed elsewhere.13 The final 
interventional strategy was left to the discretion of the 
operator, as was the utilization of periprocedural 
glycoprotein IIbIIIa inhibitors and antithrombotic 
medications.  
Patients treated with SES were considered as 
candidates for angiographic re-evaluation if presenting at 
least one following: 1) treatment of acute myocardial 
infarction, 2) treatment of in-stent restenosis, 3) 
utilization of very small SES (2.25-mm nominal diameter), 
4) treatment of the left main coronary, 5) treatment of 
chronic total occlusion (more than 3 months), 6) adjacent 
stented segment longer than 36 mm, and 7) bifurcation 
stenting (SES implanted in the both the main vessel and 
the side branch). Patients not undergoing a repeat 
intervention in the first month, and without a formal 
medical contraindication were considered eligible for 
angiographic follow-up between 6 and 8 months. 
Importantly, although all such patients were approached 
for angiographic follow-up, patient refusal was not 
considered as an exclusion criterion to be treated with 
sirolimus stents. Angiographic re-study was not requested 
for non-residents of The Netherlands. 
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During the first 6 months of enrollment, a total of 362 
consecutive patients had at least one criterion above 
(57% of all patients treated with SES in the period). From 
these, 2 patients moved to another country, 10 patients 
had died at 6-month follow-up, 6 patients had repeat 
intervention before 30 days, and 3 patients were 
considered to have a medical contra-indication to the 
angiographic follow-up. From the remaining 341 patients, 
angiographic follow-up (204±34 days) was obtained from 
238 patients (70% of eligible patients), who compose the 
present study population. A total of 441 lesions were 
treated and included in the present report.14 Apart from 
being older (63±12 years vs. 60±12 years; p=0.02), non-
included patients had similar baseline characteristics 
compared to patients with angiographic follow-up. This 
protocol was approved by the hospital ethics committee 
and written informed consent was obtained from every 
patient. 
 
Table 1. Clinical and angiographic characteristics  
 Bare stents 
(526 pts; 734 
les) 
SES 
(238 pts; 441 
les) 
p-value 
Age, y 60±10 60±12 0.6 
Male 84 73 <0.01 
Diabetes 17 22 0.1 
Acute coronary 
syndrome* 
58 46 <0.01 
Left main coronary 1 3 0.02 
Left anterior descending 41 43 0.5 
Left circumflex artery 23 22 0.7 
Right coronary artery 35 29 0.02 
Bypass graft 0 3 <0.01 
Reference diameter, mm 2.80±0.59 2.50±0.61 <0.01 
Pre-procedure minimal 
luminal diameter, mm 
0.91±0.39 0.69±0.54 <0.01 
Pre-procedure diameter 
stenosis, % 
67.0±12.6 72.2±20.0 <0.01 
Lesion length, mm 10.0±7.5 16.1±11.8 <0.01 
Post-procedure minimal 
luminal diameter, mm 
2.43±0.54 2.13±0.58 <0.01 
Post-procedure diameter 
stenosis, % 
19.9±9.1 17.2±11.1 <0.01 
Follow-up minimal 
luminal diameter, mm 
1.63±0.64 2.10±0.69 <0.01 
Follow-up diameter 
stenosis, % 
40.6±18.8 22.8±19.9 <0.01 
Late loss, mm 0.80±0.61 0.04±0.49 <0.01 
Binary restenosis 26.0 7.9 <0.01 
Values are mean±SD or percentages 
* unstable angina or acute myocardial infarction 
 
In order to better evaluate the angiographic outcomes 
of patients treated with SES, a control group for 
comparison was composed of patients treated with bare 
metal stents included in the Evaluation of Oral Xemilofiban 
in Controlling Thrombotic Events (EXCITE) trial, which 
study design and main results have been reported 
elsewhere.15 Briefly, the EXCITE randomized a total of 
7232 patients to the oral glycoprotein IIbIIIa inhibitor 
xemilofiban or placebo, administered before percutaneous 
coronary revascularization and maintained for up to 6 
months. The trial included a substudy with 526 patients 
(734 lesions) treated with coronary stenting, for whom 
baseline, post-procedure and 6-month angiographic re-
evaluation was obtained and comprised the control 
population of the present study. Due to the negative 
results of the trial in preventing restenosis, all patients 
were included in the present report regardless of the 
allocated treatment. 
Quantitative Coronary Angiography 
Coronary angiograms were obtained before 
intervention, after stenting, and at follow-up. The 
projection showing the maximal degree of stenosis 
(“worst view”) was selected at baseline and used for the 
subsequent analysis. Quantitative coronary angiographic 
analysis was performed as previously described, utilizing a 
validated computer-based edge-detection system (CASS 
II, Pie Medical, Maastricht, The Netherlands)16. 
Interpolated reference diameter, minimal luminal 
diameter, and diameter stenosis were measured at all 
time-points. Late loss was calculated as the difference 
between the minimal luminal diameter after stenting and 
at follow-up. The target lesion was defined as the entire 
segment involving the implanted stent and the 5-mm 
distal and proximal borders adjacent to the stent. 
Statistical Analysis 
Categorical variables were expressed as percentages 
and compared by Fisher’s Exact Test. Continuous 
variables were presented by their mean and standard 
deviation and compared by Student’s T test. The 
frequency distribution of late loss was graphically 
represented using histograms and tested for normality 
utilizing the Kolmogorov-Smirnov goodness-of-fit test. The 
method proposed by Bland and Altman13 was utilized to 
evaluate the variation in the measurements of luminal 
diameters at post-procedure and at follow-up as well as 
for the variations between repeated measurements in a 
random sample of segments in the index angiogram. In 
Bland and Altman’s method, the average of the two 
measurements for an individual lesion is plotted against 
the difference between them, with 95% limits of 
agreement being calculated to evaluate the measurement 
concordance. Also, the regression line of difference on 
average was depicted in the graphs as well as the 
correspondent R square value. Multivariate estimates of 
late loss were calculated by general linear models 
adjusted for stent type (bare or sirolimus stents) and for 
the following baseline and procedural variables (that 
differed between the study groups): gender, diabetes, 
clinical syndrome at presentation, treated vessel, lesion 
length, reference diameter, and post-procedure minimal 
luminal diameter. 
Results 
Patients treated with SES had a higher risk profile for 
restenosis than the control group with bare stents, 
according to previously proposed risk factors (Table 1). 
Specifically, in the sirolimus group lesion length was 
longer (16.1±11.8 mm vs. 10.0±7.5 mm; p<0.01), 
reference vessel diameter was smaller (2.50±0.61 mm vs. 
2.80±0.59 mm; p<0.01), post-procedural minimal luminal 
diameter was smaller (2.13±0.58 mm vs. 2.43±0.54 mm; 
p<0.01). Diabetes tended to be more prevalent among 
patients treated with sirolimus stents, although not 
reaching statistical significance (22% vs. 17%; p=0.1). 
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Nevertheless, the total binary restenosis rate was 
significantly lower (7.9% vs. 26.0%; p<0.01) and the 
overall late lumen loss significantly smaller (0.04±0.49 
mm vs. 0.80±0.61; p<0.01) in the sirolimus group than in 
the bare group. 
 
Figure 1. Frequency distribution of late loss values for all lesions 
treated with bare metal stents (upper panel) and with sirolimus-
eluting stents (mid panel). The lower panel shows both stent 
types together. The superimposed curves represents the normal 
probability function based on the mean and variance of the data. 
P<0.001 by Kolmogorov-Smirnov test for both stent types. 
Frequency Distribution of Late Loss 
Overall, patients treated with bare stents had an 
average late loss of 0.80 mm (range: -0.75 to 3.48 mm) 
and patients treated with SES had an average late loss of 
0.04 mm (range: -1.12 to 2.97 mm; p<0.01 vs. bare 
stents). Although presenting an apparent bell-shaped 
pattern (Figure 1), the frequency distribution of late loss 
values strongly deviated from normality for both stent 
groups (p<0.001 by Kolmogorov-Smirnov test for 
normality for both). The frequency distribution of late loss 
was then analyzed after separating the lesions into 2 
categories according to several proposed definitions for 
binary restenosis.4,17,18 Also, lesions were separated 
according to the previously described intersection point 
between lesions with and without excessive late loss after 
conventional stenting (i.e. minimal luminal diameter at 
follow-up of 1.09 mm).7 All analyses gave similar findings 
and further results in this study are presented for the 
most commonly utilized criterion of binary restenosis, 
which defines restenosis as a luminal diameter stenosis > 
50% at follow-up. 
Figure 2. Frequency distribution of late loss for all lesions with 
restenosis at follow-up (right) and for lesions with restenosis 
excluding total occlusions (left). Graphs for the bare stent group 
are shown in the upper panels and and for the sirolimus group in 
the lower panel. The superimposed curves represents the normal 
probability function based on the mean and variance of the data. 
P=0.1 by Kolmogorov-Smirnov test for all restenotic bare stents 
and P=0.5 for restenotic bare stents excluding total occlusions. 
 
The frequency of late loss values of restenotic lesions 
among controls (26.0% of lesions; mean late loss: 
1.40±0.64 mm) followed a bell-shaped format with a 
tendency to deviate from normality, although not reaching 
statistical significance (p=0.1 by Kolmogorov-Smirnov test 
for normality) (Figure 2), while the late loss of lesions 
with binary angiographic restenosis after SES implantation 
(7.9% of lesions) had a mean late loss of 1.16±0.76 mm 
(p=0.02 vs. bare stents) and presented an 
uncharacteristic distribution pattern (Figure 2). Due to the 
fact that lesions presenting with total occlusions at follow-
up (TIMI flow 0 or I) may be associated with distinct 
physiopathological processes of lumen renarrowing (e.g. 
thrombosis instead of progressive neointimal 
proliferation),7 and due to the low incidence of late total 
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occlusions in both groups (sirolimus: 0.9% vs. bare stent: 
4.1%; p<0.01), restenotic lesions were also analysed 
after exclusion of occlusions. Amongst controls, the 
frequency of late loss for non-occluded restenotic lesions 
presented a bell-shaped format resembling a normal 
distribution (p=0.5 by Kolmogorov-Smirnov test for 
normality) with an average lumen loss of 1.24±0.52 mm 
(Figure 2). In the sirolimus group, non-occluded 
restenosis presented an uncharacteristic distribution 
pattern (mean late loss: 0.96±0.64 mm; p<0.01 vs. bare 
stents) (Figure 2). 
 
Figure 3. Frequency distribution of late loss for non-restenotic 
lesions in the bare stent group (upper panel) and in the sirolimus 
group (mid panel). The lower panel shows both stent types 
together. The superimposed curves represents the normal 
probability function based on the mean and variance of the data. 
P=0.3 by Kolmogorov-Smirnov test for bare stents and P=0.5 for 
sirolimus-eluting stents. 
 
Non-restenotic lesions in the bare stent group 
presented a frequency distribution of late loss close to 
normality (p=0.3 by Kolmogorov-Smirnov test for 
normality), with an average late loss of 0.58±0.44 mm 
(Figure 3). However, non-restenotic lesions in SES 
presented a mean late loss close to zero (-0.05 mm with a 
standard deviation of 0.33 mm) and a frequency 
distribution also close to normality (p=0.5 by Kolmogorov-
Smirnov test for normality) (Figure 3). 
Repeatability of Measurements 
Previous studies from our institution have evaluated 
the repeatability of quantitative angiographic 
measurements from acquisitions performed at the 
beginning and at the end of the catheterization (i.e. 
images were acquired within an interval of some minutes, 
but the X-ray system had to be repositioned to the same 
projection after being moved to acquire other views).16,19 
The average difference between both measurements was 
reported to be 0.03 mm (medium-term repeatability 
accuracy) with a standard deviation of 0.18 mm (medium-
term repeatability precision).16,19 The calculations 
performed to assess accuracy and precision in this context 
are the same as those used for late loss and its standard 
deviation respectively. Interestingly, the late loss and 
standard deviation of lesions without binary restenosis in 
the sirolimus group (and not in the bare stent group) 
were similar to the accuracy and precision of repeated 
measurements of the same vessel segment. These 
findings suggest that the values of late loss for lesions 
with no restenosis after SES implantation may potentially 
reflect solely the variability of repeated measurements, 
with a minimal (or absent) component due to actual 
neointimal accumulation (or vessel enlargement). 
Conversely, even when not classified as restenotic 
according to binary criteria, lesions treated with bare 
stents did present some extent of luminal loss, implying 
that mild neointimal proliferation may be present also in 
non-restenotic lesions after conventional stenting. 
In order to further evaluate this concept, we analyzed 
in our patients the intra-procedural measurement 
repeatability of a random sample of 30 vessel segments 
not related to the target lesion. In this analysis, the 
selected segments were measured in the same projection 
at the beginning and at the end of the index procedure; 
all paired measurements were done blindly, without 
knowledge of the matched values. The vessel diameters 
differed between baseline and the end of the procedure 
by -0.02 mm (95% CI: -0,59 – 0,56 mm) (repeatability 
accuracy) with a standard deviation of 0.29 mm 
(repeatability precision). The corresponding Bland and 
Altman plot is depicted in Figure 4. For comparison, the 
Bland and Altman plot is also shown for late loss 
(difference in diameters after stenting and at follow-up) of 
lesions without restenosis in the sirolimus group (late loss 
-0.05 mm; 95% CI: -0.69 – 0.59 mm) and in the bare 
stent group (late loss 0.58 mm; 95% CI: -0.28 – 1.45 
mm) (Figure 4). The resemblance between the analyses 
for repeated measurements and late loss in the sirolimus 
stents was evident and clearly differed from the graph for 
bare stents. In addition, the regression lines of difference 
on average (and respective R square values) are shown, 
and demonstrate a strikingly similar behavior of the values 
through the range for the repeated measurements and 
the sirolimus group. 
70
60
50
40
30
20
10
0
-1.5 2.00 1.50.5 1.00.5-1.0
late loss (mm)
n
u
m
b
e
r 
o
f 
le
si
o
n
s
n
u
m
b
e
r 
o
f 
le
si
o
n
s
70
60
50
40
30
20
10
0
-1.5 2.00 1.50.5 1.00.5-1.0
late loss (mm)
n
u
m
b
e
r 
o
f 
le
si
o
n
s
n
u
m
b
e
r 
o
f 
le
si
o
n
s
70
60
50
40
30
20
10
0
-1.5 2.00 1.50.5 1.00.5-1.0
 































































































late loss (mm)
n
u
m
b
e
r 
o
f 
le
si
o
n
s
Bare stents
Sirolimus-eluting stents
Sirolimus-eluting stents and Bare stents
Chapter 25 ______________________________________________________________________________ 
 
 142 
Figure 4. Bland and Altman plots. Measurement repeatability of 
luminal diameters at the beginning and at the end of the index 
procedure (same projection) of a random sample of 30 vessel 
segments (upper panel); difference in minimal luminal diameters 
after stenting and at follow-up (“late loss”) for lesions without 
restenosis in the sirolimus group (mid panel) and in the bare 
stent group (lower panel). 
 
Multivariate Estimates of Late Loss 
In order to correct for baseline and procedural 
differences between the sirolimus and bare stent groups, 
we performed a multivariate analysis to estimate the 
value of late loss after adjustment for potential 
confounders. Estimates of late lumen loss for patients 
treated with bare stents or SES are shown in Table 2. 
Restenotic lesions had a comparable estimated late lumen 
loss whether occurring in bare stents (1.26 mm; 95% CI: 
1.15 – 1.36 mm) or in SES (1.32 mm; 95% CI: 1.14 – 
1.51 mm) (p-value for the effect of stent type=0.7), even 
after exclusion of late total occlusions. Adjusted estimates 
for non-restenotic lesions, however, have shown a 
different behavior for bare stents and SES. While non-
restenotic bare stents had a predicted late loss of 0.58 
mm (95% CI: 0.52 – 0.65 mm), the predicted late luminal 
loss of SES without restenosis was around zero (-0.04 
mm; 95% CI: -0.10 – 0.02) (p-value for the effect of stent 
type<0.01). 
Discussion 
The present study shows that the pattern of 
angiographic late lumen loss after sirolimus-eluting stent 
implantation follows a peculiar behavior, which differed 
from lesions treated with conventional stents. The 
distribution of late loss of sirolimus stents appeared 
largely skewed to the right (i.e. most late loss tended 
towards smaller values), which could merely represent a 
distinct feature explained by an unusual statistical 
distribution. Nevertheless, the possibility of a biological 
all-or-none response of restenosis following sirolimus-
eluting stent implantation remains to be investigated. 
Substantial luminal renarrowing occurred in a minority of 
lesions diagnosed as restenotic, according to binary 
definitions. In most patients, however, luminal dimensions 
were maintained, with zero late loss at follow-up. In the 
latter group, eventual differences in luminal 
measurements between post-stenting and follow-up 
resembled variations expected to occur in repeated 
angiographic measurements. This pattern of late 
angiographic outcome differed from that observed after 
bare stent implantation. After conventional stenting, the 
late loss of non-restenotic lesions in bare stents (adjusted 
estimate 0.58 mm) was significantly higher than in non-
restenotic sirolimus stents, which predicted late loss was 
maintaned close to zero.  
It has been reported that some degree of late loss 
occurs even for non-restenotic lesions after percutaneous 
interventions with bare stents.1,7 In a previous study with 
conventional stenting, Schomig et al. have shown that 
lesions in the lower range of lumen renarrowing still 
presented a late lumen loss of approximately 0.5 mm,7 a 
figure similar to that observed in our control group. 
Sirolimus-eluting stent implantation, however, has been 
shown in our series to virtually abolish neointimal 
formation in non-restenotic lesions. The elimination of 
neointima creates a peculiar scenario, in which the 
angiograms of non-restenotic lesions obtained 
immediately post-procedure and at follow-up are usually 
indistinguishable. In this context, the measurements 
performed to calculate the late loss (i.e. the difference in 
luminal diameters between both angiograms) actually 
mimic repeated measurements of the “same” angiogram, 
a fact that is readily appreciated by the average “late loss” 
of almost zero. Moreover, the standard deviation of late 
loss measurements (0.3 mm) represent the normal 
fluctuations of repeated measurements performed in the 
same segment. Interestingly, similar findings were 
observed in the FIM and RAVEL studies, where all cases 
were free of restenosis. In the FIM study,8 “late loss” was 
0.16±0.3 mm (slow release formulation), while in the 
RAVEL trial “late loss” was reported to be -0.01±0.33 
mm.9,10  
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Table 2. Multivariable estimates of late loss for bare stents or sirolimus-eluting stents.* 
 Estimated late loss (mm) 95% CI p-value for the effect of stent type model R2 
Overal population   <0.01 0.44 
Bare stents 0.76 0.68 – 0.84   
SES 0.11 0.02 – 0.19   
Lesions with restenosis at follow-up 
(including total occlusions) 
  0.7 0.64 
Bare stents 1.26 1.15 – 1.36   
SES 1.32 1.14 – 1.51   
Lesions with restenosis at follow-up 
(excluding total occlusions) 
  0.4 0.81 
Bare stents 1.17 1.09 – 1.24   
SES 1.20 1.06 – 1.34   
Lesions without restenosis at follow-up   <0.01 0.55 
Bare stents 0.58 0.52 – 0.65   
SES -0.04 -0.10 – 0.02   
*adjusted for the following variables: gender, diabetes, acute coronary syndromes, vessel treated, reference diameter, lesion length, 
and post-procedural minimal luminal diameter 
 
It has been reported that some degree of late loss 
occurs even for non-restenotic lesions after percutaneous 
interventions with bare stents.1,7 In a previous study with 
conventional stenting, Schomig et al. have shown that 
lesions in the lower range of lumen renarrowing still 
presented a late lumen loss of approximately 0.5 mm,7 a 
figure similar to that observed in our control group. 
Sirolimus-eluting stent implantation, however, has been 
shown in our series to virtually abolish neointimal 
formation in non-restenotic lesions. The elimination of 
neointima creates a peculiar scenario, in which the 
angiograms of non-restenotic lesions obtained 
immediately post-procedure and at follow-up are usually 
indistinguishable. In this context, the measurements 
performed to calculate the late loss (i.e. the difference in 
luminal diameters between both angiograms) actually 
mimic repeated measurements of the “same” angiogram, 
a fact that is readily appreciated by the average “late loss” 
of almost zero. Moreover, the standard deviation of late 
loss measurements (0.3 mm) represent the normal 
fluctuations of repeated measurements performed in the 
same segment. Interestingly, similar findings were 
observed in the FIM and RAVEL studies, where all cases 
were free of restenosis. In the FIM study,8 “late loss” was 
0.16±0.3 mm (slow release formulation), while in the 
RAVEL trial “late loss” was reported to be -0.01±0.33 
mm.9,10  
Our results may underscore the importance of locally 
occurring mechanisms in the pathophysiology of post-SES 
restenosis. Indeed, preliminary reports have shown that 
restenosis after SES implantation is associated with a 
variety of lesion- and stent-related conditions.12,20 
Identification of the role of specific local conditions on 
restenosis after SES is likely to lead to technical 
modifications or device improvements in an attempt to 
further reduce the restenosis rate. 
It is noteworthy that due to the relatively limited 
number of patients treated with sirolimus stents in the 
present study, it is not possible to rule out that systemic 
or patient-based factors may induce, in rare cases, some 
extent of mild neointimal proliferation even in the absence 
of restenosis. Obviously, apart from factors influencing the 
mechanisms involved in the vascular healing process, the 
presence of an intrinsic resistance to sirolimus may reduce 
the efficacy of the drug in inhibiting neointimal growth. 
However, the clinical relevance of this is still to be 
clarified. 
In addition, due to the low incidence of lesions 
presenting actual luminal renarrowing after SES 
implantation, it was not possible to identify the 
distribution pattern of late loss in this group of lesions. 
Because of this, lesions were separated into two groups 
according to the usual cutoff definition of binary 
restenosis and further analyses with increased number of 
lesions are warranted to validate the present results. A 
higher rate of angiographic follow-up would be desirable 
to fully evaluate the angiographic outcomes.4 However, 
the present study enrolled a unique cohort of unselected 
patients with complex procedures, which differs from 
patients usually included in randomized trials and may 
limit the compliance for angiographic re-study. Moreover, 
the non-randomized nature of our study with SES 
precluded the inclusion of an unbiased control group. 
However, this limitation was partially overcome by the 
comparison of patients treated with sirolimus stents with 
patients treated with conventional stents enrolled in a 
recent multicenter trial.   
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Post-Sirolimus-Eluting Stent Restenosis Treated With Repeat 
Percutaneous Intervention: Late Angiographic and Clinical 
Outcomes 
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Background: We evaluated the clinical and angiographic outcomes of patients with restenosis after sirolimus-eluting 
stent (SES) implantation undergoing treatment with repeat percutaneous intervention.  
Methods and Results: A total of 24 consecutive patients (3.8% of patients receiving SES in the period) have 
undergone repeat percutaneous intervention to treat post-SES restenosis (27 lesions). Diabetes was present in 46% and 
SES was implanted at the index procedure to treat a de novo lesion in 70%. On average 1.9 ± 1.2 SES were implanted 
at the initial intervention with a mean stented length of 41.2 ± 27.0 mm. Post-SES restenosis was located within the 
stent in 93% of lesions. An apparent mechanical cause could be identified in 44%. From the 27 lesions, 1 (4%) was re-
treated with a bare stent, 3 (11%) with balloon dilatation, and the remaining 23 lesions (85%) with repeat drug-eluting 
stent implantation (SES in 12 lesions [44%] and paclitaxel-eluting stents in 11 lesions [41%]). The event-free survival 
rate was 75.0% after 487 ± 42 days from the index procedure (269 ± 68 days from the post-SES treatment). The 
overall recurrent restenosis rate was 40%. The recurrent restenosis rate of lesions re-treated with drug-eluting stents 
was 29.4%. 
Conclusions: Our findings show that the treatment of post-SES restenosis is currently suboptimal and warrants further 
investigation.  
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Introduction 
Sirolimus-eluting stents (SES) have recently proven 
effective in reducing restenosis and the need for repeat 
revascularization compared to conventional stenting.1-4 
Nonetheless, post-SES restenosis still occurs in a small 
proportion of patients, with repeat revascularization 
procedures being required in up to 5% of patients.1-4 
However, the best therapeutic approach for patients 
presenting with restenosis after SES implantation is 
currently unknown. The present study aimed, therefore, 
to evaluate the clinical and angiographic outcomes of 
patients undergoing repeat percutaneous intervention to 
treat post-SES restenosis.  
Methods 
Since April 2002, our institution has adopted a policy 
of utilizing drug-eluting stents as the device of choice for 
all patients treated with percutaneous intervention, as 
described elsewhere.1 Until October 2003, 631 
consecutive patients have received at least one sirolimus-
eluting stent (79% of all patients treated in the period). 
From these, a total of 24 consecutive patients (3.8%) 
have undergone repeat percutaneous intervention for 
post-SES eluting stent restenosis (27 lesions) and 
comprise the present study population. Post-sirolimus 
eluting stent restenosis was defined as a significant 
luminal stenosis (> 50% diameter stenosis by quantitative 
coronary angiography) located within the stent or in its 5-
mm proximal or distal segments, identified at an 
angiogram performed > 3 months after the index 
procedure. 
Patients were treated preferably with repeat 
implantation of drug-eluting stents, according to our 
policy, as explained above. Sirolimus-eluting stents were 
available up until March 2003, since then paclitaxel-eluting 
stents have been utilized as the default drug-eluting stent 
at our hospital. Nevertheless, the final interventional 
strategy was entirely left at the discretion of the operator. 
All patients receiving repeat drug-eluting stent 
implantation were maintained on lifelong aspirin and 
clopidogrel for at least 3 months. 
Patients were followed-up to assess the incidence of 
major cardiac adverse events, defined as all-cause death, 
non-fatal myocardial infarction (> 2X creatine kinase 
increase with an increased creatine kinase-MB), or repeat 
target lesion revascularization (re-intervention to treat a 
significant lesion within the stented segment or in its 5-
mm borders). Angiographic follow-up was obtained 6 
months after the treatment of post-SES restenosis to 
evaluate the incidence of recurrent restenosis (> 50% 
diameter stenosis). 
Results 
Overall, patients frequently had diabetes (46%) and 
none had received SES during the acute phase of a 
myocardial infarction Table 1. The right coronary artery 
was treated in approximately half the lesions (44%) and 
SES were implanted at the index procedure to treat a de 
novo lesion in 70%. In-stent restenosis or failed 
brachytherapy lesions treated with SES at the index 
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procedure (26%) had complex morphologies in the 
majority of cases (Mehran Class III or IV 86%). The 
remaining lesion (4%) was a balloon restenosis. On 
average 1.9 ± 1.2 sirolimus-eluting stents were implanted 
at the initial intervention, with a mean stented length of 
41.2 ± 27.0 mm. 
 
Table 1. Patient and lesion characteristics at index procedure 
(n=24 patients, 27 lesions) 
Age, years ± SD 61 ± 12 
Male, % 71 
Diabetes, % 46 
Multivessel disease, % 67 
Clinical presentation at index procedure  
Stable angina, % 88 
Unstable angina, % 12 
Treated vessel  
Right coronary artery, % 44 
Left anterior descending, % 26 
Left circumflex, % 15 
Left main coronary, % 4 
Saphenous vein graft, % 11 
Ostial location, % 30 
Chronic total occlusion (>1 month), % 26 
Lesion type at the index procedure  
De novo lesion, % 70 
Balloon restenosis, % 4 
In-stent restenosis, % 15 
Post-brachytherapy restenosis, % 11 
Mehran Classification at the index procedure*  
Type I or II, % 14 
Type III, % 43 
Type IV, % 43 
Number of SES implanted at the index procedure, 
± SD 
1.9 ± 1.2 
Total length of SES implanted at the index 
procedure, mm ± SD 
41.2 ± 27.0 
SES=sirolimus-eluting stents 
* Related to in-stent restenosis or post-brachytherapy restenosis 
at the index procedure (N=7) 
 
Table 2. Post-SES restenosis angiographic characteristics (n=27) 
Post-SES restenosis location  
In-stent, % 93 
Proximal edge, % 4 
Distal edge, % 4 
Possible cause of post-SES *  
Ostial location, % 30 
Gap or fracture between SES, % 11 
Trauma outside the stent / residual dissection, % 7 
Stent underexpansion, % 7 
No apparent cause, % 56 
Lesion length of post-SES restenosis, mm ± SD 12.8 ± 9.9 
Treatment of the post-SES restenosis  
Balloon dilatation, % 11 
Bare stent implantation, % 4 
Repeat SES implantation, % 44 
Paclitaxel-eluting stent implantation, % 41 
Total length of repeat stent implantation, mm ± SD † 21.5 ± 15.8 
SES=sirolimus-eluting stents 
* Categories not mutually exclusive (intravascular ultrasound 
examination available for 18 lesions [67%]) 
† Related only to lesions treated with repeat stent implantation 
(n=24 lesions) 
 
 Lesion characteristics of post-SES restenosis are 
summarized in Table 2. In most cases, the restenosis was 
located within the stented portion (93%). In the majority 
of cases, post-SES restenosis occurred without an 
apparent mechanical cause (56%), as evaluated by 
angiography and intravascular ultrasound (the latter 
available for 67%). The mean length of post-SES 
restenotic lesions was 12.8 ± 9.9 mm; 14 lesions (52%) 
were short (<10 mm long), 5 lesions (19%) were multi-
focal, 7 lesions (26%) were > 10-mm long, and 1 lesion 
(4%) presented as total vessel occlusion. 
Of the 27 post-SES restenotic lesions, 3 (11%) were 
treated with balloon dilatation in small segments not 
considered suitable for repeat stenting, and 1 lesion (4%) 
in a large saphenous graft was treated with a PTFE-
covered stent. For the remaining 23 post-SES restenoses 
(85%), repeat drug-eluting stent implantation was chosen 
as the therapeutic strategy. Sirolimus-eluting stents were 
implanted in 12 lesions (44%) (patients treated up to 
March 2003) and paclitaxel-eluting stents were used for 
11 lesions (41%) (patients treated since March 2003). For 
lesions treated with repeat stent implantation, the stented 
length was significantly shorter in the repeat procedure 
than in the index procedure (21.5 ± 15.8 mm vs. 42.6 ± 
26.9 mm respectively; p<0.01). 
Complete clinical follow-up was available for all 
patients at an average of 487 ± 42 days from the index 
procedure (269 ± 68 days from the post-SES treatment). 
A 78-year old patient died 412 days after the index 
procedure (209 days after post-SES restenosis treatment) 
due to pneumonia and progressive heart failure. There 
were no myocardial infarctions during the follow-up 
period. Target lesion revascularization was required in 5 
patients (20.8%) after the treatment of post-SES 
restenosis due to recurrent restenosis. Overall, the event-
free survival rate was 75.0%. 
Angiographic follow-up was obtained for 17 patients 
with 20 lesions (71% of patients, 74% of lesions) at 271 
± 49 days. Overall, there were 8 lesions (40%) with 
recurrent restenosis after percutaneous treatment of post-
SES restenosis (Table 3). In 2 of these cases (10%), the 
target vessel was totally occluded in its proximal portion 
at the follow-up angiogram, precluding direct assessment 
of the treated site (mid/distal vessel in both cases). There 
was no clinical evidence of sudden thrombotic occlusion 
during the follow-up and both lesions were classified as 
recurrent restenosis. The recurrent restenosis rate of 17 
lesions re-treated with drug-eluting stents was 29.4%, 
with no major differences between sirolimus- or 
paclitaxel-eluting stents (33.3% vs. 25.0% respectively) 
(Table 4). 
Discussion 
The main finding of the present study was that, 
although post-sirolimus-eluting stent restenosis occurred 
as an infrequent event, its treatment with repeat 
percutaneous intervention was associated with relatively 
high rates of recurrent restenosis. Repeat drug- (sirolimus 
or paclitaxel) eluting stent implantation, the most frequent 
treatment used in our series, appeared to be safe, with no 
documented complications related to re-exposure to local 
antiproliferative agents. However, the overall recurrence 
of restenosis after repeat drug-eluting stent implantation 
was 29.4%. 
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Table 3. Quantitative Coronary Analysis of Post-SES restenosis lesions treated with percutaneous intervention* 
 Reference 
diameter, mm 
Minimal luminal 
diameter, mm 
Diameter 
stenosis, % 
Lesion length, 
mm 
Late loss, mm Restenosis 
rate, % 
Baseline at index procedure 2.57 ± 0.57 0.49 ± 0.40 79.3 ± 16.6 18.0 ± 12.9 … … 
After index SES implantation … 2.11 ± 0.46 16.6 ± 10.1 … … … 
Post-SES restenosis  … 0.76 ± 0.45 72.8 ± 14.0 12.8 ± 9.9 … … 
After treatment of post-SES restenosis … 2.26 ± 0.60 17.6 ± 16.2 … … … 
Late angiographic follow-up … 1.49 ± 1.07 49.1 ± 32.7 10.8 ± 17.8 0.77 ± 0.96 40.0 
Number are mean ± SD; SES=sirolimus-eluting stents 
* Related to 20 lesions with angiographic follow-up (74% of eligible) 
 
 
Our results may underscore the complex nature of 
lesions presenting with restenosis after initial SES 
implantation. The underlying processes associated with 
post-SES restenosis are currently unknown, which limits 
the development of more effective therapeutic 
approaches. Previous observations have shown that local 
features may play an important role in post-SES 
restenosis.5,6 Interestingly, the identification of a 
presumed contributing factor (based on procedural and 
intravascular ultrasound findings) did not influence the 
outcomes after re-treatment in our series; the recurrence 
restenosis rate in this subset was still 37.5%. One may 
speculate whether forms of constitutional or acquired 
cellular mechanisms leading to drug resistance may 
influence the recurrence of post-SES restenosis.7 It is 
worth noting that the recurrent rates were at least 25% 
across several subsets, including some lesion types that 
have been traditionally considered to have a benign 
prognosis for in-stent restenosis (e.g. short restenotic 
lesions).  
 
Table 4. Subset analysis - restenosis recurrence after repeat 
percutaneous intervention for post-SES restenosis * 
Subgroup  
Recurrent 
restenosis 
rate (%) 
De novo lesion at index procedure (n=13) 30.8 
Restenotic lesion at index procedure (n=7) 57.1 
Ostial location (n=6 lesions) 33.3 
Non-ostial location (n=14 lesions) 42.9 
Short (<10mm) post-SES restenosis (n=11) 36.4 
Multifocal or long (>10mm) post-SES restenosis 
(n=9) 
44.4 
Post-SES with possible known cause (n=8) 37.5 
Post-SES with no apparent cause (n=12) 41.7 
Post-SES treated with drug-eluting stent implantation 
(n=17) 
29.4 
Post-SES treated with sirolimus-eluting stent 
implantation (n=9) 
33.3 
Post-SES treated with paclitaxel-eluting stent 
implantation (n=8) 
25.0 
Post-SES treated with balloon dilatation or bare 
metal stent implantation (n=3) 
100.0 
SES = sirolimus-eluting stent 
* Related to 20 lesions with angiographic follow-up (74% of 
eligible) 
 
The present study has several limitations related to its 
small sample size, its non-randomized, observational 
design, and the heterogeneity of the study population. 
Nevertheless, our findings have shown that the treatment 
of this new medical condition, namely post-SES 
restenosis, is currently suboptimal and warrants further 
investigation. 
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Aims - To assess the balance between costs and effects of the sirolimus-eluting stent in the treatment of single native 
de novo coronary lesions in the RAVEL study. 
Methods and results – In total, 238 patients with single, de novo lesions were randomised to percutaneous coronary 
intervention with sirolimus-eluting stents or conventional bare stents. Patients were followed-up to 1 year and the 
treatment effects were expressed as 1 year survival free of major cardiac events (MACE). Costs were estimated as the 
product of resource utilization and Dutch unit costs. At 1 year, the absolute difference in MACE free survival was 23% in 
favour of the sirolimus-eluting stent group. At the index procedure, sirolimus-eluting stent implantation had an 
estimated additional procedural cost of € 1,286. At 1 year, however, the estimated additional cost difference has 
decreased to € 54 due to the reduction in the need for repeat revascularisations in the sirolimus group (0.8% vs. 
23.6%; p<0.01). After adjustment of actual results for the consequences of angiographic follow-up (correction based on 
data from the BENESTENT II study), the difference in MACE-free survival was estimated at 11.1% and the additional 1-
year costs at € 166.  
Conclusion – The 1-year data from RAVEL suggest an attractive balance between costs and effects for the sirolimus-
eluting stents in the treatment of single native de novo coronary lesions. The cost effectiveness of drug-eluting stents in 
more complex lesion subsets remains to be determined.  
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Introduction 
Sirolimus-eluting stents have been recently proven to 
markedly reduce coronary restenosis and the need for 
subsequent revascularisation compared to conventional 
stenting.1-3 Sirolimus-eluting stents have been available 
for routine use since April 2002 in Europe and since April 
2003 in the USA. Due to the clear clinical superiority of 
these devices, it would be expected that clinicians would 
want to use the new stent as extensively as possible. 
However, sirolimus stents have been commercialised with 
a high price relative to conventional bare stents, which 
may increase up-front procedural costs and has been 
perceived as an important limitation for a more 
widespread utilization of these devices in the clinical 
practice. On the other hand, the reduction of repeat 
intervention procedures during follow-up may be cost 
saving, which may eventually lower total costs. Therefore, 
in the current era of cost containment policies, the 
question arises as to how the additional effects compare 
to the additional costs. 
The present study addresses this question for patients 
included in the RAVEL study. It is important to note that 
the RAVEL study included a protocol-mandated angiogram 
scheduled at 5-7 months of follow-up.1 It is known from 
the BElgium NEtherlands STENT II (BENESTENT II) study 
that this policy may bias both cost and effectiveness 
estimates of the treatments, when compared to patients 
without routine angiographic follow-up.4 Since routine 
angiographic follow-up is not standard practice in the 
“daily life” of most centers, the question needs to be 
raised of whether the results would differ if angiographic 
follow-up had not been performed. This issue was 
addressed in this manuscript by an analysis that combines 
estimates of costs and effects from the RAVEL study 
(comparing drug-eluting with bare stents) with estimates 
of the effect of angiographic follow-up from the 
BENESTENT II study (comparing results with and without 
scheduled angiographic follow-up).  
Material and methods 
The study protocol and main findings of the RAVEL 
study have been detailed elsewhere.1 In brief, the RAVEL 
was a randomised, double-blind study of 238 patients with 
diagnosis of stable or unstable angina scheduled to treat a 
single de novo target lesion in a native coronary vessel. 
Patients were treated with either a bare metal Bx 
VELOCITY stent (Cordis Corp, Johnson & Johnson) or a 
similar sirolimus-eluting Bx VELOCITY stent. Both stents 
were indistinguishable, except under microscopy. At 30 
days, 6 and 12 months, patients returned for evaluation- 
and were specifically questioned to identify the possible 
interim development of angina, as well as to monitor 
major adverse cardiac events including additional 
revascularisation of the index target lesion. Diagnostic 
angiography was performed at 180±30 days or preceding 
a re-intervention. The decision to perform a re-
intervention was left to the investigator’s discretion, but 
he was asked to register whether it was based on clinical 
symptoms or guided by angiographic results. 
Cost-effectiveness 
Effectiveness was assessed by using the composite of 
12-month major adverse cardiac events (MACE), which 
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included all-cause death, non-fatal myocardial infarction, 
and target lesion revascularisation (either surgical or 
percutaneous). With respect to costs, the analysis was 
limited to the direct medical costs. The balance between 
costs and effects after 12 months was assessed by 
computing the incremental cost-effectiveness ratio (the 
average 1-year costs per patient treated with drug-eluting 
stents minus the average 1-year costs with bare stent 
implantation divided by the percentage change in MACE-
free survivors after 1 year).  
For cost-effectiveness, two scenarios were 
investigated. The first scenario reflects the actual 
protocol-driven resource use and effectiveness observed 
in the RAVEL study (which included a 6-month 
angiogram). For the estimation of the costs and effects of 
this scenario, similar methods were used as in the 
assessments of costs and effects in the BENESTENT II 
study,4 the DEBATE II study,5 and the ARTS trial.6 
Resource use data were collected from the case record 
form for the initial procedure (number of balloons, type 
and number of stents, type and number of catheters, 
etc.), hospital admissions (coronary care unit, intensive 
care unit, conventional ward), and major therapeutic and 
diagnostic procedures after the initial procedure. Unit 
costs were estimated, before the analysis of the data, on 
the basis of detailed information from the Erasmus 
Medical Center, Rotterdam, The Netherlands, following a 
similar approach as reported previously.7 Costs per patient 
were calculated as the product of each patient’s resource 
utilization and the corresponding unit cost. Information 
about the price of the sirolimus-eluting stent as well as 
the bare stent was obtained from the manufacturing 
company. In both arms, the medication costs include 
those of eight weeks of anti-platelet therapy.  
The second scenario excludes follow-up angiography 
as a standard procedure. The rationale for this approach 
is to exclude the effect of the so-called “oculo-stenotic 
reflex”, which may increase the incidence of repeat 
intervention in patients undergoing protocol-mandated 
angiographic re-evaluation.4,8 It is noteworthy that the 
information collected at the time of the repeat 
revascularisations on whether the new intervention was 
driven by angina was indicative of the effect of 
angiographic follow-up. However, these records were not 
informative of the impact of follow-up angiograms on the 
number of angiographies and repeat procedures that 
would have taken place before and after 5-7 months. It is 
expected that some of the procedures performed during 
the follow-up visit would normally have been carried out 
either in the months before or after the protocol-driven 
angiogram. With respect to the angiograms and 
interventions that would have been performed before the 
pre-specified time-point, it is expected that these were 
postponed knowing that angiograms were already 
scheduled at the 5-7 month follow-up. One would 
therefore expect a lower revascularisation rate before a 
pre-specified angiographic follow-up than would have 
been the case without such a specification. Conversely, if 
there is a pre-specified angiogram, there may be less 
need for later angiography and for late repeat procedures 
than without angiographic follow-up.  
In the BENESTENT II study,4 which compared balloon 
angioplasty with stenting, a one-to-one sub-randomisation 
was carried out assigning the patients either to clinical 
follow-up alone (409 patients) or to angiographic and 
clinical follow-up (418 patients). So, half of the 
BENESTENT II study had the same design as the RAVEL 
study, with pre-specified angiographic follow-up, and the 
other half had the design without such follow-up, as it is 
preferred for the purpose of a cost-effectiveness analysis. 
In the BENESTENT II, with angiographic follow-up, the 
percentage of patients with repeat revascularisations were 
18.27% (stenting) versus 22,28% (balloon). Without 
angiographic follow-up, the percentages of repeat 
revascularisations were 7,77% versus 16,26% 
respectively. With angiographic follow-up, the percentage 
of patients with unscheduled angiograms was 8,17% 
versus 12,86% (with and without stenting). Without 
angiographic follow-up the percentages of unscheduled 
angiograms were 14,08% versus 20,20%. So, on average, 
the inclusion of angiographic follow-up increased the 
number of repeat revascularisations with a factor 1.6 and 
decreased the number of unscheduled angiograms with a 
factor 0.6. As such the data from the BENESTENT II offer 
a source for estimating the effect of angiographic follow-
up on both the occurrence of angiograms and repeat 
interventions. Moreover, it also offers information about 
the timing of these procedures.  
To estimate the effects of angiographic follow-up on 
treatment, the time after the initial procedure was divided 
into three periods: 1) from the index procedure to month 
5; 2) from month 5 to month 7; and 3) from month 7 to 
month 12. For each period, estimates were made of the 
rate of non-scheduled angiographies and repeat-
revascularisation. Differences were estimated in terms of 
relative risk ratios and those significantly different from 
1.0 were included in the analysis. Subsequently, estimates 
of patients free of repeat revascularisations were obtained 
by multiplying the number of repeat revascularisations 
observed in RAVEL with the relative risk ratios derived 
from BENESTENT for all three periods. Finally, estimates 
of average MACE-free survival were obtained by 
multiplying the revascularisation rate times the relative 
risk scores in those patients who only had repeat 
revascularisations. Patients who died or had a myocardial 
infarction were counted as having had an event.  
A similar procedure was followed with respect to costs. 
For this analysis, estimates were needed of the costs 
associated with a repeat procedure and the costs of an 
angiogram, not only of the procedure itself but also of the 
additional costs associated with these procedures. 
Estimates of these costs were obtained by using the data 
from the RAVEL study and applying a linear regression 
analysis with costs as the dependent variable and the 
various events as independent variables. It was noted that 
the resulting cost estimates were not just the cost of the 
procedure but that they had to be interpreted as the 
additional costs associated with the treatment of a patient 
who undergoes such procedures. Total costs were 
corrected on the basis of the increase in the expected 
numbers of non-scheduled angiograms and the expected 
decrease in the number of repeat revascularisations.  
Statistical analysis 
All analyses were based on the intention-to-treat 
principle. In estimating the risk ratios from BENESTENT II, 
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an assessment was made on whether these relative risks 
differed between the randomised treatments (stent or 
balloon) by testing for differences in the log transformed 
risk ratios. In case that the hypothesis of a similar effect 
could not be rejected (95% significance), data from both 
procedures were pooled to estimate the relative risks. A 
correction for the number of angiograms and repeat 
procedures was made when the risk ratios differed (95% 
significance) from one.  
With respect to the scenario assuming angiographic 
follow-up, cost effectiveness was expressed in terms of 
probability ellipses using Fieller’s approach, which was 
used to estimate the upper 95% limit of the cost-
effectiveness ratio.9  
With respect to the scenario assuming no angiographic 
follow-up, the uncertainties surrounding the estimate 
were addressed by a combination of bootstrapping and 
multivariate sensitivity analysis. Bootstrapping means that 
one simulates a number of new trials, say 1,000, of 
exactly the same size of the original trial. One does so by 
drawing patients at random (with replacement) from the 
original trial. Each bootstrap leads to a new estimate of 
average costs and average effects. The resulting 1,000 
estimates can be summarized in terms of a distribution 
and by truncating the upper and lower 2,5% one obtains 
estimates of the 95% confidence intervals. This is very 
convenient method when the distribution cannot be 
obtained in a classical way.10  
  
 
Table 1. Costs Associated with Observed Resource Use 
  
Sirolimus 
stent 
(N=120) 
Bare stent 
(N=118) 
Unit Cost (€) 
Sirolimus 
stent 
(N=120) 
Bare stent 
(N=118) 
Differen. 
  resource use per patient  cost (€) cost (€) 
Index procedure       
Procedure time (in minutes) 70.8 70.6 18 1,288 1,285 3 
Study stent 1.03 1.02 2,000/672 2,050 683 1,367 
Other stent type 0.02 0.03 712 12 24 -12 
Guiding Catheter 1.10 1.07 98 107 104 3 
Guidewire 1.08 1.04 115 124 120 4 
Balloon 1.32 1.37 491 646 674 -28 
Doppler 0.03 0.06 523 13 31 -18 
IVUS Catheter 0.23 0.29 614 143 177 -34 
Contrast medium 192.08 200.18 1 98 102 -4 
Procedure related medication    67 63 -4 
CCU days 0.30 0.26 963 289 252 37 
ICU days 0.29 0.29 1058 307 305 2 
Non-CCU/ICU days 2.12 2.24 343 727 768 -41 
Total procedure costs     5,872 4,588 1,284 
        
Follow-up       
Re-PTCA (target and non target) 0.03 0.31  107 908 -800 
CABG (target and non target) 0.01 0.01 7,448 62 126 -64 
Transfusion 0.01 0.01 60 1 1 0 
Vascular surgery 0.01 0.02 4,341 36 74 -37 
Non-scheduled angiographies 0.08 0.10 2,160 180 220 -40 
Protocol angiographies 0.90 0.74 2,160 1,944 1,592 351 
Emergency room visit 0.15 0.12 44 7 5 1 
Observation unit <24 hrs adm. 0.02 0.20 193 3 39 -36 
Outpatient rehabilitation 0.08 0.18 23 2 4 -2 
CCU days 0.17 0.64 963 161 612 -452 
ICU days 0.14 0.11 1,058 151 117 35 
Non-CCU/ICU days 2.15 2.50 343 737 858 -121 
Rehabilitation 0.24 0.37 343 83 128 -45 
Total follow up costs    3,473 4,683 -1,210 
       
Total direct medical cost (excluding medication)    9,345 9,271 74 
Medication    624 644 -20 
Total direct medical cost (including medication)    9,969 9,915 54 
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Results 
In total, 120 patients were randomised to sirolimus-
eluting-stent implantation, and 118 patients to bare metal 
stents. With the exception of a higher percentage of men 
in the control arm, the two groups had similar baseline 
and procedural characteristics. At 1 year, the sirolimus 
and bare stent group had similar mortality (1.7% vs. 
1.7% respectively) and myocardial infarction rates (3.3% 
vs. 4.2% respectively). The 1-year incidence of MACE was 
significantly reduced in the active group compared to the 
controls (5.8% vs. 28.8%; p<0.01 by log-rank test), 
mainly due to a marked decrease in the need for repeat 
revascularisation in the sirolimus group (0% vs. 22.9%; 
p<0.01). Table 1 presents the estimates of costs after one 
year. It appears that the additional costs of the initial 
procedure are almost completely recouped by the 
decrease in the costs of follow-up. Using the observed 
event rates and overall costs in RAVEL, without correcting 
for the impact of protocol-mandated follow-up 
angiograms, at the end of the first year the total costs are 
estimated to be only €54 per patient higher in the 
sirolimus-eluting stent group, compared to the bare stent 
group. Costs per MACE-free survivor are estimated at 
€234 with an upper 95% limit of €5,679. 
When considering the results in Table 1 it may be 
noted that the costs of the scheduled angiograms are 
higher in the sirolimus-group than in the bare stent group 
(which is related to the higher number of patients with 
repeat procedures in the bare stent group). This might 
suggest that without such follow-up, the costs of the 
initial procedure would have been completely recouped. 
However, that would neglect the effect of the “oculo-
stenotic reflex” since the difference in repeat 
percutaneous revascularisation procedures between the 2 
groups suggest that such a reflex may have had an effect 
on the costs and the outcomes. 
Table 2 summarizes the frequency of non-scheduled 
angiograms and repeat revascularisation procedures in 
patients with and without protocol-mandated follow-up 
angiography in BENESTENT II trial.4 The need for non-
scheduled angiography in each group is depicted 
according to the time of its occurrence, either before, 
during, or after the period in which follow-up angiograms 
were scheduled. There were no significant differences in 
the relative risk ratios for non-scheduled angiography in 
the stent and balloon arms in BENESTENT II. As shown in 
Table 2 (pooled data of the balloon and stent groups), 
protocol-mandated angiographic follow-up had no 
significant effect on the risk of unscheduled angiography 
during the first five months, and no correction factor was 
applied for this period. However, between 5 and 7 months 
(period of the scheduled angiography), patients with no 
protocol-mandated angiography had significantly more 
non-scheduled angiograms (increased by a factor of 
3.577) and less repeat procedures (reduced by a factor of 
0.387). Also, after 7 months, the group with protocol-
mandated angiography had more non-scheduled 
angiograms, which were accordingly corrected by a factor 
of 2.146. After correction of the RAVEL data according to 
the expected effects of angiographic follow-up, the 
difference in the number of repeat procedures was then 
estimated at 11.8% instead of 23.6%. Moreover, the 
difference in the number of unscheduled angiograms was 
estimated at 3.8% instead of 1.9%.  
 
Table 2. Non-scheduled angiograms and repeat revascularisation 
in the BENESTENT II trial.4 
 
Without 
angiographic 
follow-up 
(Angioplasty 
with and 
without stents) 
With 
angiographic 
follow-up 
(Angioplasty 
with and 
without stents) 
Relative Risk 
(95% C.I) 
Months 1-5    
Angiograms 8.6% 7.2% 1.192 (0.747-
1.904) 
Repeat 
revascularisations 
6.1% 8.9% 0.691 (0.424-
1.126) 
Months 6-7    
Angiograms 3.4% 1.0% 3.577 (1.187-
10.776)* 
Repeat 
revascularisations 
3.4% 4.5% 0.387 (0.212-
0.704)* 
Month 8-12    
Angiograms 5.1% 2.4% 2.146 (1.023-
4.501)* 
Repeat 
revascularisations 
2.4% 2.6% 0.929 (0.399-
2.164) 
Differences of log transformed risk-ratios where not statistically 
significant based on 95% confidence interval surrounding these 
differences 
CI=confidence interval 
* Significant risk-ratio used in RAVEL C/E model 
 
Table 3 shows the results from the regression analyses 
relating the costs per patient to the costs of the initial 
procedure and the occurrence of all major cardiac events, 
other serious adverse events, as well as angiograms 
(r2=0.35; F-value = 10.76; P-value (F-test)<0,0000). 
Applying the derived relative risks to the patient-specific 
data leads to the estimates of both costs and effects as 
presented in Table 4. Without routine angiographic follow-
up the difference in costs between the sirolimus-eluting 
stent and the bare metal stent at 1 year was estimated to 
be €166. The costs per additional MACE-free survivor are 
now estimated to be €1,495 with an upper 95% limit of 
€61,243. Figure 1 presents the estimates of both cost and 
effects after a combination of bootstrapping and 
multivariate sensitivity analysis using the normal 
distributions surrounding the estimates of the relative 
risks.  
 
Table 3. Cost Estimates Based on Multi-variate Analysis 
  
Cost 
estimate 
Standard 
error 
Initial costs 5.097 253 
Additional costs of drug-eluting stent 1.360 311 
Death* 1.194 1.197 
Myocardial infarction 3.693 788 
Coronary bypass surgery 12.147 1.316 
First repeat percutaneous intervention 4.374 455 
Additional repeat PCI 6.665 705 
Non-scheduled angiography 3.561 538 
Other serious adverse events 4.411 246 
PCI=percutaneous coronary intervention 
* Death was not a significant predictor 
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Table 4. Costs and Effects Based on Different Scenarios 
 With angiographic follow-up Without angiographic follow-up 
 
Sirolimus Stent 
(N=120) 
Bare Stent 
(N=118) 
Difference  
 
Sirolimus Stent 
(N=120) 
Bare Stent 
(N=118) 
Difference 
Clinical events, %         
Death, % 1.7 1.7 0   1.7 1.7 0 
Myocardial Infarction, % 3.3 5.1 -1.8   3.3 5.1 -1.8 
Target lesion revascularisations, % 0.8 23.6 -22.8   0.8 11.8 -11 
surgical, % 0.8 0.8 0   0.8 0.3 0.5 
percutaneous, % 0.0 22.9 -22.9   0.0 11.5 -11.5 
MACE Free, % 94.2 
(89.9-98.4) 
71.2 
(62.9-79.4) 
23.0 
(13.7-32.2) 
  94.2 
(88.9-97.5) 
83.1 
(64.2-90.9) 
11.1 
(1.7-28.0) 
          
Angiography, % 8.3 10.2 -1.9   10.3 14.1 -3.8 
         
Total direct medical cost (€) 9,969 9,915 54   8,065 7,899 166 
 (8,910-10,504) (8,722-10,449) (-1,054-1,296)  
 
 (7,052-9,463) (6,821-9,591 (-1,376-1,487) 
MACE=major adverse cardiac events 
 
Discussion 
In this report, we analysed the balance between costs 
and effects in the RAVEL trial, while recognising the 
potential increase in interventions due to the “oculo-
stenotic reflex” associated with protocol-driven 
angiographic follow-up. Two scenarios were presented: 
one with scheduled angiographic follow-up, based on 
actual data from the RAVEL study, and the second 
scenario that corrected for the effect of protocol-driven 
angiograms. The first scenario leads to an estimated cost 
difference at the end of 1 year of €54 per patient, and a 
cost per MACE-free survivor of €234. The second scenario 
leads to an estimated cost difference of €166 at the end 
of 1 year, and a cost per MACE-free survivor of €1,495. 
Both point estimates seem to be well within a range of 
what may be considered acceptable from a societal 
standpoint.  
These results need to be assessed in light of the study 
limitations. A first limitation is that the analysis is primarily 
based on data from the RAVEL study, which included only 
238 patients with a primary endpoint of angiographic late 
loss at 6 months; MACE and resource utilisation were only 
secondary endpoints. Cost-effectiveness was not a formal 
endpoint, mainly because of protocol-mandated 
angiographic follow-up, the effect of which on outcomes 
was adjusted based on the BENESTENT II study. Our 
analysis has therefore of the costs and effects without 
angiographic follow-up has at least three sources of 
uncertainty. First, there is the limited number of 
observations in the RAVEL study. Second, there is the 
estimate of effects of the “oculo-stenotic reflex” from the 
BENESTENT II study; and third, there is the estimate of 
the costs that need to be subtracted as a result of this 
reflex. All these are considered in our estimate leading to 
an upper 95% limit of €61,243. These numbers might be 
even higher when considering that the patients in the 
BENESTENT II study differ from those in RAVEL. The fact 
that the difference in MACE-free survival, when one 
considers only the revascularisations that were labelled as 
being “clinically driven”, was so close to that of the 
combined analysis suggests that this last potential source 
of error may have been relatively small.  
An alternative approach would have been to 
recalculate costs and effects by excluding the events 
which were not “clinically driven”. We decided against this 
approach, since it would not account for the effects of the 
protocol-driven angiograms on the rate of clinically-driven 
angiograms and on the reintervention rate before month 5 
and after month 7.  
The RAVEL included a relatively non-complex group of 
patients, admitted for single-lesion stenting (single-vessel 
disease in 71%) of short coronary stenosis (average 
lesion length 9.58 mm). How the sirolimus-eluting stent 
will perform in other patient populations with different 
risks of reintervention needs to be studied, not only in 
terms of efficacy but also in terms of cost-effectiveness. 
Moreover, the RAVEL was an international study and that 
no account was taken of differences in treatment 
patterns. Unit cost estimates were obtained from one 
hospital and treated as if they were not surrounded by 
uncertainty. It was noted that the estimated differences in 
costs were highly dependent on the price difference 
between the sirolimus stents (€ 2,000) and the bare 
stents (€ 672). As an example, when the price of the bare 
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metal stent was set around €500, as it is in the UK, the 
total 1-year cost difference between both treatments was 
estimated at €341 instead of €166.  
A final important limitation concerns the outcome of 
the study. Sirolimus-eluting stent implantation increased 
MACE-free survival, which is a combined endpoint of 
death, myocardial infarction, and repeat-
revascularisations. In practice it may only reduce the need 
for revacularisations.1-3,11 Furthermore, it may be 
hypothesized that the anti-restenotic effect of sirolimus 
stents may improve the rate of recurrent ischaemic 
symptoms and quality of life parameters. However, direct 
quality-of-life data have not been collected to 
demonstrate the extent of the potential benefit of 
sirolimus stents in this regard. As such, cost per additional 
MACE-free survivor may not be the optimal way of 
expressing the balance between costs and effects in this 
scenario. In addition, by calculating costs per MACE-free 
survivor, or costs per repeat procedure prevented, one 
cannot compare the results obtained to those of other 
health care interventions such as hip-replacements. Given 
the lack of comparable outcomes, one might well ask the 
question how much society is prepared to pay to prevent 
repeat intervention during the first year after the initial 
intervention. However, when doing so, it may be 
important to recognize that the burden associated with 
the need for a repeat intervention may not be limited to a 
short period of anginal pain, but also should consider 
increased anxiety and disability, and most notably an 
increased incidence of even more hospitalizations, some 
of which may result in repeat interventions.  
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INTRODUCTION 
The publication in January 2001 of the First In Man 
results showing zero restenosis after sirolimus-eluting 
stent implantation produced enormous excitement in the 
cardiological community 1. The long awaited tool, a safe 
restenosis-proof easy-to-use stent, had been found. It 
was not too long thereafter that paclitaxel-eluting stents 
also demonstrated their capability to decrease restenosis. 
Today both sirolimus- and paclitaxel-eluting stents have 
been shown in randomized trials to reduce restenosis as 
compared to conventional metallic stents (Figure 1) 2-6. 
Most of these studies have been recently released in form 
of abstracts during medical meetings and are still 
unpublished 3-6. In addition to sirolimus and paclitaxel, 
other agents have shown promising early results in recent 
studies, enlarging the body of evidence demonstrating the 
potential benefits of what are known as “drug-eluting 
stents”.7 Regulatory agencies have been very active 
evaluating some of these devices in the US, Europe, South 
America, and Asia. The sirolimus eluting-stent has been 
available for routine use in Europe, South America, and 
Asia since the first half of 2002, and is expected to be 
marketed in the US in early 2003. Paclitaxel eluting-stents 
have also received CE (Conformité Européenne) marking 
for commercialization in Europe and are now beginning to 
be commercialized. 
The case seemed to be closed. Restenosis, the 
Achilles’ heel of percutaneous revascularization, appeared 
defeated. However, since the availability of sirolimus-
eluting stents, very little has changed in the everyday life 
of almost all interventional laboratories in Europe. Why? 
Has the new treatment presented any undesirable effect? 
Was the desire to defeat restenosis not as great as 
supposed? The answer is none of the above. The 
limitation currently impeding more widespread use of the 
new technology is non-technical, non-medical, and non-
biological. The list price of the sirolimus-eluting stent in 
Europe is €2,300 (US$ 2,500). This high price relative to 
bare stents, as well as the absence of incremental 
reimbursement in most countries, has been an obstacle to 
more widespread utilization of drug-eluting stents.  
Restenosis: The Problem 
Coronary restenosis has long been considered the 
main limitation hampering the efficacy of percutaneous 
revascularization. Although stent implantation has been 
shown to reduce restenosis in vessels with reference 
diameter t 3.0mm, as compared to balloon angioplasty, 
in-stent restenosis still occurs in 10-40% of the patients. 
In the last 3 decades, a great deal of money and effort 
has been expended evaluating an endless list of failed 
“concepts”, “strategies”, devices, and drugs to decrease 
restenosis. But is in-stent restenosis really so bad? 
The occurrence of restenosis remains largely 
unpredictable for a particular patient, although powerful 
“predictors of restenosis” have been described that are 
helpful to characterize a population of patients. 
Furthermore, in-stent restenosis has a high recurrence 
rate. In its most complex forms, repeat restenosis may 
occur in up to 50-80% after re-dilatation with balloon, 
rotablator, or laser. Brachytherapy has been 
demonstrated to reduce the incidence of repeat 
restenosis. However, the use of brachytherapy has been 
restricted to a relatively small number of centers. The 
need for a multidisciplinary approach, with addition of 
radiation oncologists and physicists to the interventional 
team, poses logistic limitations to the implementation of 
the technology as a standard therapy in most hospitals. 
Nevertheless, although effective for most patients, 
treatment failure still occurs in approximately 30% of 
cases after brachytherapy.  
Patients with restenosis frequently 
express the recurrence of symptoms as a 
“déjà vu” phenomenon occurring 
unexpectedly in their daily life, with rapidly 
progressive or “new onset” angina, so-called 
“unstable angina pectoris”. However, unlike 
patients with de novo lesions, where plaque 
rupture and thrombus formation are the 
underlying substrate, “unstable angina” due 
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Figure 1. Incidence of angiographic
restenosis in randomized trials with drug-
eluting stents 2-6 
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to restenosis is related to rapidly progressive lumen 
renarrowing due to exaggerated neointimal growth. As a 
consequence, restenosis is rarely complicated by 
myocardial infarction or death 8, as in the natural history 
of unstable patients with de novo lesions. Instead, 
refractory angina pectoris is the main complication of 
untreated restenosis. The lack of any effect of restenosis 
on mortality is readily appreciated by the comparison of 
angioplasty versus surgery 9. In most randomized trials, 
death and myocardial infarction rates were virtually 
identical between the two treatment modalities in spite of 
a much higher rate of repeat-intervention due to 
restenosis after angioplasty. It is therefore unlikely that 
reduction of restenosis would have a direct impact on 
myocardial infarction or mortality rates. Nevertheless, it is 
worth noting that sirolimus-treated patients in the 
SIRolImUS-Eluting Bx Velocity™ Balloon-Expandable Stent 
trial (SIRIUS) showed a significantly smaller incidence of 
non Q-wave myocardial infarction between hospital 
discharge and 9 months follow-up (0.2% vs. 1.3%; 
p=0.037) 5.  
An anticipated high risk of in-stent restenosis is one of 
the major reasons for patients refusing angioplasty and 
opting for other treatment modalities (e.g. surgery or 
medical). Similarly, the potential occurrence of restenosis 
currently limits the use of percutaneous treatment for 
conditions such as intermediate lesions and vulnerable 
plaques. The introduction of drug-eluting stents will 
hopefully broaden the selection of appropriate candidates 
for angioplasty, with a shift of patients from medical and 
surgical treatments towards percutaneous intervention. 
Drug-Eluting Stents: What are the benefits? 
In the First In Man 10 study and in the Randomized 
Study with the Sirolimus-Eluting Bx Velocity Balloon-
Expandable Stent in the Treatment of Patients with de 
Novo Native Coronary Artery Lesions (RAVEL) 2, which 
included patients with single non-complex de novo 
lesions, the rate of binary angiographic restenosis 
(diameter stenosis > 50%) after sirolimus-eluting stent 
implantation was zero at 2 years and at 6 months, 
respectively. The efficacy of sirolimus-eluting stents was 
confirmed in the subsequent SIRIUS trial. In this study, 
in-stent binary restenosis (within the margins of the stent) 
was reduced by 91% (3.2% vs. 35.4%; p<0.01) and in-
segment restenosis (including the stented portion and the 
5mm segments proximal and distal to the stent) was 
reduced by 75% (8.9% vs. 36.3%; p<0.01)5. In the 
SIRIUS trial, long lesion length, small reference vessel 
size, and diabetes were shown to be independent 
predictors of increased risk of restenosis (in-stent and in-
segment), either in patients treated with sirolimus-eluting 
stents or with bare stents. However, sirolimus-eluting 
stents markedly reduced restenosis for patients at both 
extremes of the risk spectrum. Non-diabetics with short 
lesions (< 12mm) and large vessels (t 3.0mm) had an 
81.7% risk reduction of in-segment restenosis, while 
patients at the highest risk (diabetics with longer lesions 
[t 15mm] and small vessels [<2.5mm]) had a significant 
64.5% decrease in the risk of restenosis. Similarly, in the 
RAVEL trial 11, patients with vessel size <2.36 mm (one 
third of the population) presented with the same rate of 
binary restenosis (i.e. no restenosis) as patients in the 
upper tercile (reference diameter > 2.84). Recently, 
sirolimus-eluting stents have shown promising results for 
the treatment of in-stent restenosis in a series of 25 
patients with relatively simple lesions (4% binary 
restenosis rate at 1 year) 12. Sirolimus-eluting stents have 
also been evaluated for highly complex patients with in-
stent restenosis. In an initial experience with 16 patients 
(including 50% with multiple previous interventions, 44% 
needing implantation of t 36mm sirolimus-eluting stents, 
25% with failed brachytherapy, 19% with total occlusions, 
and 6% with transplant vasculopathy), binary restenosis 
rate at 4 months was 20% and death rate was 12.5% at 9 
months 13.  
Non-polymer coated paclitaxel-eluting stents have 
been shown to reduce binary angiographic restenosis in 
the European Evaluation of Paclitaxel Eluting Stent trial 
(ELUTES) 3 and the ASian Paclitaxel-Eluting stent Clinical 
Trial (ASPECT) 4. In these studies, non-polymer paclitaxel 
stents (high-dose formulation) were associated with 3% 
and 4% restenosis rates, respectively, versus 21% and 
27% in bare stent controls 3,4. Polymer-covered paclitaxel-
eluting stents have been evaluated in the multicenter, 
randomized Treatment of De Novo Coronary Disease 
Using a Single Paclitaxel-Eluting Stent trial-II (TAXUS-II) 
6. In this study, the incidence of in-segment restenosis at 
6 months was reduced from 20-24% in the bare stent 
group to 6% and 9% in the slow- and moderate-release 
paclitaxel stent formulations respectively. However, when 
analyzing patients treated only with the study stent, 
restenosis was observed in only 2% in the slow-release 
and 1% in the moderate-release paclitaxel stents. These 
results confirmed the previous findings of the smaller 
TAXUS-I trial 14, in which patients treated with the slow-
release polymer-covered paclitaxel stents showed no 
restenosis, as compared to 10% in the control group.  
Drug-Eluting Stents: Where are the side 
effects? 
In 2 recent reports from the same series of patients, 
Liistro et al. and Virmani et al. have described a late 
“catch up” phenomenon after implantation of a high dose 
(800 µg) paclitaxel derivative QP2-eluting stent 15,16. The 
restenosis rate was 13% at 6 months and 62% at 12 
months. Histological analysis showed signs of delayed 
healing with active inflammation still present at 1 year. 
However, the authors emphasized that “potential 
problems such as the non-erodable thick polymer sleeve, 
very high concentration of the active drug, extended 
release kinetics, open stent architecture, and 
inhomogeneous drug delivery (possibly affected by the 
interspace polymer sleeve) may have compromised the 
performance of the QuaDS-QP2 stent” and concluded that 
“…the overall clinical success of any drug-eluting stent 
may be dependent on multiple design factors and not the 
drug alone”. 
Short-term as well as long-term efficacy should be 
evaluated separately for each drug-eluting stent, since a 
“class-effect” is unlikely to occur due to the myriad of 
possible variations in the complex metallic 
platform/polymer (or not)/pharmacologic agent. Indeed, a 
number of drug-eluting stents have already been proven 
ineffective in reducing restenosis, with even worse results 
being reported, as compared to conventional bare stent17. 
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To date, the sirolimus-eluting stent has the largest body 
of data and longest period of follow-up. The First In Man 
study has shown persistent positive results up to 2 and 3 
years, without any evidence of late catch-up 
restenosis10,18. In the RAVEL trial 2, no further events due 
to restenosis were observed between 6 months and 1 
year. With paclitaxel, no rebound effect was seen from 6 
to 12 months in TAXUS-I, ELUTES, and ASPECT trials 
3,4,14. 
Obviously, a very delayed loss of the initial benefit, for 
instance after 3-4 years, cannot yet be ruled out. 
However, in this hypothetical setting, should a repeat 
intervention after 3 years be viewed as a therapeutic 
failure? In a recent analysis of surgically treated patients 
with multivessel disease included in the Bypass 
Angioplasty Revascularization Investigation (BARI) trial 19, 
significant stenoses were detected after 4 years in 10-
15% of internal mammary grafts and 25-30% of 
saphenous vein bypass grafts. It seems clear that a 
meaningful comparison between the results of treating 
multivessel disease with drug-eluting stents versus 
surgical revascularization will need an extended period of 
follow-up to fully assess the differences (or similarities) in 
outcomes with the two strategies. 
In the First In Man and RAVEL trials, no binary 
angiographic restenosis was observed 1,2. However, in the 
subsequent SIRIUS trial restenosis (in-segment) did occur 
in approximately 9% of the cases. Indeed, in diabetics 
with small vessels and long lesions, in-segment restenosis 
was observed in 23.7% of cases. Does this mean that 
sirolimus-eluting stents are not restenosis-proof? The 
populations treated in the “zero-restenosis” First In Man 
and RAVEL trials and in the “some-restenosis” SIRIUS 
trials were significantly different in terms of their intrinsic 
risk of restenosis. SIRIUS included patients with a higher 
risk profile and more complex lesion anatomy. It seems 
logical to assume that these differences in baseline 
characteristics could justify, at least in part, the 
differences in outcomes between the two studies. 
However, if so, what would be the performance of the 
new device in the “real world”, where complex cases are 
the rule? In everyday practice, will the effects still be 
worth the cost of the new treatment? To evaluate this 
question, the sirolimus-eluting stent has been used as the 
device of choice for every percutaneous intervention in 
Rotterdam since April 2002, as part of the RESEARCH 
(Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital) registry 20. Patients were treated 
without clinical or anatomical restriction and the incidence 
of major adverse cardiac events (MACE) is to be evaluated 
(defined as death, non-fatal myocardial infarction or 
repeat-revascularization). In this study, sirolimus-eluting 
stent implantation was observed to be safe in patients 
with acute coronary syndromes, with a 30-day MACE rate 
similar to a control group treated with bare stents (6.1% 
vs. 6.6% respectively; p=0.8) 20. In a preliminary analysis 
of the 6-month outcomes of first 280 patients enrolled, 
including patients with multivessel stenting, acute 
myocardial infarctions, total occlusions, bifurcation lesions, 
and in-stent restenosis, the incidence of target vessel 
revascularization and major adverse cardiac events were 
2.9% and 6.7% respectively. Although promising, these 
preliminary long-term results must be interpreted with 
caution until final results are available. 
In the RAVEL trial, stent malapposition (as observed 
by intravascular ultrasound) was more frequent at 6 
months in sirolimus-eluting stent patients than in the 
control arm 21. Moreover, in SIRIUS 5 late acquired stent 
malapposition was more commonly observed in the 
sirolimus group. However, in TAXUS-II 6 patients treated 
with bare stents or paclitaxel-eluting stents there were 
similar rates of late-acquired malapposition. Nevertheless, 
these observations of late malapposition by ultrasound 
have not been associated with any adverse events 
throughout the follow-up period in any of these studies. 
Drug-Eluting Stents: The costs 
Developmental and research costs, acquisition of 
exclusive and expensive licenses from pharmaceutical 
companies, building of new manufacturing facilities, low 
production yield in the early stages of the new product 
are all cited as reasons to explain the high cost of drug-
eluting stents. However, at the present stage, the real 
economic value of drug-eluting stents is still unclear as 
well as the profit made by the leading industries 
manufacturing these devices. In an analysis from the 
RAVEL trial (B.A. van Hout, PhD. Personal Communication, 
October 2002) the utilization of the sirolimus-eluting stent 
resulted in a mean additional procedural cost of €1,286, 
as compared to the control group based on costs in the 
Netherlands. However, due to the decrease in re-
interventions attributable to the sirolimus-eluting stent at 
the end of the first year of follow-up the estimated cost 
difference had decreased to 54 €. In other words, in the 
RAVEL trial the reduction of major event risk from 28.8% 
to 5.8% after sirolimus-eluting was accomplished at an 
extra cost of €54 per patient. To account for the so-called 
“oculo-stenotic reflex” that could have artificially increased 
the rate of re-interventions due to the protocol-mandated 
angiographic follow-up, both costs and effects were 
corrected based on the data from the BENESTENT II 
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Figure 2 – Probability ellipses concerning both costs and
effects at 1 year of sirolimus-eluting stent versus bare stent
in the RAVEL trial. The outer ellipse defines the smallest
area containing both costs and effects with 95%
probability; the middle ellipse with 50%, and the inner
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study. In this analysis, after 1 year the adjusted event 
rate was 16.9% and 5.8% in the bare and sirolimus 
groups respectively, and the sirolimus-eluting stent was 
associated with an additional cost of €166 per patient. 
The balance between costs and effects seemed highly 
attractive (Figure 2), with a minimal increase in costs for 
an approximately 60% risk reduction in the worst case. 
For comparison, previous studies evaluating the “anti-
restenotic” effect of conventional stents have shown 
“only” a 30% risk reduction of adverse event as compared 
to balloon dilatation, at an additional cost after 1 year of 
approximately US$ 1,000 per case22. 
The cost and effect estimations derived from the 
RAVEL trial cannot be directly extrapolated to other 
situations. In this study, only simple lesions were treated 
with implantation of a single stent and the late target 
lesion revascularization was zero. The balance between 
costs and effects in more complex situations, where 
restenosis may occur in a small but sizeable number of 
patients, have to be specifically analyzed. Furthermore, 
the number of stents used per procedure may markedly 
increase procedural costs, potentially limiting the use of 
this new technology for the treatment of multivessel 
disease. It is estimated that approximately 1,000,000 
percutaneous interventions are performed each year in 
the US and approximately 80% of them receive stents. 
Assuming a 100% usage of drug-eluting stent, at a rate of 
1.5 stent per patient and a potential US$ 2,000 difference 
between drug-eluting and bare stents, an extra 2.4 billion 
dollars would be added in procedural costs per year. With 
a 15% reduction in reinterventions (at a cost of 
US$10,000 –12,000 per procedure for repeat 
percutaneous coronary procedure and US$20-30,000 per 
procedure for coronary bypass surgery), the cost-offset 
with unrestricted usage of drug-eluting stents in the 
patients at present receiving bare metal stents would be 
about 1.5 billion dollars each year. However, if there is 
any substantial movement from coronary bypass surgery 
to drug-eluting stents, additional savings from avoiding 
the high cost of bypass surgery could potentially result in 
an attenuation of net costs for payors. Nevertheless, 
although potentially “cost-effective” in reducing repeat-
revascularization, it is clear that utilization of drug-eluting 
stents will require a re-distribution of budgets and 
priorities in the health system as a whole, with a shift of 
an enormous amount of money to manufacturers. This 
phenomenon is likely to be repeated with the introduction 
of other new technologies that can replace open surgical 
procedures with less invasive technologically-driven 
procedures and will continue to present a challenge for 
the foreseeable future. 
Historically, all relevant technological innovation in 
interventional cardiology has been incorporated into 
clinical practice. Today, an arsenal of multiple types of 
guiding catheters, new generation contrast agents, 
steerable guidewires, adjunctive medications, 
intracoronary diagnostic tools, dilatation devices, distal 
protection devices, and access closure devices encompass 
the armamentarium of what has been named 
“percutaneous intervention”, only vaguely resembling the 
first days of coronary angioplasty. The speed with which 
new technologies are integrated over time seems to be 
dependent on their efficacy, safety and economic factors 
and vary from country to country. Curiously, as performed 
in the late 80’s in Europe, balloon angioplasty was 
associated with a procedural cost of approximately 4,300 
US$ 23, while in the mid 90’s, coronary stenting was 
performed at a cost of approximately 4,400 US$ 22. 
History has shown that an “outsider” (not belonging to the 
leading corporations) may unexpectedly introduce a 
competitive and successful product with a lower price so 
that the major companies are compelled to reduce the 
price of their own product, triggering an overall lowering 
of the costs. We foresee that some of the manufacturers 
of new eluting-stent designs may purposely target the 
non-US market with lower regulatory barriers as a 
“profitable” field of expansion, so that the non-US patient 
in Europe, South America, Far East, and Africa may soon 
benefit from a low-priced non-FDA approved drug-eluting 
stent. 
Conclusions 
By dramatically decreasing the rate of restenosis, 
drug-eluting stents constitute one of the most important 
advances in interventional cardiology. However, at 
present cost constraints and lack of incremental 
reimbursement have limited their utilization in daily 
practice in many countries, although initial analyses of the 
sirolimus-eluting stent have shown a highly favorable 
cost-effectiveness profile in reducing repeat-
revascularization and combined major cardiac events. A 
more comprehensive understanding of the impact of the 
new treatment in a wide variety of patients, as well as 
market competition with changes in the cost of these 
device costs, are likely to redefine the relationship 
between costs and benefits. 
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Summary and Conclusions 
Unrestricted Utilization of Sirolimus-Eluting Stents in the “Real World”. The Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry 
 
Unrestrictive sirolimus-eluting stent implantation was 
shown to be overall safe and beneficial for patients with 
de novo lesions treated in the “real world”. A total of 508 
consecutive patients with de novo lesions treated with 
sirolimus-eluting stents had a cumulative rate of 1-year 
major adverse cardiac events (death, myocardial 
infarction, or target vessel revascularization) of 9.7%, 
which was significantly better than the 1-year event rate 
of 14.8% in 450 consecutive patients treated with 
conventional strategies (HR 0.62 [95% CI 0.44–0.89]; 
p=0.008), a difference that was mainly driven by a 
marked reduction in the need for clinically driven target 
vessel revascularization in the sirolimus group (3.7% vs. 
10.9%; p<0.001) (Chapter 3). Importantly, the reduction 
of restenosis and the need for further revascularization 
with sirolimus-eluting stents was accomplished while 
maintaining the excellent short-term results already 
achieved with current percutaneous techniques (Chapter 
3). Even in patients with an increased risk for thrombotic 
complications (i.e. patients with acute coronary 
syndromes), sirolimus-eluting stent implantation was 
shown to be at least as safe as conventional stenting 
(Chapters 4, 5, and 6). During the first month after the 
procedure in patients with unstable angina or acute 
myocardial infarction, the rate of major adverse events 
was similar between patients treated with sirolimus-
eluting stents (6.1%) and controls  (6.6%; p=0.8), and 
stent thrombosis occurred in 0.5% and 1.7% respectively 
(p=0.4) (Chapter 4). In addition to being safe, sirolimus-
eluting stent implantation was shown to substantially 
improve the mid-term outcomes of patients with ST 
elevation acute myocardial infarction (Chapters 5 and 6). 
At 6 months the angiographic restenosis was zero 
(Chapter 5) and the need for subsequent repeat 
revascularization was 1.1% at 10 months (compared to 
8.2% for controls; HR 0.21 [95% CI 0.06–0.74]; p=0.01). 
Importantly, no patient treated with sirolimus-eluting 
stents required additional revascularization between 1 and 
10 months (Chapter 6). However, the benefit of sirolimus-
eluting stent implantation on outcomes of patients with 
high risk for clinical complications were shown to be 
almost exclusively related to its anti-restenotic effect, with 
virtually no effect on the risk of death during the follow-
up. The presence of renal impairment at baseline was 
identified as an important independent predictor of 1-year 
death among patients treated with percutaneous 
revascularization (HR 2.15 [95% CI 1.10 – 4.28]; 
p=0.03), a hazardous effect that was not modified by 
sirolimus-eluting stent implantation (Chapter 7). 
The risk of in-stent restenosis after conventional 
stenting is an important parameter to be considered when 
evaluating the best revascularization modality for an 
individual patient. Indeed, certain subsets of patients have 
been tradionally referred for surgical or medical therapy in 
face of a presumed high risk of restenosis (or when the 
clinical consequences of restenosis, once it occurs, are 
assumed to be disastrous). The introduction of drug-
eluting stents has the potential to modify this scenario 
and was evaluated Chapters 8 to 21. Sirolimus-eluting 
stents were safe and effective for the treatment of left 
main coronary artery disease, with no post-discharge fatal 
events and percutaneous re-intervention (Chapter 9), with 
a zero angiographic restenosis rate for elective patients 
(Chapter 10). Similarly, in 99 patients with multivessel 
coronary disease involving the left anterior descending 
artery treated with sirolimus stents, the 1-year incidence 
of death, myocardial infarction, or any repeat 
revascularization (including lesions in segments not 
treated in the index procedure) was 85.6 %, which is 
comparable to previous series with surgical 
revascularization (Chapter 11). 
Sirolimus-eluting stents were utilized for the treatment 
of 56 patients with de novo chronic total occlusions and 
compared with a similar group of 28 patients treated in 
the period immediately before the introduction of 
sirolimus stents. The results were described in Chapter 
12. At 1 year, the cumulative survival-free of major 
adverse cardiac events was 96.4% in the SES group 
versus 82.8% in the BMS group (p<0.05). The clinical and 
angiographic outcomes of 91 patients (112 lesions) with 
very small vessels treated with 2.25-mm diameter 
sirolimus-eluting stents were detailed in Chapter 13. The 
reference diameter was 1.88±0.34, which was 
substantially smaller than all previous randomized studies 
of conventional stents for small vessels (vessel size in 
these series ranged from 2.23 mm to 2.55 mm). At 
follow-up, the binary restenosis rate was 10.7% and the 
late loss was 0.07±0.48 mm, which favorably contrasts 
with the late loss of bare stents for small vessel in 
previous randomized trials (range 1.12 mm to 0.54 mm). 
The 12-month target lesion revascularization rate was 
5.5%. Chapter 14 examined the impact of sirolimus stents 
on another subset at extremely high risk for restenosis. A 
total 96 patients with very long stented segments (at least 
41 mm long) had a binary restenosis rate of 11.9%, with 
an in-stent late loss of 0.13± 0.47mm. At long-term 
follow-up (mean 320 days), the overall incidence of major 
cardiac events was 8.3%. The dramatic reduction of 
restenosis with sirolimus-eluting stents opened new 
therapeutic possibilities for bifurcation lesions. 
Chapter 15 illustrates a case of multiple bifurcation 
lesions treated with different stenting techniques that 
ensure complete vessel scaffolding at the treated site. At 
6-month angiographic follow-up, no restenosis was 
present. The outcomes of patients undergoing bifurcation 
stenting is further explored in Chapter 16: restenosis rates 
in the main vessel and in the stented side branch were 
6.8% and 13.6% respectively, and at 6 months the 
incidence of major adverse cardiac events was 10.3%. In 
Chapter 17, a group of patients with angiographically 
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mildly stenotic (<50% stenosis) lesions treated with 
sirolimus stents were evaluated. After a mean follow-up 
period of 399 ± 120 days, there were no further major 
cardiac events. Although not explored in this thesis, these 
findings may indicate a future role of percutaneous 
intervention for the treatment of special groups of 
patients with mildly stenotic lesions identified to be at 
high risk for further events (e.g. plaque vulnerability). 
Chapter 18 (as well as Chapter 3) demonstrated that 
over-dilatation of undersized sirolimus-eluting stents, a 
technical adjustment that is commonly needed in the 
clinical practice, had no adverse impact on the late 
outcomes. 
Chapters 19 to 21 analyzed the impact of sirolimus-
eluting stent implantation for patients with previous failed 
percutaneous treatment. A total of 44 consecutive 
patients with 53 in-stent restenotic lesions (without 
previous brachytherapy) treated with sirolimus stents 
were described in Chapter 19. At baseline, 37% had 
complex restenosis morphologies (proliferative pattern or 
total occlusions). At follow-up, post-SES restenosis was 
observed in 14.6%. No restenosis was observed in focal 
lesions. For more complex lesions, restenosis rates ranged 
20-25%. At 1-year follow-up, the overall incidence of 
target lesion revascularization due to restenosis was 
11.6%. These findings were compared with those of 
brachytherapy, the current gold standard treatment for 
complex in-stent restenosis in Chapter 20. No differences 
in outcomes were found between patients with in-stent 
restenosis treated with sirolimus-stents or brachytherapy. 
Finally, Chapter 21 examined the effect of sirolimus-
eluting stent implantation on the outcomes of patients 
with recrudescent restenosis after brachytherapy. The 
data have demonstrated that this population was at a high 
risk for further repeat restenosis, which was found in 40% 
of patients even after sirolimus-eluting stent implantation. 
Although sirolimus-eluting stents were shown to be safe 
and effective, short-and mid-term complications were still 
identified in a number of patients and are described in 
Chapters 22 to 26. The incidence of stent thrombosis was 
shown to be low (0.4%) (Chapter 22), a figure 
comparable to that previously reported for bare stents. 
Chapter 23 described some morphological and 
mechanistic characteristics of patients with post-sirolimus 
restenosis. Restenotic lesions located within the stent 
were focal and stent scaffolding discontinuity was 
identified as a relatively common finding. Moreover, 
residual dissection after the procedure or balloon trauma 
outside the stent was identified in 83% of edge 
restenosis. Among patients with complex characteristics, 
the 6-month in-segment restenosis rate was 7.9% (6.3% 
in-stent, 0.9% at the proximal edge, 0.7% at the distal 
edge), with the following characteristics identified as 
independent multivariate predictors (Chapter 24): 
treatment of in-stent restenosis (OR 4.16; 95% CI: 1.63 – 
11.01; p<0.01), ostial location (OR 4.84; 95% CI: 1.81 – 
12.07; p<0.01), diabetes (OR 2.63; 95% CI: 1.14 – 6.31; 
p=0.02), total stented length (per 10 mm increase) (OR 
1.42; 95% CI: 1.21 – 1.68; p<0.01), reference diameter 
(per 1.0 mm increase) (OR 0.46; 95% CI: 0.24 – 0.87; 
p=0.03), and left anterior descending artery (OR 0.30; 
95% CI: 0.10 – 0.69; p<0.01). Interestingly, post-
sirolimus restenosis appeared to occur as an “all-or-none” 
phenomenon (Chapter 25), with lesion-based 
characteristics (instead of patient-based) playing an 
important role in the incidence of post-sirolimus 
restenosis. Although occurring in a small proportion of 
patients, post-sirolimus restenosis has been shown to be 
relatively resistant to repeat percutaneous treatment 
(Chapter 26). A total of 24 consecutive patients (27 
lesions) with restenosis after sirolimus-eluting stent 
implantation have undergone repeat angioplasty. From 
the 27 lesions, 1 (4%) was re-treated with a bare stent, 3 
(11%) with balloon dilatation, and the remaining 23 
lesions (85%) with repeat drug-eluting stent implantation 
(SES in 12 lesions [44%] and paclitaxel-eluting stents in 
11 lesions [41%]). The event-free survival rate was 
75.0% after 487 ± 42 days from the index procedure 
(269 ± 68 days from the post-SES treatment). The overall 
recurrent restenosis rate was 40%. The recurrent 
restenosis rate of lesions re-treated with drug-eluting 
stents was 29.4%. 
Finally, although restenosis, the Achilles’ heel of 
percutaneous revascularization, appeared under control 
after the introduction of drug-eluting stents, the 
penetration of these devices in the everyday life was 
smaller than what would be expected from their proven 
clinical benefit. The limitation currently impeding a more 
widespread use of the new technology is non-technical, 
non-medical, and non-biological. The high price relative to 
bare stents has been an obstacle to more widespread 
utilization of drug-eluting stents. The balance between 
costs and effects of sirolimus-eluting stents was studied in 
Chapter 27 utilizing the data from the randomized RAVEL 
trial. The utilization of the sirolimus-eluting stent resulted 
in a mean additional procedural cost of €1,286, as 
compared to the control group based on costs in the 
Netherlands. However, due to the decrease in re-
interventions attributable to the sirolimus-eluting stent at 
the end of the first year of follow-up the estimated cost 
difference had decreased to 54 €. In other words, in the 
RAVEL trial the reduction of major event risk from 28.8% 
to 5.8% after sirolimus-eluting was accomplished at an 
extra cost of €54 per patient. The benefits and limitations 
of drug-eluting stents as an anti-restenotic strategy and 
their relationship with potential costs is frequently 
complex and multifactorial. Chapter 28 provides a 
discussion on the main issues involved in the balance 
between costs and effects of the new technology. 
 
In conclusion, sirolimus-eluting stent implantation for 
unselected patients in the “real world’ is safe and effective 
in reducing major adverse cardiac events across several 
high-risk subsets. The reduction in the risk for restenosis 
with drug-eluting stents will potentially extent the 
indications of percutaneous treatment to subgroups 
currently considered for surgical or medical treatment. 
Although infrequent, post-sirolimus eluting stent 
restenosis still occurs in a minority of patients. The risk 
factors for restenosis after sirolimus-eluting stent 
implantation resemble those described for bare metal 
stents. Moreover, features that potentially impair 
complete lesion coverage may have an important role in 
post-sirolimus restenosis, which appears to occur as an 
all-or-none phenomenon.  
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Onbeperkt gebruik van de met sirolimus gecoate stents in de klinische praktijk: De Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registratie 
Implantatie van de met sirolimus gecoate stents is 
veilig met een gunstig effect bij patiënten met de novo 
(nieuwe) lesies in de klinische praktijk. In totaal 508 
opeenvolgende patiënten met de novo lesies werden 
behandeld met deze nieuwe stent. Het cumulatieve event 
percentage (sterfte, hartinfarct of revascularisatie van 
dezelfde kransslagader) was 9.7% in het eerste jaar, 
hetgeen significant beter was als de event-percentages 
van een controlegroep van 450 opeenvolgende patiënten 
(14.8%) (HR 0.62 [95%CI 0.44-0.89]; p=0.008). Dit 
verschil was vooral te danken aan de significante reductie 
van revascularisatie als gevolg van  restenose in dezelfde 
kransslagader (3.7% vs 10.9%; p<0.001) (Hoofdstuk 3). 
Het is belangrijk te weten dat de restenose reductie en de 
noodzaak tot een nieuwe revascularisatie met gecoate 
stents bereikt werd terwijl de uitstekende korte-termijn 
resultaten die reeds bereikt werden met behulp van de 
huidige percutane technieken gehandhaafd bleef 
(Hoofdstuk 3). Zelfs bij patiënten met een verhoogd risico 
op  trombotische complicaties (dwz patiënten met acuut 
coronair syndromen) bleek de gecoate stent tenminste 
even veilig als bij de conventionele stent (Hoofdstukken 
4,5 en 6). In de eerste maand na de procedure waren de 
event percentages bij patiënten met onstabiele angina 
pectoris of hartinfarct gelijk tussen patiënten behandeld 
met de gecoate stent (6.1%) en de conventionele stent 
(6.6%; p=0.8), en stent trombose kwam voor bij 
respectievelijk 0.5% en 1.7% (p=0.4) (Hoofdstuk 4). 
Behalve de veiligheid, bleek de gecoate stent de 
middenlange-termijn prognose van patiënten met een ST 
elevatie acuut hartinfarct substantieel te verbeteren 
(Hoofdstukken 5 en 6). Na 6 maanden was er geen 
angiografische restenose (Hoofdstuk 5) en de noodzaak 
tot een hernieuwde revascularisatie was slechts 1.1% na 
10 maanden (in vergelijking tot 8.2% in de controlegroep; 
HR 0.21 [95%CI 0.06-0.74]; p=0.01). Daarbij was het 
belangrijk te weten dat er geen noodzaak was tot een 
nieuwe revascularisatie tussen 1 en 10 maanden bij 
patiënten die werden behandeld met de gecoate stent 
(Hoofdstuk 6). Het gunstige effect van de gecoate stent 
was echter vooral te danken aan het anti-restenose effect 
waarbij er geen verschil in sterfte was gedurende de 
follow-up. Nierfalen bleek een belangrijke voorspeller te 
zijn voor 1-jaars sterfte (HR 2.15 [95%CI 1.10-4.28]; 
p=0.03), een bevinding die echter niet werd beïnvloed 
door de gecoate stent (Hoofdstuk 7). 
Het risico van in-stent restenose na conventionele 
stentimplantatie is een belangrijke parameter bij de 
evaluatie van het beste beleid van de individuele patiënt. 
Bepaalde subgroepen patiënten werden inderdaad 
traditioneel doorverwezen naar chirurgie of voor 
medicamenteuze behandeling in geval een hoog risico op 
restenose wordt verwacht (of als wordt aangenomen dat 
de eventuele klinische restenose consequenties rampzalig 
zouden zijn). De introductie van de gecoate stent zou dit 
scenario eventueel kunnen veranderen en dit werd 
geëvalueerd in de Hoofdstukken 8 tot 21. Gecoate stents 
bleken veilig en effectief te zijn voor de behandeling van 
hoofdstamstenose bij electieve patiënten na ontslag uit 
het ziekenhuis zonder fatale events en percutane 
reinterventies zonder angiografische restenose bij 
electieve patiënten (Hoofdstuk 10). Eveneens waren bij 99 
patiënten met meervatslijden, met inbegrip van de LAD, 
de 1-jaars event-percentages (sterfte, hartinfarct en 
hernieuwde revascularisaties, inclusief lesies die tijdens de 
indexprocedure onbehandeld waren) van de gecoate stent 
slechts 14.4%, (and not 85.6%??), hetgeen vergelijkbaar 
is met eerdere studies na chirurgische revascularisatie 
(Hoofdstuk 11). 
De met sirolimus gecoate stents werden gebruikt voor 
de behandeling van 56 patiënten met de novo chronische 
totale occlusies en vergeleken met een vergelijkbare 
groep van 28 patiënten die werden behandeld in de 
periode direct voorafgaand aan de introductie van de 
gecoate stent. De resultaten zijn beschreven in Hoofdstuk 
12. Na 1 jaar waren de cumulatieve event percentages in 
de gecoate stent groep 3.6% en 17.2% in de 
conventionele stent groep (p<0.05). De klinische en 
angiografische resultaten van 91 patiënten (112 lesies) 
met erg kleine vaten die werden behandeld met een 2.25-
mm sirolimus gecoate stent werden beschreven in 
Hoofdstuk 13. De referentie diameter was 1.88±0.34, 
hetgeen substantieel kleiner was dan alle eerdere 
gerandomiseerde studies van conventionele stents in 
kleine vaten (diameter varieerde in deze studies van 2.23 
mm tot 2.55 mm). Gedurende de follow-up was de binaire 
restenose percentage 10.7% en de ‘late loss’ was 
0.07±0.48 mm, hetgeen gunstig afsteekt tegen de ‘late 
loss’ van de conventionele stents in kleine vaten in 
eerdere gerandomiseerde studies (van 1.12 mm tot 0.54 
mm). De 12-maanden klinische restenose percentage was 
5.5%. Hoofdstuk 14 onderzocht het effect van de gecoate 
stent op een subgroep van patiënten met een zeer hoog 
risico op restenose. In een groep van 96 patiënten met 
erg lange gestente segmenten (tenminste 41 mm lang) 
was de binaire restenose percentage 11.9% met een in-
stent ‘late loss’ van 0.13 mm±0.47 mm. Op de lange-
termijn (gemiddeld 320 dagen) was het totale event 
percentage 8.3%. De dramatische reductie van restenose 
van de gecoate stent zorgde voor nieuwe behandelings 
mogelijkheden voor bifurcatie lesies. 
Hoofdstuk 15 illustreert een voorbeeld van 
meervoudige bifurcatie lesies behandeld met verschillende 
stent technieken om verzekerd te zijn van een volledige 
coating van het behandelde segment. Na 6 maanden 
angiografische follow-up werd er geen restenose 
gevonden. De prognose na bifurcatie stenting is verder 
onderzocht in Hoofdstuk 16: restenose percentages in de 
hoofdstam en in de gestente zijtak waren respectievelijk 
6.8% en 13.6%, en na 6 maanden was het cardiale event 
percentage 10.3%. In Hoofdstuk 17 wordt de gecoate 
stent geëvalueerd in een groep patiënten met een matige 
stenose (angiografisch <50%). Na een gemiddelde follow-
up van 399±120 dagen waren er geen additionele cardiale 
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events. Hoewel niet onderzocht in dit proefschrift, kunnen 
deze bevindingen een toekomstige rol spelen bij de 
percutane behandeling van deze speciale groep patiënten 
maar met een matige stenose met een hoog risico op 
toekomstige events (bijvoorbeeld plaque vulnerability). 
Hoofdstuk 18 (en in Hoofdstuk 3) toonde aan dat 
overdilatatie van kleinere gecoate stents, een technische 
aanpassing dat gewoonlijk nodig is in de klinische praktijk, 
geen nadelig effect had op de lange-termijn uitkomsten.  
In de Hoofdstukken 19 tot 21 wordt de invloed van de 
gecoate stent onderzocht bij patiënten waarbij een 
eerdere percutane behandeling was mislukt. In totaal 44 
opeenvolgende patiënten met 53 in-stent restenotische 
lesies (zonder eerdere brachytherapie) worden 
beschreven in Hoofdstuk 19. Tijdens baseline had 37% 
een complexe restenose morfologie (snelgroeiend patroon 
of totale occlusie). Bij follow-up werd restenose bij de 
gecoate stent geconstateerd bij 14.6%. Geen restenose 
werd waargenomen bij focale lesies. Voor de meer 
complexe lesies varieerden de restenose percentages van 
20% tot 25%. Na 1 jaar was de totale in-stent restenose 
incidentie 11.6%. Deze bevindingen werden vergeleken 
met brachytherapie, de huidige gouden standaard 
behandeling voor complexe in-stent restenose (Hoofdstuk 
20). Geen verschillen in uitkomsten werd gevonden tussen 
patiënten met in-stent restenose, behandeld met de 
gecoate stent of brachytherapie. Tenslotte werd in 
Hoofdstuk 21 het effect van de gecoate stent onderzocht 
bij patiënten met hernieuwde restenose na 
brachytherapie. De resultaten laten zien dat deze 
patiëntpopulatie een hoog risico heeft op voortdurende 
restenose, hetgeen werd gevonden in 40% van alle 
patiënten, zelfs na implementatie van de gecoate stent. 
Hoewel de gecoate stents veilig en effectief bleken te 
zijn, werden er toch complicaties gevonden op de korte- 
en middenlangetermijn bij sommige patiënten. Dit is 
beschreven in de Hoofdstukken 22-26. Stent trombose 
bleek weinig voor te komen (0.4%) (Hoofdstuk 22), 
hetgeen vergelijkbaar is met eerdere studies van de 
conventionele stent. Hoofdstuk 23 beschrijft enige 
morfologische en mechanische karakteristieken van 
patiënten met restenose in de gecoate stent. 
Restenotische lesies binnen de stent waren focaal en 
discontinuïteit in de stent structuur werd geïdentificeerd 
als een relatief normale bevinding. Bij 83% van de 
patiënten met edge restenose werd er na de procedure 
residuele dissectie of letsel ten gevolge van de ballon 
gevonden. Na 6-maanden was het in-segment restenose 
percentage onder de patiënten met complexe 
karakteristieken 7.9% (6.3% in-stent, 0.9% bij de 
proximale edge, 0.7% bij de distale edge), waarbij de 
volgende parameters werden geïdentificeerd als 
onafhankelijke multivariabele voorspellers (Hoofdstuk 24): 
behandeling van in-stent restenose (OR 4.16; 95%CI 
1.63-11.01; p<0.001), ostial locatie (OR 4.84; 95%CI 
1.81-12.07; p<0.01), diabetes mellitus (OR 2.63; 95%CI 
1.14-6.31;p=0.02), totale stent lengte (per 10 mm 
toename) (OR 1.42; 95%CI 1.21-1.68; p<0.01), 
referentie diameter (per 1.0 mm toename) (OR 0.46; 
95%CI 0.24-0.87; p=0.03) en LAD (OR 0.30; 95%CI 
0.10-0.69; p<0.01). Een interessante bevinding was dat 
in-stent restenose van de gecoate stent lijkt voor te 
komen als een “alles of niets” fenomeen (Hoofdstuk 25) 
waarbij lesie-gerelateerde karakteristieken (in plaats van 
patiënt-relateerd) een belangrijke rol spelen bij het 
voorkomen van restenose van de gecoate stent. Hoewel 
restenose van de gecoate stent slechts voorkomt in een 
klein deel van de patiënten, is het relatief resistent met 
betrekking tot een hernieuwde percutane behandeling 
(Hoofdstuk 26). In totaal 24 opeenvolgende patiënten (27 
lesies) met restenose in de gecoate stent ondergingen 
een nieuwe dotterprocedure. Van de 27 lesies, werd er 1 
(4%) behandeld met een conventionele stent, 3 (11%) 
met een ballondilatatie, en de overige 23 lesies (85%) 
opnieuw met een gecoate stent (sirolimus in 12 lesies 
[44%], en paclitaxel in 11 lesies (41%). Het event-vrije 
overlevings percentage was 75.0% na 487±42 dagen na 
de index procedure (269±68 dagen na de post-SES 
behandeling). In totaal was het hernieuwde restenose 
percentage 40%. Het hernieuwde restenose percentage 
na opnieuw te zijn behandeld door gecoate stents was 
29.4%. 
Tenslotte, hoewel restenose, de Achilleshiel van 
percutane revascularisatie, onder controle lijkt te zijn na 
de introductie van de gecoate stent, is het gebruik van 
deze stents, ondanks het gunstige effect, in de klinische 
praktijk minder dan we zouden verwachten. De 
belangrijkste beperking om deze nieuw  gecoate stent 
meer te gebruiken is niet-technisch, niet-medisch, en niet-
biologisch. Het grootste obstakel is de hoge prijs, in 
vergelijking tot de conventionele stent. De balans tussen 
kosten en baten van de gecoate stent is bestudeerd in 
Hoofdstuk 27 gebruikmakend van de gegevens van de 
RAVEL studie. Toepassing van de gecoate stent leidde tot 
een gemiddelde toename van de procedurele kosten van 
€1,286 in vergelijking tot de controle groep, gebaseerd op 
de kosten in Nederland. Aan het eind van het eerste jaar 
bleek echter dat door het gebruik van de gecoate stent dit 
verschil, dankzij een verminderde noodzaak tot 
reinterventies, te zijn verminderd tot slechts €54. Met 
andere woorden, de extra kosten om tot een event-
reductie in de RAVEL studie van 28.8% tot 5.8% te 
komen, bedroegen dankzij de gecoate stent, slechts €54 
per patiënt. De gunstige effecten en de beperkingen van 
gecoate stents als een anti-restenotisch strategie en hun 
relatie met potentiële kosten is veelal complex en 
multifactoriëel. Hoofdstuk 28 gaat in op de belangrijkste 
redenen die betrekking hebben op de balans tussen 
kosten en baten van deze nieuwe techniek. 
We kunnen concluderen dat de met sirolimus gecoate 
stent bij ongeslecteerde patiënten in de klinische praktijk 
veilig en effectief is in het terugdringen van cardiale 
events, ook bij verschillend subgroepen met een hoog 
risico. Door de restenose reductie met de gecoate stent 
zal de indicatie voor percutane behandeling zeer zeker 
worden uitgebreid, vooral bij die patiënten waarbij op dit 
moment chirurgische of medicameteuze behandeling 
wordt overwogen. Hoewel weinig voorkomend, zal 
restenose na implantatie van gecoate stents toch 
plaatsvinden bij een kleine minderheid. De risicofactoren 
voor restenose zijn dezelfde als die bij de conventionele 
stent. Tenslotte, kenmerken die mogelijk de volledige 
coating van het behandelde segment aantasten, kunnen 
een belangrijke rol spelen bij de in-stent restenose van de 
gecoate stent waarbij het lijkt op een “alles of niets” 
fenomeen. 
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Coming to the Thorax has always been the golden dream. It is the gold standard. 
Rotterdam, 26th January 2002. Wintertime. A temperature something like 30°C less than what I got just 12 hours 
before. Six suitcases (not exactly small). And me alone (Francine was still in Brazil awaiting her visa). Saturday. My new 
address written on a piece of paper. Took a cab: “Please, can we go to Claverstrati?”. Silence. “What?”. “Claverstrati 
avenue”, I said and handed the piece of paper to the driver. “Ah, Klaverstraat”. The temperature inside the taxi was 
something like 30°C more than what I got just 5 minutes before. The radio blaring in Dutch. I arrived, I thought. Not 
too fast, my friend… I did not have the keys of the apartment. I had the phone number of the owner of the apartment, 
who lived in Ireland. But no keys. “Somebody will be waiting for me, they know I’m coming today”, I thought. But there 
was no somebody. And no keys. And that was Saturday afternoon, wintertime, 6 suitcases (not exactly small), me in the 
street in front of the apartment. Fortunately, the neighbor (thanks, Miki) saved me. She saw me through the window of 
her apartment and understood that I could be me (that is, that the guy in the street with 6 suitcases [not exactly small] 
could be the new neighbor she knew was coming soon. She had a spare key and phoned my landlady. I arrived, I 
thought. Not too fast, my friend… Saturday, late afternoon, my first day in Rotterdam. Where do I eat? Do I have a 
phone? That was the turn of my landlady and her son in law to save me. Thanks a lot Lijnie and Aad, you have 
absolutely made everything much smoother for me. I bought some food and declared myself arrived. 
But the story begun much earlier. Last week of March 2001. Dr. Expedito Ribeiro had just arrived from the ACC 
meeting: “Pedrinho, I have talked to Patrick there. He said you can come”. Expedito, I have no words to thank you. Not 
only for your support in many many instances, but for the friendship that developed along the road between us and 
your family, Cida, Maira, and Henrique. You have been pivotal to this thesis since the very beginning. 
I went immediately to Dr. Eulógio Martinez, whom I will never be able to thank enough. Prof. Eulógio Martinez, I can 
say, was a turning point in my personal and professional life. Not only because of the many specific things that I have 
learned from him, but mainly and especially because of the diffuseness of his influence on my way of viewing things. 
For the uncountable times I found myself embarrassed and slightly out of key in a conversation with him by not being 
able to follow his thinking and broad generosity. For his subtle way of letting me know that life is always bigger than 
what I thought. For showing me how to exercise the tough practice of searching, recognizing, and sincerely admiring 
somebody else’s virtues. During these last 2.5 years, I have sent to him or received from him a total of 307 emails. That 
kept my “continued education” on medical and life issues going. 
Dr. Paulo Soares. My friend. Bia, Gustavo. You came here to Rotterdam at our very beginning just to check if we 
were ok and were not missing everybody too much. That touched us deeply. That is friendship. Making us feel at home 
in Rotterdam as you used to do in São Paulo. That is priceless. 
I have also to thank all my colleagues from the Cath Lab at the Heart Institute. Drs. Kajita, Gama, Horta, Esteves, 
Perin, Beck, and Zalc, to whom I am happily  coming back. I  worked closely  with Kajita and Esteves at Sirio Libanes, 
 shared the same "afternoons" with Marcus Gama, Pedro  Horta, and Marco Perin, and  Leonardo Beck was my classmate  
 during the graduation course. You have worked in my place while I was in Rotterdam, providing me support.  And above
    all, you kept my position  unquestioned  while I was  apart. That was priceless  and I  fully  acknowledge  it. Thank  you
    very much. I also thank all nurses, secretaries, and technicians. Paula, thanks for taking care of my things so devotedly. 
    I thank Prof. José A.F. Ramires for endorsing my stay in Rotterdam for these almost 2 and a half years and also for  
     kindly accepting in participating in my defense committee. That honors me and pushes my responsibilities even further. 
    I am indebted to Prof. Eduardo M. Krieger who helped me with the sponsorship application. 
    But then here I am at the Thoraxcenter. Monday. What to do? Before coming I was prepared by Marco Costa who 
    gave me lots of tips and tricks. “Take your time in the beginning. It takes a while until things start to appear. In the 
    meantime, try to know the place and don’t forget that it’s important to hold on the chances as they come out. It is also 
    important to write quickly, so you can move on to the next stuff with no delay”. Marco, since before coming (and     
    actually even before knowing you personally) you have been essential to my stay here and I foresee that our friendship 
    will strengthen more and more as time goes by. 
   But there I was. Thorax, first Monday morning. Anja soon assigned me a seat and a computer at the Cath Lab 
    (thanks, Anja for all your help with everything!). Great. Faster than I thought! Two days latter, around 18:00, Prof. 
    Serruys enters the room: “Come and take two plastic glasses with you”. And disappeared to his room. “Have I 
    understood ok?”, I thought. With some hesitation, I went to his room with the plastic glasses that I took from the coffee     
    machine. Prof. Serruys: “Here is a bottle of champagne. Why don’t you open it so we can drink something while I 
    explain to you the projects we are currently involved in?”. “Fantastic! I am in!”, I thrilled. He started to talk and write on 
    the board. But then I realized: “This champagne is too warm…”. I tried to duck it, and did not open the bottle, in the 
    hope that Prof. would forget the champagne thing. At that time I did not know Prof.’s memory… And after 5 minutes:          
    “Where is our champagne?”, he asked again. Well, no chance to escape it now. I opened it. I have kept until now my 
    impression of that 0.2 second, when the warm bottle exploded and spread champagne everywhere. I did not know what 
    to do. With one hand I tried to cover the top of the bottle (which was not exactly efficient), while with the other hand I     
    tried to reach some paper to dry it up. Prof. Serruys just glanced calmly at me: “Try to avoid the laptop. I once have     
    seen a laptop dying because of a soup. Anyway, what I was saying is that the vulnerable plaque is a hot topic…”. I 
    finally (though still stressed) managed to pour some champagne in our glasses (only half of the bottle was left) and we 
    kept our conversation. After some minutes, he continued: “And here there is something we could try to do. You know 
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that the people in the 23rd floor are outstanding. Pick up some paper and take notes. Why don’t you set up a meeting – 
take note – with Nicudeiungui and Tonfanderstin?” I still have this paper with my spelling of the names of Profs. Nico de 
Jong and Anton van der Steen. I thank Prof. Tom van der Steen, one of the first persons that I then met in Rotterdam, 
who honors me with his participation in my thesis committee. 
I was wondering where I should put my acknowledgment to Prof. Serruys. I soon understood that my recognition for 
what he has done for me could be placed anywhere. Indeed, everywhere. Through Prof. Serruys’ hands I was exposed 
to a new world (I am sorry for the jargon, but this is absolutely true). I was presented to a universe where details are 
essential. Where actually they are no longer “details”. Yet, I was taught that dissecting intricacies is what matters in the 
end. And he masters as nobody can the know-how to unravel the niceties of life. Prof. Serruys showed me that full 
understanding of the ground one is stepping in is an obligatory pre-requisite to be “au fait” with the edge of knowledge. 
And that the constant pursuit of pushing these borders forward is what distinguishes the professional researcher. But on 
the other hand, and here is the mystery, keeping a dose of improvisation is fundamental. I heard from him: “At all 
moments you must always be trying and thinking about something new. So, for a period, in that particular issue, you 
will be a beginner and that is good because it keeps the thing alive.” I must also thank Mme. Danielle Serruys, who 
always received me with a smile at their home, gave us tips for our trips (to Barcelona, Venice, skiing, etc.), and invited 
us for a wonderful New Year’s Eve. 
Soon I realized that I was the only fellow with a seat in the cath lab. I was placed at the room with the assistants. 
All others (fellows) were in “Z” building. At that time, Evelyn Regar (I owe you the arrangements for our first apartment 
and several dinners at her place with Frank her husband), Kengo Tanabe, Ronald Lee, Muzaffer Degertekin. With 
Tanabe-san, Ronald, and Muza we did the very first start for the data collection and organization of the RESEARCH. I 
remember vividly our group discussions about what to do and the day Ronald created the name: Rapamycin-Eluting 
Stent Evaluated At Rotterdam Cardiology Hospital (the RESEARCH). Kengo was an example of precision and accuracy 
and together with Muza (thanks a lot for the honor of choosing me as the paraninph of your thesis) were the first to 
show me the paths in the Thorax. 
Shortly after that, Francesco Saia and Akis Arampatzis came. My two paraninphs. Aki, mag ik gara gara classics? I 
still have to go to Greece to visit you and to be introduced to real Greek food, though the things you have showed us in 
Delft were unforgettable. Akis, have you counted how many QCA’s and other things were have worked out together? 
Akis is a conqueror. He came to Rotterdam alone, leaving his Vicky in Greece who was already waiting for the little (not 
so little) Alexandros. Even apart from his family and missing them as I know he missed, Akis managed to conquer his 
clinical and research training, and above all, the esteem of all his friends.  
Francesco Saia. Or better, France, Chico, Chicão, Chiquinho. We have worked for 1 and a half year close by about 2 
meters from each other (the “assistants room” had become progressively busy). With Chico and Barbara his wife, I 
learned more about respect and patience, food and ski (Francine’s and mine last passion), Roma and San Valentino. 
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